
<html lang="en"     class="pb-page"  data-request-id="84b9622a-7b3a-4bc3-944f-f83a1d8fc45f"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/acs.jmedchem.9b00722;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2019.62.issue-22"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of a Furanopyrimidine-Based Epidermal Growth Factor Receptor Inhibitor (DBPR112) as a Clinical Candidate for the Treatment of Non-Small Cell Lung Cancer" /></meta><meta name="dc.Creator" content="Shu-Yu  Lin" /></meta><meta name="dc.Creator" content="Yung  Chang Hsu" /></meta><meta name="dc.Creator" content="Yi-Hui  Peng" /></meta><meta name="dc.Creator" content="Yi-Yu  Ke" /></meta><meta name="dc.Creator" content="Wen-Hsing  Lin" /></meta><meta name="dc.Creator" content="Hsu-Yi  Sun" /></meta><meta name="dc.Creator" content="Hui-Yi  Shiao" /></meta><meta name="dc.Creator" content="Fu-Ming  Kuo" /></meta><meta name="dc.Creator" content="Pei-Yi  Chen" /></meta><meta name="dc.Creator" content="Tzu-Wen  Lien" /></meta><meta name="dc.Creator" content="Chun-Hwa  Chen" /></meta><meta name="dc.Creator" content="Chang-Ying  Chu" /></meta><meta name="dc.Creator" content="Sing-Yi  Wang" /></meta><meta name="dc.Creator" content="Kai-Chia  Yeh" /></meta><meta name="dc.Creator" content="Ching-Ping  Chen" /></meta><meta name="dc.Creator" content="Tsu-An  Hsu" /></meta><meta name="dc.Creator" content="Su-Ying  Wu" /></meta><meta name="dc.Creator" content="Teng-Kuang  Yeh" /></meta><meta name="dc.Creator" content="Chiung-Tong  Chen" /></meta><meta name="dc.Creator" content="Hsing-Pang  Hsieh" /></meta><meta name="dc.Description" content="Epidermal growth factor receptor (EGFR)-targeted therapy in non-small cell lung cancer represents a breakthrough in the field of precision medicine. Previously, we have identified a lead compound, ..." /></meta><meta name="Description" content="Epidermal growth factor receptor (EGFR)-targeted therapy in non-small cell lung cancer represents a breakthrough in the field of precision medicine. Previously, we have identified a lead compound, ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="September 27, 2019" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b00722" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00722" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b00722" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00722" /></link>
        
    
    

<title>Discovery of a Furanopyrimidine-Based Epidermal Growth Factor Receptor Inhibitor (DBPR112) as a Clinical Candidate for the Treatment of Non-Small Cell Lung Cancer | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b00722" /></meta><meta property="og:title" content="Discovery of a Furanopyrimidine-Based Epidermal Growth Factor Receptor Inhibitor (DBPR112) as a Clinical Candidate for the Treatment of Non-Small Cell Lung Cancer" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/large/jm9b00722_0015.jpeg" /></meta><meta property="og:description" content="Epidermal growth factor receptor (EGFR)-targeted therapy in non-small cell lung cancer represents a breakthrough in the field of precision medicine. Previously, we have identified a lead compound, furanopyrimidine 2, which contains a (S)-2-phenylglycinol structure as a key fragment to inhibit EGFR. However, compound 2 showed high clearance and poor oral bioavailability in its pharmacokinetics studies. In this work, we optimized compound 2 by scaffold hopping and exploiting the potent inhibitory activity of various warhead groups to obtain a clinical candidate, 78 (DBPR112), which not only displayed a potent inhibitory activity against EGFRL858R/T790M double mutations but also exhibited tenfold potency better than the third-generation inhibitor, osimertinib, against EGFR and HER2 exon 20 insertion mutations. Overall, pharmacokinetic improvement through lead-to-candidate optimization yielded fourfold oral AUC better that afatinib along with F = 41.5%, an encouraging safety profile, and significant antitumor efficacy in in vivo xenograft models. DBPR112 is currently undergoing phase 1 clinical trial in Taiwan." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b00722"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b00722">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b00722&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b00722&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b00722&amp;href=/doi/10.1021/acs.jmedchem.9b00722" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 22</span><span class="cit-fg-pageRange">, 10108-10123</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/22" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b00456" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.9b00952" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of a Furanopyrimidine-Based Epidermal Growth Factor Receptor Inhibitor (DBPR112) as a Clinical Candidate for the Treatment of Non-Small Cell Lung Cancer</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Shu-Yu Lin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shu-Yu Lin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli County 35053, Taiwan, ROC</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shu-Yu++Lin">Shu-Yu Lin</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yung Chang Hsu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yung Chang Hsu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli County 35053, Taiwan, ROC</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yung++Chang+Hsu">Yung Chang Hsu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yi-Hui Peng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yi-Hui Peng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli County 35053, Taiwan, ROC</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yi-Hui++Peng">Yi-Hui Peng</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yi-Yu Ke</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yi-Yu Ke</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli County 35053, Taiwan, ROC</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yi-Yu++Ke">Yi-Yu Ke</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wen-Hsing Lin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wen-Hsing Lin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli County 35053, Taiwan, ROC</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wen-Hsing++Lin">Wen-Hsing Lin</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hsu-Yi Sun</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hsu-Yi Sun</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli County 35053, Taiwan, ROC</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hsu-Yi++Sun">Hsu-Yi Sun</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hui-Yi Shiao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hui-Yi Shiao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli County 35053, Taiwan, ROC</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hui-Yi++Shiao">Hui-Yi Shiao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Fu-Ming Kuo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Fu-Ming Kuo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli County 35053, Taiwan, ROC</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Fu-Ming++Kuo">Fu-Ming Kuo</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Pei-Yi Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Pei-Yi Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli County 35053, Taiwan, ROC</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Pei-Yi++Chen">Pei-Yi Chen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tzu-Wen Lien</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tzu-Wen Lien</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli County 35053, Taiwan, ROC</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tzu-Wen++Lien">Tzu-Wen Lien</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Chun-Hwa Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chun-Hwa Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli County 35053, Taiwan, ROC</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chun-Hwa++Chen">Chun-Hwa Chen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Chang-Ying Chu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chang-Ying Chu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli County 35053, Taiwan, ROC</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chang-Ying++Chu">Chang-Ying Chu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sing-Yi Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sing-Yi Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli County 35053, Taiwan, ROC</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sing-Yi++Wang">Sing-Yi Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kai-Chia Yeh</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kai-Chia Yeh</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli County 35053, Taiwan, ROC</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kai-Chia++Yeh">Kai-Chia Yeh</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ching-Ping Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ching-Ping Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli County 35053, Taiwan, ROC</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ching-Ping++Chen">Ching-Ping Chen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tsu-An Hsu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tsu-An Hsu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli County 35053, Taiwan, ROC</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tsu-An++Hsu">Tsu-An Hsu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Su-Ying Wu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Su-Ying Wu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli County 35053, Taiwan, ROC</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Su-Ying++Wu">Su-Ying Wu</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2816-6961" title="Orcid link">http://orcid.org/0000-0003-2816-6961</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Teng-Kuang Yeh</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Teng-Kuang Yeh</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli County 35053, Taiwan, ROC</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Teng-Kuang++Yeh">Teng-Kuang Yeh</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Chiung-Tong Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chiung-Tong Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli County 35053, Taiwan, ROC</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chiung-Tong++Chen">Chiung-Tong Chen</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Hsing-Pang Hsieh</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hsing-Pang Hsieh</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli County 35053, Taiwan, ROC</div><div class="loa-info-affiliations-info">Department of Chemistry, National Tsing Hua University, Hsinchu 30013, Taiwan, ROC</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#0c647c647f6569644c62647e6522637e6b22787b"><span class="__cf_email__" data-cfemail="bed6ced6cdd7dbd6fed0d6ccd790d1ccd990cac9">[email protected]</span></a>. Phone: +886-37-246-166 ext. 35708. Fax: +886-37-586-456.</span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hsing-Pang++Hsieh">Hsing-Pang Hsieh</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1332-005X" title="Orcid link">http://orcid.org/0000-0002-1332-005X</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00722&amp;href=/doi/10.1021%2Facs.jmedchem.9b00722" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 22</span><span class="cit-pageRange">, 10108–10123</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">September 27, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>3 May 2019</li><li><span class="item_label"><b>Published</b> online</span>27 September 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 27 November 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b00722" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00722</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D10108%26pageCount%3D16%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DShu-Yu%2BLin%252C%2BYung%2BChang%2BHsu%252C%2BYi-Hui%2BPeng%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D22%26contentID%3Dacs.jmedchem.9b00722%26title%3DDiscovery%2Bof%2Ba%2BFuranopyrimidine-Based%2BEpidermal%2BGrowth%2BFactor%2BReceptor%2BInhibitor%2B%2528DBPR112%2529%2Bas%2Ba%2BClinical%2BCandidate%2Bfor%2Bthe%2BTreatment%2Bof%2BNon-Small%2BCell%2BLung%2BCancer%26numPages%3D16%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D10123%26publicationDate%3DNovember%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b00722"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2199</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">5</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b00722" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of a Furanopyrimidine-Based Epidermal Growth Factor Receptor Inhibitor (DBPR112) as a Clinical Candidate for the Treatment of Non-Small Cell Lung Cancer&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Shu-Yu&quot;,&quot;last_name&quot;:&quot;Lin&quot;},{&quot;first_name&quot;:&quot;Yung&quot;,&quot;last_name&quot;:&quot;Chang Hsu&quot;},{&quot;first_name&quot;:&quot;Yi-Hui&quot;,&quot;last_name&quot;:&quot;Peng&quot;},{&quot;first_name&quot;:&quot;Yi-Yu&quot;,&quot;last_name&quot;:&quot;Ke&quot;},{&quot;first_name&quot;:&quot;Wen-Hsing&quot;,&quot;last_name&quot;:&quot;Lin&quot;},{&quot;first_name&quot;:&quot;Hsu-Yi&quot;,&quot;last_name&quot;:&quot;Sun&quot;},{&quot;first_name&quot;:&quot;Hui-Yi&quot;,&quot;last_name&quot;:&quot;Shiao&quot;},{&quot;first_name&quot;:&quot;Fu-Ming&quot;,&quot;last_name&quot;:&quot;Kuo&quot;},{&quot;first_name&quot;:&quot;Pei-Yi&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Tzu-Wen&quot;,&quot;last_name&quot;:&quot;Lien&quot;},{&quot;first_name&quot;:&quot;Chun-Hwa&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Chang-Ying&quot;,&quot;last_name&quot;:&quot;Chu&quot;},{&quot;first_name&quot;:&quot;Sing-Yi&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Kai-Chia&quot;,&quot;last_name&quot;:&quot;Yeh&quot;},{&quot;first_name&quot;:&quot;Ching-Ping&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Tsu-An&quot;,&quot;last_name&quot;:&quot;Hsu&quot;},{&quot;first_name&quot;:&quot;Su-Ying&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Teng-Kuang&quot;,&quot;last_name&quot;:&quot;Yeh&quot;},{&quot;first_name&quot;:&quot;Chiung-Tong&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Hsing-Pang&quot;,&quot;last_name&quot;:&quot;Hsieh&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;09&quot;,&quot;day&quot;:&quot;27&quot;,&quot;issue&quot;:&quot;22&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;10108-10123&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b00722&quot;},&quot;abstract&quot;:&quot;Epidermal growth factor receptor (EGFR)-targeted therapy in non-small cell lung cancer represents a breakthrough in the field of precision medicine. Previously, we have identified a lead compound, furanopyrimidine 2, which contains a (S)-2-phenylglycinol structure as a key fragment to inhibit EGFR. However, compound 2 showed high clearance and poor oral bioavailability in its pharmacokinetics studies. In this work, we optimized compound 2 by scaffold hopping and exploiting the potent inhibitory activity of various warhead groups to obtain a clinical candidate, 78 (DBPR112), which not only displayed a potent inhibitory activity against EGFRL858R/T790M double mutations but also exhibited tenfold potency better than the third-generation inhibitor, osimertinib, against EGFR and HER2 exon 20 insertion mutations. Overall, pharmacokinetic improvement through lead-to-candidate optimization yielded fourfold oral AUC better that afatinib along with F = 41.5%, an encouraging safety profile, and significant antitumor eff&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00722&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00722" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00722&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00722" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00722&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00722" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00722&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00722&amp;href=/doi/10.1021/acs.jmedchem.9b00722" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b00722" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b00722" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00722&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b00722%26sid%3Dliteratum%253Aachs%26pmid%3D31560541%26genre%3Darticle%26aulast%3DLin%26date%3D2019%26atitle%3DDiscovery%2Bof%2Ba%2BFuranopyrimidine-Based%2BEpidermal%2BGrowth%2BFactor%2BReceptor%2BInhibitor%2B%2528DBPR112%2529%2Bas%2Ba%2BClinical%2BCandidate%2Bfor%2Bthe%2BTreatment%2Bof%2BNon-Small%2BCell%2BLung%2BCancer%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D22%26spage%3D10108%26epage%3D10123%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290658" title="Amides">Amides</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/22" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/jmcmar.2019.62.issue-22/20191127/jmcmar.2019.62.issue-22.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/medium/jm9b00722_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/large/jm9b00722_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00722&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Epidermal growth factor receptor (EGFR)-targeted therapy in non-small cell lung cancer represents a breakthrough in the field of precision medicine. Previously, we have identified a lead compound, furanopyrimidine <b>2</b>, which contains a (<i>S</i>)-2-phenylglycinol structure as a key fragment to inhibit EGFR. However, compound <b>2</b> showed high clearance and poor oral bioavailability in its pharmacokinetics studies. In this work, we optimized compound <b>2</b> by scaffold hopping and exploiting the potent inhibitory activity of various warhead groups to obtain a clinical candidate, <b>78</b> (DBPR112), which not only displayed a potent inhibitory activity against EGFR<sup>L858R/T790M</sup> double mutations but also exhibited tenfold potency better than the third-generation inhibitor, osimertinib, against EGFR and HER2 exon 20 insertion mutations. Overall, pharmacokinetic improvement through lead-to-candidate optimization yielded fourfold oral AUC better that afatinib along with <i>F</i> = 41.5%, an encouraging safety profile, and significant antitumor efficacy in in vivo xenograft models. DBPR112 is currently undergoing phase 1 clinical trial in Taiwan.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78808" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78808" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Lung cancer has the highest rate of morbidity and mortality among various cancer types, being responsible for over 1.69 million deaths per year.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> Approximately 80–85% of the lung cancer patients diagnosed exhibit non-small cell lung cancer (NSCLC).<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3,4)</a> Mutations in the epidermal growth factor receptor (EGFR) have been observed in ∼50% of NSCLC patients, in particular, in East Asian patients.<a onclick="showRef(event, 'ref4 ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref6">(4−6)</a> The EGFR exon 19 deletions or exon 21 (L858R) substitution mutations constitute 90% of all EGFR-activating mutations.<a onclick="showRef(event, 'ref3 ref7'); return false;" href="javascript:void(0);" class="ref ref3 ref7">(3,7)</a></div><div class="NLM_p">The first-generation EGFR-targeted inhibitors, gefitinib and erlotinib, were approved by US FDA in 2003<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> and 2004 to treat mutation-positive patients.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Even though the two drugs showed remarkable objective response rates (ORR) in EGFR-mutant NSCLC patients,<a onclick="showRef(event, 'ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref10 ref11">(10,11)</a> resistance can be acquired because of a secondary T790M mutation after treatment.<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12,13)</a> More recently, the irreversible second-generation EGFR tyrosine kinase inhibitor (TKI) afatinib was developed. It contains an acrylamide moiety that can undergo covalent interaction with Cys797 at the active site to enhance the binding affinity and prolong progression-free survival.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> FDA initially approved afatinib in 2013<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> and broadened its indication in 2018 for patients with NSCLC.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> However, afatinib showed potent activity against the wild-type (WT) EGFR, resulting in toxicity and serious adverse effects.<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17,18)</a> Very recently, AstraZeneca developed the selective covalent EGFR inhibitor AZD9291 (osimertinib), which received regular approval in 2017 for EGFR-T790M-mutation-positive NSCLC patients that showed cancer progression on EGFR TKI therapy.<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19,20)</a> Osimertinib also has been approved by FDA as a frontline treatment in 2018.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> However, the cost for a one-month treatment of osimertinib is $12 750 USD,<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> and several studies have revealed that patients acquire resistance after clinical use.<a onclick="showRef(event, 'ref23 ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref23 ref24 ref25">(23−25)</a> On September 27, 2018, FDA approved dacomitinib for the first-line treatment of metastatic NSCLC patients.<a onclick="showRef(event, 'ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref26 ref27">(26,27)</a> Dacomitinib is orally irreversible second-generation EGFR-TKI same as afatinib.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></div><div class="NLM_p">In a previous effort to develop EGFR inhibitors, we rapidly constructed a furanopyrimidine kinase-targeted library and screened it for Aurora and EGFR kinase activities. Also, we identified compound <b>1</b> with (<i>S</i>)-2-phenylglycinol moiety as a potent WT EGFR inhibitor, with an IC<sub>50</sub> value of 223 nM and no Aurora kinase inhibition. The docking of <b>1</b> into EGFR revealed a possible enhancement of the EGFR kinase activity through the introduction of a Michael acceptor group on the 3-position of the furan ring.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Based on this, we introduced an acrylamide group as a Michael acceptor, resulting in compound <b>2</b>,<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> which showed potent in vitro activity in both wild and mutant EGFR kinases and potent antiproliferative activity against HCC827 lung cancer cells. In addition, because the DFG (Asp-Phe-Gly) motif plays an important role in regulating the kinase activity of EGFR,<a onclick="showRef(event, 'ref29 ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref29 ref30 ref31">(29−31)</a> we prepared compound <b>3</b> by structure-based drug design (SBDD), which is able to interact with the DFG motif by H-bonding and salt bridge formation.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> The <i>N</i>,<i>N</i>-dimethylamino tail of <b>3</b> moves toward the DFG motif and forms a salt bridge with the side chain of Asp855, which greatly contributes to its potency against EGFR.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a></div><div class="NLM_p">In this work, we apply SBDD to guide the optimization of lead compound <b>2</b> and perform intensive lead-to-candidate optimization to identify promising candidate into the next development stage. As a result of this study, we hybridized the characteristic moieties of <b>2</b> and <b>3</b> to identify the EGFR-targeted drug candidate DBPR112 (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). DBPR112 has received investigational new drug (IND) application approval from US FDA (NCT03246854) in 2016 and Taiwan FDA in 2017 and is currently ongoing phase I clinical trials in Taiwan.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/medium/jm9b00722_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/large/jm9b00722_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. EGFR inhibitors design strategy from initial hit compound <b>1</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/large/jm9b00722_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00722&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34035" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34035" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Binding Mode Analysis of Compound <b>2</b></h3><div class="NLM_p">The crystalline structure of EGFR kinase complex with <b>1</b> (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JQ7">4JQ7</a>) was used to initiate the covalent docking study of <b>2</b>. As shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>, the binding mode of <b>2</b> in the ATP-binding cleft was very similar to that of <b>1</b>, except that the additional acryl group of <b>2</b> formed a covalent bond with the SH group of Cys797.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> A hydrogen bond was also formed between the pyrimidine N1 and Met793 in the kinase hinge region. The hydroxyl group of (<i>S</i>)-2-phenylglycinol formed an additional H-bond with Asp855. Moreover, the furanopyrimidine core and the three phenyl moieties made close contact as sigma–pi hydrophobic interactions with the residues of Val726, Ala743, Lys745, Leu788, Leu718, and Thr790. The above analysis indicated that the structure–activity relationship (SAR) studies should focus on the 5,6-fused pyrimidine (hinge binding) and the perpendicular phenyl ring with the Michael acceptor group (covalent binding) and also explore possible modification sites to expand the structural diversity and identify the most promising drug candidate.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/medium/jm9b00722_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/large/jm9b00722_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Binding site analysis for compound <b>2</b> (orange) docking with EGFR X-ray protein (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JQ7">4JQ7</a>). Compound <b>2</b> forms a covalent bond with Cys797 (as shown in the white color residue) and hydrogen bond with Met793 (as shown in the green color residue). The hydrophobic effect was contributed by Leu718, Val726, Ala743, Lys745, Leu788, and Leu844 (as shown in cyan color residues).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/large/jm9b00722_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00722&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Chemistry</h3><div class="NLM_p">Compounds <b>42–48</b> were synthesized as illustrated in <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a> and <a class="ref internalNav" href="#sch2" aria-label="2">2</a>. We synthesized the building blocks <b>7</b>, <b>10</b>, <b>13</b>, and <b>17</b> from appropriate nitrobenzene derivatives (<b>5</b>, <b>8</b>, <b>11</b>, and <b>14</b>) through modification of published procedures or known methods.<a onclick="showRef(event, 'ref35 ref36 ref37 ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref35 ref36 ref37 ref38 ref39">(35−39)</a> In short, the cyclization of the 2-hydroxy-1-(3-nitrophenyl)-1-ethanone (<b>6</b>) or <i>N</i>-hydroxy-3-nitrobenzimidoyl chloride (<b>16</b>) with malononitrile under basic conditions yielded the furan <b>7</b> and the isoxazole <b>17</b>, respectively. The nitrobenzene derivatives <b>8</b> and <b>11</b> were individually condensed with ethyl cyanoacetate and malononitrile followed by cyclization in the presence of octasulfur to obtain the thiophenes <b>10</b> and <b>13</b>.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> The required five-membered heteroaryl compounds <b>7</b>, <b>10</b>, <b>13</b>, and <b>17</b> were cyclized and then chlorinated to synthesize the bicyclic [2,3-<i>d</i>]pyrimidines <b>22–26</b>, as shown in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. The nucleophilic aromatic substitution with (<i>S</i>)-(+)-2-phenylglycinol derivatives gave the desired compounds <b>29–35</b>. Bromo-substituent <b>30</b> was cross-coupled with methyl zinc chloride using Negishi coupling to prepare the methylated compound <b>31</b>. The reduction of <b>29–35</b> using 10% Pd/C in the presence of hydrogen gas, iron powder under acidic condition, or stannic chloride yielded the corresponding amino analogues <b>36–41</b>. Amide bond formation of compounds <b>36–41</b> with acrylic acid was accomplished in the presence of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI·HCl) to obtain the corresponding acrylamides <b>42</b>, <b>43</b>, and <b>45–47</b>. The desilylation of OTBS-protected <b>47</b> was carried out with tetrabutylammonium fluoride (TBAF) to give the desired isoxazolo[5,4-<i>d</i>]pyrimidine <b>48</b>. On the other hand, acrylation of the aniline <b>38</b> using acryloyl chloride led to the acrylamide <b>44</b>. The synthetic routes for the preparation of amide <b>70–85</b> are outlined in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>, considering various functional groups attached to the terminal end of the Michael acceptor. Starting compounds <b>49–51</b> were synthesized by modifying reported procedures.<a onclick="showRef(event, 'ref36 ref41'); return false;" href="javascript:void(0);" class="ref ref36 ref41">(36,41)</a> Bromination of the furan and the thiophene rings at 3-position with <i>N</i>-bromosuccinimide followed by nucleophilic substitution by (<i>R</i>)-(+)-1-phenylethylamine, (<i>R</i>)-(−)-, or (<i>S</i>)-(+)-2-phenylglycinol led to analogues <b>55–59</b>. Suzuki cross-coupling of analogues <b>55–59</b> with 3-nitrophenylboronic acid yielded the nitro analogues <b>60–64</b>. Similarly to the synthesis of <b>42–48</b>, aniline compounds <b>65–69</b> were obtained by reduction of the corresponding nitro compounds <b>60–64</b> and subsequent coupling with various carboxylic acids or 2-chloroethanesulfonyl chloride to obtain the analogues <b>70–85</b>.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/medium/jm9b00722_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/large/jm9b00722_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of the Building Blocks <b>7</b>, <b>10</b>, <b>13</b>, and <b>17</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/large/jm9b00722_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00722&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) AgNO<sub>3</sub>, H<sub>2</sub>O, acetone, reflux, 68%; (b) malononitrile, Et<sub>2</sub>NH, DMF, rt, 52%; (c) morpholine, S<sub>8</sub>, ethanol, 60 °C, 43%; (d) malononitrile, NH<sub>4</sub>OAc, acetic acid, benzene, reflux, 71%; (e) S<sub>8</sub>, Et<sub>2</sub>NH, ethanol, reflux, 83%; (f) NH<sub>2</sub>OH(aq), ethanol, rt; (g) NCS, DMF, rt; (h) NaOEt, malononitrile, rt to 45 °C, 51%.</p></p></figure><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/medium/jm9b00722_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/large/jm9b00722_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthetic Route of the EGFR Inhibitors for Simplification and Replacement of Furanopyrimidine through Scaffold Hopping<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/large/jm9b00722_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00722&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Ac<sub>2</sub>O, HCO<sub>2</sub>H, 100 °C; (b) HCONH<sub>2</sub>, 200 °C; (c) HCO<sub>2</sub>H, H<sub>2</sub>SO<sub>4</sub>, microwave; (d) (i) HC(OEt)<sub>3</sub>, toluene, 150 °C; (ii) NH<sub>3</sub> in methanol, ethanol, rt; (e) POCl<sub>3</sub>, heat; (f) <i>tert</i>-butyl nitrile, TMSCl, DMF, rt; (g) NBS, DMF, rt; (h) Et<sub>3</sub>N, ethanol, reflux; (i) Pd(PPh<sub>3</sub>)<sub>4</sub>, MeZnCl, THF, 80 °C; (j) NCS, DMF, rt; (k) SnCl<sub>2</sub>, ethanol, reflux; (l) H<sub>2</sub>, Pd/C; (m) iron powder, acid condition, ethanol, heat; (n) acrylic acid, EDCI; (o) acryloyl chloride, pyridine, rt; (p) TBAF, THF, rt.</p></p></figure><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/medium/jm9b00722_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/large/jm9b00722_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of EGFR Inhibitors with Various Michael Acceptors<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/large/jm9b00722_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00722&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NBS, DMF; (b) <b>27</b> or (<i>R</i>)-(−)-2-phenylglycinol, Et<sub>3</sub>N, ethanol, heat; (c) Pd(dppf)<sub>2</sub>Cl<sub>2</sub>, 3-nitrophenylboronic acid, Na<sub>2</sub>CO<sub>3(aq)</sub>, heat; (d) SnCl<sub>2</sub>, ethanol, reflux; (e) H<sub>2</sub>, Pd/C; (f) iron powder, acetic acid, ethanol, 90 °C; (g) acryloyl chloride, pyridine, rt; (h) acrylic acid, EDCI; (i) 2-chloroethanesulfonyl chloride, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>; (j) (i) 4-bromocrotonoic acid, EDCI-HCl; (ii) various amine.</p></p></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Biological Evaluation of EGFR Activating Mutations and SAR Analysis</h3><div class="NLM_p">All the novel synthesized compounds were evaluated by EGFR<sup>WT</sup>, EGFR<sup>L858R/T790M</sup> kinase assays, as well as on two NSCLC cell lines: HCC827<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> (expressing EGFR<sup>del19</sup>) and H1975 (expressing EGFR<sup>L858/T790M</sup>). The biological data are shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>. Compound <b>2</b> was used as the starting point for the structure–activity and lead optimization studies.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. SAR Investigation by Scaffold Modifications<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/medium/jm9b00722_0012.gif" alt="" id="GRAPHIC-d7e939-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound no.</th><th class="colsep0 rowsep0" align="center">X</th><th class="colsep0 rowsep0" align="center">Y</th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center">EGFR<sup>WT</sup> IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">EGFR<sup>L858R/T790M</sup> IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">HCC827 CC<sub>50</sub> (nM)<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">H1975 CC<sub>50</sub> (nM)<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">CPh</td><td class="colsep0 rowsep0" align="left">OH</td><td class="colsep0 rowsep0" align="left">20 ± 10</td><td class="colsep0 rowsep0" align="left">27 ± 10</td><td class="colsep0 rowsep0" align="left">24 ± 11</td><td class="colsep0 rowsep0" align="left">1258 ± 302</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>70</b></td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">CPh</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">117</td><td class="colsep0 rowsep0" align="left">500</td><td class="colsep0 rowsep0" align="left">58</td><td class="colsep0 rowsep0" align="left">4300</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>42</b></td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">OH</td><td class="colsep0 rowsep0" align="left">159 ± 65</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">744 ± 197</td><td class="colsep0 rowsep0" align="left">>20 000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>43</b></td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">CCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">OH</td><td class="colsep0 rowsep0" align="left">62 ± 22</td><td class="colsep0 rowsep0" align="left">1322 ± 487</td><td class="colsep0 rowsep0" align="left">46 ± 5</td><td class="colsep0 rowsep0" align="left">>20 000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>82</b></td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">C-2′OMePh</td><td class="colsep0 rowsep0" align="left">OH</td><td class="colsep0 rowsep0" align="left">24 ± 10</td><td class="colsep0 rowsep0" align="left">157 ± 54</td><td class="colsep0 rowsep0" align="left">34 ± 4</td><td class="colsep0 rowsep0" align="left">4076 ± 1600</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44</b></td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">OH</td><td class="colsep0 rowsep0" align="left">82 ± 44</td><td class="colsep0 rowsep0" align="left">2316 ± 819</td><td class="colsep0 rowsep0" align="left">56 ± 21</td><td class="colsep0 rowsep0" align="left">>20 000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>45</b></td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">CCl</td><td class="colsep0 rowsep0" align="left">OH</td><td class="colsep0 rowsep0" align="left">81 ± 36</td><td class="colsep0 rowsep0" align="left">1080 ± 365</td><td class="colsep0 rowsep0" align="left">51 ± 11</td><td class="colsep0 rowsep0" align="left">8656 ± 4490</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>46</b></td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">CCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">OH</td><td class="colsep0 rowsep0" align="left">107 ± 35</td><td class="colsep0 rowsep0" align="left">1259 ± 201</td><td class="colsep0 rowsep0" align="left">35 ± 13</td><td class="colsep0 rowsep0" align="left">12 564 ± 5945</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>85</b></td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">CPh</td><td class="colsep0 rowsep0" align="left">OH</td><td class="colsep0 rowsep0" align="left">136 ± 36</td><td class="colsep0 rowsep0" align="left">650 ± 209</td><td class="colsep0 rowsep0" align="left">146 ± 32</td><td class="colsep0 rowsep0" align="left">10 721 ± 1267</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>48</b></td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">OH</td><td class="colsep0 rowsep0" align="left">416 ± 244</td><td class="colsep0 rowsep0" align="left">4626 ± 2359</td><td class="colsep0 rowsep0" align="left">105 ± 16</td><td class="colsep0 rowsep0" align="left">>20 000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">gefitinib</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">29 ± 13</td><td class="colsep0 rowsep0" align="left">6746 ± 1205</td><td class="colsep0 rowsep0" align="left">26 ± 6</td><td class="colsep0 rowsep0" align="left">18 755 ± 2778</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">afatinib</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">14 ± 6</td><td class="colsep0 rowsep0" align="left">22 ± 7</td><td class="colsep0 rowsep0" align="left">14 ± 4</td><td class="colsep0 rowsep0" align="left">224 ± 58</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> and CC<sub>50</sub> data are expressed as the mean of at least three independent determinations, presented as mean ± SD.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">The IC<sub>50</sub> value was defined as the amount of compound that induced a 50% inhibition in enzyme activity in comparison with DMSO-treated controls.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">The CC<sub>50</sub> value was defined as the amount of compound that caused 50% reduction in cell viability in comparison with DMSO-treated controls.</p></div></div></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. SAR Investigation of Michael Acceptors and Side-Chain Chirality<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/medium/jm9b00722_0013.gif" alt="" id="GRAPHIC-d7e1280-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/medium/jm9b00722_0014.gif" alt="" id="gr12" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> and CC<sub>50</sub> data are expressed as the mean of at least three independent determinations, presented as mean ± SD.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">The IC<sub>50</sub> value was defined as the amount of compound that induced a 50% inhibition in enzyme activity in comparison with DMSO-treated controls.</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">The CC<sub>50</sub> value was defined as the amount of compound that caused 50% reduction in cell viability in comparison with DMSO-treated controls.</p></div></div><div></div></div><div class="NLM_p">In order to understand how the EGFR inhibitory activity was affected by the compound structure, a preliminary SAR study was performed. Removal of the hydroxyl group from the 2-phenylglycinol fragment of <b>2</b> significantly decreased EGFR<sup>WT</sup> and EGFR<sup>L858R/T790M</sup> activity by over 6-fold and 18-fold, respectively (cf. <b>2</b> vs <b>70</b>). This result is in good agreement with our SBDD analysis and indicates that the hydroxyl group (forming a H-bond with Asp855) plays an important role in maintaining a potent activity against both WT and double mutant EGFR kinases.</div><div class="NLM_p">Replacement of the phenyl group in the 6-position of the furanopyrimidine scaffold with H and Me led to a significantly reduced inhibition of EGFR<sup>WT</sup> and EGFR<sup>L858R/T790M</sup> (cf. <b>2</b> vs <b>42</b> and <b>43</b>). These results indicate that the sigma–pi interactions formed by the phenyl group at the 6-position are essential for EGFR inhibition, especially of EGFR<sup>L858R/T790M</sup>. Compounds <b>2</b> and <b>42</b> were then used by the docking method to illustrate the binding interaction in the EGFR double mutation X-ray structure (PDBID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CAS">5CAS</a>). As shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A, the binding mode of compound <b>42</b> was twisted and induced a steric clash with Met790 as well as influenced on the Michael acceptor binding, which is a crucial factor that compound <b>42</b> lost the activity of EGFR<sup>L858R/T790M</sup>. Furthermore, the introduction of the <i>ortho</i>-methoxy group on the 6-phenyl moiety caused a 6-fold loss of EGFR<sup>L858R/T790M</sup> inhibitory activity likely because of the steric hindrance between two phenyl rings at 5- and 6-position. It can be concluded from these observations that the 6-phenyl ring lies perpendicular to the 5-phenyl, and that the right positioning of the acrylamide relative to the thiol of Cys797 is crucial for covalent bond formation. High EGFR<sup>L858R/T790M</sup> inhibition activity can be achieved when the acrylamide moiety points to the Cys797 in the protein-binding pocket.</div><figure id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/medium/jm9b00722_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/large/jm9b00722_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Characterization of inhibitor-binding modes: (A) the binding mode of compound <b>2</b> (pink) overlaid with <b>42</b> (green) in EGFR<sup>L858R/T790M</sup> protein (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CAS">5CAS</a>); (B) EGFR<sup>WT</sup> protein–inhibitor interactions for compound <b>74</b> (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JQ7">4JQ7</a>); (C) EGFR<sup>WT</sup> protein–inhibitor interactions for compound <b>77</b> (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JQ7">4JQ7</a>); (D) EGFR<sup>L858R/T790M</sup> protein–inhibitor interactions for compound <b>74</b> (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CAS">5CAS</a>); (E) EGFR<sup>L858R/T790M</sup> protein–inhibitor interactions for compound <b>77</b> (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CAS">5CAS</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/large/jm9b00722_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00722&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Furthermore, we conducted a scaffold-hopping strategy by replacing the furanopyrimidine with thieno[2,3-<i>d</i>]pyrimidine and isoxazolo[5,4-<i>d</i>]pyrimidine to obtain <b>44–46</b>, <b>48</b>, and <b>85</b>. Although these compounds maintained submicromolar IC<sub>50</sub> and CC<sub>50</sub> against EGFR<sup>WT</sup> kinase inhibition and HCC827 cell proliferation, their inhibitory activity for EGFR<sup>L858R/T790M</sup> was greatly reduced (<b>44–46</b>, <b>48</b>, and <b>85</b>; EGFR<sup>L858R/T790M</sup> IC<sub>50</sub> = 650–4626 nM). It is thus concluded that furanopyrimidine along with two phenyl rings at 5 and 6-positions is a promising scaffold on which to conduct further SAR studies in order to identify potential EGFR clinical candidates.</div><div class="NLM_p">Next, we explored the possibility of attaching a variety of Michael acceptors to the 5-phenyl group of the furanopyrimidine core (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). At first, we attempted to replace the acrylamide group with butynamide and vinyl sulfonamide. The butynamide <b>71</b> inhibited EGFR in a concentration range very similar to that of gefitinib, while the vinyl sulfonamide <b>72</b> drastically reduced the kinase activities of WT and double mutant. The acrylamide group was thus concluded to be an appropriate Michael acceptor to have in the optimized molecule.</div><div class="NLM_p last">A series of functional groups were introduced into C═C in order to improve cellular activity, including hydrophobic groups (alkyl and phenyl groups) and hydrophilic groups (acid, ester, amine, and alcohol). Molecule extension with various hydrophobic groups at the terminal double bond resulted in a loss of potency against WT and double mutant kinases, respectively (cf. <b>2</b> vs <b>73–75</b>). To explain the poor activities of compounds <b>73–76</b>, we applied the covalent docking strategy for compound <b>74</b> with the EGFR wild-type X-ray (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JQ7">4JQ7</a>) and double mutation X-ray (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CAS">5CAS</a>) as representatives. In both of binding mode analysis, the isopropyl group in terminal double bond of compound <b>74</b> has a steric clash with the Asp800 of WT and double mutation proteins, which may give an explanation why introduction of hydrophobic alkyl or phenyl group lost their inhibition activities (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B,D). However, attachment of carboxylic acid ethyl ester to Michael acceptor led to compound <b>77</b>, displaying moderate inhibition in EGFR assays. According to its binding modes with EGFR<sup>WT</sup> and EGFR<sup>L858R/T790M</sup>, the ethyl ester group of <b>77</b> evaded a steric clash from Asp800 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>C,E). In T790M and L858R mutation proteins, the modeling exhibited an extra strong hydrogen bond interaction with the Cys797 backbone NH and two hydrogen bonds with Asn842 and Arg855 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>E). By contrast, introduction of −CO<sub>2</sub>H lost its bioactivities because of electronic repulsion with −CO<sub>2</sub>H of Asp800 (i.e., <b>76</b>). Moreover, extension with di-substituted amino groups at the terminal double bond (i.e., <b>78–81</b>) maintained EGFR activities (i.e., <b>78–81</b>). It is noteworthy that di-substituted amino functionalities are well tolerated for the activity against HCC827 cells (<b>78–81</b>, CC<sub>50</sub> = 17–62 nM). When the size of the alkyl substituent of amino group increased, inhibition of EGFR<sup>L858R/T790M</sup> slightly decreased (cf. <b>78</b> vs <b>79–81</b>), but inhibition of EGFR<sup>WT</sup> remained comparable to that by lead compound <b>2</b>. Based on the X-ray structure of EGFR proteins, Asp800 is adjacent to Cys797 in the binding pocket.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Incorporating a nitrogen containing a basic group onto the acrylamide β-position may form a plausible ionic interaction between the protonated nitrogen of amino side chain and the acid residue of Asp800, which improved the recognition of compound <b>78–81</b> in the active site.<a onclick="showRef(event, 'ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref42 ref43">(42,43)</a> It may also assist the nucleophilic attack at the Michael acceptor by Cys797.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Among all the new EGFR inhibitors synthesized, dimethylamino compound <b>78</b> showed the highest inhibitory activity against HCC827 (CC<sub>50</sub> = 25 nM) and H1975 (CC<sub>50</sub> = 620 nM) cell lines. In addition, (<i>R</i>)-enantiomers <b>83</b> and <b>84</b> led to over fivefold lower kinase activity and 10-fold antiproliferative activity compared to the corresponding (<i>S</i>)-isomers (cf. <b>2</b> vs <b>83</b> and <b>78</b> vs <b>84</b>), respectively (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). These results indicated that the (<i>S</i>) configuration of 2-phenylglycinol side chain is essential for the EGFR activities. Compound <b>78</b> with an acrylamide moiety possesses the irreversible kinase inhibitor character, which showed potent activity against EGFR<sup>L858R/T790M</sup> similar to afatinib. However, further toxicity study and antitumor efficacy of <b>78</b> in in vivo experiments are evaluated in the following section.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Biological Evaluation of EGFR and HER2 Exon 20 Insertion Mutations</h3><div class="NLM_p">Amino acid deletions of exon 19 and the exon 21 L858R point mutation are most common EGFR mutations and considered as the classic activating mutations in NSCLC.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Patients with classic mutations are highly responsive to first and second-line standard EGFR TKI therapy, including erlotinib, gefitinib, afatinib, and osimertinib.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Highly heterogeneous exon 20 insertions are the third most prevalent nonclassic EGFR activating mutations and accounted for approximately 4–10% of all EGFR mutations.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Response rates of patients with exon 20 insertions to standard EGFR-targeted therapy are generally poor compared with classic mutations.<a onclick="showRef(event, 'ref45 ref46 ref47'); return false;" href="javascript:void(0);" class="ref ref45 ref46 ref47">(45−47)</a> Oncogenic function of HER2 mutations and overexpression play an important role in various cancer types. In particular, HER2 exon 20 insertions are found in 1–3% of NSCLC patients.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Currently, no EGFR- or HER2-directed therapies are approved specifically for the treatment of both mutations. Two investigational drugs, poziotinib and TAK-788, are undergoing phase II (NCT03066206) and phase I/II clinical trial (NCT02716116), respectively.<a onclick="showRef(event, 'ref49 ref50'); return false;" href="javascript:void(0);" class="ref ref49 ref50">(49,50)</a> Recent trial data displayed that poziotinib achieved 64% of ORR in EGFR and HER2 exon 20 mutant NSCLC (NCT03066206).<a onclick="showRef(event, 'ref51 ref52'); return false;" href="javascript:void(0);" class="ref ref51 ref52">(51,52)</a> Herein, we selected four compounds (<b>70</b>, <b>78</b>, <b>82</b>, <b>85</b>) to examine their inhibitory activities against three types of EGFR and one type of HER2 exon 20 insertion enzymatic assays along with pozitotinib and osimertinib as references. These compounds were also evaluated for their inhibitory activity in A431 cell line (expressing EGFR<sup>WT</sup>). As seen in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>, among of three furanopyrimidines (<b>70</b>, <b>78</b>, <b>82</b>), <b>78</b> exhibited equal potency compared with poziotinib and 7–25 folds more potent than osimertinib in both EGFR and HER2 exon 20 insertion assays.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> Moreover, <b>78</b> showed 33-fold weaker inhibition than poziotinib against A431 cells and similar inhibition to osimertinib that spares WT EGFR. The results indicated that <b>78</b> exhibited potentially higher therapeutic window than poziotinib. Furanopyrimidines <b>70</b> and <b>82</b> possessed moderate activities against three EGFR exon 20 insertion enzymes but almost lost activity against HER2 exon 20 insertion enzyme. More interestingly, thienopyrimidine <b>85</b> dramatically decreased its inhibition in both exon 20 insertion assays, which indicated that oxygen-containing scaffold <b>78</b> is much tighter binding to exon 20 insertion enzymes than thiol-containing scaffold <b>85</b>.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Inhibition of EGFR and HER2 Exon 20 Insertions Assays and A431 Cellular Assay<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a><sup>,</sup><a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">EGFR exon 20 insertions IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" align="center" char=".">HER2 exon 20 insertion IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char=".">EGFR<sup>A763_Y764insFHEA</sup></th><th class="colsep0 rowsep0" align="center" char=".">EGFR<sup>D770GY</sup></th><th class="colsep0 rowsep0" align="center" char=".">EGFR<sup>D770_N771insNPG</sup></th><th class="colsep0 rowsep0" align="center" char=".">HER2<sup>V777_G778insCG</sup></th><th class="colsep0 rowsep0" align="center">A431 CC<sub>50</sub> (nM)<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>70</b></td><td class="colsep0 rowsep0" align="char" char=".">0.214</td><td class="colsep0 rowsep0" align="char" char=".">0.641</td><td class="colsep0 rowsep0" align="char" char=".">1.48</td><td class="colsep0 rowsep0" align="char" char=".">8.13</td><td class="colsep0 rowsep0" align="left">449</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>78</b></td><td class="colsep0 rowsep0" align="char" char=".">0.043</td><td class="colsep0 rowsep0" align="char" char=".">0.033</td><td class="colsep0 rowsep0" align="char" char=".">0.133</td><td class="colsep0 rowsep0" align="char" char=".">0.203</td><td class="colsep0 rowsep0" align="left">1020</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>82</b></td><td class="colsep0 rowsep0" align="char" char=".">0.145</td><td class="colsep0 rowsep0" align="char" char=".">0.295</td><td class="colsep0 rowsep0" align="char" char=".">0.636</td><td class="colsep0 rowsep0" align="char" char=".">5.20</td><td class="colsep0 rowsep0" align="left">>8010</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>85</b></td><td class="colsep0 rowsep0" align="char" char=".">1.15</td><td class="colsep0 rowsep0" align="char" char=".">4.82</td><td class="colsep0 rowsep0" align="char" char=".">17.8</td><td class="colsep0 rowsep0" align="char" char=".">369</td><td class="colsep0 rowsep0" align="left">>20 000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">poziotinib</td><td class="colsep0 rowsep0" align="char" char=".">0.078</td><td class="colsep0 rowsep0" align="char" char=".">0.082</td><td class="colsep0 rowsep0" align="char" char=".">0.218</td><td class="colsep0 rowsep0" align="char" char=".">0.206</td><td class="colsep0 rowsep0" align="left">31</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">osimertinib</td><td class="colsep0 rowsep0" align="char" char=".">0.421</td><td class="colsep0 rowsep0" align="char" char=".">0.858</td><td class="colsep0 rowsep0" align="char" char=".">0.950</td><td class="colsep0 rowsep0" align="char" char=".">3.31</td><td class="colsep0 rowsep0" align="left">967</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">The IC<sub>50</sub> value was defined as the amount of compound that induced a 50% inhibition in the enzyme activity in comparison with DMSO-treated controls; compounds were tested in 10-dose IC<sub>50</sub> mode with fourfold serial dilution starting at 5 μM. Also, control compound, staurosporine, was tested in 10-dose IC<sub>50</sub> mode with fourfold serial dilution starting at 20 μM.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">In cell-based assay, compounds were tested in 9-dose CC<sub>50</sub> mode with fourfold serial dilution starting at 20 μM; the CC<sub>50</sub> data are expressed as the mean of at least three independent determinations.</p></div></div></div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> X-ray Cocrystal Study of WT EGFR Kinase in the Complex with <b>78</b></h3><div class="NLM_p">EGFR crystals were soaked in compound <b>78</b>, and the resulting EGFR/<b>78</b> complex crystal structure was resolved to 2.86 Å. The electron density map clearly showed that <b>78</b> formed a covalent bond with Cys797 in the ATP-binding site through the Michael acceptor (enone) (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). The (<i>S</i>)-2-phenylglycinol fragment of <b>78</b> occupied the region around the gatekeeper and formed hydrophobic interactions with Thr790, Lys745, and Met766 (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). The hydroxyl group of <b>78</b> formed hydrogen bonds with Asp855 on the DFG motif. The pyrimidine core structure aligned with the hinge region and formed hydrophobic interactions with Leu718 in the starting site of P-loop and also with Ala743, Thr790, and Leu844. Two separated phenyl rings extended from the furanopyrimidine core are perpendicular to each other. The 6-phenyl group on the same plane as the pyrimidine core formed hydrophobic interactions with Leu844, while the perpendicular 5-phenyl ring formed hydrophobic interactions with Val726 on the β-sheet. The Michael acceptor linked to this perpendicular 5-phenyl ring formed the important covalent bond with residue Cys797. This Michael addition was close to the acidic residue Asp800.</div><figure id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/medium/jm9b00722_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/large/jm9b00722_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Crystal structure of EGFR in the complex with <b>78</b> (yellow). For clarity, M766 (on αC helix) and P-loop were omitted in the figure (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6JZ0">6JZ0</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/large/jm9b00722_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00722&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Moreover, the conserved DFG motif and His-Arg-Asp (HRD) triad motif of protein kinase play a major role in the regulation of kinase activity.<a onclick="showRef(event, 'ref54 ref55 ref56'); return false;" href="javascript:void(0);" class="ref ref54 ref55 ref56">(54−56)</a> In the EGFR/<b>78</b> complex crystal structure, a unique hydrogen bond network was observed between the hydroxyl group of the (<i>S</i>)-2-phenylglycinol fragment of <b>78</b> and the DFG and HRD motifs in the activation loop of EGFR (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). The hydroxyl group formed hydrogen bonds with Asp855 of the DFG motif and to the HRD motif via Asp855 and Asn842. While the hydrogen bond interactions are absent by the removed hydroxyl group from the (<i>S</i>)-2-phenylglycinol moiety, the inhibitory activity decreased significantly (cf. <b>70</b> vs <b>78</b> and <b>2</b>). The hydrogen bond network interactions between <b>78</b> and the DFG and HRD motif greatly contribute to its potency. Altogether, compound <b>78</b> occupied the ATP-binding site and interacted with surrounding residues by covalent bonding, hydrogen bonds, and hydrophobic interactions, which gave it a potent inhibitory activity against WT EGFR.</div><figure id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/medium/jm9b00722_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/large/jm9b00722_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Compound <b>78</b> (yellow) forms a hydrogen bond network with the DFG (pink) and HRD motifs (magenta) in the activation loop through the hydroxyl group of the (<i>S</i>)-2-phenylglycinol fragment. The distances between <b>78</b> and EGFR kinase domain were labeled (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6JZ0">6JZ0</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/large/jm9b00722_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00722&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Pharmacokinetic Study</h3><div class="NLM_p">We carried out pharmacokinetic (PK) evaluations of compounds <b>2</b> and <b>78</b> in rats. We found that <b>78</b> showed a much better PK profile than compound <b>2</b> (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Moreover, when administered by IV injection, <b>78</b> exhibited a lower clearance and volume distribution, as well as 50% higher AUC than the approved irreversible-binding drug, afatinib. When administered orally (P.O.), <b>78</b> displayed an approximately 4-fold higher AUC than afatinib and around 41.5% oral bioavailability.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. PK Profile of Compound <b>2</b>, <b>78</b>, and Afatinib in Rats</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center" char=".">I.V. (5 mg/kg)</th><th class="rowsep1 colsep0" colspan="5" align="center" char=".">P.O. (20 mg/kg)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char="."><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char=".">CL (mL/min/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>V</i><sub>ss</sub> (l/kg)</th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub>(0–inf)</sub> (ng/mL h)</th><th class="colsep0 rowsep0" align="center" char="."><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub> (ng/mL)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>max</sub> (h)</th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub>(0–inf)</sub> (ng/mL h)</th><th class="colsep0 rowsep0" align="center" char="."><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="char" char=".">0.5</td><td class="colsep0 rowsep0" align="char" char=".">76.5</td><td class="colsep0 rowsep0" align="char" char=".">2.3</td><td class="colsep0 rowsep0" align="char" char=".">1096</td><td class="colsep0 rowsep0" align="char" char=".">0.9</td><td class="colsep0 rowsep0" align="char" char=".">193</td><td class="colsep0 rowsep0" align="char" char=".">1.2</td><td class="colsep0 rowsep0" align="char" char=".">303</td><td class="colsep0 rowsep0" align="char" char=".">5.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>78</b><a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char=".">2.3</td><td class="colsep0 rowsep0" align="char" char=".">55.6</td><td class="colsep0 rowsep0" align="char" char=".">8.6</td><td class="colsep0 rowsep0" align="char" char=".">1520</td><td class="colsep0 rowsep0" align="char" char=".">3.4</td><td class="colsep0 rowsep0" align="char" char=".">508</td><td class="colsep0 rowsep0" align="char" char=".">3.3</td><td class="colsep0 rowsep0" align="char" char=".">2978</td><td class="colsep0 rowsep0" align="char" char=".">41.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">afatinib</td><td class="colsep0 rowsep0" align="char" char=".">5.7</td><td class="colsep0 rowsep0" align="char" char=".">79.2</td><td class="colsep0 rowsep0" align="char" char=".">28.7</td><td class="colsep0 rowsep0" align="char" char=".">1063</td><td class="colsep0 rowsep0" align="char" char=".">6</td><td class="colsep0 rowsep0" align="char" char=".">75.2</td><td class="colsep0 rowsep0" align="char" char=".">4.2</td><td class="colsep0 rowsep0" align="char" char=".">676</td><td class="colsep0 rowsep0" align="char" char=".">15.9</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">5 mg/kg for I.V. injection and 23.6 mg/kg for P.O. administration.</p></div></div></div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Western Blotting Analysis</h3><div class="NLM_p">In order to probe the full potential of <b>78</b>, we evaluated its ability to interfere with EGFR signaling inside the cell by western blotting. To this end, HCC827 and H1975 cells were treated with different doses of <b>78</b> and then were analyzed for EGFR autophosphorylation (pEGFR at residue Tyr1068). As shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A, <b>78</b> showed a similar inhibitory level of EGFR autophosphorylation compared to gefitinib in HCC827 cells. In <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B, it is observed that <b>78</b> induced reduction of phosphorylated EGFR in a dose-dependent manner in H1975 cells. The western blotting results were consistent with two cell-based growth inhibition data, which are showed in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>.</div><figure id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/medium/jm9b00722_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/large/jm9b00722_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Western blot analysis: (A) by using antiphospho-EGFR Y1068 and anti-EGFR immunoblots of HCC827 cell lysates treated with <b>78</b> and gefitinib; (B) by using antiphospho-EGFR Y1068 and anti-EGFR immunoblots of H1975 cell lysates treated with <b>78</b> and afatinib.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/large/jm9b00722_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00722&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Kinase Profiling</h3><div class="NLM_p">To examine the specificity of the highly promising compound <b>78</b>, we subjected it to kinase profiling using the KINOME<i>scan</i> technology against a panel of 456 kinases (containing 395 non-mutant kinases) at a concentration of 10 000 nM (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). EGFR<sup>WT</sup> and all EGFR mutants were potently inhibited by <b>78</b> (0–7.6% of control value at 10 000 nM). Because of the irreversible inhibition it causes, <b>78</b> also exhibited high affinity against kinases bearing a cysteine structurally analogous to Cys797 in EGFR, such as BLK (0.25%), BMX (4.8%), BTK (3%), ERBB2 (0%), ERBB4 (0.05%), JAK3 (0%), and TEC (5.6%). Moreover, other off-target kinases showing apparent binding included LOK, SLK, and TXK (<10% of control value). The selectivity score is a quantitative measure of compound selectivity, and it is defined as <i>S</i>(10) = (number of non-mutant kinases with <10% control value inhibition)/(number of non-mutant kinases tested). The <i>S</i>(10) selectivity score, calculated using <10% of control as potency threshold at a concentration of 10 000 nM, was determined to be 0.028 (11/395). These results overall indicated that <b>78</b> has a high selectivity and low off-target effects, suggesting a safety index suitable for further development.</div><figure id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/medium/jm9b00722_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/large/jm9b00722_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Kinase profiling of <b>78</b> using the KINOMEScan technology.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/large/jm9b00722_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00722&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Toxicity and Efficacy in Vivo of Compound <b>78</b></h3><div class="NLM_p">First of all, we evaluated acute toxicity of <b>78</b> by orally treating <b>78</b> into ICR mice at a dose of 100 mg/kg once a day (QD) for 2 weeks. Afatinib (100 mg/kg) was also examined at the same dosing schedule for comparison. Mice treated with afatinib were observed with severe fur loss in the nose and abdomen and skin rash, but no apparent changes were observed for the group treated with <b>78</b>. It is indicated that furanopyrimidine <b>78</b> possessed lower off-target effects and higher dose tolerance than afatinib.</div><div class="NLM_p">The compound profile of <b>78</b> encouraged us to assess its in vivo anticancer activity in EGFR mutant NSCLC models. HCC827 and H1975 xenograft models were developed by inoculating nude mice subcutaneously with the corresponding cancer cells. In the HCC827 tumor model, mice were treated with oral administration of <b>78</b> for 5 days/week for 2 consecutive weeks (days 1–5 and 8–12). At dosages of 20 and 50 mg/kg of <b>78</b>, tumor growth was significantly reduced (<i>p</i> < 0.05), demonstrating the potent in vivo anticancer activity of <b>78</b> (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). No significant differences in body weight change or other adverse effects were observed upon treatment with compound <b>78</b>. Administration of the reference compound gefitinib (20 mg/kg) and afatinib (20 mg/kg) by the perioral route using the same schedule also shrank the tumor significantly (<i>p</i> < 0.05). Approximately 5% body weight loss was observed in afatinib-treated mice.</div><figure id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/medium/jm9b00722_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/large/jm9b00722_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (A) In vivo antitumor efficacy of gefitinib, afatinib, and <b>78</b> in the HCC827 xenograft mouse model. (B) Body weight change (%) of the mice in the HCC827 xenograft mouse model.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/large/jm9b00722_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00722&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In the H1975 tumor model, the in vivo efficacy was evaluated through oral administration of afatinib (15 mg/kg) and <b>78</b> (50 mg/kg) QD for 15 days, respectively (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). The mean tumor size of the vehicle control group reached 2044 mm<sup>3</sup> on day 22 after tumor inoculation. Treatment with afatinib at 15 mg/kg had a significant antitumor effect compared with the control group, suppressing tumor growth by 65%. Treatment with <b>78</b> only at 50 mg/kg also had a significant antitumor effect (mean tumor growth inhibition of 34%, range: 22–48%). The test compound <b>78</b> and afatinib were tolerated well by the tumor-bearing mice at 50 and 15 mg/kg, respectively, and no severe body weight loss was observed during the studies.<named-content content-type="anchor" rid="tbl5" type="simple"></named-content></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78785" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78785" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Over the past years, we developed a focused library of furanopyrimidines, which was rapidly synthesized using a variety of primary and secondary amines as nucleophiles in parallel reactors and in situ screened for EGFR kinase inhibitory activity to identify an initial hit (<b>1</b>). Very interestingly, the initial hit (<b>1</b>) possesses an (<i>S</i>)-2-phenylglycinol functional group on the furanopyrimidine core as the key fragment for its bioactivity. Through hit-to-lead optimization, introduction of an acrylamide into the meta-position of the phenyl group in the 5-position of the furanopyrimidine core led to lead compound <b>2</b>, which showed enhanced potency in both enzymatic and cellular assays. However, lead <b>2</b> exhibited a poor PK profile and moderate inhibition of H1975 cell line. To improve these properties in this work, we have designed and synthesized a series of fused pyrimidine analogues using a scaffold-hopping strategy and a SBDD through lead-to-candidate optimization. In particular, compound <b>78</b>, which bears a <i>N</i>,<i>N</i>-dimethylamino group on the terminal double bond of acrylamide, showed a twofold improvement in the H1975 activity compared to lead <b>2</b>, while maintaining its inhibitory activity against HCC827 cells. Moreover, <b>78</b> showed fourfold oral AUC better that afatinib along with <i>F</i> = 41.5% and exhibited excellent antitumor efficacy in both HCC827 and H1975 xenograft mouse models with minimal toxicity. Although compound <b>78</b> belongs to second-generation EGFR-TKIs similar to afatinib and dacomitinib, most interestingly, we identified that furanopyrimidine <b>78</b> exhibited comparable potency to poziotinib, but 10-fold potency better than third generation inhibitor, osimertinib, against three EGFR and one HER2 exon 20 insertion mutations, because there are currently no EGFR-directed therapies approved specifically for the treatment of both mutations. The outcome represents that compound <b>78</b> is a potential new efficacious drug candidate in many cancers with EGFR or HER2 exon 20 mutations. X-ray cocrystal study of EGFR<sup>WT</sup> kinase and compound <b>78</b> revealed the potential of future design for mutant-selective inhibitors. Finally, clinical candidate <b>78</b> conducted all preclinical experiments and is currently undergoing phase 1 clinical trial (NCT03246854) in Taiwan.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63248" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63248" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> General Methods for Chemistry</h3><div class="NLM_p">All commercial chemicals and solvents are of reagent grade and were used without further purification unless otherwise stated. All reactions were carried out under a dry nitrogen atmosphere and were monitored for completion by thin-layer chromatography using Merck 60 F<sub>254</sub> silica gel glass-backed plates (5 × 10 cm); zones were detected visually under UV irradiation (254 nm) or by spraying with the phosphomolybdic acid reagent (Aldrich) followed by heating at 80 °C. Flash column chromatography was carried out using silica gel (Merck Kieselgel 60, no. 9385, 230–400 mesh ASTM). <sup>1</sup>H and <sup>13</sup>C NMR spectra were obtained with Varian Mercury-300, Varian Mercury-400, or Bruker DMX-600 spectrometers, and the chemical shifts were recorded in parts per million (ppm, δ) and reported relative to tetramethylsilane or the solvent peak. Low-resolution mass spectra were obtained with an Agilent MSD-1100 ESI-MS/MS system. High-resolution mass spectra (HRMS) were measured with a VARIAN 901-MS mass spectrometer. Purity of the final compounds was determined with a Hitachi 2000 series HPLC system using C-18 column (Agilent ZORBAX Eclipse XDB-C18 5 μm. 4.6 mm × 150 mm) operating at 25 °C. For method A, elution was carried out using acetonitrile as mobile phase A, and water containing 0.1% formic acid + 10 mmol NH<sub>4</sub>OAc as mobile phase B. Elution conditions: at 0 min, phase A 10% + phase B 90%; at 45 min, phase A 90% + phase B 10%; at 50 min, phase A 10% + phase B 90%; at 60 min, phase A 10% + phase B 90%. For method B, elution was carried out using acetonitrile as mobile phase A, and water containing 0.1% formic acid + 2 mmol NH<sub>4</sub>OAc as mobile phase B. Elution conditions: at 0 min, phase A 10% + phase B 90%; at 25 min, phase A 90% + phase B 10%; at 30 min, phase A 90% + phase B 10%; at 30.5 min, phase A 10% + phase B 90%; at 37 min, phase A 10% + phase B 90%. The flow-rate of the mobile phase was 0.5 mL/min, and the injection volume of the sample was 10 or 20 μL. Peaks were detected at 254 nm. The purity of all tested compounds was determined and confirmed to be greater than 95% by HPLC analysis except for compound <b>45</b> (93.5%), <b>71</b> (92.3%), <b>72</b> (90.8%), <b>74</b> (93.9%), <b>76</b> (93.6%), <b>82</b> (94.3%), and <b>83</b> (92.4%). IUPAC nomenclature of compounds was obtained with the software ACD/Name Pro. A JASCO P-1020 polarimeter with a sodium lamp was used for the determination of specific rotations at 25 °C. Melting points were obtained with an Electrothermal 9100 melting point apparatus.</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> <i>N</i>-[3-(4-{[(1<i>S</i>)-2-Hydroxy-1-phenylethyl]amino}furo[2,3-<i>d</i>]pyrimidin-5-yl)phenyl]prop-2-enamide (<b>42</b>)</h4><div class="NLM_p last">A solution of <b>36</b> (48 mg, 0.14 mmol), acrylic acid (12 mg, 0.17 mmol), and EDCI·HCl (31 mg, 0.17 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (2 mL) was stirred at 0 °C for 1 h. The solution was quenched by water and extracted with dichloromethane. The organic layers were dried over MgSO<sub>4(s)</sub> and concentrated to give a residue. The residue was purified by preparative layer chromatography (ethyl acetate/hexanes = 2:1) to give the product <b>42</b> (21 mg, 38%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.24 (s, 1H), 8.04 (s, 1H), 7.65 (d, <i>J</i> = 8.1 Hz, 1H), 7.50–7.30 (m, 7H), 7.01 (s, 1H), 6.46–6.39 (m, 2H), 5.80 (dd, <i>J</i> = 9.6, 1.8 Hz, 1H), 5.38 (br s, 1H), 4.04–3.98 (m, 2H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub> + CD<sub>3</sub>OD): δ 165.8, 164.8, 157.4, 153.2, 139.1, 139.0, 137.7, 131.2, 130.5, 129.8, 128.2, 127.6, 127.2, 126.2, 124.0, 120.7, 120.0, 119.7, 100.2, 65.4, 56.7; LC–MS (ESI) <i>m</i>/<i>z</i>: 401.0 [M + H]<sup>+</sup>; HRMS (ESI) calcd for C<sub>23</sub>H<sub>20</sub>N<sub>4</sub>O<sub>3</sub>Na, 423.1433 [M + Na]<sup>+</sup>; found, 423.1442; HPLC purity (method B): 97.7%, <i>t</i><sub>R</sub> = 19.31 min.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> <i>N</i>-[3-(4-{[(1<i>S</i>)-2-Hydroxy-1-phenylethyl]amino}-6-methylfuro[2,3-<i>d</i>]pyrimidin-5-yl)phenyl]prop-2-enamide (<b>43</b>)</h4><div class="NLM_p last">Compound <b>43</b> was prepared from acrylic acid and <b>37</b>, similarly to <b>42</b>. After work-up, the residue was purified by preparative layer chromatography (methanol/CH<sub>2</sub>Cl<sub>2</sub> = 1:19) to give the product <b>43</b> (3.3 mg, 57%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.34 (br s, 1H, NH), 8.21 (s, 1H), 7.98 (s, 1H), 7.69 (d, <i>J</i> = 8.1 Hz, 1H), 7.53 (dd, <i>J</i> = 8.1, 7.5 Hz, 1H), 7.26–7.17 (m, 6H), 6.47 (dd, <i>J</i> = 17.1, 9.9 Hz, 1H), 6.30 (dd, <i>J</i> = 17.1, 1.8 Hz, 1H), 5.92 (d, <i>J</i> = 7.5 Hz, 1H, NH), 5.80 (dd, <i>J</i> = 9.9, 1.8 Hz, 1H), 5.25–5.21 (m, 1H), 4.87 (t, <i>J</i> = 4.8 Hz, 1H, OH), 3.66–3.61 (m, 1H), 3.54–3.47 (m, 1H), 2.43 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub> + CD<sub>3</sub>OD): δ 164.7, 164.6, 156.6, 152.5 148.2, 139.2, 138.9, 132.1, 130.7, 129.8, 128.5, 127.9, 127.4, 126.2, 125.2, 120.8, 119.8, 114.7, 101.8, 66.3, 56.9, 11.9; LC–MS (ESI) <i>m</i>/<i>z</i>: 415.1 [M + H]<sup>+</sup>; HRMS (ESI) calcd for C<sub>24</sub>H<sub>23</sub>N<sub>4</sub>O<sub>3</sub>, 415.1770 [M + H]<sup>+</sup>; found, 415.1772; HPLC purity (method B): 98.7%, <i>t</i><sub>R</sub> = 19.91 min.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> <i>N</i>-[3-(4-{[(1<i>S</i>)-2-Hydroxy-1-phenylethyl]amino}thieno[2,3-<i>d</i>]pyrimidin-5-yl)phenyl]prop-2-enamide (<b>44</b>)</h4><div class="NLM_p last">To a solution of <b>38</b> (16.3 mg, 0.045 mmol) and pyridine (5.5 μL, 0.067 mmol) in diethyl ether (5 mL) was added acryloyl chloride (5.5 μL, 0.067 mmol) at 0 °C in one portion. The reaction mixture was stirred at room temperature overnight. The solution was quenched by water and extracted with ethyl acetate. The combined organic layers were dried over MgSO<sub>4(s)</sub> and concentrated to give a residue. The residue was purified by preparative layer chromatography (methanol/CH<sub>2</sub>Cl<sub>2</sub> = 1:15) to give the product <b>44</b> (4.6 mg, 25%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.39 (s, 1H), 7.79 (d, <i>J</i> = 8.4 Hz, 1H), 7.71 (s, 1H), 7.44 (t, <i>J</i> = 8.0 Hz, 1H), 7.32 (s, 1H), 7.26–7.21 (m, 4H), 7.19 (s, 1H), 7.02 (d, <i>J</i> = 7.6 Hz, 2H), 6.45 (dd, <i>J</i> = 17.2, 1.6 Hz, 1H), 6.32 (dd, <i>J</i> = 17.2, 10.0 Hz, 1H), 5.94 (d, <i>J</i> = 6.8 Hz, 1H), 5.78 (dd, <i>J</i> = 10.0, 1.6 Hz, 1H), 5.32 (br s, 1H), 3.82–3.80 (m, 1H), 3.64–3.59 (m, 1H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub> + CD<sub>3</sub>OD): δ 166.2, 164.6, 157.1, 157.0, 153.3, 138.9, 138.7, 136.3, 134.4, 130.7, 129.8, 128.5, 128.0, 127.5, 126.2, 125.0, 120.7, 114.3, 66.3, 56.7; LC–MS (ESI) <i>m</i>/<i>z</i>: 417.0 [M + H]<sup>+</sup>; HRMS (ESI) calcd for C<sub>23</sub>H<sub>20</sub>N<sub>4</sub>O<sub>2</sub>SNa, 439.1205 [M + Na]<sup>+</sup>; found, 439.1219; HPLC purity (method B): 98.6%, <i>t</i><sub>R</sub> = 19.17 min.</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> <i>N</i>-[3-(6-Chloro-4-{[(1<i>S</i>)-2-hydroxy-1-phenylethyl]amino}thieno[2,3-<i>d</i>]pyrimidin-5-yl)phenyl]prop-2-enamide (<b>45</b>)</h4><div class="NLM_p last">Compound <b>45</b> was prepared from acrylic acid and <b>39</b>, similarly to <b>42</b>. After work-up, the residue was purified by preparative layer chromatography (methanol/CH<sub>2</sub>Cl<sub>2</sub> = 1:30) to give the product <b>45</b> (66 mg, 62%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.41–8.40 (m, 1H), 7.73–7.44 (m, 3H), 7.26–7.22 (m, 4H), 6.97–6.93 (m, 2H), 6.51–6.39 (m, 1H), 6.31–6.09 (m, 1H), 5.86–5.79 (m, 1H), 5.70–5.53 (m, 1H), 5.35–5.17 (m, 1H), 3.84–3.60 (m, 2H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 164.7, 163.6, 163.5, 163.4, 155.9, 153.7, 153.5, 139.1, 139.0, 138.6, 133.5, 133.3, 130.7, 130.4, 130.3, 130.1, 128.8, 128.8, 128.6, 128.3, 127.9, 127.6, 126.5, 126.2, 125.7, 125.6, 125.3, 122.4, 122.1, 120.6, 114.6, 67.4, 66.5, 57.7, 56.5; LC–MS (ESI) <i>m</i>/<i>z</i>: 451.0 [M + H]<sup>+</sup>; HRMS (ESI) calcd for C<sub>23</sub>H<sub>19</sub>ClN<sub>4</sub>O<sub>2</sub>SNa, 473.0815 [M + Na]<sup>+</sup>; found, 473.0809; HPLC purity (method A): 93.5%, <i>t</i><sub>R</sub> = 31.37 min.</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> <i>N</i>-[3-(4-{[(1<i>S</i>)-2-Hydroxy-1-phenylethyl]amino}-6-methylthieno[2,3-<i>d</i>]pyrimidin-5-yl)phenyl]prop-2-enamide (<b>46</b>)</h4><div class="NLM_p last">Compound <b>46</b> was prepared from acrylic acid and <b>40</b>, similarly to <b>42</b>. After work-up, the residue was purified by preparative layer chromatography (methanol/CH<sub>2</sub>Cl<sub>2</sub> = 1:15) to give the product <b>46</b> (97.9 mg, 86%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.39–8.38 (m, 1H), 7.70–7.49 (m, 2H), 7.38–7.34 (m, 1H), 7.24–7.09 (m, 4H), 6.95–6.90 (m, 2H), 6.51–6.38 (m, 1H), 6.31–6.08 (m, 1H), 5.85–5.78 (m, 1H), 5.55–5.39 (m, 1H), 5.30–5.13 (m, 1H), 3.84–3.61 (m, 2H), 2.33 (s, 3H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 164.6, 163.9, 163.8, 163.7, 156.2, 152.6, 152.3, 139.2, 138.8, 138.6, 135.5, 135.4, 133.5, 133.2, 130.9, 130.6, 129.9, 129.5, 129.4, 128.8, 128.6, 128.4, 128.0, 127.9, 127.8, 127.6, 126.2, 125.6, 122.3, 121.2, 120.7, 119.9, 115.6, 67.8, 66.9, 58.0, 56.9, 13.8; LC–MS (ESI) <i>m</i>/<i>z</i>: 431.1 [M + H]<sup>+</sup>; HRMS (ESI) calcd for C<sub>24</sub>H<sub>22</sub>N<sub>4</sub>O<sub>2</sub>SNa, 453.1361 [M + Na]<sup>+</sup>; found, 453.1364; HPLC purity (method B): 97.3%, <i>t</i><sub>R</sub> = 20.13 min.</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> <i>N</i>-[3-(4-{[(1<i>S</i>)-2-{[<i>tert</i>-Butyl(dimethyl)silyl]oxy}-1-phenylethyl]amino}[1,2]oxazolo[5,4-<i>d</i>]pyrimidin-3-yl)phenyl]prop-2-enamide (<b>47</b>)</h4><div class="NLM_p last">Compound <b>47</b> was prepared from acrylic acid and <b>41</b>, similarly to <b>42</b>. After work-up, the residue was purified by preparative layer chromatography (methanol/CH<sub>2</sub>Cl<sub>2</sub> = 1:15) to give the product <b>47</b> (18.1 mg, 78%) as a white solid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.46 (s, 1H), 8.05 (s, 1H), 7.99 (d, <i>J</i> = 8.1 Hz, 1H), 7.58 (dd, <i>J</i> = 8.1, 8.1 Hz, 1H), 7.49–7.46 (m, 1H), 7.35–7.24 (m, 5H), 6.4 (d, <i>J</i> = 7.2 Hz, 1H, NH), 6.48 (dd, <i>J</i> = 16.8, 1.8 Hz, 1H), 6.35 (dd, <i>J</i> = 16.8, 9.9 Hz, 1H), 5.81 (dd, <i>J</i> = 8.8, 1.8 Hz, 1H), 5.46–5.43 (m, 1H), 3.96 (dd, <i>J</i> = 10.5, 4.5 Hz, 1H), 3.83 (dd, <i>J</i> = 10.5, 4.8 Hz, 1H), 0.667 (s, 9H), −0.232 (s, 6H); LC–MS (ESI) <i>m</i>/<i>z</i>: 516 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> <i>N</i>-[3-(4-{[(1<i>S</i>)-2-Hydroxy-1-phenylethyl]amino}[1,2]oxazolo[5,4-<i>d</i>]pyrimidin-3-yl)phenyl]prop-2-enamide (<b>48</b>)</h4><div class="NLM_p last">To a solution of <b>47</b> (18.1 mg, 0.0350 mmol) in tetrahydrofuran (THF, 5.0 mL) was added 1.0 M of TBAF solution in THF (0.350 mL, 0.350 mmol). The reaction mixture was stirred at room temperature for 1 h. The solution was quenched with water and extracted with ethyl acetate. The organic layers were washed with brine, dried over MgSO<sub>4(s)</sub>, filtered, and concentrated to afford a residue. The residue was purified by preparative layer chromatography (methanol/CH<sub>2</sub>Cl<sub>2</sub> = 1:15) to give the product <b>48</b> (13.1 mg, 93%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.46 (s, 1H), 8.22 (s, 1H), 7.74–7.71 (m, 1H), 7.58–7.57 (m, 2H), 7.31–7.22 (m, 5H), 6.47 (dd, <i>J</i> = 17.2, 1.2 Hz, 1H), 6.35 (dd, <i>J</i> = 17.2, 10.0 Hz, 1H), 5.82 (dd, <i>J</i> = 10.0, 1.2 Hz, 1H), 5.61–5.58 (m, 1H), 3.99 (dd, <i>J</i> = 11.8, 3.6 Hz, 1H), 3.86 (dd, <i>J</i> = 11.8, 5.1 Hz, 1H); <sup>13</sup>C NMR (75 MHz, CD<sub>3</sub>OD/CDCl<sub>3</sub>): δ 176.6, 166.3, 159.6, 159.3, 158.7, 141.2, 140.7, 132.1, 131.6, 130.2, 129.5, 128.6, 128.5, 127.9, 125.0, 123.4, 120.8, 96.1, 65.8, 58.4; LC–MS (ESI) <i>m</i>/<i>z</i>: 402.1 [M + H]<sup>+</sup>; HRMS (ESI) calcd for C<sub>22</sub>H<sub>19</sub>N<sub>5</sub>O<sub>3</sub>Na, 424.1386 [M + Na]<sup>+</sup>; found, 424.1383; HPLC purity (method A): 99.7%, <i>t</i><sub>R</sub> = 25.66 min.</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> (2<i>S</i>)-2-[(5-Bromo-6-phenylfuro[2,3-<i>d</i>]pyrimidin-4-yl)amino]-2-phenylethanol (<b>56</b>)</h4><div class="NLM_p last">A solution of 5-bromo-4-chloro-6-phenylfuro[2,3-<i>d</i>]pyrimidine (<b>52</b>,<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> 20 g, 65 mmol), triethyamine (46 mL, 0.33 mol), and (<i>S</i>)-(+)-phenylglycinol (10.6 g, 77.2 mmol) in ethanol (185 mL) was refluxed overnight. The reaction solution was cooled and concentrated, water was added, and then it was extracted with ethyl acetate. The combined organic layers were dried over MgSO<sub>4(s)</sub>, filtered, and concentrated to give the residue. The residue was purified by flash column chromatography (ethyl acetate/hexanes = 1:9) to give the product <b>56</b> (10 g, 37%). [α]<sub class="stack">D</sub><sup class="stack">25</sup> −223.96° (<i>c</i> = 0.25, CH<sub>2</sub>Cl<sub>2</sub>); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.33 (s, 1H), 8.08–8.06 (m, 2H), 7.51–7.30 (m, 8H), 6.89 (d, 1H), 5.50–5.45 (m, 1H), 4.08–4.05 (m, 2H), 3.39 (t, <i>J</i> = 6.0 Hz, 1H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 164.0, 156.8, 154.2, 147.0, 139.1, 129.4, 129.0, 128.7, 128.2, 127.9, 126.5, 126.5, 102.7, 88.8, 67.1, 57.2; LC–MS (ESI) <i>m</i>/<i>z</i>: 410, 412 [M + H]<sup>+</sup>; HRMS (EI) calcd for C<sub>20</sub>H<sub>16</sub>BrN<sub>3</sub>O<sub>2</sub>, 409.0426 [M]<sup>+</sup>; found, 409.0412.</div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> (2<i>S</i>)-2-{[5-(3-Nitrophenyl)-6-phenylfuro[2,3-<i>d</i>]pyrimidin-4-yl]amino}-2-phenylethanol (<b>61</b>)</h4><div class="NLM_p last">To a solution of <b>56</b> (4.60 g, 11.2 mmol) in 1,4-dioxane (10 mL) was added 3-nitrophenylboronic acid (1.87 g, 11.2 mmol), Pd(dppf)<sub>2</sub>Cl<sub>2</sub> (0.90 g, 1.1 mmol), and 2.0 M Na<sub>2</sub>CO<sub>3(aq)</sub> (10 mL, 20 mmol). The reaction was degassed, refilled with argon<sub>(g)</sub>, and stirred at reflux overnight. The mixture was quenched by water and extracted with ethyl acetate. The combined organic layers were dried over MgSO<sub>4(s)</sub>, filtered, and concentrated to give a residue. The residue was purified by flash column chromatography (ethyl acetate/hexane = 1:3) to give the product <b>61</b> (2.14 g, 43%). [α]<sub class="stack">D</sub><sup class="stack">25</sup> −226.92° (<i>c</i> = 0.25, CH<sub>2</sub>Cl<sub>2</sub>); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.41 (s, 1H), 8.40 (s, 1H), 8.32–8.29 (m, 1H), 7.82 (d, <i>J</i> = 7.6 Hz, 1H), 7.65 (t, <i>J</i> = 8.0 Hz, 1H), 7.51–7.48 (m, 2H), 7.33–7.26 (m, 6H), 7.10–7.08 (m, 2H), 5.25–5.20 (m, 2H), 3.86–3.84 (m, 2H), 3.27 (t, <i>J</i> = 5.6 Hz, 1H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 165.1, 156.8, 154.0, 148.8, 138.9, 136.1, 134.1, 130.8, 129.3, 128.9, 128.8, 128.5, 128.1, 126.7, 126.2, 124.5, 123.7, 112.4, 102.9, 67.2, 57.7; LC–MS (ESI) <i>m</i>/<i>z</i>: 453.1 [M + H]<sup>+</sup>; HRMS (EI) calcd for C<sub>26</sub>H<sub>20</sub>N<sub>4</sub>O<sub>4</sub>, 452.1485 [M]<sup>+</sup>; found, 452.1491.</div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> (2<i>S</i>)-2-{[5-(3-Aminophenyl)-6-phenylfuro[2,3-<i>d</i>]pyrimidin-4-yl]amino}-2-phenylethanol (<b>66</b>)</h4><div class="NLM_p last">A solution of <b>61</b> (2.14 g, 4.73 mmol) and iron powder (2.10 g, 37.6 mmol) in ethanol (16 mL), acetic acid (16 mL), and water (8 mL) was stirred at 90 °C for 2 h. The solution was cooled and concentrated to give a residue. The residue was treated with water and extracted with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic layers were dried over MgSO<sub>4(s)</sub>, filtered, and concentrated to obtain a residue. The residue was purified by flash column chromatography (methanol/CH<sub>2</sub>Cl<sub>2</sub> = 1:30, containing 0.10% NH<sub>3(aq)</sub>) to give the product <b>66</b> (1.57 g, 79%). [α]<sub class="stack">D</sub><sup class="stack">25</sup> −185.04° (<i>c</i> = 0.25, CH<sub>2</sub>Cl<sub>2</sub>); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.36 (s, 1H), 7.63 (dd, <i>J</i> = 7.6, 1.6 Hz, 2H), 7.34–7.27 (m, 8H), 7.10–7.07 (m, 2H), 6.76–6.63 (m, 2H), 5.62 (d, <i>J</i> = 5.2 Hz, 1H), 5.26 (td, <i>J</i> = 6.4, 3.6 Hz, 1H), 4.00–3.69 (m, 4H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 164.5, 156.9, 153.1, 147.5, 147.0, 138.8, 132.9, 130.8, 129.3, 128.9, 128.6, 128.5, 127.9, 126.3, 110.5, 115.5, 115.1, 103.7, 67.9, 58.1; LC–MS (ESI) <i>m</i>/<i>z</i>: 423.0 [M + H]<sup>+</sup>; HRMS (EI) calcd for C<sub>26</sub>H<sub>22</sub>N<sub>4</sub>O<sub>2</sub>, 422.1743 [M]<sup>+</sup>; found, 422.1728.</div></div><div id="sec4_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> <i>N</i>-[3-(6-Phenyl-4-{[(1<i>R</i>)-1-phenylethyl]amino}furo[2,3-<i>d</i>]pyrimidin-5-yl)phenyl]prop-2-enamide (<b>70</b>)</h4><div class="NLM_p last">To a solution of <b>65</b> (51 mg, 0.12 mmol) and pyridine (11 mg, 0.12 mmol) in diethylether (2.0 mL) was added acryloyl chloride (16 mg, 0.20 mmol) at 0 °C. The solution was stirred at room temperature for 2 h, and then it was quenched by water and extracted with ethyl acetate. The combined organic layers were dried over MgSO<sub>4(s)</sub>, filtered, and concentrated to give a residue. The residue was purified by preparative layer chromatography (ethyl acetate/hexanes = 1:2) to give the product <b>70</b> (89 mg, 11%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.38 (s, 1H), 7.94 (d, 1H), 7.55–7.47 (m, 4H), 7.30–7.18 (m, 6H), 7.13–7.11 (m, 2H), 6.96 (d, <i>J</i> = 6.9 Hz, 1H), 6.46 (dd, <i>J</i> = 16.8, 1.2 Hz, 1H), 6.23 (dd, <i>J</i> = 16.8, 10.2 Hz, 1H), 5.80 (dd, <i>J</i> = 10.2, 1.2 Hz, 1H), 5.31 (quint, <i>J</i> = 6.9 Hz, 1H), 5.05 (d, <i>J</i> = 7.5 Hz, 1H), 1.39 (d, <i>J</i> = 6.9 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 164.5, 163.9, 156.6, 153.9, 146.6, 143.3, 139.6, 132.9, 130.9, 130.4, 129.0, 128.6, 128.5, 128.2, 127.2, 126.2, 125.6, 125.2, 120.5, 120.2, 114.4, 103.1, 50.3, 22.8; LC–MS (ESI) <i>m</i>/<i>z</i>: 461.2 [M + H]<sup>+</sup>; HRMS (ESI) calcd for C<sub>29</sub>H<sub>24</sub>N<sub>4</sub>O<sub>2</sub>Na, 483.1797 [M + Na]<sup>+</sup>; found, 483.1791; HPLC purity (method B): 97.9%, <i>t</i><sub>R</sub> = 28.69 min.</div></div><div id="sec4_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> <i>N</i>-[3-(4-{[(1<i>S</i>)-2-Hydroxy-1-phenylethyl]amino}-6-phenylfuro[2,3-<i>d</i>]pyrimidin-5-yl)phenyl]but-2-ynamide (<b>71</b>)</h4><div class="NLM_p last">A solution of <b>66</b> (211 mg, 0.499 mmol), 2-butynoic acid (51.0 mg, 0.607 mmol), and EDCI·HCl (115 mg, 0.600 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (5 mL) was stirred at room temperature overnight. The solution was concentrated and purified by preparative layer chromatography (ethyl acetate/hexanes = 3:2) to obtain product <b>71</b> (83.0 mg, 34% yield). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.37 (s, 1H), 7.67–7.53 (m, 4H), 7.43 (br t, 1H), 7.29–7.22 (m, 7H), 7.08–7.05 (m, 2H), 5.48 (br s, 1H), 5.30 (br s, 1H), 3.88–3.75 (m, 2H), 2.02 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 164.8, 157.4, 153.7, 151.7, 147.3, 139.3, 139.0, 133.1, 130.9, 130.8, 129.2, 129.0, 128.9, 128.7, 128.0, 126.6, 126.4, 126.2, 120.8, 114.4, 103.6, 85.5, 75.4, 67.4, 57.7, 3.95; LC–MS (ESI) <i>m</i>/<i>z</i>: 489.1 [M + H]<sup>+</sup>; HRMS (ESI) calcd for C<sub>30</sub>H<sub>24</sub>N<sub>4</sub>O<sub>3</sub>Na, 511.1746 [M + Na]<sup>+</sup>; found, 511.1747; HPLC purity (method B): 92.3%, <i>t</i><sub>R</sub> = 24.19 min.</div></div><div id="sec4_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> <i>N</i>-[3-(4-{[(1<i>S</i>)-2-Hydroxy-1-phenylethyl]amino}-6-phenylfuro[2,3-<i>d</i>]pyrimidin-5-yl)phenyl]ethenesulfonamide (<b>72</b>)</h4><div class="NLM_p last">To a solution of <b>66</b> (200 mg, 0.473 mmol) and triethylamine (0.50 mL) in CH<sub>2</sub>Cl<sub>2</sub> (5.0 mL) was added 2-chloroethanesulfonyl chloride (0.30 mL, 2.87 mmol) at room temperature. The solution was stirred at room temperature for 4 h and concentrated. The crude was treated with by water and CH<sub>2</sub>Cl<sub>2</sub>. The organic layer was dried over MgSO<sub>4(s)</sub>, filtered, and concentrated to obtain a residue. The residue was purified by flash column chromatography (2.5–5% methanol in CH<sub>2</sub>Cl<sub>2</sub> containing 0.10% NH<sub>3(aq)</sub>) to give the product <b>72</b> (4.7 mg, 2%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD-<i>d</i><sub>4</sub>): δ 8.24 (s, 1H), 7.59–7.51 (m, 3H), 7.42–7.21 (m, 9H), 7.16 (d, <i>J</i> = 8.4 Hz, 1H), 6.62 (dd, 1H), 6.10 (d, <i>J</i> = 16.8 Hz, 1H), 5.85 (d, <i>J</i> = 9.6 Hz, 1H), 5.27 (dd, <i>J</i> = 5.2, 4.8 Hz, 1H), 3.76 (dd, <i>J</i> = 11.2 4.8 Hz, 1H), 3.64 (dd, <i>J</i> = 11.2, 5.2 Hz, 1H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 164.5, 157.2, 153.7, 147.1, 139.0, 138.4, 135.3, 133.3, 130.9, 128.9, 128.8, 128.7, 128.5, 128.3, 127.8, 126.3, 126.2, 125.8, 121.1, 120.4, 114.0, 103.3, 67.0, 57.2; LC–MS (ESI) <i>m</i>/<i>z</i>: 513.1 [M + H]<sup>+</sup>; HRMS (ESI) calcd for C<sub>28</sub>H<sub>24</sub>N<sub>4</sub>O<sub>4</sub>SNa, 535.1416 [M + Na]<sup>+</sup>; found, 535.1420; HPLC purity (method B): 90.8%, <i>t</i><sub>R</sub> = 24.11 min.</div></div><div id="sec4_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> (2<i>E</i>)-<i>N</i>-[3-(4-{[(1<i>S</i>)-2-Hydroxy-1-phenylethyl]amino}-6-phenylfuro[2,3-<i>d</i>]pyrimidin-5-yl)phenyl]but-2-enamide (<b>73</b>)</h4><div class="NLM_p last">Compound <b>73</b> was prepared from (<i>E</i>)-but-2-enoic acid and <b>66</b>, similarly to <b>71</b>. After work-up, the residue was purified by flash column chromatography [5% methanol in CH<sub>2</sub>Cl<sub>2</sub> containing 0.10% NH<sub>3(aq)</sub> to give the product <b>73</b> (77.9 mg, 67%)]. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.17 (s, 1H, NH), 8.28 (s, 1H), 7.97 (s, 1H), 7.80 (d, <i>J</i> = 8.4 Hz, 1H), 7.62–7.14 (m, 11H), 6.84–6.77 (m, 2H), 6.12 (d, <i>J</i> = 15.2 Hz, 1H), 5.75 (d, 1H, NH), 5.25–5.20 (m, 1H), 4.82 (t, <i>J</i> = 4.8 Hz, 1H, OH), 3.63–3.56 (m, 1H), 3.47–3.38 (m, 1H), 1.87 (d, <i>J</i> = 6.8 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 164.8, 164.5, 157.4, 153.9, 147.0, 142.9, 139.3, 139.0, 132.8, 133.1, 130.5, 129.2, 128.7, 128.6, 128.5, 127.6, 126.5, 126.3, 126.0, 124.7, 121.3, 120.8, 114.4, 103.5, 67.2, 57.3, 17.9; LC–MS (ESI) <i>m</i>/<i>z</i>: 491.2 [M + H]<sup>+</sup>; HRMS (ESI) calcd for C<sub>30</sub>H<sub>26</sub>N<sub>4</sub>O<sub>3</sub>Na, 513.1903 [M + Na]<sup>+</sup>; found, 513.1904; HPLC purity (method B): 96.2%, <i>t</i><sub>R</sub> = 24.79 min.</div></div><div id="sec4_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> (2<i>E</i>)-<i>N</i>-[3-(4-{[(1<i>S</i>)-2-Hydroxy-1-phenylethyl]amino}-6-phenylfuro[2,3-<i>d</i>]pyrimidin-5-yl)phenyl]-5-methylhex-2-enamide (<b>74</b>)</h4><div class="NLM_p last">Compound <b>74</b> was prepared from (2<i>E</i>)-5-methyl-2-hexenoic acid and <b>66</b>, similarly to <b>71</b>. After work-up, the residue was purified by flash column chromatography (methanol/CH<sub>2</sub>Cl<sub>2</sub> = 1:40) to give the product <b>74</b> (60 mg, 45%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.38 (s, 1H), 7.82–7.60 (m, 2H), 7.58–7.50 (m, 2H), 7.48–7.39 (m, 1H), 7.32–7.17 (m, 7H), 7.10–6.93 (m, 3H), 5.83 (d, <i>J</i> = 15.6 Hz, 1H), 5.60 (br s, 1H), 5.38 (br s, 1H), 3.94–3.82 (m, 1H), 3.80–3.70 (m, 1H), 2.18–2.08 (m, 2H), 1.83–1.71 (m, 1H), 0.98–0.88 (m, 6H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 164.7, 164.6, 157.3, 153.6, 147.0, 146.4, 139.2, 132.8, 130.5, 129.1, 128.7, 128.6, 128.5, 127.6, 126.4, 126.2, 125.7, 124.4, 121.2, 120.8, 114.5, 103.4, 67.0, 57.3, 41.4, 27.7, 22.2; LC–MS (ESI) <i>m</i>/<i>z</i>: 533.2 [M + H]<sup>+</sup>; HRMS (ESI) calcd for C<sub>33</sub>H<sub>32</sub>N<sub>4</sub>O<sub>3</sub>Na, 555.2372 [M + Na]<sup>+</sup>; found, 555.2368; HPLC purity (method A): 93.9%, <i>t</i><sub>R</sub> = 42.71 min.</div></div><div id="sec4_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> (2<i>E</i>)-<i>N</i>-[3-(4-{[(1<i>S</i>)-2-Hydroxy-1-phenylethyl]amino}-6-phenylfuro[2,3-<i>d</i>]pyrimidin-5-yl)phenyl]-3-phenylprop-2-enamide (<b>75</b>)</h4><div class="NLM_p last">Compound <b>75</b> was prepared from <i>trans</i>-cinnamic acid and <b>66</b>, similarly to <b>71</b>. After work-up, the residue was purified by flash column chromatography (5% methanol in CH<sub>2</sub>Cl<sub>2</sub> containing 0.10% NH<sub>3(aq)</sub>) to give the product <b>75</b> (62.5 mg, 48%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.45 (s, 1H, NH), 8.29 (s, 1H), 8.01 (s, 1H), 7.89 (d, <i>J</i> = 8.0 Hz, 1H), 7.64–7.16 (m, 18H), 6.84 (d, <i>J</i> = 15.6 Hz, 1H), 5.77 (d, 1H, NH), 5.24–5.19 (m, 1H), 4.84 (t, <i>J</i> = 4.8 Hz, 1H, OH), 3.63–3.58 (m, 1H), 3.47–3.41 (m, 1H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 164.9, 164.6, 157.3, 153.6, 147.0, 142.9, 139.4, 139.2, 134.3, 132.8, 130.5, 130.1, 129.7, 129.0, 128.8, 128.7, 128.5, 127.9, 127.6, 126.4, 126.2, 125.8, 121.1, 120.7, 120.3, 114.4, 103.4, 66.9, 57.2; LC–MS (ESI) <i>m</i>/<i>z</i>: 553.2 [M + H]<sup>+</sup>; HRMS (ESI) calcd for C<sub>35</sub>H<sub>28</sub>N<sub>4</sub>O<sub>3</sub>Na, 575.2059 [M + Na]<sup>+</sup>; found, 575.2065; HPLC purity (method A): 99.1%, <i>t</i><sub>R</sub> = 41.19 min.</div></div><div id="sec4_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> (2<i>E</i>)-4-{[3-(4-{[(1<i>S</i>)-2-Hydroxy-1-phenylethyl]amino}-6-phenylfuro[2,3-<i>d</i>]pyrimidin-5-yl)phenyl]amino}-4-oxobut-2-enoic Acid (<b>76</b>)</h4><div class="NLM_p last">Compound <b>76</b> was prepared from <i>trans</i>-2-butenedioic acid and <b>66</b>, similarly to <b>71</b>. After work-up, the residue was purified by flash column chromatography (5% methanol in CH<sub>2</sub>Cl<sub>2</sub> containing 0.10% NH<sub>3(aq)</sub>) to give the product <b>76</b> (39.5 mg, 33%). <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD-<i>d</i><sub>4</sub>): δ 8.25 (s, 1H), 7.98 (s, 1H), 7.87 (d, <i>J</i> = 8.1 Hz, 1H), 7.61–7.56 (m, 3H), 7.32–7.14 (m, 9H), 7.02 (d, <i>J</i> = 15.3 Hz, 1H), 6.87 (d, <i>J</i> = 15.3 Hz, 1H), 5.26 (dd, <i>J</i> = 5.1, 4.8 Hz, 1H), 3.75 (dd, <i>J</i> = 10.8, 4.8 Hz, 1H), 3.62 (dd, <i>J</i> = 10.8, 5.1 Hz, 1H); <sup>13</sup>C NMR (75 MHz, CD<sub>3</sub>OD-<i>d</i><sub>4</sub>): δ 168.6, 165.8, 164.6, 158.6, 154.9, 148.5, 141.4, 141.3, 137.8, 134.2, 131.9, 130.6, 130.1, 129.9, 129.7, 128.6, 127.9, 127.6, 127.1, 122.2, 121.7, 116.4, 104.6, 66.93, 57.7; LC–MS (ESI) <i>m</i>/<i>z</i>: 521.2 [M + H]<sup>+</sup>; HRMS (ESI) calcd for C<sub>30</sub>H<sub>24</sub>N<sub>4</sub>O<sub>5</sub>Na, 543.1644 [M + Na]<sup>+</sup>; found, 543.1626; HPLC purity (method A): 93.6%, <i>t</i><sub>R</sub> = 43.58 min.</div></div><div id="sec4_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> Ethyl (2<i>E</i>)-4-{[3-(4-{[(1<i>S</i>)-2-Hydroxy-1-phenylethyl]amino}-6-phenylfuro[2,3-<i>d</i>]pyrimidin-5-yl)phenyl]amino}-4-oxobut-2-enoate (<b>77</b>)</h4><div class="NLM_p last">Compound <b>77</b> was prepared from <i>trans</i>-2-butenedioic acid and <b>66</b>, similarly to <b>71</b>. After work-up, the residue was purified by flash column chromatography (5% methanol in CH<sub>2</sub>Cl<sub>2</sub> containing 0.10% NH<sub>3(aq)</sub>) to give the product <b>77</b> (52.6 mg, 40%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.78 (s, 1H, NH), 8.28 (s, 1H), 8.02 (s, 1H), 7.83 (d, <i>J</i> = 8.4 Hz, 1H), 7.60 (t, <i>J</i> = 8.0 Hz, 1H), 7.53–7.51 (m, 2H), 7.41–7.15 (m, 10H), 6.71 (d, <i>J</i> = 15.2 Hz, 1H), 5.75 (d, <i>J</i> = 7.6 Hz, 1H), 5.22–5.17 (m, 1H), 4.83 (t, <i>J</i> = 4.8 Hz, 1H, OH), 4.21 (q, <i>J</i> = 7.2 Hz, 2H), 3.62–3.57 (m, 1H), 3.45–3.40 (m, 1H), 1.26 (t, <i>J</i> = 7.2 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 165.6, 164.5, 162.2, 157.2, 153.5, 147.1, 139.1, 139.0, 136.5, 132.8, 131.5, 130.6, 128.9, 128.7, 128.6, 128.5, 127.7, 126.3, 126.2, 120.9, 120.7, 114.2, 103.3, 66.8, 61.4, 57.2, 14.0; LC–MS (ESI) <i>m</i>/<i>z</i>: 549.3 [M + H]<sup>+</sup>; HRMS (ESI) calcd for C<sub>32</sub>H<sub>28</sub>N<sub>4</sub>O<sub>5</sub>Na, 571.1957 [M + Na]<sup>+</sup>; found, 571.1967; HPLC purity (method A): 98.6%, <i>t</i><sub>R</sub> = 37.99 min.</div></div><div id="sec4_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> (2<i>E</i>)-4-(Dimethylamino)-<i>N</i>-[3-(4-{[(1<i>S</i>)-2-hydroxy-1-phenylethyl]amino}-6-phenylfuro[2,3-<i>d</i>]pyrimidin-5-yl)phenyl]but-2-enamide (<b>78</b>)</h4><div class="NLM_p last">To a solution of <b>66</b> (20.00 g, 47.34 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (400 mL) was added 4-bromocrotonoic acid (8.59 g, 52.07 mmol) and EDCI·HCl (14.52 g, 75.74 mmol), and it was stirred at room temperature overnight. The solution was concentrated and then was added by THF (400 mL) and dimethylamine (40 wt % in water, 30.30 mL, 236.7 mmol) and continued stirring for 8 h. The resulting solution was concentrated and partitioned with CH<sub>2</sub>Cl<sub>2</sub> (500 mL × 4) and saturated NaHCO<sub>3(aq)</sub>. The combined organic layers were dried over MgSO<sub>4(s)</sub>, filtered, and concentrated in vacuo. The residue was purified by flash column chromatography (methanol/acetone = 1:20) to give the product <b>78</b> (12.56 g, 50%) as a pale yellow solid. mp 185–186 °C; [α]<sub class="stack">D</sub><sup class="stack">25</sup> −265.3° (<i>c</i> = 0.25, CH<sub>2</sub>Cl<sub>2</sub>); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.28 (s, 1H), 8.27 (s, 1H), 7.98 (br s, 1H), 7.81 (d, <i>J</i> = 8.0 Hz, 1H), 7.55 (t, <i>J</i> = 8.0 Hz, 1H), 7.53–7.50 (m, 2H), 7.40–7.13 (m, 9H), 6.74 (dt, <i>J</i> = 15.4, 5.8 Hz, 1H), 6.28 (d, <i>J</i> = 15.4 Hz, 1H), 5.49 (d, <i>J</i> = 8.0 Hz, 1H), 5.23–5.19 (m, 1H), 4.81 (br t, <i>J</i> = 4.8 Hz, 1H), 3.60–3.55 (m, 1H), 3.44–3.39 (m, 1H), 3.05 (d, <i>J</i> = 5.8 Hz, 1H), 2.16 (s, 6H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>): δ 164.5, 163.7, 156.7, 154.1, 145.8, 142.0, 140.8, 140.6, 132.0, 130.6, 129.0, 129.0, 128.9, 128.2, 127.0, 126.6, 126.0, 125.8, 124.3, 119.8, 119.7, 115.2, 102.7, 64.5, 59.8, 55.5, 45.2; LC–MS (ESI) <i>m</i>/<i>z</i>: 534.1 [M + H]<sup>+</sup>; HRMS (ESI) calcd for C<sub>32</sub>H<sub>32</sub>N<sub>5</sub>O<sub>3</sub>, 534.2505 [M + H]<sup>+</sup>; found, 534.2474; HPLC purity (method B): 95.7%, <i>t</i><sub>R</sub> = 16.01 min.</div></div><div id="sec4_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> (2<i>E</i>)-4-(Diethylamino)-<i>N</i>-[3-(4-{[(1<i>S</i>)-2-hydroxy-1-phenylethyl]amino}-6-phenylfuro[2,3-<i>d</i>]pyrimidin-5-yl)phenyl]but-2-enamide (<b>79</b>)</h4><div class="NLM_p last">Compound <b>79</b> was prepared from 4-bromocrotonoic acid, <i>N</i>,<i>N</i>-diethylamine and <b>66</b>, similarly to <b>78</b>. After work-up, the residue was purified by flash column chromatography (5% methanol in CH<sub>2</sub>Cl<sub>2</sub> containing 0.10% NH<sub>3(aq)</sub>) to give the product <b>79</b> (43.7 mg, 32%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.30 (s, 1H), 7.77–7.75 (m, 2H), 7.53–7.48 (m, 2H), 7.41 (dd, <i>J</i> = 8.4, 7.5 Hz, 1H), 7.27–7.17 (m, 7H), 7.11–7.00 (m, 2H), 6.97 (dt, <i>J</i> = 15.3, 5.7 Hz, 1H), 6.17 (d, <i>J</i> = 15.3 Hz, 1H), 5.68 (d, <i>J</i> = 6.6 Hz, 1H), 5.33 (br s, 1H), 3.89–3.84 (m, 1H), 3.72–3.63 (m, 1H), 3.24 (d, <i>J</i> = 5.7 Hz, 2H), 2.54 (q, <i>J</i> = 7.2 Hz, 4H), 1.02 (t, <i>J</i> = 7.2 Hz, 6H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 164.6, 164.3, 157.2, 153.7, 146.9, 142.7, 139.4, 132.8, 130.5, 129.1, 128.6, 128.5, 127.5, 126.4, 126.3, 126.0, 125.7, 121.0, 120.8, 114.5, 103.3, 66.6, 57.0, 53.8, 47.0, 11.4; LC–MS (ESI) <i>m</i>/<i>z</i>: 562.3 [M + H]<sup>+</sup>; HRMS (ESI) calcd for C<sub>34</sub>H<sub>36</sub>N<sub>5</sub>O<sub>3</sub>, 562.2818 [M + H]<sup>+</sup>; found, 562.2841; HPLC purity (method A): 97.0%, <i>t</i><sub>R</sub> = 24.47 min.</div></div><div id="sec4_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> (2<i>E</i>)-4-[Ethyl(2-hydroxyethyl)amino]-<i>N</i>-[3-(4-{[(1<i>S</i>)-2-hydroxy-1-phenylethyl]amino}-6-phenylfuro[2,3-<i>d</i>]pyrimidin-5-yl)phenyl]but-2-enamide (<b>80</b>)</h4><div class="NLM_p last">Compound <b>80</b> was prepared from 4-bromocrotonoic acid, 2-(ethylamino)ethanol and <b>66</b>, similarly to <b>78</b>. After work-up, the residue was purified by flash column chromatography (5% methanol in CH<sub>2</sub>Cl<sub>2</sub> containing 0.10% NH<sub>3(aq)</sub>) to give the product <b>80</b> (35.7 mg, 26%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.33 (s, 1H), 7.79–7.72 (m, 2H), 7.55–7.52 (m, 2H), 7.42 (t, <i>J</i> = 7.8 Hz, 1H), 7.27–7.20 (m, 7H), 7.08–7.06 (m, 2H), 6.94 (dt, <i>J</i> = 15.3, 5.7 Hz, 1H), 6.15 (d, <i>J</i> = 15.3 Hz, 1H), 5.69 (d, <i>J</i> = 6.6 Hz, 1H), 5.34 (br s, 1H), 3.84 (dd, <i>J</i> = 11.4, 3.3 Hz, 1H), 3.69 (dd, <i>J</i> = 11.4, 6.0 Hz, 1H), 3.57 (t, <i>J</i> = 5.4 Hz, 2H), 3.31 (d, <i>J</i> = 5.7 Hz, 2H), 2.64–2.52 (m, 4H), 1.05 (t, <i>J</i> = 7.2 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 169.4, 164.8, 157.3, 157.28, 153.9, 146.9, 139.4, 139.0, 133.1, 130.5, 130.46, 129.3, 128.7, 128.6, 128.5, 127.6, 126.5, 126.3, 125.9, 121.1, 120.6, 114.5, 103.5, 72.6, 66.9, 57.4, 52.3, 41.6, 29.67, 11.5; LC–MS (ESI) <i>m</i>/<i>z</i>: 578.3 [M + H]<sup>+</sup>; HRMS (ESI) calcd for C<sub>34</sub>H<sub>36</sub>N<sub>5</sub>O<sub>4</sub>, 578.2767 [M + H]<sup>+</sup>; found, 578.2764; HPLC purity (method B): 96.8%, <i>t</i><sub>R</sub> = 16.65 min.</div></div><div id="sec4_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> (2<i>E</i>)-<i>N</i>-[3-(4-{[(1<i>S</i>)-2-Hydroxy-1-phenylethyl]amino}-6-phenylfuro[2,3-<i>d</i>]pyrimidin-5-yl)phenyl]-4-(morpholin-4-yl)but-2-enamide (<b>81</b>)</h4><div class="NLM_p last">Compound <b>81</b> was prepared from 4-bromocrotonoic acid, morpholine, and <b>66</b>, similarly to <b>78</b>. After work-up, the residue was purified by flash column chromatography (3.3% methanol in CH<sub>2</sub>Cl<sub>2</sub>) to give the product <b>81</b> (201 mg, 26%). <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD-<i>d</i><sub>4</sub>): δ 8.24 (s, 1H), 7.94 (s, 1H), 7.83 (d, <i>J</i> = 8.4 Hz, 1H), 7.58–7.54 (m, 3H), 7.32–7.13 (m, 9H), 6.90 (dt, <i>J</i> = 15.3, 5.7 Hz, 1H), 6.31 (d, <i>J</i> = 15.3 Hz, 1H), 5.27 (t, <i>J</i> = 5.1 Hz, 1H), 3.69–3.58 (m, 6H), 3.21 (d, <i>J</i> = 5.7 Hz, 2H), 2.52–2.49 (m, 4H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 164.5, 164.1, 157.2, 153.6, 147.0, 141.9, 139.3, 139.25, 132.8, 130.5, 129.0, 128.6, 128.5, 127.6, 126.3, 126.2, 126.0, 125.8, 121.0, 120.8, 114.4, 103.4, 66.7, 59.4, 57.0, 53.6; LC–MS (ESI) <i>m</i>/<i>z</i>: 576.0 [M + H]<sup>+</sup>; HRMS (ESI) calcd for C<sub>34</sub>H<sub>34</sub>N<sub>5</sub>O<sub>4</sub>, 576.2611 [M + H]<sup>+</sup>; found, 576.2608; HPLC purity (method A): 98.3%, <i>t</i><sub>R</sub> = 23.79 min.</div></div><div id="sec4_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> <i>N</i>-{3-[4-{[(1<i>S</i>)-2-Hydroxy-1-phenylethyl]amino}-6-(2-methoxyphenyl)furo[2,3-<i>d</i>]pyrimidin-5-yl]phenyl}prop-2-enamide (<b>82</b>)</h4><div class="NLM_p last">Compound <b>82</b> was prepared from acrylic acid and <b>68</b>, similarly to <b>71</b>. After work-up, the residue was purified by preparative layer chromatography (5% methanol in CH<sub>2</sub>Cl<sub>2</sub>) to give the product <b>82</b> (6.7 mg, 66% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.25 (s, 1H, NH), 8.27 (s, 1H), 7.84 (s, 1H), 7.69 (d, <i>J</i> = 8.0 Hz, 1H), 7.44–7.38 (m, 3H), 7.28–7.20 (m, 5H), 7.11–7.05 (m, 2H), 7.01–6.97 (m, 1H), 6.43 (dd, <i>J</i> = 16.8, 10.0 Hz, 1H), 6.26 (dd, <i>J</i> = 16.8, 2.0 Hz, 1H), 5.96 (d, <i>J</i> = 7.2 Hz, 1H, NH), 5.76 (dd, <i>J</i> = 10.0, 2.0 Hz, 1H), 5.27–5.25 (m, 1H), 4.87 (t, <i>J</i> = 4.8 Hz, 1H), 3.65–3.47 (m, 2H), 3.51 (s, 3H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 165.0, 163.4, 157.1, 156.5, 153.6, 145.1, 140.9, 139.7, 132.7, 131.8, 131.3, 131.2, 129.6, 128.2, 127.2, 126.9, 126.7, 124.0, 120.4, 119.4, 118.8, 117.7, 116.8, 111.9, 11.5, 64.4, 55.7, 55.1; LC–MS (ESI) <i>m</i>/<i>z</i>: 507.2 [M + H]<sup>+</sup>; HRMS (ESI) calcd for C<sub>30</sub>H<sub>27</sub>N<sub>4</sub>O<sub>4</sub>, 507.2032 [M + H]<sup>+</sup>; found, 507.2034; HPLC purity (method A): 94.3%, <i>t</i><sub>R</sub> = 32.05 min.</div></div><div id="sec4_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> <i>N</i>-[3-(4-{[(1<i>R</i>)-2-Hydroxy-1-phenylethyl]amino}-6-phenylfuro[2,3-<i>d</i>]pyrimidin-5-yl)phenyl]prop-2-enamide (<b>83</b>)</h4><div class="NLM_p last">Compound <b>83</b> was prepared from acrylic acid and <b>67</b>, similarly to <b>82</b>. After work-up, the residue was purified by CombiFlash automated flash chromatography (0–10% methanol in CH<sub>2</sub>Cl<sub>2</sub>) to give the product <b>83</b> (75 mg, 65%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.35 (s, 1H), 7.73 (br m, 2H), 7.54–7.51 (m, 2H), 7.44 (dd, <i>J</i> = 8.0, 7.6 Hz, 1H), 7.28–7.20 (m, 7H), 7.07–7.04 (m, 2H), 6.48 (d, <i>J</i> = 16.8 Hz, 1H), 6.26 (br dd, 1H), 5.82 (d, <i>J</i> = 4.0 Hz, 1H), 5.56 (br s, 1H), 5.33 (br s, 1H), 3.89–3.86 (m, 1H), 3.76–3.72 (m, 1H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 164.4, 164.3, 157.2, 153.4, 147.0, 139.3, 139.1, 132.6, 130.7, 130.5, 128.9, 128.6, 128.4, 128.3, 127.6, 126.3, 126.2, 125.8, 121.0, 120.8, 114.4, 103.3, 66.6, 57.1; LC–MS (ESI) <i>m</i>/<i>z</i>: 477.2 [M + H]<sup>+</sup>; HRMS (ESI) calcd for C<sub>29</sub>H<sub>24</sub>N<sub>4</sub>O<sub>3</sub>Na, 499.1746 [M + Na]<sup>+</sup>; found, 499.1745; HPLC purity (method B): 92.4%, <i>t</i><sub>R</sub> = 23.81 min.</div></div><div id="sec4_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> (2<i>E</i>)-4-(Dimethylamino)-<i>N</i>-[3-(4-{[(1<i>R</i>)-2-hydroxy-1-phenylethyl]amino}-6-phenylfuro[2,3-<i>d</i>]pyrimidin-5-yl)phenyl]but-2-enamide (<b>84</b>)</h4><div class="NLM_p last">Compound <b>84</b> was prepared from 4-bromocrotonoic acid, <i>N</i>,<i>N</i>-dimethylamine, and <b>67</b>, similarly to <b>78</b>. After work-up, the residue was purified by CombiFlash automated flash chromatography (0–10% methanol in CH<sub>2</sub>Cl<sub>2</sub>) to give the product <b>84</b> (135 mg, 60%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.37 (s, 1H), 7.88–7.61 (br m, 2H), 7.56–7.54 (m, 2H), 7.44 (br t, 1H), 7.30–7.22 (m, 7H), 7.12–6.95 (m, 3H), 6.17 (d, <i>J</i> = 16.8 Hz, 1H), 5.64 (br s, 1H), 5.35 (br s, 1H), 3.89–3.86 (m, 1H), 3.75–3.71 (m, 1H), 3.09 (d, <i>J</i> = 5.2 Hz, 2H), 2.26 (s, 6H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 164.8, 164.1, 157.3, 153.9, 147.0, 141.8, 139.4, 139.1, 133.0, 130.6, 129.2, 128.7, 128.6, 127.6, 126.5, 126.3, 126.1, 121.2, 120.9, 114.4, 103.4, 66.9, 60.0, 57.2, 45.2; LC–MS (ESI) <i>m</i>/<i>z</i>: 534.3 [M + H]<sup>+</sup>; HRMS (ESI) calcd for C<sub>32</sub>H<sub>32</sub>N<sub>5</sub>O<sub>3</sub>, 534.2505 [M + H]<sup>+</sup>; found, 534.2507; HPLC purity (method A): 98.9%, <i>t</i><sub>R</sub> = 22.72 min.</div></div><div id="sec4_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> <i>N</i>-[3-(4-{[(1<i>S</i>)-2-Hydroxy-1-phenylethyl]amino}-6-phenylthieno[2,3-<i>d</i>]pyrimidin-5-yl)phenyl]prop-2-enamide (<b>85</b>)</h4><div class="NLM_p last">Compound <b>85</b> was prepared from acryloyl chloride and <b>69</b>, similarly to <b>70</b>. After work-up, the residue was purified by preparative layer chromatography (ethyl acetate/hexanes = 1:1) to give the product <b>85</b> (67 mg, 68%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.90 (s, 1H, NH), 8.30–8.27 (m, 1H), 7.80–7.46 (m, 2H), 7.39–7.10 (m, 9H), 7.08–7.00 (m, 1H), 6.94–6.90 (m, 2H), 6.45–6.16 (m, 2H), 5.71–5.54 (m, 1H), 5.32–5.15 (m, 1H), 3.82–3.52 (m, 2H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 164.9, 164.8, 164.4, 163.3, 157.1, 157.0, 153.4, 153.0, 139.2, 138.9, 138.8, 138.3, 136.8, 136.5, 136.3, 136.1, 132.9, 132.8, 130.8, 130.5, 130.2, 129.4, 129.3, 128.9, 128.8, 128.6, 128.5, 128.2, 128.1, 128.1, 127.9, 127.6, 127.0, 126.3, 122.7, 121.5, 120.7, 120.0, 116.4, 68.0, 67.0, 58.3, 56.9; LC–MS (ESI) <i>m</i>/<i>z</i>: 493.1 [M + H]<sup>+</sup>; HRMS (ESI) calcd for C<sub>29</sub>H<sub>24</sub>N<sub>4</sub>O<sub>2</sub>SNa, 515.1518 [M + Na]<sup>+</sup>; found, 515.1526; HPLC purity (method A): 99.4%, <i>t</i><sub>R</sub> = 35.28 min.</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> Docking Analysis of Compound <b>2</b> with EGFR Protein</h3><div class="NLM_p last">The protein structures of EGFR [Protein Data Bank identifier (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JQ7">4JQ7</a>)]<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> were used for this study. The docking analysis was conducted by using the CovalentDock<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> program with the CHARMm force field.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> The number of docking poses was set as 20 with default parameters. The decision of the best pose was according to the lowest binding energy of the compound will form a covalent bond with Cys797 and hinge binding with Met793.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> X-ray Cocrystal Study of WT EGFR Kinase in the Complex with <b>78</b></h3><div class="NLM_p last">WT human EGFR (residues 696–1022) was constructed and expressed in High Five insect cells. Protein purification and crystallization were performed as described.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> The EGFR/<b>78</b> complex crystal was obtained by soaking the apo-form crystal with <b>78</b> in reservoir solution containing 0.6 mM compound for 5–6 h at room temperature. Data for the complex structure were collected at NSRRC (beamline BL13C1) at 100K and processed using HKL2000.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> Model building and structure determinations were carried out as previously described<a onclick="showRef(event, 'ref28 ref32'); return false;" href="javascript:void(0);" class="ref ref28 ref32">(28,32)</a> except that structural refinement was done by program PHENIX.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> The data collection and refinement statistics of EGFR/<b>78</b> complex crystal are summarised in the <a href="/doi/suppl/10.1021/acs.jmedchem.9b00722/suppl_file/jm9b00722_si_001.pdf" class="ext-link">Supporting Information</a>.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> Biology</h3><div id="sec4_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> Reagents, Materials, Plasmids, and Cell Lines (with Name, Manufacturer)</h4><div class="NLM_p last">For the baculoviral expression vector of GST-tagged EGFR kinase domain (GST-EGFR-KD, L858R/T790M), the PCR-amplified cDNA fragment covering human EGFR from amino acids 696–1022 was attached to the C-terminal coding region (30 region) of the glutathione S-transferase gene. The fused DNA fragment was cloned into a baculovirus expression vector pBacBAK8 (Clontech, Palo Alto, CA, USA). H1975 cell lines were obtained from the American Type Culture Collection (ATCC, USA) and they were grown in RPMI 1640 (ATCC, USA) with 10% fetal bovine serum (FBS) (Gibco, USA). EGFR L858R/T790M (DM) substrate peptide (GGMEDIYFEFMGGKKK) (GMbiolab), HEPES (Gene Mark, 7365-45-9), MnCl<sub>2</sub> (JT Baker), MgCl<sub>2</sub> (Sigma-Aldrich, M8260), Triton X-100 (Sigma-Aldrich), dithiothreitol (DTT, MDBio, Inc), bovine serum albumin (BSA, Sigma-Aldrich), sodium orthovanadate (Na<sub>3</sub>VO<sub>4</sub>) (Sigma-Aldrich), poly(Glu, Tyr) sodium salt Glu/Tyr (4:1) (Sigma-Aldrich), ATP (Sigma-Aldrich), 96 well microplates (Greiner Bio One), Black 96 well microplate (SPL), Plate sealers (Basic Life), Wallac 1420 Victor 2 multilabel counter (PerkinElmer), and Kinase-Glo Plus Luminescent Kinase Assays (Promega).</div></div><div id="sec4_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> Purified Kinase Confirmatory Activity Assay for EGFR WT, EGFR L858R, and EGFR L858R/T790M</h4><div class="NLM_p last">Kinase-Glo Plus Luminescent Kinase Assays (Promega) were used to test the kinase activities of GST-EGFR (G696-G1022) WT, L858R, and L858R/T790M double-mutant recombinant proteins. The assay was performed in the round-bottom 96-well microplate in a final volume of 50 μL containing the following components: 50 ng WT EGFR, 50 ng single-mutant EGFR or 200 ng double-mutant EGFR, 25 mM HEPES pH 7.4, 4 mM MnCl<sub>2</sub>, 2 mM DTT, 10 mM MgCl<sub>2</sub>, 0.01% BSA, 0.02% Triton X-100, 0.5 mM Na<sub>3</sub>VO<sub>4</sub>, 2 μM poly(Glu, Tyr) 4:1 (for WT EGFR and single-mutant EGFR) or 25 μM EGFR L858R/T790M substrate peptide (for double-mutant EGFR), 1–5 μM ATP, and varying concentrations of the tested compounds. After incubation at 37 °C for 60 min(for WT EGFR) or 30 °C for 120 min (for single- and double-mutant EGFR), the 50 μL Kinase-Glo Plus reagent was added to each well of the black microplate and placed in the dark for 10 min at room temperature. Finally, the luminescence was measured on a Wallac 1420 Victor2 multilabel counter (PerkinElmer). Data were normalized using DMSO-only controls and background controls (no kinase added) to verify compound inhibition. The IC<sub>50</sub> value was calculated using GraphPad Prism version 4 software (San Diego, CA, USA).</div></div><div id="sec4_4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> Cellular Proliferation Assays</h4><div class="NLM_p last">The proliferation assays were performed by seeding 3000 cells per well in a 96-well culture plate. After 16 h, cells were treated with vehicle or test compounds at various concentrations of the tested compound in medium for 96 h. Cell viability was quantitated using the MTS method (Promega, Madison, WI, USA), according to the manufacturer recommended protocol. Results were determined by measuring the absorbance at 490 nm using a plate reader (PowerWave X; BioTek Instruments, Inc., USA). The CC<sub>50</sub> value was defined as the amount of compound that caused 50% reduction in cell viability in comparison with the DMSO-treated (vehicle) control and was calculated using GraphPad Prism version 4 software (GraphPad, USA).</div></div><div id="sec4_4_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> Data Analysis</h4><div class="NLM_p last">For Kinase-Glo kinase assays, the measured data were normalized using DMSO-only controls (0% inhibition) and background controls (100% inhibition) to verify inhibition by the compounds. The IC<sub>50</sub> value was defined as the amount of compound that induced a 50% inhibition in enzyme activity in comparison with DMSO-treated controls and was calculated using GraphPad Prism version 4 software. <i>Z</i><sub>0</sub> values were calculated using the method of Zhang et al.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a></div></div><div id="sec4_4_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> In Vivo Antitumor Efficacy Studies in the HCC827 Human Lung Cancer Xenograft Model</h4><div class="NLM_p">The antitumor activity of orally gavaged compounds formulated in several vehicles was measured in HCC827 (Del E746_A750 in exon19) tumor-bearing male nude mice (6- to 8-week-old athymic NU-Fox1<sup>nu</sup> nude mice from BioLASCO, Taiwan). Each mouse was inoculated subcutaneously at the left flank region with HCC827 tumor cells (5 × 10<sup>6</sup> cells/mouse). Oral gavage treatment was started when the mean tumor size reached approximately 500 mm<sup>3</sup>. <b>78</b> prepared in vehicle 1 (1% methylcellulose-4000cps/0.5% Tween 80/98.5% H<sub>2</sub>O) was orally gavaged at dose levels of 10, 20, and 50 mg/kg to the tumor-bearing mice once a day, 5 days a week for 2 consecutive weeks.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Antitumor Activity of <b>78</b> and Afatinib as a Single Agent in the Treatment of the Subcutaneous H1975 Human Lung Cancer Xenograft Model</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">treatment</th><th class="colsep0 rowsep0" align="center" char="±">tumor size (mm<sup>3</sup>)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">tumor growth inhibition (TGI, %)</th><th class="colsep0 rowsep0" align="center"><i>p</i>-value<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">vehicle</td><td class="colsep0 rowsep0" align="char" char="±">2044 ± 161</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">afatinib (15 mg/kg)</td><td class="colsep0 rowsep0" align="char" char="±">706 ± 92</td><td class="colsep0 rowsep0" align="char" char=".">65</td><td class="colsep0 rowsep0" align="left"><0.001</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>78</b> (50 mg/kg)</td><td class="colsep0 rowsep0" align="char" char="±">1354 ± 115</td><td class="colsep0 rowsep0" align="char" char=".">34</td><td class="colsep0 rowsep0" align="left">0.002</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">Data are presented as the mean ± SD.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">Compared to the vehicle control.</p></div></div></div></div><div id="sec4_4_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> In Vivo Antitumor Efficacy Studies in the NCI–H1975 Human Lung Cancer Xenograft Model</h4><div class="NLM_p last">The antitumor efficacy studies of the compounds were examined by CrownBio Inc. <b>78</b> powder (52.5 mg) was weighed and dissolved with 10.5 mL of vehicle (1% MC, 0.5% Tween 80) and mixed well by vortexing or sonication. The NCI–H1975 tumor cells were maintained in vitro as a monolayer culture in the RPMI1640 medium supplemented with 10% heat-inactivated FBS at 37 °C in an atmosphere of 5% CO<sub>2</sub> in air. The tumor cells were routinely subcultured twice weekly by trypsin–EDTA treatment. Cells in the exponential growth phase were harvested and counted for tumor inoculation. Each BALB/c nude mice was inoculated subcutaneously at the right flank region with NCI–H1975 tumor cells (5 × 10<sup>6</sup>) in 0.1 mL of PBS for tumor development. Treatments were started when the mean tumor size reached 147 mm<sup>3</sup>. The test article was administered to the tumor-bearing mice (<i>n</i> = 5/compound), according to the predetermined regimen for 15 days (QD). The date of tumor cell inoculation is denoted as day 0. TGI (%) is an indication of antitumor effectiveness, and it is defined as TGI (%) = 100 × (1 – <i>T</i>/<i>C</i>). <i>T</i> and <i>C</i> were the mean tumor volume of the treated and control groups, respectively. Tumor volumes were measured in two dimensions using a caliper, and the volume was expressed in mm<sup>3</sup> using the formula: <i>V</i> = 0.5<i>a</i> × <i>b</i><sup>2</sup>, where <i>a</i> and <i>b</i> are the major and minor diameters of the tumor, respectively. Studies were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of CrownBio prior to conduct. During the study, care and use of animals were conducted in accordance with the regulations of the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC).</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i59"><a href="/doi/suppl/10.1021/acs.jmedchem.9b00722" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40520" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40520" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.9b00722" class="ext-link">10.1021/acs.jmedchem.9b00722</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Supplementary methods and general procedures for the  preparation of the compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00722/suppl_file/jm9b00722_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings of the final compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00722/suppl_file/jm9b00722_si_001.pdf" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00722/suppl_file/jm9b00722_si_001.pdf">jm9b00722_si_001.pdf (794.11 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00722/suppl_file/jm9b00722_si_002.csv">jm9b00722_si_002.csv (1.85 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB ID for EGFR WT with compound <b>78</b> is <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6JZ0">6JZ0</a>. The authors will release the atomic coordinates and experimental data upon article publication.</p><div class="testing" data-doi="10.1021/acs.jmedchem.9b00722" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56468" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56468" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hsing-Pang Hsieh</span> - <span class="hlFld-Affiliation affiliation">Institute
of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli County 35053, Taiwan, ROC</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Chemistry, National Tsing Hua University, Hsinchu 30013, Taiwan, ROC</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1332-005X" title="Orcid link">http://orcid.org/0000-0002-1332-005X</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#650d150d160c000d250b0d170c4b0a17024b1112"><span class="__cf_email__" data-cfemail="462e362e352f232e06282e342f68293421683231">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shu-Yu Lin</span> - <span class="hlFld-Affiliation affiliation">Institute
of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli County 35053, Taiwan, ROC</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yung Chang Hsu</span> - <span class="hlFld-Affiliation affiliation">Institute
of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli County 35053, Taiwan, ROC</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yi-Hui Peng</span> - <span class="hlFld-Affiliation affiliation">Institute
of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli County 35053, Taiwan, ROC</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yi-Yu Ke</span> - <span class="hlFld-Affiliation affiliation">Institute
of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli County 35053, Taiwan, ROC</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wen-Hsing Lin</span> - <span class="hlFld-Affiliation affiliation">Institute
of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli County 35053, Taiwan, ROC</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hsu-Yi Sun</span> - <span class="hlFld-Affiliation affiliation">Institute
of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli County 35053, Taiwan, ROC</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hui-Yi Shiao</span> - <span class="hlFld-Affiliation affiliation">Institute
of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli County 35053, Taiwan, ROC</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fu-Ming Kuo</span> - <span class="hlFld-Affiliation affiliation">Institute
of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli County 35053, Taiwan, ROC</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pei-Yi Chen</span> - <span class="hlFld-Affiliation affiliation">Institute
of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli County 35053, Taiwan, ROC</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tzu-Wen Lien</span> - <span class="hlFld-Affiliation affiliation">Institute
of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli County 35053, Taiwan, ROC</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chun-Hwa Chen</span> - <span class="hlFld-Affiliation affiliation">Institute
of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli County 35053, Taiwan, ROC</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chang-Ying Chu</span> - <span class="hlFld-Affiliation affiliation">Institute
of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli County 35053, Taiwan, ROC</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sing-Yi Wang</span> - <span class="hlFld-Affiliation affiliation">Institute
of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli County 35053, Taiwan, ROC</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kai-Chia Yeh</span> - <span class="hlFld-Affiliation affiliation">Institute
of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli County 35053, Taiwan, ROC</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ching-Ping Chen</span> - <span class="hlFld-Affiliation affiliation">Institute
of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli County 35053, Taiwan, ROC</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tsu-An Hsu</span> - <span class="hlFld-Affiliation affiliation">Institute
of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli County 35053, Taiwan, ROC</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Su-Ying Wu</span> - <span class="hlFld-Affiliation affiliation">Institute
of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli County 35053, Taiwan, ROC</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2816-6961" title="Orcid link">http://orcid.org/0000-0003-2816-6961</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Teng-Kuang Yeh</span> - <span class="hlFld-Affiliation affiliation">Institute
of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli County 35053, Taiwan, ROC</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chiung-Tong Chen</span> - <span class="hlFld-Affiliation affiliation">Institute
of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli County 35053, Taiwan, ROC</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i61">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48518" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48518" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Support from the National Health Research Institute and Ministry of Science and Technology, Taiwan (MOST 106-2113-M-400-001 and MOST 105-2325-B-400-010 for H.-P.H.) is acknowledged. This work is also financially supported by the Center of Applied Nanomedicine, National Cheng Kung University from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan. S.-Y.L. is supported by a postdoctoral fellowship from Ministry of Science and Technology, Taiwan. We thank Dr. Vincent Blay for help with English editing.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">non-small cell lung cancer</p></td></tr><tr><td class="NLM_term">SCLC</td><td class="NLM_def"><p class="first last">small-cell lung cancer</p></td></tr><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine triphosphate</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">food and drug administration</p></td></tr><tr><td class="NLM_term">TKI</td><td class="NLM_def"><p class="first last">tyrosine kinase inhibitor</p></td></tr><tr><td class="NLM_term">DFG</td><td class="NLM_def"><p class="first last">Asp-Phe-Gly</p></td></tr><tr><td class="NLM_term">SBDD</td><td class="NLM_def"><p class="first last">structure-based drug design</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">IND</td><td class="NLM_def"><p class="first last">investigational new drug</p></td></tr><tr><td class="NLM_term">EDCI·HCl</td><td class="NLM_def"><p class="first last">1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride</p></td></tr><tr><td class="NLM_term">TBAF</td><td class="NLM_def"><p class="first last">tetrabutylammonium fluoride</p></td></tr><tr><td class="NLM_term">HRD</td><td class="NLM_def"><p class="first last">His-Arg-Asp</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under curve</p></td></tr><tr><td class="NLM_term">TGI</td><td class="NLM_def"><p class="first last">tumor growth inhibition</p></td></tr><tr><td class="NLM_term">QD</td><td class="NLM_def"><p class="first last">once a day</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i63">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18407" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18407" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 61 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">World Health Organization (WHO)</span>. <span> </span><span class="NLM_article-title">Statistics Reports for Lung Cancer</span>. <a href="http://www.who.int/news-room/fact-sheets/detail/cancer" class="extLink">http://www.who.int/news-room/fact-sheets/detail/cancer</a> (accessed
Feb 1, <span class="NLM_year">2018</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=World+Health+Organization+%28WHO%29&title=Statistics+Reports+for+Lung+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DStatistics%2520Reports%2520for%2520Lung%2520Cancer%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jemal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bray, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Center, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferlay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forman, D.</span></span> <span> </span><span class="NLM_article-title">Global cancer statistics</span>. <i>Ca-Cancer J. Clin.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">69</span>– <span class="NLM_lpage">90</span>, <span class="refDoi"> DOI: 10.3322/caac.20107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.3322%2Fcaac.20107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=21296855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A280%3ADC%252BC3M3lt1Olsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2011&pages=69-90&author=A.+Jemalauthor=F.+Brayauthor=M.+M.+Centerauthor=J.+Ferlayauthor=E.+Wardauthor=D.+Forman&title=Global+cancer+statistics&doi=10.3322%2Fcaac.20107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Global cancer statistics</span></div><div class="casAuthors">Jemal Ahmedin; Bray Freddie; Center Melissa M; Ferlay Jacques; Ward Elizabeth; Forman David</div><div class="citationInfo"><span class="NLM_cas:title">CA: a cancer journal for clinicians</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">69-90</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The global burden of cancer continues to increase largely because of the aging and growth of the world population alongside an increasing adoption of cancer-causing behaviors, particularly smoking, in economically developing countries.  Based on the GLOBOCAN 2008 estimates, about 12.7 million cancer cases and 7.6 million cancer deaths are estimated to have occurred in 2008; of these, 56% of the cases and 64% of the deaths occurred in the economically developing world.  Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death among females, accounting for 23% of the total cancer cases and 14% of the cancer deaths.  Lung cancer is the leading cancer site in males, comprising 17% of the total new cancer cases and 23% of the total cancer deaths.  Breast cancer is now also the leading cause of cancer death among females in economically developing countries, a shift from the previous decade during which the most common cause of cancer death was cervical cancer.  Further, the mortality burden for lung cancer among females in developing countries is as high as the burden for cervical cancer, with each accounting for 11% of the total female cancer deaths.  Although overall cancer incidence rates in the developing world are half those seen in the developed world in both sexes, the overall cancer mortality rates are generally similar.  Cancer survival tends to be poorer in developing countries, most likely because of a combination of a late stage at diagnosis and limited access to timely and standard treatment.  A substantial proportion of the worldwide burden of cancer could be prevented through the application of existing cancer control knowledge and by implementing programs for tobacco control, vaccination (for liver and cervical cancers), and early detection and treatment, as well as public health campaigns promoting physical activity and a healthier dietary intake.  Clinicians, public health professionals, and policy makers can play an active role in accelerating the application of such interventions globally.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSpm5184kVGTVQKX3ooHxWjfW6udTcc2ebVbrk0X72AZ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M3lt1Olsw%253D%253D&md5=4b8f63930a6c3e9749e0053a80132fd6</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.3322%2Fcaac.20107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3322%252Fcaac.20107%26sid%3Dliteratum%253Aachs%26aulast%3DJemal%26aufirst%3DA.%26aulast%3DBray%26aufirst%3DF.%26aulast%3DCenter%26aufirst%3DM.%2BM.%26aulast%3DFerlay%26aufirst%3DJ.%26aulast%3DWard%26aufirst%3DE.%26aulast%3DForman%26aufirst%3DD.%26atitle%3DGlobal%2520cancer%2520statistics%26jtitle%3DCa-Cancer%2520J.%2520Clin.%26date%3D2011%26volume%3D61%26spage%3D69%26epage%3D90%26doi%3D10.3322%2Fcaac.20107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Settleman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haber, D. A.</span></span> <span> </span><span class="NLM_article-title">Epidermal growth factor receptor mutations in lung cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">169</span>– <span class="NLM_lpage">181</span>, <span class="refDoi"> DOI: 10.1038/nrc2088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1038%2Fnrc2088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=17318210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=169-181&author=S.+V.+Sharmaauthor=D.+W.+Bellauthor=J.+Settlemanauthor=D.+A.+Haber&title=Epidermal+growth+factor+receptor+mutations+in+lung+cancer&doi=10.1038%2Fnrc2088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor mutations in lung cancer</span></div><div class="casAuthors">Sharma, Sreenath V.; Bell, Daphne W.; Settleman, Jeffrey; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">169-181</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The development and clin. application of inhibitors that target the epidermal growth factor receptor (EGFR) provide important insights for new lung cancer therapies, as well as for the broader field of targeted cancer therapies.  We review the results of genetic, biochem. and clin. studies focused on somatic mutations of EGFR that are assocd. with the phenomenon of oncogene addiction, describing 'oncogenic shock' as a mechanistic explanation for the apoptosis that follows the acute treatment of susceptible cells with kinase inhibitors.  Understanding the genetic heterogeneity of epithelial tumors and devising strategies to circumvent their rapid acquisition of resistance to targeted kinase inhibitors are essential to the successful use of targeted therapies in common epithelial cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMKw7Y4FUFM7Vg90H21EOLACvtfcHk0ljg37XbPlZOrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D&md5=46219ea3ae7b9f0977e4a4b7243fd875</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrc2088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2088%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520mutations%2520in%2520lung%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D169%26epage%3D181%26doi%3D10.1038%2Fnrc2088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prabhakar, C. N.</span></span> <span> </span><span class="NLM_article-title">Epidermal growth factor receptor in non-small cell lung cancer</span>. <i>Transl. Lung Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">110</span>– <span class="NLM_lpage">118</span>, <span class="refDoi"> DOI: 10.3978/j.issn.2218-6751.2015.01.01</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.3978%2Fj.issn.2218-6751.2015.01.01" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=25870793" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFCmt7fO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&pages=110-118&author=C.+N.+Prabhakar&title=Epidermal+growth+factor+receptor+in+non-small+cell+lung+cancer&doi=10.3978%2Fj.issn.2218-6751.2015.01.01"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor in non-small cell lung cancer</span></div><div class="casAuthors">Prabhakar, Charles N.</div><div class="citationInfo"><span class="NLM_cas:title">Translational Lung Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">110-118</span>CODEN:
                <span class="NLM_cas:coden">TLCRA9</span>;
        ISSN:<span class="NLM_cas:issn">2226-4477</span>.
    
            (<span class="NLM_cas:orgname">Pioneer Bioscience Publishing Co.</span>)
        </div><div class="casAbstract">Following the identification of a group of patients in the initial tyrosine kinase inhibitor (TKI) trials for lung cancer, there has been detailed focus on which patients may benefit from inhibitor therapy.  This article reviews the background, genetics and prevalence of epidermal growth factor mutations in non-small cell lung cancer (NSCLC).  Addnl., the prevalence in unselected patients is compared against various other reviews.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwFfYVYyyBkbVg90H21EOLACvtfcHk0ljg37XbPlZOrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFCmt7fO&md5=93c2024d68169f9b7f0167b7c25ce8e6</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.3978%2Fj.issn.2218-6751.2015.01.01&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3978%252Fj.issn.2218-6751.2015.01.01%26sid%3Dliteratum%253Aachs%26aulast%3DPrabhakar%26aufirst%3DC.%2BN.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520in%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DTransl.%2520Lung%2520Cancer%2520Res.%26date%3D2015%26volume%3D4%26spage%3D110%26epage%3D118%26doi%3D10.3978%2Fj.issn.2218-6751.2015.01.01" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Au, J. S.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thongprasert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivasan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khoa, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heeroma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itoh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornelio, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P.-C.</span></span> <span> </span><span class="NLM_article-title">A prospective, molecular epidemiology study of EGFR mutations in asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">154</span>– <span class="NLM_lpage">162</span>, <span class="refDoi"> DOI: 10.1097/jto.0000000000000033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1097%2Fjto.0000000000000033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=24419411" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpvVemsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=154-162&author=Y.+Shiauthor=J.+S.-K.+Auauthor=S.+Thongprasertauthor=S.+Srinivasanauthor=C.-M.+Tsaiauthor=M.+T.+Khoaauthor=K.+Heeromaauthor=Y.+Itohauthor=G.+Cornelioauthor=P.-C.+Yang&title=A+prospective%2C+molecular+epidemiology+study+of+EGFR+mutations+in+asian+patients+with+advanced+non-small-cell+lung+cancer+of+adenocarcinoma+histology+%28PIONEER%29&doi=10.1097%2Fjto.0000000000000033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)</span></div><div class="casAuthors">Shi, Yuankai; Au, Joseph Siu-Kie; Thongprasert, Sumitra; Srinivasan, Sankar; Tsai, Chun-Ming; Khoa, Mai Trong; Heeroma, Karin; Itoh, Yohji; Cornelio, Gerardo; Yang, Pan-Chyr</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thoracic Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">154-162</span>CODEN:
                <span class="NLM_cas:coden">JTOOB7</span>;
        ISSN:<span class="NLM_cas:issn">1556-0864</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Introduction: PIONEER (NCT01185314) was a prospective, multinational, epidemiol. study of epidermal growth factor receptor (EGFR) mutations in patients from Asia with newly diagnosed advanced lung adenocarcinoma.  Methods: Eligible patients (aged ≥20 years) had untreated stage IIIB/IV adenocarcinoma.  The EGFR mutation status (primary end point: pos., neg., or undetd.) of tumor samples (biopsy, surgical specimen, or cytol.) was detd. (Scorpion amplification refractory mutation system).  EGFR mutation frequency was calcd. and compared between demog. and clin. subgroups.  Results: Of 1482 patients from seven Asian regions, 43.4% of patients were female, median age was 60 years (range, 17-94), and 52.6% of patients were never-smokers.  EGFR mutation status was evaluable in tumors from 1450 patients (97.8%) (746 [51.4%] pos.; 704 [48.6%] neg.).  Country, sex, ethnicity, smoking status, pack-years (all p < 0.001), disease stage (p = 0.009), and histol. type (p = 0.016) correlated significantly with EGFR mutation frequency.  Mutation frequency was 61.1% in females, 44.0% in males; lower in patients from India (22.2%) compared with other areas (47.2%-64.2%); highest among never-smokers (60.7%); and decreased as pack-year no. increased (>0-10 pack-years, 57.9%; >50 pack-years, 31.4%) (similar trend by sex).  Ethnic group (p < 0.001) and pack-years (p < 0.001) had statistically significant assocns. with mutation frequency (multivariate anal.); sex was not significant when adjusted for smoking status.  Conclusion: PIONEER is the first prospective study to confirm high EGFR mutation frequency (51.4% overall) in tumors from Asian patients with adenocarcinoma.  The obsd. high mutation frequency in demog./clin. subgroups compared with white populations suggests that mutation testing should be considered for all patients with stage IIIB/IV adenocarcinoma, even males and regular smokers, among Asian populations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp__VKooo6Da7Vg90H21EOLACvtfcHk0ljIPUC8DgNMSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpvVemsw%253D%253D&md5=3059251c81506dd1bd1ea4488a0f42e4</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1097%2Fjto.0000000000000033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252Fjto.0000000000000033%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DY.%26aulast%3DAu%26aufirst%3DJ.%2BS.-K.%26aulast%3DThongprasert%26aufirst%3DS.%26aulast%3DSrinivasan%26aufirst%3DS.%26aulast%3DTsai%26aufirst%3DC.-M.%26aulast%3DKhoa%26aufirst%3DM.%2BT.%26aulast%3DHeeroma%26aufirst%3DK.%26aulast%3DItoh%26aufirst%3DY.%26aulast%3DCornelio%26aufirst%3DG.%26aulast%3DYang%26aufirst%3DP.-C.%26atitle%3DA%2520prospective%252C%2520molecular%2520epidemiology%2520study%2520of%2520EGFR%2520mutations%2520in%2520asian%2520patients%2520with%2520advanced%2520non-small-cell%2520lung%2520cancer%2520of%2520adenocarcinoma%2520histology%2520%2528PIONEER%2529%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2014%26volume%3D9%26spage%3D154%26epage%3D162%26doi%3D10.1097%2Fjto.0000000000000033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan, D. L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segelov, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, R. S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbertson, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebbutt, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavlakis, N.</span></span> <span> </span><span class="NLM_article-title">Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer</span>. <i>Cochrane Database Syst. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">CD007047</span>, <span class="refDoi"> DOI: 10.1002/14651858.cd007047.pub2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1002%2F14651858.cd007047.pub2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=28654140" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2017&pages=CD007047&author=D.+L.+H.+Chanauthor=E.+Segelovauthor=R.+S.+H.+Wongauthor=A.+Smithauthor=R.+A.+Herbertsonauthor=B.+T.+Liauthor=N.+Tebbuttauthor=T.+Priceauthor=N.+Pavlakis&title=Epidermal+growth+factor+receptor+%28EGFR%29+inhibitors+for+metastatic+colorectal+cancer&doi=10.1002%2F14651858.cd007047.pub2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1002%2F14651858.cd007047.pub2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F14651858.cd007047.pub2%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DD.%2BL.%2BH.%26aulast%3DSegelov%26aufirst%3DE.%26aulast%3DWong%26aufirst%3DR.%2BS.%2BH.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DHerbertson%26aufirst%3DR.%2BA.%26aulast%3DLi%26aufirst%3DB.%2BT.%26aulast%3DTebbutt%26aufirst%3DN.%26aulast%3DPrice%26aufirst%3DT.%26aulast%3DPavlakis%26aufirst%3DN.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520inhibitors%2520for%2520metastatic%2520colorectal%2520cancer%26jtitle%3DCochrane%2520Database%2520Syst.%2520Rev.%26date%3D2017%26volume%3D6%26spage%3DCD007047%26doi%3D10.1002%2F14651858.cd007047.pub2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tan, C.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soo, R. A.</span></span> <span> </span><span class="NLM_article-title">Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer</span>. <i>Lung Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">68</span>, <span class="refDoi"> DOI: 10.1016/j.lungcan.2016.01.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1016%2Fj.lungcan.2016.01.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=26898616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A280%3ADC%252BC28jivVymtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2016&pages=59-68&author=C.-S.+Tanauthor=B.-C.+Choauthor=R.+A.+Soo&title=Next-generation+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitors+in+epidermal+growth+factor+receptor+-mutant+non-small+cell+lung+cancer&doi=10.1016%2Fj.lungcan.2016.01.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer</span></div><div class="casAuthors">Tan Chee-Seng; Cho Byoung-Chul; Soo Ross A</div><div class="citationInfo"><span class="NLM_cas:title">Lung cancer (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">59-68</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Since the discovery of sensitizing EGFR mutations as a predictive marker of sensitivity to EGFR tyrosine kinase inhibitors (TKIs), the field of targeted therapy in non-small cell lung cancer (NSCLC) has been revolutionized.  Patients harbouring these sensitizing mutations treated with EGFR TKI have derived significant clinical outcome when compared with standard platinum based chemotherapy doublets.  However disease progression invariably occurs at a median of about 9-13 months from initiation treatment, if acquired resistance commonly due to the development of EGFR T790M mutation.  A novel class of "third generation" EGFR TKIs have been developed that is sensitising and T790M mutant-specific whilst sparing WT EGFR, representing a significant breakthrough in the treatment in NSCLC patients with acquired resistance harboring these genotypes.  Early phase clinical data suggest the third generation EGFR TKIs such as osimertinib, rociletinib, and HM61713 are highly efficacious and well tolerated.  Another promising class of EGFR TKI such as AZD3759 has been designed to penetrate blood brain barrier to treat brain metastases and leptomeningeal disease and has showed promising responses in patients with brain metastases.  Acquired resistance to third generation EGFR TKIs has been reported including EGFR C797S.  Given its non-invasive nature, plasma ctDNA is being explored as a possible approach to detect T790M mutation and to also inform on novel molecular mechansims of tertiary resistance to third generation EGFR TKIs.  An understanding of the mechanisms of acquired resistance to the third-generation EGFR TKIs will greatly aid in the development of the next generation of EGFR TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ6MbARC-V4Af3jf77P2BG3fW6udTcc2eaCr3Po2GXfObntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28jivVymtA%253D%253D&md5=b1ab30df28665605ce44ce1b5de385ff</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2016.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2016.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DC.-S.%26aulast%3DCho%26aufirst%3DB.-C.%26aulast%3DSoo%26aufirst%3DR.%2BA.%26atitle%3DNext-generation%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitors%2520in%2520epidermal%2520growth%2520factor%2520receptor%2520-mutant%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DLung%2520Cancer%26date%3D2016%26volume%3D93%26spage%3D59%26epage%3D68%26doi%3D10.1016%2Fj.lungcan.2016.01.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muhsin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkpatrick, P.</span></span> <span> </span><span class="NLM_article-title">Gefitinib</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">515</span>– <span class="NLM_lpage">516</span>, <span class="refDoi"> DOI: 10.1038/nrd1136</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1038%2Fnrd1136" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=12841190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BD3sXks1Oqsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2003&pages=515-516&author=M.+Muhsinauthor=J.+Grahamauthor=P.+Kirkpatrick&title=Gefitinib&doi=10.1038%2Fnrd1136"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Fresh from the pipeline: Gefitinib</span></div><div class="casAuthors">Muhsin, Mohamed; Graham, Joanne; Kirkpatrick, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">515-516</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Gefitinib (Iressa; AstraZeneca) is the first in a new class of targeted anticancer drugs that inhibit the tyrosine kinase activity of the epidermal growth factor receptor.  Following Japanese approval in 2002, gefitinib was approved by the US FDA in May 2003 for the treatment of advanced non-small-cell lung cancer after other treatment options have failed.  Despite several setbacks during the development of gefitinib, might it now be back on the path to blockbuster status.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiu6Whpw8u7rVg90H21EOLACvtfcHk0lhU-10IRrnHFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXks1Oqsr0%253D&md5=e9fb650f4d801eb2026a795db1b9f6bd</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnrd1136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1136%26sid%3Dliteratum%253Aachs%26aulast%3DMuhsin%26aufirst%3DM.%26aulast%3DGraham%26aufirst%3DJ.%26aulast%3DKirkpatrick%26aufirst%3DP.%26atitle%3DGefitinib%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2003%26volume%3D2%26spage%3D515%26epage%3D516%26doi%3D10.1038%2Fnrd1136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridhara, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">FDA drug approval summary: erlotinib (Tarceva) tablets</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">461</span>– <span class="NLM_lpage">466</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.10-7-461</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1634%2Ftheoncologist.10-7-461" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=461-466&author=M.+H.+Cohenauthor=J.+R.+Johnsonauthor=Y.+F.+Chenauthor=R.+Sridharaauthor=R.+Pazdur&title=FDA+drug+approval+summary%3A+erlotinib+%28Tarceva%29+tablets&doi=10.1634%2Ftheoncologist.10-7-461"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.10-7-461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.10-7-461%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DM.%2BH.%26aulast%3DJohnson%26aufirst%3DJ.%2BR.%26aulast%3DChen%26aufirst%3DY.%2BF.%26aulast%3DSridhara%26aufirst%3DR.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DFDA%2520drug%2520approval%2520summary%253A%2520erlotinib%2520%2528Tarceva%2529%2520tablets%26jtitle%3DOncologist%26date%3D2015%26volume%3D10%26spage%3D461%26epage%3D466%26doi%3D10.1634%2Ftheoncologist.10-7-461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peters, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adjei, A. A.</span></span> <span> </span><span class="NLM_article-title">Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug–drug interactions</span>. <i>Cancer Treat. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">917</span>– <span class="NLM_lpage">926</span>, <span class="refDoi"> DOI: 10.1016/j.ctrv.2014.06.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1016%2Fj.ctrv.2014.06.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=25027951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFGmtbrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2014&pages=917-926&author=S.+Petersauthor=S.+Zimmermannauthor=A.+A.+Adjei&title=Oral+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitors+for+the+treatment+of+non-small+cell+lung+cancer%3A+comparative+pharmacokinetics+and+drug%E2%80%93drug+interactions&doi=10.1016%2Fj.ctrv.2014.06.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: Comparative pharmacokinetics and drug-drug interactions</span></div><div class="casAuthors">Peters, Solange; Zimmermann, Stefan; Adjei, Alex A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">917-926</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The development of orally active small mol. inhibitors of the epidermal growth factor receptor (EGFR) has led to new treatment options for non-small cell lung cancer (NSCLC).  Patients with activating mutations of the EGFR gene show sensitivity to, and clin. benefit from, treatment with EGFR tyrosine kinase inhibitors (EGFR-TKls).  First generation reversible ATP-competitive EGFR-TKls, gefitinib and erlotinib, are effective as first, second-line or maintenance therapy.  Despite initial benefit, most patients develop resistance within a year, 50-60% of cases being related to the appearance of a T790M gatekeeper mutation.  Newer, irreversible EGFR-TKls - afatinib and dacomitinib - covalently bind to and inhibit multiple receptors in the ErbB family (EGFR, HER2 and HER4).  These agents have been mainly evaluated for first-line treatment but also in the setting of acquired resistance to first-generation EGFR-TKls.  Afatinib is the first ErbB family blocker approved for patients with NSCLC with activating EGFR mutations; dacomitinib is in late stage clin. development.  Mutant-selective EGFR inhibitors (AZD9291, CO-1686, HM61713) that specifically target the T790M resistance mutation are in early development.  The EGFR-TKIs differ in their spectrum of target kinases, reversibility of binding to EGFR receptor, pharmacokinetics and potential for drug-drug interactions, as discussed in this review.  For the clinician, these differences are relevant in the setting of polymedicated patients with NSCLC, as well as from the perspective of innovative anticancer drug combination strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLFElQmV4ha7Vg90H21EOLACvtfcHk0lhU-10IRrnHFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFGmtbrP&md5=31253f81e203aa012a5d87ad29ff6fc3</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2014.06.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2014.06.010%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DS.%26aulast%3DZimmermann%26aufirst%3DS.%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26atitle%3DOral%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520non-small%2520cell%2520lung%2520cancer%253A%2520comparative%2520pharmacokinetics%2520and%2520drug%25E2%2580%2593drug%2520interactions%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2014%26volume%3D40%26spage%3D917%26epage%3D926%26doi%3D10.1016%2Fj.ctrv.2014.06.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Molina, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassivi, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schild, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adjei, A. A.</span></span> <span> </span><span class="NLM_article-title">Non–small cell lung cancer: epidemiology, risk factors, treatment, and survivorship</span>. <i>Mayo Clin. Proc.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">584</span>– <span class="NLM_lpage">594</span>, <span class="refDoi"> DOI: 10.4065/83.5.584</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.4065%2F83.5.584" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=18452692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A280%3ADC%252BD1c3ovFyhtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2008&pages=584-594&author=J.+R.+Molinaauthor=P.+Yangauthor=S.+D.+Cassiviauthor=S.+E.+Schildauthor=A.+A.+Adjei&title=Non%E2%80%93small+cell+lung+cancer%3A+epidemiology%2C+risk+factors%2C+treatment%2C+and+survivorship&doi=10.4065%2F83.5.584"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship</span></div><div class="casAuthors">Molina Julian R; Yang Ping; Cassivi Stephen D; Schild Steven E; Adjei Alex A</div><div class="citationInfo"><span class="NLM_cas:title">Mayo Clinic proceedings</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">584-94</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Lung cancer is the leading cause of cancer-related mortality not only in the United States but also around the world.  In North America, lung cancer has become more predominant among former than current smokers.  Yet in some countries, such as China, which has experienced a dramatic increase in the cigarette smoking rate during the past 2 decades, a peak in lung cancer incidence is still expected.  Approximately two-thirds of adult Chinese men are smokers, representing one-third of all smokers worldwide.  Non-small cell lung cancer accounts for 85% of all lung cancer cases in the United States.  After the initial diagnosis, accurate staging of non-small cell lung cancer using computed tomography or positron emission tomography is crucial for determining appropriate therapy.  When feasible, surgical resection remains the single most consistent and successful option for cure.  However, close to 70% of patients with lung cancer present with locally advanced or metastatic disease at the time of diagnosis.  Chemotherapy is beneficial for patients with metastatic disease, and the administration of concurrent chemotherapy and radiation is indicated for stage III lung cancer.  The introduction of angiogenesis, epidermal growth factor receptor inhibitors, and other new anti-cancer agents is changing the present and future of this disease and will certainly increase the number of lung cancer survivors.  We identified studies for this review by searching the MEDLINE and PubMed databases for English-language articles published from January 1, 1980, through January 31, 2008.  Key terms used for this search included non-small cell lung cancer, adenocarcinoma, squamous cell carcinoma, bronchioalveolar cell carcinoma, large cell carcinoma, lung cancer epidemiology, genetics, survivorship, surgery, radiation therapy, chemotherapy, targeted therapy, bevacizumab, erlotinib, and epidermal growth factor receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSmyOu2OSFHeW52AMpI4GK2fW6udTcc2ebBKKyyG6jJZbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c3ovFyhtQ%253D%253D&md5=7d7f1147c10a3c6b0fd344757694b4aa</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.4065%2F83.5.584&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4065%252F83.5.584%26sid%3Dliteratum%253Aachs%26aulast%3DMolina%26aufirst%3DJ.%2BR.%26aulast%3DYang%26aufirst%3DP.%26aulast%3DCassivi%26aufirst%3DS.%2BD.%26aulast%3DSchild%26aufirst%3DS.%2BE.%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26atitle%3DNon%25E2%2580%2593small%2520cell%2520lung%2520cancer%253A%2520epidemiology%252C%2520risk%2520factors%252C%2520treatment%252C%2520and%2520survivorship%26jtitle%3DMayo%2520Clin.%2520Proc.%26date%3D2008%26volume%3D83%26spage%3D584%26epage%3D594%26doi%3D10.4065%2F83.5.584" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Politi, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somwar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zakowski, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kris, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varmus, H.</span></span> <span> </span><span class="NLM_article-title">Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain</span>. <i>PLoS Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>2</i></span>, <span class="NLM_elocation-id">e73</span> <span class="refDoi"> DOI: 10.1371/journal.pmed.0020073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1371%2Fjournal.pmed.0020073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=15737014" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A280%3ADC%252BD2MzjtVehsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&author=W.+Paoauthor=V.+A.+Millerauthor=K.+A.+Politiauthor=G.+J.+Rielyauthor=R.+Somwarauthor=M.+F.+Zakowskiauthor=M.+G.+Krisauthor=H.+Varmus&title=Acquired+resistance+of+lung+adenocarcinomas+to+gefitinib+or+erlotinib+is+associated+with+a+second+mutation+in+the+EGFR+kinase+domain&doi=10.1371%2Fjournal.pmed.0020073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain</span></div><div class="casAuthors">Pao William; Miller Vincent A; Politi Katerina A; Riely Gregory J; Somwar Romel; Zakowski Maureen F; Kris Mark G; Varmus Harold</div><div class="citationInfo"><span class="NLM_cas:title">PLoS medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e73</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Lung adenocarcinomas from patients who respond to the tyrosine kinase inhibitors gefitinib (Iressa) or erlotinib (Tarceva) usually harbor somatic gain-of-function mutations in exons encoding the kinase domain of the epidermal growth factor receptor (EGFR).  Despite initial responses, patients eventually progress by unknown mechanisms of "acquired" resistance.  METHODS AND FINDINGS:  We show that in two of five patients with acquired resistance to gefitinib or erlotinib, progressing tumors contain, in addition to a primary drug-sensitive mutation in EGFR, a secondary mutation in exon 20, which leads to substitution of methionine for threonine at position 790 (T790M) in the kinase domain.  Tumor cells from a sixth patient with a drug-sensitive EGFR mutation whose tumor progressed on adjuvant gefitinib after complete resection also contained the T790M mutation.  This mutation was not detected in untreated tumor samples.  Moreover, no tumors with acquired resistance had KRAS mutations, which have been associated with primary resistance to these drugs.  Biochemical analyses of transfected cells and growth inhibition studies with lung cancer cell lines demonstrate that the T790M mutation confers resistance to EGFR mutants usually sensitive to either gefitinib or erlotinib.  Interestingly, a mutation analogous to T790M has been observed in other kinases with acquired resistance to another kinase inhibitor, imatinib (Gleevec).  CONCLUSION:  In patients with tumors bearing gefitinib- or erlotinib-sensitive EGFR mutations, resistant subclones containing an additional EGFR mutation emerge in the presence of drug.  This observation should help guide the search for more effective therapy against a specific subset of lung cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcREkXMV3u1nwwMthz5_Rx5rfW6udTcc2eb1EARTGSSvIrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MzjtVehsw%253D%253D&md5=3e626105e0dea2a38997156ae513f56b</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pmed.0020073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pmed.0020073%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPoliti%26aufirst%3DK.%2BA.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DSomwar%26aufirst%3DR.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DVarmus%26aufirst%3DH.%26atitle%3DAcquired%2520resistance%2520of%2520lung%2520adenocarcinomas%2520to%2520gefitinib%2520or%2520erlotinib%2520is%2520associated%2520with%2520a%2520second%2520mutation%2520in%2520the%2520EGFR%2520kinase%2520domain%26jtitle%3DPLoS%2520Med.%26date%3D2005%26volume%3D2%26doi%3D10.1371%2Fjournal.pmed.0020073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of resistance to EGFR tyrosine kinase inhibitors</span>. <i>Acta Pharm. Sin. B</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">390</span>– <span class="NLM_lpage">401</span>, <span class="refDoi"> DOI: 10.1016/j.apsb.2015.07.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1016%2Fj.apsb.2015.07.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=26579470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A280%3ADC%252BC28rgtlOqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=390-401&author=L.+Huangauthor=L.+Fu&title=Mechanisms+of+resistance+to+EGFR+tyrosine+kinase+inhibitors&doi=10.1016%2Fj.apsb.2015.07.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of resistance to EGFR tyrosine kinase inhibitors</span></div><div class="casAuthors">Huang Lihua; Fu Liwu</div><div class="citationInfo"><span class="NLM_cas:title">Acta pharmaceutica Sinica. B</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">390-401</span>
        ISSN:<span class="NLM_cas:issn">2211-3835</span>.
    </div><div class="casAbstract">Since the discovery that non-small cell lung cancer (NSCLC) is driven by epidermal growth factor receptor (EGFR) mutations, the EGFR tyrosine kinase inhibitors (EGFR-TKIs, e.g., gefitinib and elrotinib) have been effectively used for clinical treatment.  However, patients eventually develop drug resistance.  Resistance to EGFR-TKIs is inevitable due to various mechanisms, such as the secondary mutation (T790M), activation of alternative pathways (c-Met, HGF, AXL), aberrance of the downstream pathways (K-RAS mutations, loss of PTEN), impairment of the EGFR-TKIs-mediated apoptosis pathway (BCL2-like 11/BIM deletion polymorphism), histologic transformation, ATP binding cassette (ABC) transporter effusion, etc.  Here we review and summarize the known resistant mechanisms to EGFR-TKIs and provide potential targets for development of new therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ-qtzzXrDFl75XHngOXiV_fW6udTcc2eb1EARTGSSvIrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rgtlOqsw%253D%253D&md5=8429fc78384f6e540b1fa8f6c57c363b</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.apsb.2015.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.apsb.2015.07.001%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DFu%26aufirst%3DL.%26atitle%3DMechanisms%2520of%2520resistance%2520to%2520EGFR%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DActa%2520Pharm.%2520Sin.%2520B%26date%3D2015%26volume%3D5%26spage%3D390%26epage%3D401%26doi%3D10.1016%2Fj.apsb.2015.07.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziehr, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agulnik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M.</span></span> <span> </span><span class="NLM_article-title">Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC</span>. <i>OncoTargets Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>2013</i></span>,  <span class="NLM_fpage">135</span>– <span class="NLM_lpage">143</span>, <span class="refDoi"> DOI: 10.2147/OTT.S23165</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.2147%2FOTT.S23165" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2013&publication_year=2013&pages=135-143&author=V.+Nelsonauthor=J.+Ziehrauthor=M.+Agulnikauthor=M.+Johnson&title=Afatinib%3A+emerging+next-generation+tyrosine+kinase+inhibitor+for+NSCLC&doi=10.2147%2FOTT.S23165"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.2147%2FOTT.S23165&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FOTT.S23165%26sid%3Dliteratum%253Aachs%26aulast%3DNelson%26aufirst%3DV.%26aulast%3DZiehr%26aufirst%3DJ.%26aulast%3DAgulnik%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DM.%26atitle%3DAfatinib%253A%2520emerging%2520next-generation%2520tyrosine%2520kinase%2520inhibitor%2520for%2520NSCLC%26jtitle%3DOncoTargets%2520Ther.%26date%3D2013%26volume%3D2013%26spage%3D135%26epage%3D143%26doi%3D10.2147%2FOTT.S23165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dungo, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keating, G. M.</span></span> <span> </span><span class="NLM_article-title">Afatinib: first global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">1503</span>– <span class="NLM_lpage">1515</span>, <span class="refDoi"> DOI: 10.1007/s40265-013-0111-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1007%2Fs40265-013-0111-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=23982599" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVWmurnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=1503-1515&author=R.+T.+Dungoauthor=G.+M.+Keating&title=Afatinib%3A+first+global+approval&doi=10.1007%2Fs40265-013-0111-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Afatinib: First Global Approval</span></div><div class="casAuthors">Dungo, Rosselle T.; Keating, Gillian M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1503-1515</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Afatinib, an irreversible inhibitor of the ErbB family of tyrosine kinases, is under development with Boehringer Ingelheim for the once-daily, oral treatment of cancer.  Afatinib downregulates ErbB signalling by covalently binding to epidermal growth factor receptor (EGFR), human epidermal growth factor receptor (HER) 2 and HER4, irreversibly inhibiting tyrosine kinase autophosphorylation.  It also inhibits transphosphorylation of HER3.  Oral afatinib (Gilotrif®) has been approved in the US for the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) who have tumors with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by a US FDA-approved test.  Afatinib has also been approved in Taiwan for the first-line treatment of patients with EGFR mutation-pos. NSCLC.  In addn., the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of afatinib (Giotrif) for the treatment of patients with locally advanced or metastatic NSCLC with activating EGFR mutations who are EGFR tyrosine kinase inhibitor naive.  Afatinib is also under regulatory review in Canada, Japan and other Asian countries.  This article summarizes the milestones in the development of afatinib, leading to this first approval in patients with metastatic NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdPcU5aIqrY7Vg90H21EOLACvtfcHk0lgScTAIVbZjgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVWmurnM&md5=21851cbfac56e2fffcba6c731f123cff</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1007%2Fs40265-013-0111-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-013-0111-6%26sid%3Dliteratum%253Aachs%26aulast%3DDungo%26aufirst%3DR.%2BT.%26aulast%3DKeating%26aufirst%3DG.%2BM.%26atitle%3DAfatinib%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2013%26volume%3D73%26spage%3D1503%26epage%3D1515%26doi%3D10.1007%2Fs40265-013-0111-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">U.S. Food and
Drug Administration</span>. <span> </span><span class="NLM_article-title">FDA Broadens
Afatinib Indication
to Previously Untreated, Metastatic NSCLC with Other Non-Resistant
EGFR Mutations</span>. <a href="https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm592558.htm" class="extLink">https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm592558.htm</a> (accessed Jan 16, <span class="NLM_year">2018</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=U.S.+Food+and%0ADrug+Administration&title=FDA+Broadens%0AAfatinib+Indication%0Ato+Previously+Untreated%2C+Metastatic+NSCLC+with+Other+Non-Resistant%0AEGFR+Mutations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DFDA%2520Broadens%250AAfatinib%2520Indication%250Ato%2520Previously%2520Untreated%252C%2520Metastatic%2520NSCLC%2520with%2520Other%2520Non-Resistant%250AEGFR%2520Mutations%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planchard, D.</span></span> <span> </span><span class="NLM_article-title">Next-generation EGFR tyrosine kinase inhibitors for treating EGFR-mutant lung cancer beyond first line</span>. <i>Front. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">76</span>, <span class="refDoi"> DOI: 10.3389/fmed.2016.00076</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.3389%2Ffmed.2016.00076" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2017&pages=76&author=I.+Sullivanauthor=D.+Planchard&title=Next-generation+EGFR+tyrosine+kinase+inhibitors+for+treating+EGFR-mutant+lung+cancer+beyond+first+line&doi=10.3389%2Ffmed.2016.00076"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.3389%2Ffmed.2016.00076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffmed.2016.00076%26sid%3Dliteratum%253Aachs%26aulast%3DSullivan%26aufirst%3DI.%26aulast%3DPlanchard%26aufirst%3DD.%26atitle%3DNext-generation%2520EGFR%2520tyrosine%2520kinase%2520inhibitors%2520for%2520treating%2520EGFR-mutant%2520lung%2520cancer%2520beyond%2520first%2520line%26jtitle%3DFront.%2520Med.%26date%3D2017%26volume%3D3%26spage%3D76%26doi%3D10.3389%2Ffmed.2016.00076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Y.</span></span> <span> </span><span class="NLM_article-title">Recent development of the second and third generation irreversible epidermal growth factor receptor inhibitors</span>. <i>Chem. Biodiversity</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>14</i></span>, <span class="NLM_elocation-id">e1600372</span> <span class="refDoi"> DOI: 10.1002/cbdv.201600372</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1002%2Fcbdv.201600372" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2017&author=W.+Hanauthor=Y.+Du&title=Recent+development+of+the+second+and+third+generation+irreversible+epidermal+growth+factor+receptor+inhibitors&doi=10.1002%2Fcbdv.201600372"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1002%2Fcbdv.201600372&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbdv.201600372%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DW.%26aulast%3DDu%26aufirst%3DY.%26atitle%3DRecent%2520development%2520of%2520the%2520second%2520and%2520third%2520generation%2520irreversible%2520epidermal%2520growth%2520factor%2520receptor%2520inhibitors%26jtitle%3DChem.%2520Biodiversity%26date%3D2017%26volume%3D14%26doi%3D10.1002%2Fcbdv.201600372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">U.S. Food and Drug Administration</span>. <span> </span><span class="NLM_article-title">Osimertinib (TAGRISSO)</span>. <a href="https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm549683.htm" class="extLink">https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm549683.htm</a> (accessed Jul 28, <span class="NLM_year">2017</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=U.S.+Food+and+Drug+Administration&title=Osimertinib+%28TAGRISSO%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DOsimertinib%2520%2528TAGRISSO%2529%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Finlay, M. R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bethel, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Box, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradbury, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butterworth, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chorley, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colclough, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D. A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grist, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassall, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemmitt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinowska, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McFarland, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orme, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkins, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkins, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waring, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrigley, G. L.</span></span> <span> </span><span class="NLM_article-title">Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">8249</span>– <span class="NLM_lpage">8267</span>, <span class="refDoi"> DOI: 10.1021/jm500973a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500973a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1KhurrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=8249-8267&author=M.+R.+V.+Finlayauthor=M.+Andertonauthor=S.+Ashtonauthor=P.+Ballardauthor=P.+A.+Bethelauthor=M.+R.+Boxauthor=R.+H.+Bradburyauthor=S.+J.+Brownauthor=S.+Butterworthauthor=A.+Campbellauthor=C.+Chorleyauthor=N.+Colcloughauthor=D.+A.+E.+Crossauthor=G.+S.+Currieauthor=M.+Gristauthor=L.+Hassallauthor=G.+B.+Hillauthor=D.+Jamesauthor=M.+Jamesauthor=P.+Kemmittauthor=T.+Klinowskaauthor=G.+Lamontauthor=S.+G.+Lamontauthor=N.+Martinauthor=H.+L.+McFarlandauthor=M.+J.+Mellorauthor=J.+P.+Ormeauthor=D.+Perkinsauthor=P.+Perkinsauthor=G.+Richmondauthor=P.+Smithauthor=R.+A.+Wardauthor=M.+J.+Waringauthor=D.+Whittakerauthor=S.+Wellsauthor=G.+L.+Wrigley&title=Discovery+of+a+potent+and+selective+EGFR+inhibitor+%28AZD9291%29+of+both+sensitizing+and+T790M+resistance+mutations+that+spares+the+wild+type+form+of+the+receptor&doi=10.1021%2Fjm500973a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor</span></div><div class="casAuthors">Finlay, M. Raymond V.; Anderton, Mark; Ashton, Susan; Ballard, Peter; Bethel, Paul A.; Box, Matthew R.; Bradbury, Robert H.; Brown, Simon J.; Butterworth, Sam; Campbell, Andrew; Chorley, Christopher; Colclough, Nicola; Cross, Darren A. E.; Currie, Gordon S.; Grist, Matthew; Hassall, Lorraine; Hill, George B.; James, Daniel; James, Michael; Kemmitt, Paul; Klinowska, Teresa; Lamont, Gillian; Lamont, Scott G.; Martin, Nathaniel; McFarland, Heather L.; Mellor, Martine J.; Orme, Jonathon P.; Perkins, David; Perkins, Paula; Richmond, Graham; Smith, Peter; Ward, Richard A.; Waring, Michael J.; Whittaker, David; Wells, Stuart; Wrigley, Gail L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8249-8267</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) inhibitors have been used clin. in the treatment of nonsmall-cell lung cancer (NSCLC) patients harboring sensitizing (or activating) mutations for a no. of years.  Despite encouraging clin. efficacy with these agents, in many patients resistance develops leading to disease progression.  In most cases, this resistance is in the form of the T790M mutation.  In addn., EGFR wild type receptor inhibition inherent with these agents can lead to dose limiting toxicities of rash and diarrhea.  The authors describe herein the evolution of an early, mutant selective lead to the clin. candidate AZD9291 I, an irreversible inhibitor of both EGFR sensitizing (EGFRm+) and T790M resistance mutations with selectivity over the wild type form of the receptor.  Following observations of significant tumor inhibition in preclin. models, the clin. candidate was administered clin. to patients with T790M pos. EGFR-TKI resistant NSCLC and early efficacy has been obsd., accompanied by an encouraging safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouPAWG9N0Ro7Vg90H21EOLACvtfcHk0lgSV6MBZoL0eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1KhurrI&md5=db9db624bb4324c2e22b1ab12035263b</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm500973a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500973a%26sid%3Dliteratum%253Aachs%26aulast%3DFinlay%26aufirst%3DM.%2BR.%2BV.%26aulast%3DAnderton%26aufirst%3DM.%26aulast%3DAshton%26aufirst%3DS.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DBethel%26aufirst%3DP.%2BA.%26aulast%3DBox%26aufirst%3DM.%2BR.%26aulast%3DBradbury%26aufirst%3DR.%2BH.%26aulast%3DBrown%26aufirst%3DS.%2BJ.%26aulast%3DButterworth%26aufirst%3DS.%26aulast%3DCampbell%26aufirst%3DA.%26aulast%3DChorley%26aufirst%3DC.%26aulast%3DColclough%26aufirst%3DN.%26aulast%3DCross%26aufirst%3DD.%2BA.%2BE.%26aulast%3DCurrie%26aufirst%3DG.%2BS.%26aulast%3DGrist%26aufirst%3DM.%26aulast%3DHassall%26aufirst%3DL.%26aulast%3DHill%26aufirst%3DG.%2BB.%26aulast%3DJames%26aufirst%3DD.%26aulast%3DJames%26aufirst%3DM.%26aulast%3DKemmitt%26aufirst%3DP.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DLamont%26aufirst%3DG.%26aulast%3DLamont%26aufirst%3DS.%2BG.%26aulast%3DMartin%26aufirst%3DN.%26aulast%3DMcFarland%26aufirst%3DH.%2BL.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DPerkins%26aufirst%3DD.%26aulast%3DPerkins%26aufirst%3DP.%26aulast%3DRichmond%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26aulast%3DWhittaker%26aufirst%3DD.%26aulast%3DWells%26aufirst%3DS.%26aulast%3DWrigley%26aufirst%3DG.%2BL.%26atitle%3DDiscovery%2520of%2520a%2520potent%2520and%2520selective%2520EGFR%2520inhibitor%2520%2528AZD9291%2529%2520of%2520both%2520sensitizing%2520and%2520T790M%2520resistance%2520mutations%2520that%2520spares%2520the%2520wild%2520type%2520form%2520of%2520the%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D8249%26epage%3D8267%26doi%3D10.1021%2Fjm500973a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">U.S. Food and Drug Administration</span>. <span> </span><span class="NLM_article-title">FDA Approves Osimertinib for First-Line
Treatment of Metastatic NSCLC with Most Common EGFR Mutations</span>. <a href="https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm605113.htm" class="extLink">https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm605113.htm</a> (accessed Apr 19, <span class="NLM_year">2018</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=U.S.+Food+and+Drug+Administration&title=FDA+Approves+Osimertinib+for+First-Line%0ATreatment+of+Metastatic+NSCLC+with+Most+Common+EGFR+Mutations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DFDA%2520Approves%2520Osimertinib%2520for%2520First-Line%250ATreatment%2520of%2520Metastatic%2520NSCLC%2520with%2520Most%2520Common%2520EGFR%2520Mutations%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, D. B.</span></span> <span> </span><span class="NLM_article-title">The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer</span>. <i>Expert Rev. Anticancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">383</span>– <span class="NLM_lpage">390</span>, <span class="refDoi"> DOI: 10.1586/14737140.2016.1162103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1586%2F14737140.2016.1162103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=26943236" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BC28Xks1yhtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=383-390&author=X.+Gaoauthor=X.+Leauthor=D.+B.+Costa&title=The+safety+and+efficacy+of+osimertinib+for+the+treatment+of+EGFR+T790M+mutation+positive+non-small-cell+lung+cancer&doi=10.1586%2F14737140.2016.1162103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer</span></div><div class="casAuthors">Gao, Xin; Le, Xiuning; Costa, Daniel B.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anticancer Therapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">383-390</span>CODEN:
                <span class="NLM_cas:coden">ERATBJ</span>;
        ISSN:<span class="NLM_cas:issn">1473-7140</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">First- and second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the evidence-based first-line treatment for metastatic non-small-cell lung cancers (NSCLCs) that harbor sensitizing EGFR mutations (i.e. exon 19 deletions or L858R).  However, acquired resistance to EGFR TKI monotherapy occurs invariably within a median time frame of one year.  The most common form of biol. resistance is through the selection of tumor clones harboring the EGFR T790M mutation, present in >50% of repeat biopsies.  The presence of the EGFR T790M mutation negates the inhibitory activity of gefitinib, erlotinib, and afatinib.  A novel class of third-generation EGFR TKIs has been identified by probing a series of covalent pyrimidine EGFR inhibitors that bind to amino-acid residue C797 of EGFR and preferentially inhibit mutant forms of EGFR vs. the wild-type receptor.  We review the rapid clin. development and approval of the third-generation EGFR TKI osimertinib for treatment of NSCLCs with EGFR-T790M.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnBfOip3HqtrVg90H21EOLACvtfcHk0lgqBaJfmxDE_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xks1yhtb0%253D&md5=6fd22c935476d396b1560f9a784cb9df</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1586%2F14737140.2016.1162103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14737140.2016.1162103%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DX.%26aulast%3DLe%26aufirst%3DX.%26aulast%3DCosta%26aufirst%3DD.%2BB.%26atitle%3DThe%2520safety%2520and%2520efficacy%2520of%2520osimertinib%2520for%2520the%2520treatment%2520of%2520EGFR%2520T790M%2520mutation%2520positive%2520non-small-cell%2520lung%2520cancer%26jtitle%3DExpert%2520Rev.%2520Anticancer%2520Ther.%26date%3D2016%26volume%3D16%26spage%3D383%26epage%3D390%26doi%3D10.1586%2F14737140.2016.1162103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Z.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.-J.</span></span> <span> </span><span class="NLM_article-title">Osimertinib resistance in non-small cell lung cancer: mechanisms and therapeutic strategies</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>420</i></span>,  <span class="NLM_fpage">242</span>– <span class="NLM_lpage">246</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2018.02.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1016%2Fj.canlet.2018.02.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=29425688" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjtFalt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=420&publication_year=2018&pages=242-246&author=Z.-H.+Tangauthor=J.-J.+Lu&title=Osimertinib+resistance+in+non-small+cell+lung+cancer%3A+mechanisms+and+therapeutic+strategies&doi=10.1016%2Fj.canlet.2018.02.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies</span></div><div class="casAuthors">Tang, Zheng-Hai; Lu, Jin-Jian</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">420</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">242-246</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Given the successful identification of epidermal growth factor receptor EGFR T790M, the third-generation EGFR tyrosine kinase inhibitor (TKI), osimertinib (OSI, AZD9291), was developed to target EGFR T790M mutation.  OSI was approved for the treatment of patients with non-small cell lung cancer (NSCLC) harboring EGFR T790M mutation.  However, the disease would progress after the patient received OSI treatment for approx. 10 mo.  Resistance mechanisms to OSI, such as addnl. mutation of EGFR and alternative kinase activation, were recently identified, and some novel therapeutic strategies were proposed to overcome OSI resistance.  In this review, the resistance mechanisms and therapeutic strategies for OSI-resistant NSCLC were summarized to direct further use of OSI and aid in the development of novel drugs or strategies for OSI-resistant NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7MEZOSD4CQrVg90H21EOLACvtfcHk0lgqBaJfmxDE_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjtFalt74%253D&md5=a2f1d0d576a24d137bd23584f40df973</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2018.02.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2018.02.004%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DZ.-H.%26aulast%3DLu%26aufirst%3DJ.-J.%26atitle%3DOsimertinib%2520resistance%2520in%2520non-small%2520cell%2520lung%2520cancer%253A%2520mechanisms%2520and%2520therapeutic%2520strategies%26jtitle%3DCancer%2520Lett.%26date%3D2018%26volume%3D420%26spage%3D242%26epage%3D246%26doi%3D10.1016%2Fj.canlet.2018.02.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Russo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franchina, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricciardi, G. R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smiroldo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picciotto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanghì, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolfo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adamo, V.</span></span> <span> </span><span class="NLM_article-title">Third generation EGFR TKIs in EGFR-mutated NSCLC: where are we now and where are we going</span>. <i>Crit. Rev. Oncol. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">38</span>– <span class="NLM_lpage">47</span>, <span class="refDoi"> DOI: 10.1016/j.critrevonc.2017.07.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1016%2Fj.critrevonc.2017.07.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=28807234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A280%3ADC%252BC1cfnsVyktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2017&pages=38-47&author=A.+Russoauthor=T.+Franchinaauthor=G.+R.+R.+Ricciardiauthor=V.+Smiroldoauthor=M.+Picciottoauthor=M.+Zangh%C3%ACauthor=C.+Rolfoauthor=V.+Adamo&title=Third+generation+EGFR+TKIs+in+EGFR-mutated+NSCLC%3A+where+are+we+now+and+where+are+we+going&doi=10.1016%2Fj.critrevonc.2017.07.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going</span></div><div class="casAuthors">Russo A; Franchina T; Ricciardi G R R; Smiroldo V; Picciotto M; Zanghi M; Rolfo C; Adamo V</div><div class="citationInfo"><span class="NLM_cas:title">Critical reviews in oncology/hematology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">38-47</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The therapeutic landscape of Non Small Lung Cancer (NSCLC) has been profoundly changed over the last decade with the clinical introduction of Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors (TKIs) and the discovery of EGFR activating mutations as the major predictive factor to these agents.  Despite impressive clinical activity against EGFR-mutated NSCLCs, the benefit seen with 1st and 2nd generation EGFR TKIs is usually transient and virtually all patients become resistant.  Several different mechanisms of acquired resistance have been reported to date, but the vast majority of patients develop a secondary exon 20 mutation in the ATP-binding site of EGFR, namely T790M.  The discovery of mutant-selective EGFR TKIs that selectively inhibit EGFR-mutants, including T790M-harboring NSCLCs, while sparing EGFR wild type, provide the opportunity for overcoming the major mechanism of acquired resistance to 1st and 2nd generation EGFR TKIs, with a relatively favorable toxicity profile.  The development of this novel class of EGFR inhibitors poses novel challenges in the rapidly evolving therapeutic paradigm of EGFR-mutated NSCLCs and the next few years will witness the beginning of a new era for EGFR inhibition in lung cancer.  The aim of this paper is to provide a comprehensive overview of the increasing body of data emerging from the ongoing clinical trials with this promising novel therapeutic class of EGFR inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRY-2a_VQlONY2y4bB4mnvYfW6udTcc2easH7e0W_GP-bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cfnsVyktA%253D%253D&md5=216afe73f667516142ebd4eb04425a57</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.critrevonc.2017.07.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.critrevonc.2017.07.003%26sid%3Dliteratum%253Aachs%26aulast%3DRusso%26aufirst%3DA.%26aulast%3DFranchina%26aufirst%3DT.%26aulast%3DRicciardi%26aufirst%3DG.%2BR.%2BR.%26aulast%3DSmiroldo%26aufirst%3DV.%26aulast%3DPicciotto%26aufirst%3DM.%26aulast%3DZangh%25C3%25AC%26aufirst%3DM.%26aulast%3DRolfo%26aufirst%3DC.%26aulast%3DAdamo%26aufirst%3DV.%26atitle%3DThird%2520generation%2520EGFR%2520TKIs%2520in%2520EGFR-mutated%2520NSCLC%253A%2520where%2520are%2520we%2520now%2520and%2520where%2520are%2520we%2520going%26jtitle%3DCrit.%2520Rev.%2520Oncol.%2520Hematol.%26date%3D2017%26volume%3D117%26spage%3D38%26epage%3D47%26doi%3D10.1016%2Fj.critrevonc.2017.07.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smaill, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">Targeting EGFRL858R/T790M and EGFRL858R/T790M/C797S resistance mutations in NSCLC: current developments in medicinal chemistry</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">1550</span>– <span class="NLM_lpage">1581</span>, <span class="refDoi"> DOI: 10.1002/med.21488</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1002%2Fmed.21488" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=29377179" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVyqu73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2018&pages=1550-1581&author=X.+Luauthor=L.+Yuauthor=Z.+Zhangauthor=X.+Renauthor=J.+B.+Smaillauthor=K.+Ding&title=Targeting+EGFRL858R%2FT790M+and+EGFRL858R%2FT790M%2FC797S+resistance+mutations+in+NSCLC%3A+current+developments+in+medicinal+chemistry&doi=10.1002%2Fmed.21488"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting EGFRL858R/T790M and EGFRL858R/T790M/C797S resistance mutations in NSCLC: Current developments in medicinal chemistry</span></div><div class="casAuthors">Lu, Xiaoyun; Yu, Lei; Zhang, Zhang; Ren, Xiaomei; Smaill, Jeff B.; Ding, Ke</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1550-1581</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Both the first-generation reversible epidermal growth factor receptor (EGFR) inhibitors gefitinib and erlotinib and the second-generation covalent epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) afatinib have significantly improved the survival of non-small-cell lung cancer (NSCLC) patients with activating EGFR mutations.  However, a secondary EGFRT790M mutation leads to the clin. acquired resistance to the first- and second-generation EGFR-TKIs drugs.  A no. of the third-generation wild-type sparing EGFR inhibitors, for example, WZ4002, CO1686, AZD9291, HM61713, EGF816, ASP8173, and PF0674775, have been developed, among which AZD9291 has been approved by US FDA for the treatment of NSCLC patients with EGFRT790M.  More recently, a tertiary EGFRC797S mutation was reported as the dominant resistance mechanism to the third-generation irreversible inhibitors.  It is highly desirable to develop the fourth-generation EGFR inhibitors.  This review summarizes the mechanisms of acquired resistance and the latest medicinal chem. advances on the third- and fourth-generation EGFR inhibitors, with special attention being paid to the allosteric and reversible inhibitors combating the tertiary EGFRC797S mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNK_1c8SI0qbVg90H21EOLACvtfcHk0lhyNtX8pI2NRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVyqu73P&md5=71288118ca1d9eaab6d07b056bb5ab56</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1002%2Fmed.21488&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21488%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DTargeting%2520EGFRL858R%252FT790M%2520and%2520EGFRL858R%252FT790M%252FC797S%2520resistance%2520mutations%2520in%2520NSCLC%253A%2520current%2520developments%2520in%2520medicinal%2520chemistry%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2018%26volume%3D38%26spage%3D1550%26epage%3D1581%26doi%3D10.1002%2Fmed.21488" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">U.S. Food and Drug Administration</span>. <span> </span><span class="NLM_article-title">FDA Approves Dacomitinib for Metastatic
Non-Small Cell Lung Cancer</span>. <a href="https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm621967.htm" class="extLink">https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm621967.htm</a> (accessed Sep 28, <span class="NLM_year">2018</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=U.S.+Food+and+Drug+Administration&title=FDA+Approves+Dacomitinib+for+Metastatic%0ANon-Small+Cell+Lung+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DFDA%2520Approves%2520Dacomitinib%2520for%2520Metastatic%250ANon-Small%2520Cell%2520Lung%2520Cancer%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niho, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuji, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linke, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corral, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Migliorino, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pluzanski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sbar, E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadanaciva, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mok, T. S.</span></span> <span> </span><span class="NLM_article-title">Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1454</span>– <span class="NLM_lpage">1466</span>, <span class="refDoi"> DOI: 10.1016/s1470-2045(17)30608-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1016%2Fs1470-2045%2817%2930608-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=28958502" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFGntLfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=1454-1466&author=Y.-L.+Wuauthor=Y.+Chengauthor=X.+Zhouauthor=K.+H.+Leeauthor=K.+Nakagawaauthor=S.+Nihoauthor=F.+Tsujiauthor=R.+Linkeauthor=R.+Rosellauthor=J.+Corralauthor=M.+R.+Migliorinoauthor=A.+Pluzanskiauthor=E.+I.+Sbarauthor=T.+Wangauthor=J.+L.+Whiteauthor=S.+Nadanacivaauthor=R.+Sandinauthor=T.+S.+Mok&title=Dacomitinib+versus+gefitinib+as+first-line+treatment+for+patients+with+EGFR-mutation-positive+non-small-cell+lung+cancer+%28ARCHER+1050%29%3A+a+randomised%2C+open-label%2C+phase+3+trial&doi=10.1016%2Fs1470-2045%2817%2930608-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial</span></div><div class="casAuthors">Wu, Yi-Long; Cheng, Ying; Zhou, Xiangdong; Lee, Ki Hyeong; Nakagawa, Kazuhiko; Niho, Seiji; Tsuji, Fumito; Linke, Rolf; Rosell, Rafael; Corral, Jesus; Migliorino, Maria Rita; Pluzanski, Adam; Sbar, Eric I.; Wang, Tao; White, Jane Liang; Nadanaciva, Sashi; Sandin, Rickard; Mok, Tony S.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1454-1466</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Dacomitinib is a second-generation, irreversible EGFR tyrosine kinase inhibitor.  We compared its efficacy and safety with that of the reversible EGFR tyrosine kinase inhibitor gefitinib in the first-line treatment of patients with advanced EGFR-mutation-pos. non-small-cell lung cancer (NSCLC).  In this international, multicenter, randomized, open-label, phase 3 study (ARCHER 1050), we enrolled adults (aged ≥18 years or ≥20 years in Japan and South Korea) with newly diagnosed advanced NSCLC and one EGFR mutation (exon 19 deletion or Leu858Arg) at 71 academic medical centers and university hospitals in seven countries or special administrative regions.  We randomly assigned participants (1:1) to receive oral dacomitinib 45 mg/day (in 28-day cycles) or oral gefitinib 250 mg/day (in 28-day cycles) until disease progression or another discontinuation criterion was met.  Randomisation, stratified by race and EGFR mutation type, was done with a computer-generated random code assigned by a central interactive web response system.  The primary endpoint was progression-free survival assessed by masked independent review in the intention-to-treat population.  Safety was assessed in all patients who received at least one dose of study treatment.  This study is registered with ClinicalTrials.gov, no. NCT01774721, and is ongoing but no longer recruiting patients.  Between May 9, 2013, and March 20, 2015, 452 eligible patients were randomly assigned to receive dacomitinib (n=227) or gefitinib (n=225).  Median duration of follow-up for progression-free survival was 22·1 mo (95% CI 20·3-23·9).  Median progression-free survival according to masked independent review was 14·7 mo (95% CI 11·1-16·6) in the dacomitinib group and 9·2 mo (9·1-11·0) in the gefitinib group (hazard ratio 0·59, 95% CI 0·47-0·74; p<0·0001).  The most common grade 3-4 adverse events were dermatitis acneiform (31 [14%] of 227 patients given dacomitinib vs none of 224 patients given gefitinib), diarrhea (19 [8%] vs two [1%]), and raised alanine aminotransferase levels (two [1%] vs 19 [8%]).  Treatment-related serious adverse events were reported in 21 (9%) patients given dacomitinib and in ten (4%) patients given gefitinib.  Two treatment-related deaths occurred in the dacomitinib group (one related to untreated diarrhea and one to untreated cholelithases/liver disease) and one in the gefitinib group (related to sigmoid colon diverticulitis/rupture complicated by pneumonia).  Dacomitinib significantly improved progression-free survival over gefitinib in first-line treatment of patients with EGFR-mutation-pos. NSCLC and should be considered as a new treatment option for this population.  SFJ Pharmaceuticals Group and Pfizer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqZ8AKr7cDZLVg90H21EOLACvtfcHk0lhyNtX8pI2NRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFGntLfI&md5=89eb8749060bfa3dfe79a84537b2b27b</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fs1470-2045%2817%2930608-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs1470-2045%252817%252930608-3%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DY.-L.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3DNakagawa%26aufirst%3DK.%26aulast%3DNiho%26aufirst%3DS.%26aulast%3DTsuji%26aufirst%3DF.%26aulast%3DLinke%26aufirst%3DR.%26aulast%3DRosell%26aufirst%3DR.%26aulast%3DCorral%26aufirst%3DJ.%26aulast%3DMigliorino%26aufirst%3DM.%2BR.%26aulast%3DPluzanski%26aufirst%3DA.%26aulast%3DSbar%26aufirst%3DE.%2BI.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DWhite%26aufirst%3DJ.%2BL.%26aulast%3DNadanaciva%26aufirst%3DS.%26aulast%3DSandin%26aufirst%3DR.%26aulast%3DMok%26aufirst%3DT.%2BS.%26atitle%3DDacomitinib%2520versus%2520gefitinib%2520as%2520first-line%2520treatment%2520for%2520patients%2520with%2520EGFR-mutation-positive%2520non-small-cell%2520lung%2520cancer%2520%2528ARCHER%25201050%2529%253A%2520a%2520randomised%252C%2520open-label%252C%2520phase%25203%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2017%26volume%3D18%26spage%3D1454%26epage%3D1466%26doi%3D10.1016%2Fs1470-2045%2817%2930608-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coumar, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiao, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leou, J.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lien, T.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, M.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chittimalla, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J. T.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, H.-P.</span></span> <span> </span><span class="NLM_article-title">Fast-forwarding hit to lead: aurora and epidermal growth factor receptor kinase inhibitor lead identification</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">4980</span>– <span class="NLM_lpage">4988</span>, <span class="refDoi"> DOI: 10.1021/jm1000198</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1000198" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnsFyhs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=4980-4988&author=M.+S.+Coumarauthor=C.-Y.+Chuauthor=C.-W.+Linauthor=H.-Y.+Shiaoauthor=Y.-L.+Hoauthor=R.+Reddyauthor=W.-H.+Linauthor=C.-H.+Chenauthor=Y.-H.+Pengauthor=J.-S.+Leouauthor=T.-W.+Lienauthor=C.-T.+Huangauthor=M.-Y.+Fangauthor=S.-H.+Wuauthor=J.-S.+Wuauthor=S.+K.+Chittimallaauthor=J.-S.+Songauthor=J.+T.-A.+Hsuauthor=S.-Y.+Wuauthor=C.-C.+Liaoauthor=Y.-S.+Chaoauthor=H.-P.+Hsieh&title=Fast-forwarding+hit+to+lead%3A+aurora+and+epidermal+growth+factor+receptor+kinase+inhibitor+lead+identification&doi=10.1021%2Fjm1000198"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Fast-Forwarding Hit to Lead: Aurora and Epidermal Growth Factor Receptor Kinase Inhibitor Lead Identification</span></div><div class="casAuthors">Coumar, Mohane Selvaraj; Chu, Chang-Ying; Lin, Cheng-Wei; Shiao, Hui-Yi; Ho, Yun-Lung; Reddy, Randheer; Lin, Wen-Hsing; Chen, Chun-Hwa; Peng, Yi-Hui; Leou, Jiun-Shyang; Lien, Tzu-Wen; Huang, Chin-Ting; Fang, Ming-Yu; Wu, Szu-Huei; Wu, Jian-Sung; Chittimalla, Santhosh Kumar; Song, Jen-Shin; Hsu, John T.-A.; Wu, Su-Ying; Liao, Chun-Chen; Chao, Yu-Sheng; Hsieh, Hsing-Pang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4980-4988</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Furanopyrimidines such as I [R = (S)-HOCH2CHPh; R1 = 3-(H2C:CCONH)C6H4] are prepd. as Aurora A kinase and epidermal growth factor receptor (EGFR) inhibitors by prepn. of a combinatorial library of approx. 350 furanopyridines and optimization of the inhibitors found from the library.  The initial hit compd. I (R = HOCH2CH2; R1 = Ph) was modified to better fit the back pocket to produce the potent Aurora A kinase inhibitor I (R = 4-PhNHCONHC6H4; R1 = Ph) with submicromolar antiproliferative activity in the HCT-116 human colon cancer cell line.  On the basis of docking studies with EGFR hit I [R = (S)-HOCH2CHPh; R1 = Ph], introduction of an acrylamide Michael acceptor group led to I [R = (S)-HOCH2CHPh; R1 = 3-(H2C:CCONH)C6H4], which inhibited both the wild and mutant EGFR kinases and also showed antiproliferative activity in the gefitinib-resistant HCC827 human lung cancer cells.  The X-ray cocrystal structures of I (R = HOCH2CH2, 4-PhNHCONHC6H4; R1 = Ph) bound to Aurora A kinase and the crystal structure of I [R = (S)-HOCH2CHPh; R1 = 3-(H2C:CCONH)C6H4] bound to EGFR confirmed their hypothesized binding modes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCOPMtJ1xilrVg90H21EOLACvtfcHk0lhk_rMJvwd04Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnsFyhs7s%253D&md5=8064e99d8d31603c7186b5fa33e019a6</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm1000198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1000198%26sid%3Dliteratum%253Aachs%26aulast%3DCoumar%26aufirst%3DM.%2BS.%26aulast%3DChu%26aufirst%3DC.-Y.%26aulast%3DLin%26aufirst%3DC.-W.%26aulast%3DShiao%26aufirst%3DH.-Y.%26aulast%3DHo%26aufirst%3DY.-L.%26aulast%3DReddy%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DW.-H.%26aulast%3DChen%26aufirst%3DC.-H.%26aulast%3DPeng%26aufirst%3DY.-H.%26aulast%3DLeou%26aufirst%3DJ.-S.%26aulast%3DLien%26aufirst%3DT.-W.%26aulast%3DHuang%26aufirst%3DC.-T.%26aulast%3DFang%26aufirst%3DM.-Y.%26aulast%3DWu%26aufirst%3DS.-H.%26aulast%3DWu%26aufirst%3DJ.-S.%26aulast%3DChittimalla%26aufirst%3DS.%2BK.%26aulast%3DSong%26aufirst%3DJ.-S.%26aulast%3DHsu%26aufirst%3DJ.%2BT.-A.%26aulast%3DWu%26aufirst%3DS.-Y.%26aulast%3DLiao%26aufirst%3DC.-C.%26aulast%3DChao%26aufirst%3DY.-S.%26aulast%3DHsieh%26aufirst%3DH.-P.%26atitle%3DFast-forwarding%2520hit%2520to%2520lead%253A%2520aurora%2520and%2520epidermal%2520growth%2520factor%2520receptor%2520kinase%2520inhibitor%2520lead%2520identification%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D4980%26epage%3D4988%26doi%3D10.1021%2Fjm1000198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagar, B.</span></span> <span> </span><span class="NLM_article-title">c-Abl tyrosine kinase and inhibition by the cancer drug imatinib (Gleevec/STI-571)</span>. <i>J. Nutr.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">1518S</span>– <span class="NLM_lpage">1523S</span>, <span class="refDoi"> DOI: 10.1093/jn/137.6.1518s</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1093%2Fjn%2F137.6.1518s" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=17513418" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmt1elur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2007&pages=1518S-1523S&author=B.+Nagar&title=c-Abl+tyrosine+kinase+and+inhibition+by+the+cancer+drug+imatinib+%28Gleevec%2FSTI-571%29&doi=10.1093%2Fjn%2F137.6.1518s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">c-Abl tyrosine kinase and inhibition by the cancer drug imatinib (Gleevec/STI-571)</span></div><div class="casAuthors">Nagar, Bhushan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nutrition</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">6S-1</span>),
    <span class="NLM_cas:pages">1518S-1523S</span>CODEN:
                <span class="NLM_cas:coden">JONUAI</span>;
        ISSN:<span class="NLM_cas:issn">0022-3166</span>.
    
            (<span class="NLM_cas:orgname">American Society for Nutrition</span>)
        </div><div class="casAbstract">The search for specific protein kinase inhibitors is an intense area of research because of the potential for drug development.  The small-mol. inhibitor imatinib (Gleevec/STI-571) can specifically inactivate the tyrosine kinase c-Abl, whose normal mechanism of autoinhibition is disrupted in chronic myelogenous leukemia.  Crystallog. anal. of c-Abl reveals that imatinib recognizes a distinct inactive conformation of the Abl kinase domain that relies on the mechanism of autoinhibition achieved in the context of a larger fragment of the protein.  This mechanism is distinct from that seen in the related Src family kinases, where autoinhibition is achieved through the internal engagement of a C-terminal phosphotyrosine residue by the Src homol. 2 domain (SH2) domain.  Notably, this phosphotyrosine residue is lacking in c-Abl, where instead autoinhibition is mediated by an interaction between the kinase domain and the N-terminal myristoyl modification.  Within the framework of these 2 distinct modes of autoinhibition, the SH3-SH2 unit is structurally conserved between Abl and Src, leading to large conformational differences in their kinase domains.  These differences help explain the ability of imatinib to preferentially inhibit Abl over Src.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbSjfYUuL1FLVg90H21EOLACvtfcHk0lhk_rMJvwd04Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmt1elur4%253D&md5=8c11f5f4abed3ab4b86ad99158ef0d8d</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1093%2Fjn%2F137.6.1518s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjn%252F137.6.1518s%26sid%3Dliteratum%253Aachs%26aulast%3DNagar%26aufirst%3DB.%26atitle%3Dc-Abl%2520tyrosine%2520kinase%2520and%2520inhibition%2520by%2520the%2520cancer%2520drug%2520imatinib%2520%2528Gleevec%252FSTI-571%2529%26jtitle%3DJ.%2520Nutr.%26date%3D2007%26volume%3D137%26spage%3D1518S%26epage%3D1523S%26doi%3D10.1093%2Fjn%2F137.6.1518s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, S. R.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">5572</span>– <span class="NLM_lpage">5581</span>, <span class="refDoi"> DOI: 10.1093/emboj/16.18.5572</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1093%2Femboj%2F16.18.5572" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=9312016" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADyaK2sXmsFWmt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1997&pages=5572-5581&author=S.+R.+Hubbard&title=Crystal+structure+of+the+activated+insulin+receptor+tyrosine+kinase+in+complex+with+peptide+substrate+and+ATP+analog&doi=10.1093%2Femboj%2F16.18.5572"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog</span></div><div class="casAuthors">Hubbard, Stevan R.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5572-5581</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The crystal structure of the phosphorylated, activated form of insulin receptor tyrosine kinase (I) in complex with an 18-residue peptide substrate (KKKLPATGDYMNMSPVGD), and the nonhydrolyzable ATP analog, AMP-PNP, was detd. at 1.9 Å resoln.  The activation loop (A-loop) of I undergoes a major conformational change upon autophosphorylation of Tyr-1158, Tyr-1162, and Tyr-1163 within the loop, resulting in unrestricted access of ATP and protein substrates to the I active site.  Phosphorylated Tyr-1163 (pTyr-1163) was the key phospho-Tyr group in stabilizing the conformation of the tris-phosphorylated A-loop, whereas pTyr-1158 was completely solvent-exposed, suggesting an availability for interaction with downstream signaling proteins.  The YMXM-contg. peptide substrate bound as a short anti-parallel β-strand to the C-terminal end of the A-loop, with the Met side-chains occupying 2 hydrophobic pockets on the C-terminal lobe of I.  The structure thus reveals the mol. basis for insulin receptor activation via autophosphorylation, and provides insights into I substrate specificity and the mechanism of phosphotransfer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlJGdy9gorfbVg90H21EOLACvtfcHk0lhk_rMJvwd04Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmsFWmt74%253D&md5=99c1865418541c085220185310b7b533</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1093%2Femboj%2F16.18.5572&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Femboj%252F16.18.5572%26sid%3Dliteratum%253Aachs%26aulast%3DHubbard%26aufirst%3DS.%2BR.%26atitle%3DCrystal%2520structure%2520of%2520the%2520activated%2520insulin%2520receptor%2520tyrosine%2520kinase%2520in%2520complex%2520with%2520peptide%2520substrate%2520and%2520ATP%2520analog%26jtitle%3DEMBO%2520J.%26date%3D1997%26volume%3D16%26spage%3D5572%26epage%3D5581%26doi%3D10.1093%2Femboj%2F16.18.5572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, N. P.</span></span> <span> </span><span class="NLM_article-title">Ins and outs of kinase DFG motifs</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">745</span>– <span class="NLM_lpage">746</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2013.06.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1016%2Fj.chembiol.2013.06.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=23790484" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVWgtLrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=745-746&author=D.+K.+Treiberauthor=N.+P.+Shah&title=Ins+and+outs+of+kinase+DFG+motifs&doi=10.1016%2Fj.chembiol.2013.06.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Ins and Outs of Kinase DFG Motifs</span></div><div class="casAuthors">Treiber, Daniel K.; Shah, Neil P.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">745-746</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  In this issue of Chem. & Biol., Hari and colleagues show that two positions in kinase active sites, including the well-known "gatekeeper" residue, regulate "in" vs. "out" conformations of the conserved "DFG" motif.  These findings suggest yet another role for the gatekeeper residue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXsx2RYZgddLVg90H21EOLACvtfcHk0ljw2V7ZVwfwyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVWgtLrI&md5=f2c8ebbdadd4a9c485a95dc7b9b56449</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2013.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2013.06.001%26sid%3Dliteratum%253Aachs%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DShah%26aufirst%3DN.%2BP.%26atitle%3DIns%2520and%2520outs%2520of%2520kinase%2520DFG%2520motifs%26jtitle%3DChem.%2520Biol.%26date%3D2013%26volume%3D20%26spage%3D745%26epage%3D746%26doi%3D10.1016%2Fj.chembiol.2013.06.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiao, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J. T.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amancha, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coumar, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyu, P.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, H.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.-Y.</span></span> <span> </span><span class="NLM_article-title">Protein kinase inhibitor design by targeting the Asp-Phe-Gly (DFG) motif: the role of the DFG motif in the design of epidermal growth factor receptor inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">3889</span>– <span class="NLM_lpage">3903</span>, <span class="refDoi"> DOI: 10.1021/jm400072p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400072p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmtlWgs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=3889-3903&author=Y.-H.+Pengauthor=H.-Y.+Shiaoauthor=C.-H.+Tuauthor=P.-M.+Liuauthor=J.+T.-A.+Hsuauthor=P.+K.+Amanchaauthor=J.-S.+Wuauthor=M.+S.+Coumarauthor=C.-H.+Chenauthor=S.-Y.+Wangauthor=W.-H.+Linauthor=H.-Y.+Sunauthor=Y.-S.+Chaoauthor=P.-C.+Lyuauthor=H.-P.+Hsiehauthor=S.-Y.+Wu&title=Protein+kinase+inhibitor+design+by+targeting+the+Asp-Phe-Gly+%28DFG%29+motif%3A+the+role+of+the+DFG+motif+in+the+design+of+epidermal+growth+factor+receptor+inhibitors&doi=10.1021%2Fjm400072p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Protein Kinase Inhibitor Design by Targeting the Asp-Phe-Gly (DFG) Motif: The Role of the DFG Motif in the Design of Epidermal Growth Factor Receptor Inhibitors</span></div><div class="casAuthors">Peng, Yi-Hui; Shiao, Hui-Yi; Tu, Chih-Hsiang; Liu, Pang-Min; Hsu, John Tsu-An; Amancha, Prashanth Kumar; Wu, Jian-Sung; Coumar, Mohane Selvaraj; Chen, Chun-Hwa; Wang, Sing-Yi; Lin, Wen-Hsing; Sun, Hsu-Yi; Chao, Yu-Sheng; Lyu, Ping-Chiang; Hsieh, Hsing-Pang; Wu, Su-Ying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3889-3903</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The Asp-Phe-Gly (DFG) motif plays an important role in the regulation of kinase activity.  Structure-based drug design was performed to design compds. able to interact with the DFG motif; epidermal growth factor receptor (EGFR) was selected as an example.  Structural insights obtained from the EGFR/2a complex suggested that an extension from the meta-position on the Ph group (ring-5) would improve interactions with the DFG motif.  Indeed, introduction of an N,N-dimethylamino tail resulted in N-[3-(4-{[(1S)-2-Hydroxy-1-phenylethyl]amino}-6phenylfuro[2,3-d]pyrimidin-5-yl)phenyl]-N3,N3-dimethyl-y-alaninamide, which showed almost 50-fold improvement in inhibition compared to (2S)-2-[(5,6-Diphenylfuro[2,3-d]pyrimidin-4-yl)amino]-2phenylethanol.  Structural studies confirmed this N,N-dimethylamino tail moved toward the DFG motif to form a salt bridge with the side chain of Asp831.  That the interactions with the DFG motif greatly contribute to the potency of N-[3-(4-{[(1S)-2-Hydroxy-1-phenylethyl]amino}-6phenylfuro[2,3-d]pyrimidin-5-yl)phenyl]-N3,N3-dimethyl-y-alaninamide is strongly evidenced by synthesizing and testing compds. (2S)-2-[(5,6-Diphenylfuro[2,3-d]pyrimidin-4-yl)amino]-2phenylethanol, N-[3-(4-{[(1S)-2-Hydroxy-1-phenylethyl]amino}-6phenylfuro[2,3-d]pyrimidin-5-yl)phenyl]acetamide, and N-[3-(4-{[(1S)-2-Hydroxy-1-phenylethyl]amino}-6phenylfuro[2,3-d]pyrimidin-5-yl)phenyl]-5-methylhexanamide: when the charge interactions are absent, the inhibitory activity decreased significantly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpww4-N_WLlNrVg90H21EOLACvtfcHk0ljw2V7ZVwfwyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmtlWgs7Y%253D&md5=76994a666b2223510c09bb7e4524eae9</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm400072p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400072p%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DY.-H.%26aulast%3DShiao%26aufirst%3DH.-Y.%26aulast%3DTu%26aufirst%3DC.-H.%26aulast%3DLiu%26aufirst%3DP.-M.%26aulast%3DHsu%26aufirst%3DJ.%2BT.-A.%26aulast%3DAmancha%26aufirst%3DP.%2BK.%26aulast%3DWu%26aufirst%3DJ.-S.%26aulast%3DCoumar%26aufirst%3DM.%2BS.%26aulast%3DChen%26aufirst%3DC.-H.%26aulast%3DWang%26aufirst%3DS.-Y.%26aulast%3DLin%26aufirst%3DW.-H.%26aulast%3DSun%26aufirst%3DH.-Y.%26aulast%3DChao%26aufirst%3DY.-S.%26aulast%3DLyu%26aufirst%3DP.-C.%26aulast%3DHsieh%26aufirst%3DH.-P.%26aulast%3DWu%26aufirst%3DS.-Y.%26atitle%3DProtein%2520kinase%2520inhibitor%2520design%2520by%2520targeting%2520the%2520Asp-Phe-Gly%2520%2528DFG%2529%2520motif%253A%2520the%2520role%2520of%2520the%2520DFG%2520motif%2520in%2520the%2520design%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D3889%26epage%3D3903%26doi%3D10.1021%2Fjm400072p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Center of Drug Evaluation</span>. <span> </span><span class="NLM_article-title">Taiwan, Phase I Clinical Trial for
DBPR112</span>. <a href="http://www1.cde.org.tw/ct_taiwan/search_case2_tornado.php?caseno=2107" class="extLink">http://www1.cde.org.tw/ct_taiwan/search_case2_tornado.php?caseno=2107</a> (accessed Jul 28, <span class="NLM_year">2018</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=Center+of+Drug+Evaluation&title=Taiwan%2C+Phase+I+Clinical+Trial+for%0ADBPR112"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DTaiwan%252C%2520Phase%2520I%2520Clinical%2520Trial%2520for%250ADBPR112%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karikios, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyer, M. J.</span></span> <span> </span><span class="NLM_article-title">Irreversible EGFR inhibitors in advanced non-small-cell lung carcinoma: rationale and clinical evidence</span>. <i>Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">317</span>– <span class="NLM_lpage">325</span>, <span class="refDoi"> DOI: 10.4155/cli.12.7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.4155%2Fcli.12.7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BC38XktVGgur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=317-325&author=D.+J.+Karikiosauthor=M.+J.+Boyer&title=Irreversible+EGFR+inhibitors+in+advanced+non-small-cell+lung+carcinoma%3A+rationale+and+clinical+evidence&doi=10.4155%2Fcli.12.7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Irreversible EGFR inhibitors in advanced non-small-cell lung carcinoma: rationale and clinical evidence</span></div><div class="casAuthors">Karikios, Deme John; Boyer, Michael Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Investigation (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">317-325</span>CODEN:
                <span class="NLM_cas:coden">CILUAP</span>;
        ISSN:<span class="NLM_cas:issn">2041-6792</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  The EGFR has become an important target in lung cancer treatment.  Reversible inhibitors of this receptor have been shown to improve outcomes for patients whose tumors harbor EGFR mutations, as well as for those with wild-type EGFR.  The development of resistance (either primary or acquired) to EGFR tyrosine kinase inhibitors is a common occurrence and irreversible EGFR inhibitors have been developed to overcome this problem.  There are now emerging clin. data for the two major irreversible inhibitors; afatinib and dacomitinib.  The question of how and when we use these irreversible inhibitors still needs to be answered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjR73MvS5xZrVg90H21EOLACvtfcHk0ljw2V7ZVwfwyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktVGgur8%253D&md5=b487cb2d247f308000f7bec7be1d60c0</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.4155%2Fcli.12.7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Fcli.12.7%26sid%3Dliteratum%253Aachs%26aulast%3DKarikios%26aufirst%3DD.%2BJ.%26aulast%3DBoyer%26aufirst%3DM.%2BJ.%26atitle%3DIrreversible%2520EGFR%2520inhibitors%2520in%2520advanced%2520non-small-cell%2520lung%2520carcinoma%253A%2520rationale%2520and%2520clinical%2520evidence%26jtitle%3DClin.%2520Invest.%26date%3D2012%26volume%3D2%26spage%3D317%26epage%3D325%26doi%3D10.4155%2Fcli.12.7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ho, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luh, T. Y.</span></span> <span> </span><span class="NLM_article-title">Transition metal promoted reactions. Part 27. Nickel(II)-lithium aluminum hydride mediated reduction of carbon-sulfur bonds</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">4474</span>– <span class="NLM_lpage">4476</span>, <span class="refDoi"> DOI: 10.1021/jo00279a046</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo00279a046" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADyaL1MXltlegsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=1989&pages=4474-4476&author=K.+M.+Hoauthor=C.+H.+Lamauthor=T.+Y.+Luh&title=Transition+metal+promoted+reactions.+Part+27.+Nickel%28II%29-lithium+aluminum+hydride+mediated+reduction+of+carbon-sulfur+bonds&doi=10.1021%2Fjo00279a046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Transition metal promoted reactions.  Part 27.  Nickel(II)-lithium aluminum hydride mediated reduction of carbon-sulfur bonds</span></div><div class="casAuthors">Ho, Kim Man; Lam, Chun Hon; Luh, Tien Yau</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4474-6</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    </div><div class="casAbstract">Bis(triphenylphospine)nickel dibromide-lithium aluminum hydride was shown to be an effective desulfurization reagent.  Carbon-sulfur bonds in thiols, thioethers, sulfoxides and sulfones can be readily reduced in satisfactory to excellent yields.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpl98KzWd3ve7Vg90H21EOLACvtfcHk0lhT16rMdLTFGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXltlegsbw%253D&md5=8f8cc57906646d4be10528883b39d635</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjo00279a046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00279a046%26sid%3Dliteratum%253Aachs%26aulast%3DHo%26aufirst%3DK.%2BM.%26aulast%3DLam%26aufirst%3DC.%2BH.%26aulast%3DLuh%26aufirst%3DT.%2BY.%26atitle%3DTransition%2520metal%2520promoted%2520reactions.%2520Part%252027.%2520Nickel%2528II%2529-lithium%2520aluminum%2520hydride%2520mediated%2520reduction%2520of%2520carbon-sulfur%2520bonds%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1989%26volume%3D54%26spage%3D4474%26epage%3D4476%26doi%3D10.1021%2Fjo00279a046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coumar, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, M.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uang, B.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, T.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leou, J.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, M.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J. T.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, H.-P.</span></span> <span> </span><span class="NLM_article-title">Identification, SAR studies, and x-ray co-crystallographic analysis of a novel furanopyrimidine aurora kinase an inhibitor</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">255</span>– <span class="NLM_lpage">267</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200900339</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1002%2Fcmdc.200900339" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=20039358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtl2nsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=255-267&author=M.+S.+Coumarauthor=M.-T.+Tsaiauthor=C.-Y.+Chuauthor=B.-J.+Uangauthor=W.-H.+Linauthor=C.-Y.+Changauthor=T.-Y.+Changauthor=J.-S.+Leouauthor=C.-H.+Tengauthor=J.-S.+Wuauthor=M.-Y.+Fangauthor=C.-H.+Chenauthor=J.+T.-A.+Hsuauthor=S.-Y.+Wuauthor=Y.-S.+Chaoauthor=H.-P.+Hsieh&title=Identification%2C+SAR+studies%2C+and+x-ray+co-crystallographic+analysis+of+a+novel+furanopyrimidine+aurora+kinase+an+inhibitor&doi=10.1002%2Fcmdc.200900339"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Identification, SAR Studies, and X-ray Co-crystallographic Analysis of a Novel Furanopyrimidine Aurora Kinase A Inhibitor</span></div><div class="casAuthors">Coumar, Mohane Selvaraj; Tsai, Ming-Tsung; Chu, Chang-Ying; Uang, Biing-Jiun; Lin, Wen-Hsing; Chang, Chun-Yu; Chang, Teng-Yuan; Leou, Jiun-Shyang; Teng, Chi-Huang; Wu, Jian-Sung; Fang, Ming-Yu; Chen, Chun-Hwa; Hsu, John T.-A.; Wu, Su-Ying; Chao, Yu-Sheng; Hsieh, Hsing-Pang</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">255-267</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Herein we reveal a simple method for the identification of novel Aurora kinase A inhibitors through substructure searching of an inhouse compd. library to select compds. for testing.  A hydrazone fragment conferring Aurora kinase activity and heterocyclic rings most frequently reported in kinase inhibitors were used as substructure queries to filter the inhouse compd. library collection prior to testing.  Five new series of Aurora kinase inhibitors were identified through this strategy, with IC50 values ranging from ∼300 nM to ∼15 μM, by testing only 133 compds. from a database of ∼125 000 compds.  Structure-activity relationship studies and X-ray co-crystallog. anal. of the most potent compd., 8 (I), a furanopyrimidine deriv. with an IC50 value of 309 nM toward Aurora kinase A, were carried out.  The knowledge gained through these studies could help in the future design of potent Aurora kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEUSBLKwZNYrVg90H21EOLACvtfcHk0lhT16rMdLTFGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtl2nsLk%253D&md5=c43554591b114d09047bdd74a01b0f64</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200900339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200900339%26sid%3Dliteratum%253Aachs%26aulast%3DCoumar%26aufirst%3DM.%2BS.%26aulast%3DTsai%26aufirst%3DM.-T.%26aulast%3DChu%26aufirst%3DC.-Y.%26aulast%3DUang%26aufirst%3DB.-J.%26aulast%3DLin%26aufirst%3DW.-H.%26aulast%3DChang%26aufirst%3DC.-Y.%26aulast%3DChang%26aufirst%3DT.-Y.%26aulast%3DLeou%26aufirst%3DJ.-S.%26aulast%3DTeng%26aufirst%3DC.-H.%26aulast%3DWu%26aufirst%3DJ.-S.%26aulast%3DFang%26aufirst%3DM.-Y.%26aulast%3DChen%26aufirst%3DC.-H.%26aulast%3DHsu%26aufirst%3DJ.%2BT.-A.%26aulast%3DWu%26aufirst%3DS.-Y.%26aulast%3DChao%26aufirst%3DY.-S.%26aulast%3DHsieh%26aufirst%3DH.-P.%26atitle%3DIdentification%252C%2520SAR%2520studies%252C%2520and%2520x-ray%2520co-crystallographic%2520analysis%2520of%2520a%2520novel%2520furanopyrimidine%2520aurora%2520kinase%2520an%2520inhibitor%26jtitle%3DChemMedChem%26date%3D2010%26volume%3D5%26spage%3D255%26epage%3D267%26doi%3D10.1002%2Fcmdc.200900339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iyengar, R. R.</span>; <span class="NLM_string-name">Judd, A. S.</span>; <span class="NLM_string-name">Zhao, G.</span>; <span class="NLM_string-name">Kym, P. R.</span>; <span class="NLM_string-name">Sham, H. L.</span>; <span class="NLM_string-name">Gu, Y.</span>; <span class="NLM_string-name">Liu, G.</span>; <span class="NLM_string-name">Liu, M.</span>; <span class="NLM_string-name">Zhao, H.</span>; <span class="NLM_string-name">Clark, R. F.</span>; <span class="NLM_string-name">Frevert, E. U.</span>; <span class="NLM_string-name">Cool, B. L.</span>; <span class="NLM_string-name">Zhang, T.</span>; <span class="NLM_string-name">Keyes, R. F.</span>; <span class="NLM_string-name">Hansen, T. M.</span>; <span class="NLM_string-name">Xin, Z.</span></span> <span> </span><span class="NLM_article-title">Thienopyridones as AMPK Activators for the Treatment of Diabetes and Obesity</span>. U.S. Patent <span class="NLM_patent">0,038,068 A1</span>, Feb 17, <span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=R.+R.+Iyengar&author=A.+S.+Judd&author=G.+Zhao&author=P.+R.+Kym&author=H.+L.+Sham&author=Y.+Gu&author=G.+Liu&author=M.+Liu&author=H.+Zhao&author=R.+F.+Clark&author=E.+U.+Frevert&author=B.+L.+Cool&author=T.+Zhang&author=R.+F.+Keyes&author=T.+M.+Hansen&author=Z.+Xin&title=Thienopyridones+as+AMPK+Activators+for+the+Treatment+of+Diabetes+and+Obesity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DIyengar%26aufirst%3DR.%2BR.%26atitle%3DThienopyridones%2520as%2520AMPK%2520Activators%2520for%2520the%2520Treatment%2520of%2520Diabetes%2520and%2520Obesity%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frey, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtin, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albert, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arries, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlozzari, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauch, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouska, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bousquet, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunha, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glaser, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcotte, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moskey, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pease, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoll, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tapang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wishart, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidsen, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michaelides, M. R.</span></span> <span> </span><span class="NLM_article-title">Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">6066</span>– <span class="NLM_lpage">6083</span>, <span class="refDoi"> DOI: 10.1021/jm050458h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm050458h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpt1Wht7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6066-6083&author=Y.+Daiauthor=Y.+Guoauthor=R.+R.+Freyauthor=Z.+Jiauthor=M.+L.+Curtinauthor=A.+A.+Ahmedauthor=D.+H.+Albertauthor=L.+Arnoldauthor=S.+S.+Arriesauthor=T.+Barlozzariauthor=J.+L.+Bauchauthor=J.+J.+Bouskaauthor=P.+F.+Bousquetauthor=G.+A.+Cunhaauthor=K.+B.+Glaserauthor=J.+Guoauthor=J.+Liauthor=P.+A.+Marcotteauthor=K.+C.+Marshauthor=M.+D.+Moskeyauthor=L.+J.+Peaseauthor=K.+D.+Stewartauthor=V.+S.+Stollauthor=P.+Tapangauthor=N.+Wishartauthor=S.+K.+Davidsenauthor=M.+R.+Michaelides&title=Thienopyrimidine+ureas+as+novel+and+potent+multitargeted+receptor+tyrosine+kinase+inhibitors&doi=10.1021%2Fjm050458h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Thienopyrimidine Ureas as Novel and Potent Multitargeted Receptor Tyrosine Kinase Inhibitors</span></div><div class="casAuthors">Dai, Yujia; Guo, Yan; Frey, Robin R.; Ji, Zhiqin; Curtin, Michael L.; Ahmed, Asma A.; Albert, Daniel H.; Arnold, Lee; Arries, Shannon S.; Barlozzari, Teresa; Bauch, Joy L.; Bouska, Jennifer J.; Bousquet, Peter F.; Cunha, George A.; Glaser, Keith B.; Guo, Jun; Li, Junling; Marcotte, Patrick A.; Marsh, Kennan C.; Moskey, Maria D.; Pease, Lori J.; Stewart, Kent D.; Stoll, Vincent S.; Tapang, Paul; Wishart, Neil; Davidsen, Steven K.; Michaelides, Michael R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6066-6083</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of novel thienopyrimidine-based receptor tyrosine kinase inhibitors has been discovered.  Investigation of structure-activity relationships at the 5- and 6-positions of the thienopyrimidine nucleus led to a series of N,N'-diaryl ureas that potently inhibit all of the vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptor tyrosine kinases.  A kinase insert domain-contg. receptor (KDR) homol. model suggests that these compds. bind to the "inactive conformation" of the enzyme with the urea portion extending into the back hydrophobic pocket adjacent to the ATP (ATP) binding site.  A no. of compds. have been identified as displaying excellent in vivo potency.  In particular, compds. 28 and 76 possess favorable pharmacokinetic (PK) profiles and demonstrate potent antitumor efficacy against the HT1080 human fibrosarcoma xenograft tumor growth model (tumor growth inhibition (TGI) = 75% at 25 mg/kg·day, per os (po)).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYifOiC_HYHrVg90H21EOLACvtfcHk0lgk6Fyv3s-RHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpt1Wht7Y%253D&md5=ef245a26e40d18cfaf7f98260827f274</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm050458h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050458h%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DY.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DFrey%26aufirst%3DR.%2BR.%26aulast%3DJi%26aufirst%3DZ.%26aulast%3DCurtin%26aufirst%3DM.%2BL.%26aulast%3DAhmed%26aufirst%3DA.%2BA.%26aulast%3DAlbert%26aufirst%3DD.%2BH.%26aulast%3DArnold%26aufirst%3DL.%26aulast%3DArries%26aufirst%3DS.%2BS.%26aulast%3DBarlozzari%26aufirst%3DT.%26aulast%3DBauch%26aufirst%3DJ.%2BL.%26aulast%3DBouska%26aufirst%3DJ.%2BJ.%26aulast%3DBousquet%26aufirst%3DP.%2BF.%26aulast%3DCunha%26aufirst%3DG.%2BA.%26aulast%3DGlaser%26aufirst%3DK.%2BB.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DMarcotte%26aufirst%3DP.%2BA.%26aulast%3DMarsh%26aufirst%3DK.%2BC.%26aulast%3DMoskey%26aufirst%3DM.%2BD.%26aulast%3DPease%26aufirst%3DL.%2BJ.%26aulast%3DStewart%26aufirst%3DK.%2BD.%26aulast%3DStoll%26aufirst%3DV.%2BS.%26aulast%3DTapang%26aufirst%3DP.%26aulast%3DWishart%26aufirst%3DN.%26aulast%3DDavidsen%26aufirst%3DS.%2BK.%26aulast%3DMichaelides%26aufirst%3DM.%2BR.%26atitle%3DThienopyrimidine%2520ureas%2520as%2520novel%2520and%2520potent%2520multitargeted%2520receptor%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6066%26epage%3D6083%26doi%3D10.1021%2Fjm050458h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beccalli, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manfredi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchesini, A.</span></span> <span> </span><span class="NLM_article-title">Alkynes from 5-aminoisoxazoles</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">2372</span>– <span class="NLM_lpage">2375</span>, <span class="refDoi"> DOI: 10.1021/jo00213a034</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo00213a034" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADyaL2MXkt1Wru78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1985&pages=2372-2375&author=E.+M.+Beccalliauthor=A.+Manfrediauthor=A.+Marchesini&title=Alkynes+from+5-aminoisoxazoles&doi=10.1021%2Fjo00213a034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Alkynes from 5-aminoisoxazoles</span></div><div class="casAuthors">Beccalli, Egle M.; Manfredi, Amadea; Marchesini, Alessandro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2372-5</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    </div><div class="casAbstract">Diazotization of 5-aminoisoxazoles I [R = Ph, H, CO2Et, Me; R1 = CONH2, CO2Et, p-O2NC6H4, 4-pyridyl, etc. (≥1 of R and R1 is an electron-withdrawing group)] by reaction with NaNO2 in AcOH-H2O afforded the corresponding RC≡CR1.  A reaction path involving an intermediate isoxazol-5-yl radical is proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHMoVHKHwRFbVg90H21EOLACvtfcHk0lgk6Fyv3s-RHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXkt1Wru78%253D&md5=f97bd280fc4db2675a1abb732acac8c0</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjo00213a034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00213a034%26sid%3Dliteratum%253Aachs%26aulast%3DBeccalli%26aufirst%3DE.%2BM.%26aulast%3DManfredi%26aufirst%3DA.%26aulast%3DMarchesini%26aufirst%3DA.%26atitle%3DAlkynes%2520from%25205-aminoisoxazoles%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1985%26volume%3D50%26spage%3D2372%26epage%3D2375%26doi%3D10.1021%2Fjo00213a034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tormyshev, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flinn, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trukhin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogozhnikova, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikhalina, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troitskaya, T.</span></span> <span> </span><span class="NLM_article-title">Aryl alkyl ketones in a one-pot Gewald synthesis of 2-aminothiophenes</span>. <i>Synlett</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_fpage">2559</span>– <span class="NLM_lpage">2564</span>, <span class="refDoi"> DOI: 10.1055/s-2006-951484</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1055%2Fs-2006-951484" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1WkurbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&pages=2559-2564&author=V.+Tormyshevauthor=A.+Flinnauthor=D.+Trukhinauthor=O.+Rogozhnikovaauthor=T.+Mikhalinaauthor=T.+Troitskaya&title=Aryl+alkyl+ketones+in+a+one-pot+Gewald+synthesis+of+2-aminothiophenes&doi=10.1055%2Fs-2006-951484"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Aryl alkyl ketones in a one-pot Gewald synthesis of 2-aminothiophenes</span></div><div class="casAuthors">Tormyshev, Victor M.; Trukhin, Dmitry V.; Rogozhnikova, Olga Yu.; Mikhalina, Tatiana V.; Troitskaya, Tatiana I.; Flinn, Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Synlett</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2559-2564</span>CODEN:
                <span class="NLM_cas:coden">SYNLES</span>;
        ISSN:<span class="NLM_cas:issn">0936-5214</span>.
    
            (<span class="NLM_cas:orgname">Georg Thieme Verlag</span>)
        </div><div class="casAbstract">2-Aminothiophene-3-carboxylates, e.g., I, bearing various aryl groups at the 4-position are readily obtained in good to moderate yields by the one-pot Gewald reaction of aryl alkyl ketones with Et cyanoacetate and elemental sulfur in the presence of morpholinium acetate and excess morpholine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUx_V-SKs367Vg90H21EOLACvtfcHk0lgk6Fyv3s-RHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1WkurbM&md5=625f8985df859b6405bc3764c9e12276</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1055%2Fs-2006-951484&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2006-951484%26sid%3Dliteratum%253Aachs%26aulast%3DTormyshev%26aufirst%3DV.%26aulast%3DFlinn%26aufirst%3DA.%26aulast%3DTrukhin%26aufirst%3DD.%26aulast%3DRogozhnikova%26aufirst%3DO.%26aulast%3DMikhalina%26aufirst%3DT.%26aulast%3DTroitskaya%26aufirst%3DT.%26atitle%3DAryl%2520alkyl%2520ketones%2520in%2520a%2520one-pot%2520Gewald%2520synthesis%2520of%25202-aminothiophenes%26jtitle%3DSynlett%26date%3D2006%26spage%3D2559%26epage%3D2564%26doi%3D10.1055%2Fs-2006-951484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Therkelsen, F. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rottländer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorup, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedersen, E. B.</span></span> <span> </span><span class="NLM_article-title">4-Metalated condensed pyrimidines: their preparation and reaction with aldehydes under Barbier-type conditions</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1991</span>– <span class="NLM_lpage">1994</span>, <span class="refDoi"> DOI: 10.1021/ol049432v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol049432v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjslOhsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2004&pages=1991-1994&author=F.+D.+Therkelsenauthor=M.+Rottl%C3%A4nderauthor=N.+Thorupauthor=E.+B.+Pedersen&title=4-Metalated+condensed+pyrimidines%3A+their+preparation+and+reaction+with+aldehydes+under+Barbier-type+conditions&doi=10.1021%2Fol049432v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">4-Metalated Condensed Pyrimidines: Their Preparation and Reaction with Aldehydes under Barbier-Type Conditions</span></div><div class="casAuthors">Therkelsen, Frans D.; Rottlaender, Mario; Thorup, Niels; Pedersen, Erik Bjerregaard</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1991-1994</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The organometallic intermediate obtained from halogen-metal exchanges of 4-iodo-6-phenylthieno[2,3-d]pyrimidine under Barbier-type conditions was reacted with aldehydes to form the corresponding alcs. in moderate yields.  The reaction involving an organolithium intermediate proceeded only at low temp., whereas the reaction involving a magnesium ate intermediate also proceeded at room temp.  A crystal structure confirms that the expected constitutional alc. isomer is formed, where no migration has taken place.  The conditions were also suitable for 9-benzyl-6-iodopurine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdJIUdumgrdrVg90H21EOLACvtfcHk0lhxikbKrVB1Hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjslOhsbk%253D&md5=e797a069a3e7095dfbae72d99897e503</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fol049432v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol049432v%26sid%3Dliteratum%253Aachs%26aulast%3DTherkelsen%26aufirst%3DF.%2BD.%26aulast%3DRottl%25C3%25A4nder%26aufirst%3DM.%26aulast%3DThorup%26aufirst%3DN.%26aulast%3DPedersen%26aufirst%3DE.%2BB.%26atitle%3D4-Metalated%2520condensed%2520pyrimidines%253A%2520their%2520preparation%2520and%2520reaction%2520with%2520aldehydes%2520under%2520Barbier-type%2520conditions%26jtitle%3DOrg.%2520Lett.%26date%3D2004%26volume%3D6%26spage%3D1991%26epage%3D1994%26doi%3D10.1021%2Fol049432v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Capoferri, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lodola, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mor, M.</span></span> <span> </span><span class="NLM_article-title">Quantum mechanics/molecular mechanics modeling of covalent addition between EGFR-cysteine 797 and N-(4-anilinoquinazolin-6-yl) acrylamide</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">589</span>– <span class="NLM_lpage">599</span>, <span class="refDoi"> DOI: 10.1021/ci500720e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci500720e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BC2MXit12rtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2015&pages=589-599&author=L.+Capoferriauthor=A.+Lodolaauthor=S.+Rivaraauthor=M.+Mor&title=Quantum+mechanics%2Fmolecular+mechanics+modeling+of+covalent+addition+between+EGFR-cysteine+797+and+N-%284-anilinoquinazolin-6-yl%29+acrylamide&doi=10.1021%2Fci500720e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Quantum Mechanics/Molecular Mechanics Modeling of Covalent Addition between EGFR-Cysteine 797 and N-(4-Anilinoquinazolin-6-yl) Acrylamide</span></div><div class="casAuthors">Capoferri, Luigi; Lodola, Alessio; Rivara, Silvia; Mor, Marco</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">589-599</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Irreversible epidermal growth factor receptor (EGFR) inhibitors can circumvent resistance to first-generation ATP-competitive inhibitors in the treatment of nonsmall-cell lung cancer.  They covalently bind a noncatalytic cysteine (Cys797) at the surface of EGFR active site by an acrylamide warhead.  Herein, we used a hybrid quantum mechanics/mol. mechanics (QM/MM) potential in combination with umbrella sampling in the path-collective variable space to investigate the mechanism of alkylation of Cys797 by the prototypical covalent inhibitor N-(4-anilinoquinazolin-6-yl) acrylamide.  Calcns. show that Cys797 reacts with the acrylamide group of the inhibitor through a direct addn. mechanism, with Asp800 acting as a general base/general acid in distinct steps of the reaction.  The obtained reaction free energy is neg. (ΔA = -12 kcal/mol) consistent with the spontaneous and irreversible alkylation of Cys797 by N-(4-anilinoquinazolin-6-yl) acrylamide.  Our calcns. identify desolvation of Cys797 thiolate anion as a key step of the alkylation process, indicating that changes in the intrinsic reactivity of the acrylamide would have only a minor impact on the inhibitor potency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowDcsiGT9gD7Vg90H21EOLACvtfcHk0lhxikbKrVB1Hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXit12rtrY%253D&md5=8f1c5df9cd62228ff22711e41a7d7a5c</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fci500720e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci500720e%26sid%3Dliteratum%253Aachs%26aulast%3DCapoferri%26aufirst%3DL.%26aulast%3DLodola%26aufirst%3DA.%26aulast%3DRivara%26aufirst%3DS.%26aulast%3DMor%26aufirst%3DM.%26atitle%3DQuantum%2520mechanics%252Fmolecular%2520mechanics%2520modeling%2520of%2520covalent%2520addition%2520between%2520EGFR-cysteine%2520797%2520and%2520N-%25284-anilinoquinazolin-6-yl%2529%2520acrylamide%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2015%26volume%3D55%26spage%3D589%26epage%3D599%26doi%3D10.1021%2Fci500720e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carmi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lodola, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacondio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavazzoni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfieri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ardizzoni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petronini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mor, M.</span></span> <span> </span><span class="NLM_article-title">Epidermal growth factor receptor irreversible inhibitors: chemical exploration of the cysteine-trap portion</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1019</span>– <span class="NLM_lpage">1030</span>, <span class="refDoi"> DOI: 10.2174/138955711797247725</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.2174%2F138955711797247725" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=21861809" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1OnsL3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=1019-1030&author=C.+Carmiauthor=A.+Lodolaauthor=S.+Rivaraauthor=F.+Vacondioauthor=A.+Cavazzoniauthor=R.+Alfieriauthor=A.+Ardizzoniauthor=P.+Petroniniauthor=M.+Mor&title=Epidermal+growth+factor+receptor+irreversible+inhibitors%3A+chemical+exploration+of+the+cysteine-trap+portion&doi=10.2174%2F138955711797247725"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor irreversible inhibitors: chemical exploration of the cysteine-trap portion</span></div><div class="casAuthors">Carmi, C.; Lodola, A.; Rivara, S.; Vacondio, F.; Cavazzoni, A.; Alfieri, R. R.; Ardizzoni, A.; Petronini, P. G.; Mor, M.</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1019-1030</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Covalent EGFR irreversible inhibitors showed promising potential for the treatment of gefitinib-resistant tumors and for imaging purposes.  They contain a cysteine-reactive portion forming a covalent bond with the protein.  Irreversible kinase inhibitors have been advanced to clin. studies, mostly characterized by an acrylamide or butynamide warhead.  However, the clin. usefulness of these compds. has been hampered by resistances, toxicity and pharmacokinetic problems.  Investigation on the structure-activity and structure-reactivity relationships may provide useful information for compds. with improved selectivity and pharmacokinetic properties.  This review focuses on the exploration of the cysteine-trap portions able to irreversibly inhibit EGFR and other erbB receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoupbZjLNpfFrVg90H21EOLACvtfcHk0lhxikbKrVB1Hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1OnsL3O&md5=d531960c09e4676366b3611c3187533d</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.2174%2F138955711797247725&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955711797247725%26sid%3Dliteratum%253Aachs%26aulast%3DCarmi%26aufirst%3DC.%26aulast%3DLodola%26aufirst%3DA.%26aulast%3DRivara%26aufirst%3DS.%26aulast%3DVacondio%26aufirst%3DF.%26aulast%3DCavazzoni%26aufirst%3DA.%26aulast%3DAlfieri%26aufirst%3DR.%26aulast%3DArdizzoni%26aufirst%3DA.%26aulast%3DPetronini%26aufirst%3DP.%26aulast%3DMor%26aufirst%3DM.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520irreversible%2520inhibitors%253A%2520chemical%2520exploration%2520of%2520the%2520cysteine-trap%2520portion%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2011%26volume%3D11%26spage%3D1019%26epage%3D1030%26doi%3D10.2174%2F138955711797247725" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Kane, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradbury, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feld, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leighl, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pisters, K.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamel-Reid, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsao, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepherd, F. A.</span></span> <span> </span><span class="NLM_article-title">Uncommon EGFR mutations in advanced non-small cell lung cancer</span>. <i>Lung Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">137</span>– <span class="NLM_lpage">144</span>, <span class="refDoi"> DOI: 10.1016/j.lungcan.2017.04.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1016%2Fj.lungcan.2017.04.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=28577943" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A280%3ADC%252BC1cnks1Wrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2017&pages=137-144&author=G.+M.+O%E2%80%99Kaneauthor=P.+A.+Bradburyauthor=R.+Feldauthor=N.+B.+Leighlauthor=G.+Liuauthor=K.-M.+Pistersauthor=S.+Kamel-Reidauthor=M.+S.+Tsaoauthor=F.+A.+Shepherd&title=Uncommon+EGFR+mutations+in+advanced+non-small+cell+lung+cancer&doi=10.1016%2Fj.lungcan.2017.04.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Uncommon EGFR mutations in advanced non-small cell lung cancer</span></div><div class="casAuthors">O'Kane Grainne M; Bradbury Penelope A; Feld Ronald; Leighl Natasha B; Liu Geoffrey; Pisters Katherine-M; Kamel-Reid Suzanne; Tsao Ming S; Shepherd Frances A</div><div class="citationInfo"><span class="NLM_cas:title">Lung cancer (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">137-144</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Molecular profiling in advanced non-small cell lung cancer (NSCLC) has allowed for the detection of actionable mutations, which has revolutionized the treatment paradigm in this highly fatal disease.  Mutations involving the epidermal growth factor receptor (EGFR) gene are most common and the 'classical mutations', exon 19 deletions and the point mutation L858R at exon 21, predict response to EGFR tyrosine kinase inhibitors (TKIs).  The 'uncommon' EGFR mutations account for 10-18% of all EGFR mutations and primarily consist of exon 20 insertions, exon 18 point mutations and complex mutations.  Improved detection techniques have broadened the spectrum of reported aberrations within the 'uncommon group' but response to TKIs is variable and not fully elucidated.  This review provides an overview of the biology and incidence of uncommon EGFR mutations and summarizes reported outcomes when treated with EGFR-TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRiqu-LITqhZMAKB7Fa-xrUfW6udTcc2eb-sXb6OFQiy7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cnks1Wrtg%253D%253D&md5=fd51b60c9b8a5a65fb52e21c8223b66d</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2017.04.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2017.04.016%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Kane%26aufirst%3DG.%2BM.%26aulast%3DBradbury%26aufirst%3DP.%2BA.%26aulast%3DFeld%26aufirst%3DR.%26aulast%3DLeighl%26aufirst%3DN.%2BB.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DPisters%26aufirst%3DK.-M.%26aulast%3DKamel-Reid%26aufirst%3DS.%26aulast%3DTsao%26aufirst%3DM.%2BS.%26aulast%3DShepherd%26aufirst%3DF.%2BA.%26atitle%3DUncommon%2520EGFR%2520mutations%2520in%2520advanced%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DLung%2520Cancer%26date%3D2017%26volume%3D109%26spage%3D137%26epage%3D144%26doi%3D10.1016%2Fj.lungcan.2017.04.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arcila, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nafa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaft, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rekhtman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reva, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zakowski, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kris, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladanyi, M.</span></span> <span> </span><span class="NLM_article-title">EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">220</span>– <span class="NLM_lpage">229</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.mct-12-0620</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1158%2F1535-7163.mct-12-0620" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=23371856" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BC3sXitlWisrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=220-229&author=M.+E.+Arcilaauthor=K.+Nafaauthor=J.+E.+Chaftauthor=N.+Rekhtmanauthor=C.+Lauauthor=B.+A.+Revaauthor=M.+F.+Zakowskiauthor=M.+G.+Krisauthor=M.+Ladanyi&title=EGFR+exon+20+insertion+mutations+in+lung+adenocarcinomas%3A+prevalence%2C+molecular+heterogeneity%2C+and+clinicopathologic+characteristics&doi=10.1158%2F1535-7163.mct-12-0620"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics</span></div><div class="casAuthors">Arcila, Maria E.; Nafa, Khedoudja; Chaft, Jamie E.; Rekhtman, Natasha; Lau, Christopher; Reva, Boris A.; Zakowski, Maureen F.; Kris, Mark G.; Ladanyi, Marc</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">220-229</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">In contrast to other primary epidermal growth factor receptor (EGFR) mutations in lung adenocarcinomas, insertions in exon 20 of EGFR have been generally assocd. with resistance to EGFR-tyrosine kinase inhibitors.  Their mol. spectrum, clinicopathol. characteristics, and prevalence are not well established.  Tumors harboring EGFR exon 20 insertions were identified through an algorithmic screen of 1,500 lung adenocarcinomas.  Cases were first tested for common mutations in EGFR (exons 19 and 21) and KRAS (exon 2) and, if neg., further analyzed for EGFR exon 20 insertions.  All samples underwent extended genotyping for other driver mutations in EGFR, KRAS, BRAF, ERBB2/HER2, NRAS, PIK3CA, MEK1, and AKT by mass spectrometry; a subset was evaluated for ALK rearrangements.  We identified 33 EGFR exon 20 insertion cases [2.2%, 95% confidence interval (CI), 1.6-3.1], all mutually exclusive with mutations in the other genes tested (except PIK3CA).  They were more common among never-smokers (P < 0.0001).  There was no assocn. with age, sex, race, or stage.  Morphol., tumors were similar to those with common EGFR mutations but with frequent solid histol.  Insertions were highly variable in position and size, ranging from 3 to 12 bp, resulting in 13 different insertions, which, by mol. modeling, are predicted to have potentially different effects on erlotinib binding.  EGFR exon 20 insertion testing identifies a distinct subset of lung adenocarcinomas, accounting for at least 9% of all EGFR-mutated cases, representing the third most common type of EGFR mutation after exon 19 deletions and L858R.  Insertions are structurally heterogeneous with potential implications for response to EGFR inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv1GpDUzx3KLVg90H21EOLACvtfcHk0lhOyZaRiPaZbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXitlWisrc%253D&md5=5f9c4df38f65a6948af8572c5dbfd222</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.mct-12-0620&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.mct-12-0620%26sid%3Dliteratum%253Aachs%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DNafa%26aufirst%3DK.%26aulast%3DChaft%26aufirst%3DJ.%2BE.%26aulast%3DRekhtman%26aufirst%3DN.%26aulast%3DLau%26aufirst%3DC.%26aulast%3DReva%26aufirst%3DB.%2BA.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DLadanyi%26aufirst%3DM.%26atitle%3DEGFR%2520exon%252020%2520insertion%2520mutations%2520in%2520lung%2520adenocarcinomas%253A%2520prevalence%252C%2520molecular%2520heterogeneity%252C%2520and%2520clinicopathologic%2520characteristics%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2013%26volume%3D12%26spage%3D220%26epage%3D229%26doi%3D10.1158%2F1535-7163.mct-12-0620" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oxnard, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlberg, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindeman, N. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butaney, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackman, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span> <span> </span><span class="NLM_article-title">Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">179</span>– <span class="NLM_lpage">184</span>, <span class="refDoi"> DOI: 10.1097/jto.0b013e3182779d18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1097%2Fjto.0b013e3182779d18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=23328547" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1Kms7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=179-184&author=G.+R.+Oxnardauthor=P.+C.+Loauthor=M.+Nishinoauthor=S.+E.+Dahlbergauthor=N.+I.+Lindemanauthor=M.+Butaneyauthor=D.+M.+Jackmanauthor=B.+E.+Johnsonauthor=P.+A.+J%C3%A4nne&title=Natural+history+and+molecular+characteristics+of+lung+cancers+harboring+EGFR+exon+20+insertions&doi=10.1097%2Fjto.0b013e3182779d18"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions</span></div><div class="casAuthors">Oxnard, Geoffrey R.; Lo, Peter C.; Nishino, Mizuki; Dahlberg, Suzanne E.; Lindeman, Neal I.; Butaney, Mohit; Jackman, David M.; Johnson, Bruce E.; Jaenne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thoracic Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">179-184</span>CODEN:
                <span class="NLM_cas:coden">JTOOB7</span>;
        ISSN:<span class="NLM_cas:issn">1556-0864</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Introduction: Exon 20 insertions are the third most common family of epidermal growth factor receptor (EGFR) mutations found in non-small-cell lung cancer (NSCLC).  Little is known about cancers harboring these mutations aside from their lack of response to EGFR tyrosine kinase inhibitors, impairing the development of effective targeted therapies.  Methods: NSCLC patients with EGFR genotyping were studied using a mechanism approved by the Institutional Review Board.  Cancers with exon 20 insertions were indentified, sequences were characterized, and effectiveness of different treatment regimens was reviewed retrospectively.  Clin. characteristics and survival were compared with cancers harboring common EGFR mutations and cancers with wild-type EGFR.  Results: One thousand eighty-six patients underwent EGFR genotyping from 2004 to 2012.  Twenty seven (2.5%) harbored exon 20 insertions, making up 9.2% of all cancers with documented EGFR mutations.  Compared with wild-type cancers, those with exon 20 insertions were more commonly found in never-smokers and Asian patients.  Insertion sequences were highly variable, with the most common variant (V769D770insASV) making up only 22% of cases.  Median survival of patients with exon 20 insertions was 16 mo, similar to the survival of wild-type cancers and shorter than the survival of cancers with common EGFR mutations.  Conclusions: Patients with EGFR exon 20 insertions have similar clin. characteristics to those with common EGFR mutations but a poorer prognosis.  The prevalence of this subset of NSCLC is similar to that of other genotype-defined subsets of lung adenocarcinoma (e.g. those with BRAF mutations, HER2 insertions, ROS1 rearrangements) and is a population of interest for trials of new targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvsALCA978j7Vg90H21EOLACvtfcHk0lhOyZaRiPaZbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1Kms7k%253D&md5=1448f6533853c20970ca59fe23649df3</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1097%2Fjto.0b013e3182779d18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252Fjto.0b013e3182779d18%26sid%3Dliteratum%253Aachs%26aulast%3DOxnard%26aufirst%3DG.%2BR.%26aulast%3DLo%26aufirst%3DP.%2BC.%26aulast%3DNishino%26aufirst%3DM.%26aulast%3DDahlberg%26aufirst%3DS.%2BE.%26aulast%3DLindeman%26aufirst%3DN.%2BI.%26aulast%3DButaney%26aufirst%3DM.%26aulast%3DJackman%26aufirst%3DD.%2BM.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DNatural%2520history%2520and%2520molecular%2520characteristics%2520of%2520lung%2520cancers%2520harboring%2520EGFR%2520exon%252020%2520insertions%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2013%26volume%3D8%26spage%3D179%26epage%3D184%26doi%3D10.1097%2Fjto.0b013e3182779d18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ning, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wery, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.-X.</span></span> <span> </span><span class="NLM_article-title">NSCLC harboring EGFR exon-20 insertions after the regulatory C-helix of kinase domain responds poorly to known EGFR inhibitors</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>139</i></span>,  <span class="NLM_fpage">171</span>– <span class="NLM_lpage">176</span>, <span class="refDoi"> DOI: 10.1002/ijc.30047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1002%2Fijc.30047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=26891175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BC28XkvVyht7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2016&pages=171-176&author=M.+Yangauthor=X.+Xuauthor=J.+Caiauthor=J.+Ningauthor=J.+P.+Weryauthor=Q.-X.+Li&title=NSCLC+harboring+EGFR+exon-20+insertions+after+the+regulatory+C-helix+of+kinase+domain+responds+poorly+to+known+EGFR+inhibitors&doi=10.1002%2Fijc.30047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">NSCLC harboring EGFR exon-20 insertions after the regulatory C-helix of kinase domain responds poorly to known EGFR inhibitors</span></div><div class="casAuthors">Yang, Mengmeng; Xu, Xiaoxi; Cai, Jie; Ning, Jinying; Wery, Jean Pierre; Li, Qi-Xiang</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">139</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">171-176</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Anecdote clin. observations hint that non-small cell lung cancer (NSCLC) with exon-20 insertions might respond poorly to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), contrasting to those with classic mutations.  Lack of patient-derived exptl. models has been a major hurdle for the discovery of new treatment for the diseases.  We established two NSCLC-PDXs harboring two different exon-20 insertions, LU0387-adenocarcinoma (ADC) with a nine-base insertion at 2319 (H773-V774insNPH) and LU3075-squamous cell carcinoma (SCC) with a nine-base insertion at 2316 (P772-H773insDNP).  Both insertions immediately follow the regulatory C-helix of the kinase domain.  Contrary to the generally good responses to EGFR inhibitors obsd. in PDXs with classic mutations, both exon-20 insertions are largely resistant to cetuximab and TKIs in vivo, suggesting fundamental difference from the classic EGFR mutations, consistent with the poor response rate to TKI seen in anecdotal clinic reports.  It is worth noting that although responses are generally poor, they differ between the two exon-20 mutants depending on the type of TKI.  In vitro drug sensitivity assays using established primary cell lines from our two PDXs largely confirmed the in vivo data.  Our data from patient-derived exptl. models confirmed that exon-20 insertions in domain immediately following the C-helix confer poor response to all known EGFR inhibitors, and suggested that these models can be utilized to facilitate the discovery of new therapies targeting NSCLC harboring exon-20 insertions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroWeElBAFqVLVg90H21EOLACvtfcHk0lgCnnhpE-DU5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XkvVyht7o%253D&md5=19df87ac0356538b8fee4cc0bc7b92f3</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1002%2Fijc.30047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.30047%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DCai%26aufirst%3DJ.%26aulast%3DNing%26aufirst%3DJ.%26aulast%3DWery%26aufirst%3DJ.%2BP.%26aulast%3DLi%26aufirst%3DQ.-X.%26atitle%3DNSCLC%2520harboring%2520EGFR%2520exon-20%2520insertions%2520after%2520the%2520regulatory%2520C-helix%2520of%2520kinase%2520domain%2520responds%2520poorly%2520to%2520known%2520EGFR%2520inhibitors%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2016%26volume%3D139%26spage%3D171%26epage%3D176%26doi%3D10.1002%2Fijc.30047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aisner, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaft, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kako, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kris, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varella-Garcia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arcila, M. E.</span></span> <span> </span><span class="NLM_article-title">HER2 amplification and HER2 mutation are distinct molecular targets in lung cancers</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">414</span>– <span class="NLM_lpage">419</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2015.10.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1016%2Fj.jtho.2015.10.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=26723242" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A280%3ADC%252BC28rmsFSlug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=414-419&author=B.+T.+Liauthor=D.+S.+Rossauthor=D.+L.+Aisnerauthor=J.+E.+Chaftauthor=M.+Hsuauthor=S.+L.+Kakoauthor=M.+G.+Krisauthor=M.+Varella-Garciaauthor=M.+E.+Arcila&title=HER2+amplification+and+HER2+mutation+are+distinct+molecular+targets+in+lung+cancers&doi=10.1016%2Fj.jtho.2015.10.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers</span></div><div class="casAuthors">Li Bob T; Ross Dara S; Aisner Dara L; Kako Severine L; Varella-Garcia Marileila; Chaft Jamie E; Kris Mark G; Hsu Meier; Arcila Maria E</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">414-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  Human epidermal growth factor receptor 2 gene (HER2 [also known as ERBB2]) alterations have been identified as oncogenic drivers and potential therapeutic targets in lung cancers.  The molecular associations of HER2 gene amplification, mutation, and HER2 protein overexpression in lung cancers have not been distinctly defined.  To explore these associations, Memorial Sloan Kettering Cancer Center and the University of Colorado combined their data on HER2 alterations in lung cancers.  METHODS:  Tumor specimens from 175 patients with lung adenocarcinomas and no prior targeted therapy were evaluated for the presence of HER2 amplification and mutation and HER2 protein overexpression.  Amplification was assessed by fluorescence in situ hybridization (FISH) and defined as an HER2-to-chromosome enumeration probe 17 ratio of at least 2.0.  Mutation was assessed by fragment analysis, mass spectrometry genotyping, and Sanger sequencing.  Overexpression was assessed by immunohistochemical (IHC) staining.  The frequencies of HER2 amplification and mutation and HER2 overexpression were calculated and their overlap examined.  RESULTS:  HER2 amplification was detected by FISH in 5 of 175 cases (3%).  HER2 mutation was detected in 4 of 148 specimens (3%), including three identical 12-base pair insertions (p.A775_G776insYVMA) and a 9-base pair insertion, all in exon 20.  None of the HER2-mutant cases was amplified.  HER2 overexpression (2+ or 3+) on IHC staining was not detected in the 25 specimens available for testing, and negative IHC staining correlated with the negative results according to FISH.  CONCLUSIONS:  HER2 mutations are not associated with HER2 amplification, thus suggesting a distinct entity and therapeutic target.  HER2-positive lung cancer may not be an adequate term, and patient cohorts for the study of HER2-targeted agents should be defined by the specific HER2 alteration present.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS9sBZvWYUoddFxYDaSSP8XfW6udTcc2eZXqrTjb4p9crntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rmsFSlug%253D%253D&md5=c127ca81946d6a6d9b0f5b93cc47c0b9</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2015.10.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2015.10.025%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DB.%2BT.%26aulast%3DRoss%26aufirst%3DD.%2BS.%26aulast%3DAisner%26aufirst%3DD.%2BL.%26aulast%3DChaft%26aufirst%3DJ.%2BE.%26aulast%3DHsu%26aufirst%3DM.%26aulast%3DKako%26aufirst%3DS.%2BL.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DVarella-Garcia%26aufirst%3DM.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26atitle%3DHER2%2520amplification%2520and%2520HER2%2520mutation%2520are%2520distinct%2520molecular%2520targets%2520in%2520lung%2520cancers%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2016%26volume%3D11%26spage%3D414%26epage%3D419%26doi%3D10.1016%2Fj.jtho.2015.10.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">U.S.
National Library of Medicine</span>. <span> </span><span class="NLM_article-title">ClinicalTrials.gov</span>. <a href="https://clinicaltrials.gov/ct2/show/NCT03066206" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03066206</a> (accessed Mar 15, <span class="NLM_year">2019</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=U.S.%0ANational+Library+of+Medicine&title=ClinicalTrials.gov"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DClinicalTrials.gov%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">U.S. National Library of Medicine</span>. <span> </span><span class="NLM_article-title">ClinicalTrials.gov</span>. <a href="https://clinicaltrials.gov/ct2/show/NCT02716116" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02716116</a> (accessed Mar 15, <span class="NLM_year">2019</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=U.S.+National+Library+of+Medicine&title=ClinicalTrials.gov"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DClinicalTrials.gov%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robichaux, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elamin, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poteete, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrada-Bernal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roarty, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brahmer, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadimitrakopoulou, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Politi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doebele, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heymach, J. V.</span></span> <span> </span><span class="NLM_article-title">Mechanisms and clinical activity of an EGFR and HER2 exon 20 selective kinase inhibitor in non–small cell Lung cancer</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">638</span>– <span class="NLM_lpage">646</span>, <span class="refDoi"> DOI: 10.1038/s41591-018-0007-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1038%2Fs41591-018-0007-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=29686424" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BC1cXosVCnsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=638-646&author=J.+P.+Robichauxauthor=Y.+Y.+Elaminauthor=Z.+Tanauthor=B.+W.+Carterauthor=S.+Zhangauthor=S.+Liuauthor=S.+Liauthor=T.+Chenauthor=A.+Poteeteauthor=A.+Estrada-Bernalauthor=A.+T.+Leauthor=A.+Truiniauthor=M.+B.+Nilssonauthor=H.+Sunauthor=E.+Roartyauthor=S.+B.+Goldbergauthor=J.+R.+Brahmerauthor=M.+Altanauthor=C.+Luauthor=V.+Papadimitrakopoulouauthor=K.+Politiauthor=R.+C.+Doebeleauthor=K.-K.+Wongauthor=J.+V.+Heymach&title=Mechanisms+and+clinical+activity+of+an+EGFR+and+HER2+exon+20+selective+kinase+inhibitor+in+non%E2%80%93small+cell+Lung+cancer&doi=10.1038%2Fs41591-018-0007-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer</span></div><div class="casAuthors">Robichaux, Jacqulyne P.; Elamin, Yasir Y.; Tan, Zhi; Carter, Brett W.; Zhang, Shuxing; Liu, Shengwu; Li, Shuai; Chen, Ting; Poteete, Alissa; Estrada-Bernal, Adriana; Le, Anh T.; Truini, Anna; Nilsson, Monique B.; Sun, Huiying; Roarty, Emily; Goldberg, Sarah B.; Brahmer, Julie R.; Altan, Mehmet; Lu, Charles; Papadimitrakopoulou, Vassiliki; Politi, Katerina; Doebele, Robert C.; Wong, Kwok-Kin; Heymach, John V.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">638-646</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Although most activating mutations of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancers (NSCLCs) are sensitive to available EGFR tyrosine kinase inhibitors (TKIs), a subset with alterations in exon 20 of EGFR and HER2 are intrinsically resistant and lack an effective therapy.  We used in silico, in vitro, and in vivo testing to model structural alterations induced by exon 20 mutations and to identify effective inhibitors. 3D modeling indicated alterations restricted the size of the drug-binding pocket, limiting the binding of large, rigid inhibitors.  We found that poziotinib, owing to its small size and flexibility, can circumvent these steric changes and is a potent inhibitor of the most common EGFR and HER2 exon 20 mutants.  Poziotinib demonstrated greater activity than approved EGFR TKIs in vitro and in patient-derived xenograft models of EGFR or HER2 exon 20 mutant NSCLC and in genetically engineered mouse models of NSCLC.  In a phase 2 trial, the first 11 patients with NSCLC with EGFR exon 20 mutations receiving poziotinib had a confirmed objective response rate of 64%.  These data identify poziotinib as a potent, clin. active inhibitor of EGFR and HER2 exon 20 mutations and illuminate the mol. features of TKIs that may circumvent steric changes induced by these mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrk6UyVpv0h47Vg90H21EOLACvtfcHk0lgCnnhpE-DU5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXosVCnsLs%253D&md5=316a0a0765ebc9eec9b6460d27b28bb5</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1038%2Fs41591-018-0007-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41591-018-0007-9%26sid%3Dliteratum%253Aachs%26aulast%3DRobichaux%26aufirst%3DJ.%2BP.%26aulast%3DElamin%26aufirst%3DY.%2BY.%26aulast%3DTan%26aufirst%3DZ.%26aulast%3DCarter%26aufirst%3DB.%2BW.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DPoteete%26aufirst%3DA.%26aulast%3DEstrada-Bernal%26aufirst%3DA.%26aulast%3DLe%26aufirst%3DA.%2BT.%26aulast%3DTruini%26aufirst%3DA.%26aulast%3DNilsson%26aufirst%3DM.%2BB.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DRoarty%26aufirst%3DE.%26aulast%3DGoldberg%26aufirst%3DS.%2BB.%26aulast%3DBrahmer%26aufirst%3DJ.%2BR.%26aulast%3DAltan%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DPapadimitrakopoulou%26aufirst%3DV.%26aulast%3DPoliti%26aufirst%3DK.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DHeymach%26aufirst%3DJ.%2BV.%26atitle%3DMechanisms%2520and%2520clinical%2520activity%2520of%2520an%2520EGFR%2520and%2520HER2%2520exon%252020%2520selective%2520kinase%2520inhibitor%2520in%2520non%25E2%2580%2593small%2520cell%2520Lung%2520cancer%26jtitle%3DNat.%2520Med.%26date%3D2018%26volume%3D24%26spage%3D638%26epage%3D646%26doi%3D10.1038%2Fs41591-018-0007-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heymach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negrao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robichaux, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbons, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fossella, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumenschein, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsao, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mott, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mack, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roeck, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadimitrakopoulou, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elamin, Y.</span></span> <span> </span><span class="NLM_article-title">A phase II trial of poziotinib in EGFR and HER2 exon 20 mutant non-small cell lung cancer (NSCLC)</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">S323</span>– <span class="NLM_lpage">S324</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2018.08.243</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1016%2Fj.jtho.2018.08.243" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=29396253" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=S323-S324&author=J.+Heymachauthor=M.+Negraoauthor=J.+Robichauxauthor=B.+Carterauthor=A.+Patelauthor=M.+Altanauthor=D.+Gibbonsauthor=F.+Fossellaauthor=G.+Simonauthor=V.+Lamauthor=G.+Blumenscheinauthor=A.+Tsaoauthor=J.+Kurieauthor=F.+Mottauthor=D.+Jenkinsauthor=D.+Mackauthor=L.+Fengauthor=B.+Roeckauthor=Z.+Yangauthor=V.+Papadimitrakopoulouauthor=Y.+Elamin&title=A+phase+II+trial+of+poziotinib+in+EGFR+and+HER2+exon+20+mutant+non-small+cell+lung+cancer+%28NSCLC%29&doi=10.1016%2Fj.jtho.2018.08.243"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2018.08.243&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2018.08.243%26sid%3Dliteratum%253Aachs%26aulast%3DHeymach%26aufirst%3DJ.%26aulast%3DNegrao%26aufirst%3DM.%26aulast%3DRobichaux%26aufirst%3DJ.%26aulast%3DCarter%26aufirst%3DB.%26aulast%3DPatel%26aufirst%3DA.%26aulast%3DAltan%26aufirst%3DM.%26aulast%3DGibbons%26aufirst%3DD.%26aulast%3DFossella%26aufirst%3DF.%26aulast%3DSimon%26aufirst%3DG.%26aulast%3DLam%26aufirst%3DV.%26aulast%3DBlumenschein%26aufirst%3DG.%26aulast%3DTsao%26aufirst%3DA.%26aulast%3DKurie%26aufirst%3DJ.%26aulast%3DMott%26aufirst%3DF.%26aulast%3DJenkins%26aufirst%3DD.%26aulast%3DMack%26aufirst%3DD.%26aulast%3DFeng%26aufirst%3DL.%26aulast%3DRoeck%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DPapadimitrakopoulou%26aufirst%3DV.%26aulast%3DElamin%26aufirst%3DY.%26atitle%3DA%2520phase%2520II%2520trial%2520of%2520poziotinib%2520in%2520EGFR%2520and%2520HER2%2520exon%252020%2520mutant%2520non-small%2520cell%2520lung%2520cancer%2520%2528NSCLC%2529%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2018%26volume%3D13%26spage%3DS323%26epage%3DS324%26doi%3D10.1016%2Fj.jtho.2018.08.243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span> </span><span class="NLM_article-title">Reaction Biology Corporation Home Page</span>. <a href="http://www.reactionbiology.com/webapps/site/KinaseAssay.aspx" class="extLink">http://www.reactionbiology.com/webapps/site/KinaseAssay.aspx</a> (accessed Jan 6, <span class="NLM_year">2019</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Reaction+Biology+Corporation+Home+Page.+http%3A%2F%2Fwww.reactionbiology.com%2Fwebapps%2Fsite%2FKinaseAssay.aspx+%28accessed+Jan+6%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DReaction%2520Biology%2520Corporation%2520Home%2520Page%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan-Jacob, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moebitz, H.</span></span> <span> </span><span class="NLM_article-title">Ten things you should know about protein kinases: IUPHAR review 14</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">2675</span>– <span class="NLM_lpage">2700</span>, <span class="refDoi"> DOI: 10.1111/bph.13096</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1111%2Fbph.13096" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=25630872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVent7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2015&pages=2675-2700&author=D.+Fabbroauthor=S.+W.+Cowan-Jacobauthor=H.+Moebitz&title=Ten+things+you+should+know+about+protein+kinases%3A+IUPHAR+review+14&doi=10.1111%2Fbph.13096"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Ten things you should know about protein kinases: IUPHAR Review 14</span></div><div class="casAuthors">Fabbro, Doriano; Cowan-Jacob, Sandra W.; Moebitz, Henrik</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2675-2700</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Many human malignancies are assocd. with aberrant regulation of protein or lipid kinases due to mutations, chromosomal rearrangements and/or gene amplification.  Protein and lipid kinases represent an important target class for treating human disorders.  This review focus on 'the 10 things you should know about protein kinases and their inhibitors', including a short introduction on the history of protein kinases and their inhibitors and ending with a perspective on kinase drug discovery.  Although the '10 things' have been, to a certain extent, chosen arbitrarily, they cover in a comprehensive way the past and present efforts in kinase drug discovery and summarize the status quo of the current kinase inhibitors as well as knowledge about kinase structure and binding modes.  Besides describing the potentials of protein kinase inhibitors as drugs, this review also focus on their limitations, particularly on how to circumvent emerging resistance against kinase inhibitors in oncol. indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryyzn-icN30rVg90H21EOLACvtfcHk0liRPMKQqjj4PA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVent7zP&md5=160b754efc7f29460712fa03bb2274b1</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1111%2Fbph.13096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.13096%26sid%3Dliteratum%253Aachs%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DMoebitz%26aufirst%3DH.%26atitle%3DTen%2520things%2520you%2520should%2520know%2520about%2520protein%2520kinases%253A%2520IUPHAR%2520review%252014%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2015%26volume%3D172%26spage%3D2675%26epage%3D2700%26doi%3D10.1111%2Fbph.13096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hasenahuer, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barletta, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Alberti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parisi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fornasari, M. S.</span></span> <span> </span><span class="NLM_article-title">Pockets as structural descriptors of EGFR kinase conformations</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>, <span class="NLM_elocation-id">e0189147</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0189147</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1371%2Fjournal.pone.0189147" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=29228029" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsV2rurvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&author=M.+A.+Hasenahuerauthor=G.+P.+Barlettaauthor=S.+Fernandez-Albertiauthor=G.+Parisiauthor=M.+S.+Fornasari&title=Pockets+as+structural+descriptors+of+EGFR+kinase+conformations&doi=10.1371%2Fjournal.pone.0189147"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Pockets as structural descriptors of EGFR kinase conformations</span></div><div class="casAuthors">Hasenahuer, Marcia Anahi; Barletta, German Patricio; Fernandez-Alberti, Sebastian; Parisi, Gustavo; Fornasari, Maria Silvina</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">e0189147/1-e0189147/17</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Epidermal Growth Factor Receptor (EGFR), a tyrosine kinase receptor, is one of the main tumor markers in different types of cancers.  The kinase native state is mainly composed of two populations of conformers: active and inactive.  Several sequence variations in EGFR kinase region promote the differential enrichment of conformers with higher activity.  Some structural characteristics have been proposed to differentiate kinase conformations, but these considerations could lead to ambiguous classifications.  We present a structural characterization of EGFR kinase conformers, focused on active site pocket comparisons, and the mapping of known pathol. sequence variations.  A structural based clustering of this pocket accurately discriminates active from inactive, well-characterised conformations.  Furthermore, this main pocket contains, or is in close contact with, ≈65% of cancer-related variation positions.  Although the relevance of protein dynamics to explain biol. function has been extensively recognized, the usage of the ensemble of conformations in dynamic equil. to represent the functional state of proteins and the importance of pockets, cavities and/or tunnels was often neglected in previous studies.  These functional structures and the equil. between them could be structurally analyzed in wild type as well as in sequence variants.  Our results indicate that biol. important pockets, as well as their shape and dynamics, are central to understanding protein function in wild-type, polymorphic or disease-related variations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpul4xajmXXhbVg90H21EOLACvtfcHk0liRPMKQqjj4PA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsV2rurvL&md5=eeb15ac0d039f004bdcef80d87556d01</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0189147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0189147%26sid%3Dliteratum%253Aachs%26aulast%3DHasenahuer%26aufirst%3DM.%2BA.%26aulast%3DBarletta%26aufirst%3DG.%2BP.%26aulast%3DFernandez-Alberti%26aufirst%3DS.%26aulast%3DParisi%26aufirst%3DG.%26aulast%3DFornasari%26aufirst%3DM.%2BS.%26atitle%3DPockets%2520as%2520structural%2520descriptors%2520of%2520EGFR%2520kinase%2520conformations%26jtitle%3DPLoS%2520One%26date%3D2017%26volume%3D12%26doi%3D10.1371%2Fjournal.pone.0189147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Songtawee, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gleeson, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choowongkomon, K.</span></span> <span> </span><span class="NLM_article-title">Computational study of EGFR inhibition: molecular dynamics studies on the active and inactive protein conformations</span>. <i>J. Mol. Model.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">497</span>– <span class="NLM_lpage">509</span>, <span class="refDoi"> DOI: 10.1007/s00894-012-1559-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1007%2Fs00894-012-1559-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=22955422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1ehtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=497-509&author=N.+Songtaweeauthor=M.+P.+Gleesonauthor=K.+Choowongkomon&title=Computational+study+of+EGFR+inhibition%3A+molecular+dynamics+studies+on+the+active+and+inactive+protein+conformations&doi=10.1007%2Fs00894-012-1559-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Computational study of EGFR inhibition: molecular dynamics studies on the active and inactive protein conformations</span></div><div class="casAuthors">Songtawee, Napat; Gleeson, M. Paul; Choowongkomon, Kiattawee</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Modeling</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">497-509</span>CODEN:
                <span class="NLM_cas:coden">JMMOFK</span>;
        ISSN:<span class="NLM_cas:issn">0948-5023</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The structural diversity obsd. across protein kinases, resulting in subtly different active site cavities, is highly desirable in the pursuit of selective inhibitors, yet it can also be a hindrance from a structure-based design perspective.  An important challenge in structure-based design is to better understand the dynamic nature of protein kinases and the underlying reasons for specific conformational preferences in the presence of different inhibitors.  To investigate this issue, we performed mol. dynamics simulation on both the active and inactive wild type epidermal growth factor receptor (EGFR) protein with both type-I and type-II inhibitors.  Our goal is to better understand the origin of the two distinct EGFR protein conformations, their dynamic differences, and their relative preference for Type-I inhibitors such as gefitinib and Type-II inhibitors such as lapatinib.  We discuss the implications of protein dynamics from a structure-based design perspective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPx-eH9xSM3rVg90H21EOLACvtfcHk0lj8maxpIt1KIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1ehtLw%253D&md5=18f66b72eb206a39f580f749d2e8cd01</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1007%2Fs00894-012-1559-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00894-012-1559-0%26sid%3Dliteratum%253Aachs%26aulast%3DSongtawee%26aufirst%3DN.%26aulast%3DGleeson%26aufirst%3DM.%2BP.%26aulast%3DChoowongkomon%26aufirst%3DK.%26atitle%3DComputational%2520study%2520of%2520EGFR%2520inhibition%253A%2520molecular%2520dynamics%2520studies%2520on%2520the%2520active%2520and%2520inactive%2520protein%2520conformations%26jtitle%3DJ.%2520Mol.%2520Model.%26date%3D2013%26volume%3D19%26spage%3D497%26epage%3D509%26doi%3D10.1007%2Fs00894-012-1559-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, C. T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwoh, C. K.</span></span> <span> </span><span class="NLM_article-title">CovalentDock: automated covalent docking with parameterized covalent linkage energy estimation and molecular geometry constraints</span>. <i>J. Comput. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">326</span>– <span class="NLM_lpage">336</span>, <span class="refDoi"> DOI: 10.1002/jcc.23136</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1002%2Fjcc.23136" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=23034731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVKksLbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2013&pages=326-336&author=X.+Ouyangauthor=S.+Zhouauthor=C.+T.+T.+Suauthor=Z.+Geauthor=R.+Liauthor=C.+K.+Kwoh&title=CovalentDock%3A+automated+covalent+docking+with+parameterized+covalent+linkage+energy+estimation+and+molecular+geometry+constraints&doi=10.1002%2Fjcc.23136"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">CovalentDock: Automated covalent docking with parameterized covalent linkage energy estimation and molecular geometry constrains</span></div><div class="casAuthors">Ouyang, Xuchang; Zhou, Shuo; Su, Chinh Tran To; Ge, Zemei; Li, Runtao; Kwoh, Chee Keong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">326-336</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Covalent linkage formation is a very important mechanism for many covalent drugs to work.  However, partly due to the limitations of proper computational tools for covalent docking, most covalent drugs are not discovered systematically.  In this article, we present a new covalent docking package, the CovalentDock, built on the top of the source code of Autodock.  We developed an empirical model of free energy change estn. for covalent linkage formation, which is compatible with existing scoring functions used in docking, while handling the mol. geometry constrains of the covalent linkage with special atom types and directional grid maps.  Integrated prepn. scripts are also written for the automation of the whole covalent docking workflow.  The result tested on existing crystal structures with covalent linkage shows that CovalentDock can reproduce the native covalent complexes with significant improved accuracy when compared with the default covalent docking method in Autodock.  Expts. also suggest that CovalentDock is capable of covalent virtual screening with satisfactory enrichment performance.  In addn., the investigation on the results also shows that the chirality and target selectivity along with the mol. geometry constrains are well preserved by CovalentDock, showing great capability of this method in the application for covalent drug discovery. © 2012 Wiley Periodicals, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1kpnxsCasoLVg90H21EOLACvtfcHk0lj8maxpIt1KIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVKksLbJ&md5=5f548c115755f2e1470848ba6f6d701b</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1002%2Fjcc.23136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.23136%26sid%3Dliteratum%253Aachs%26aulast%3DOuyang%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DS.%26aulast%3DSu%26aufirst%3DC.%2BT.%2BT.%26aulast%3DGe%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DR.%26aulast%3DKwoh%26aufirst%3DC.%2BK.%26atitle%3DCovalentDock%253A%2520automated%2520covalent%2520docking%2520with%2520parameterized%2520covalent%2520linkage%2520energy%2520estimation%2520and%2520molecular%2520geometry%2520constraints%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D2013%26volume%3D34%26spage%3D326%26epage%3D336%26doi%3D10.1002%2Fjcc.23136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, C. L.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackerell, A. D.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrella, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roux, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Won, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Archontis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartels, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boresch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caflisch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caves, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinner, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feig, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodoscek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuczera, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazaridis, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ovchinnikov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paci, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastor, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Post, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaefer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tidor, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venable, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodcock, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">York, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karplus, M.</span></span> <span> </span><span class="NLM_article-title">CHARMM: the biomolecular simulation program</span>. <i>J. Comput. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">1545</span>– <span class="NLM_lpage">1614</span>, <span class="refDoi"> DOI: 10.1002/jcc.21287</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1002%2Fjcc.21287" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=19444816" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BD1MXms1Ciu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2009&pages=1545-1614&author=B.+R.+Brooksauthor=C.+L.+Brooksauthor=A.+D.+Mackerellauthor=L.+Nilssonauthor=R.+J.+Petrellaauthor=B.+Rouxauthor=Y.+Wonauthor=G.+Archontisauthor=C.+Bartelsauthor=S.+Boreschauthor=A.+Caflischauthor=L.+Cavesauthor=Q.+Cuiauthor=A.+R.+Dinnerauthor=M.+Feigauthor=S.+Fischerauthor=J.+Gaoauthor=M.+Hodoscekauthor=W.+Imauthor=K.+Kuczeraauthor=T.+Lazaridisauthor=J.+Maauthor=V.+Ovchinnikovauthor=E.+Paciauthor=R.+W.+Pastorauthor=C.+B.+Postauthor=J.+Z.+Puauthor=M.+Schaeferauthor=B.+Tidorauthor=R.+M.+Venableauthor=H.+L.+Woodcockauthor=X.+Wuauthor=W.+Yangauthor=D.+M.+Yorkauthor=M.+Karplus&title=CHARMM%3A+the+biomolecular+simulation+program&doi=10.1002%2Fjcc.21287"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">CHARMM: The biomolecular simulation program</span></div><div class="casAuthors">Brooks, B. R.; Brooks, C. L., III; Mackerell, A. D., Jr.; Nilsson, L.; Petrella, R. J.; Roux, B.; Won, Y.; Archontis, G.; Bartels, C.; Boresch, S.; Caflisch, A.; Caves, L.; Cui, Q.; Dinner, A. R.; Feig, M.; Fischer, S.; Gao, J.; Hodoscek, M.; Im, W.; Kuczera, K.; Lazaridis, T.; Ma, J.; Ovchinnikov, V.; Paci, E.; Pastor, R. W.; Post, C. B.; Pu, J. Z.; Schaefer, M.; Tidor, B.; Venable, R. M.; Woodcock, H. L.; Wu, X.; Yang, W.; York, D. M.; Karplus, M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1545-1614</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  CHARMM (Chem. at HARvard Mol. Mechanics) is a highly versatile and widely used mol. simulation program.  It has been developed over the last three decades with a primary focus on mols. of biol. interest, including proteins, peptides, lipids, nucleic acids, carbohydrates, and small mol. ligands, as they occur in soln., crystals, and membrane environments.  For the study of such systems, the program provides a large suite of computational tools that include numerous conformational and path sampling methods, free energy estimators, mol. minimization, dynamics, and anal. techniques, and model-building capabilities.  The CHARMM program is applicable to problems involving a much broader class of many-particle systems.  Calcns. with CHARMM can be performed using a no. of different energy functions and models, from mixed quantum mech.-mol. mech. force fields, to all-atom classical potential energy functions with explicit solvent and various boundary conditions, to implicit solvent and membrane models.  The program has been ported to numerous platforms in both serial and parallel architectures.  This article provides an overview of the program as it exists today with an emphasis on developments since the publication of the original CHARMM article in 1983.  © 2009 Wiley Periodicals, Inc. J Comput Chem, 2009.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOXZCtNIqoCbVg90H21EOLACvtfcHk0lj8maxpIt1KIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXms1Ciu70%253D&md5=2c6a2be869362d7131f5aea8411c1552</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1002%2Fjcc.21287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.21287%26sid%3Dliteratum%253Aachs%26aulast%3DBrooks%26aufirst%3DB.%2BR.%26aulast%3DBrooks%26aufirst%3DC.%2BL.%26aulast%3DMackerell%26aufirst%3DA.%2BD.%26aulast%3DNilsson%26aufirst%3DL.%26aulast%3DPetrella%26aufirst%3DR.%2BJ.%26aulast%3DRoux%26aufirst%3DB.%26aulast%3DWon%26aufirst%3DY.%26aulast%3DArchontis%26aufirst%3DG.%26aulast%3DBartels%26aufirst%3DC.%26aulast%3DBoresch%26aufirst%3DS.%26aulast%3DCaflisch%26aufirst%3DA.%26aulast%3DCaves%26aufirst%3DL.%26aulast%3DCui%26aufirst%3DQ.%26aulast%3DDinner%26aufirst%3DA.%2BR.%26aulast%3DFeig%26aufirst%3DM.%26aulast%3DFischer%26aufirst%3DS.%26aulast%3DGao%26aufirst%3DJ.%26aulast%3DHodoscek%26aufirst%3DM.%26aulast%3DIm%26aufirst%3DW.%26aulast%3DKuczera%26aufirst%3DK.%26aulast%3DLazaridis%26aufirst%3DT.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DOvchinnikov%26aufirst%3DV.%26aulast%3DPaci%26aufirst%3DE.%26aulast%3DPastor%26aufirst%3DR.%2BW.%26aulast%3DPost%26aufirst%3DC.%2BB.%26aulast%3DPu%26aufirst%3DJ.%2BZ.%26aulast%3DSchaefer%26aufirst%3DM.%26aulast%3DTidor%26aufirst%3DB.%26aulast%3DVenable%26aufirst%3DR.%2BM.%26aulast%3DWoodcock%26aufirst%3DH.%2BL.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DYork%26aufirst%3DD.%2BM.%26aulast%3DKarplus%26aufirst%3DM.%26atitle%3DCHARMM%253A%2520the%2520biomolecular%2520simulation%2520program%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D2009%26volume%3D30%26spage%3D1545%26epage%3D1614%26doi%3D10.1002%2Fjcc.21287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Otwinowski, Z.</span>; <span class="NLM_string-name">Minor, W.</span></span> <span> </span><span class="NLM_article-title">Processing of X-ray Diffraction Data Collected in Oscillation Mode</span>. In  <i>Methods in Enzymology</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, C. W.,  Jr.</span></span>, Ed.; <span class="NLM_publisher-name">Academic</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">1997</span>; Vol.  <span class="NLM_volume">276</span>, pp <span class="NLM_fpage">307</span>– <span class="NLM_lpage">326</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1016%2FS0076-6879%2897%2976066-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1997&pages=307-326&author=Z.+Otwinowski&author=W.+Minorauthor=C.+W.+Carter&title=Methods+in+Enzymology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2FS0076-6879%2897%2976066-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FS0076-6879%252897%252976066-X%26sid%3Dliteratum%253Aachs%26aulast%3DOtwinowski%26aufirst%3DZ.%26atitle%3DProcessing%2520of%2520X-ray%2520Diffraction%2520Data%2520Collected%2520in%2520Oscillation%2520Mode%26btitle%3DMethods%2520in%2520Enzymology%26aulast%3DCarter%26aufirst%3DC.%2BW.%26pub%3DAcademic%26date%3D1997%26volume%3D276%26spage%3D307%26epage%3D326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adams, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afonine, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunkóczi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Echols, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Headd, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, L.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapral, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosse-Kunstleve, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriarty, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oeffner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terwilliger, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zwart, P. H.</span></span> <span> </span><span class="NLM_article-title">PHENIX: a comprehensive python-based system for macromolecular structure solution</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.1107/s0907444909052925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1107%2FS0907444909052925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=20124702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1Sisbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=213-221&author=P.+D.+Adamsauthor=P.+V.+Afonineauthor=G.+Bunk%C3%B3cziauthor=V.+B.+Chenauthor=I.+W.+Davisauthor=N.+Echolsauthor=J.+J.+Headdauthor=L.-W.+Hungauthor=G.+J.+Kapralauthor=R.+W.+Grosse-Kunstleveauthor=A.+J.+McCoyauthor=N.+W.+Moriartyauthor=R.+Oeffnerauthor=R.+J.+Readauthor=D.+C.+Richardsonauthor=J.+S.+Richardsonauthor=T.+C.+Terwilligerauthor=P.+H.+Zwart&title=PHENIX%3A+a+comprehensive+python-based+system+for+macromolecular+structure+solution&doi=10.1107%2Fs0907444909052925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">PHENIX: a comprehensive Python-based system for macromolecular structure solution</span></div><div class="casAuthors">Adams, Paul D.; Afonine, Pavel V.; Bunkoczi, Gabor; Chen, Vincent B.; Davis, Ian W.; Echols, Nathaniel; Headd, Jeffrey J.; Hung, Li Wei; Kapral, Gary J.; Grosse-Kunstleve, Ralf W.; McCoy, Airlie J.; Moriarty, Nigel W.; Oeffner, Robert; Read, Randy J.; Richardson, David C.; Richardson, Jane S.; Terwilliger, Thomas C.; Zwart, Peter H.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">213-221</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">A review.  Macromol. X-ray crystallog. is routinely applied to understand biol. processes at a mol. level.  However, significant time and effort are still required to solve and complete many of these structures because of the need for manual interpretation of complex numerical data using many software packages and the repeated use of interactive three-dimensional graphics.  PHENIX has been developed to provide a comprehensive system for macromol. crystallog. structure soln. with an emphasis on the automation of all procedures.  This has relied on the development of algorithms that minimize or eliminate subjective input, the development of algorithms that automate procedures that are traditionally performed by hand and, finally, the development of a framework that allows a tight integration between the algorithms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm_HgKRpa-ObVg90H21EOLACvtfcHk0li94DOqJd_SuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1Sisbc%253D&md5=67b439ff4bd61c659cae37ca4209b7bc</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1107%2FS0907444909052925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909052925%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DP.%2BD.%26aulast%3DAfonine%26aufirst%3DP.%2BV.%26aulast%3DBunk%25C3%25B3czi%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DV.%2BB.%26aulast%3DDavis%26aufirst%3DI.%2BW.%26aulast%3DEchols%26aufirst%3DN.%26aulast%3DHeadd%26aufirst%3DJ.%2BJ.%26aulast%3DHung%26aufirst%3DL.-W.%26aulast%3DKapral%26aufirst%3DG.%2BJ.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DMcCoy%26aufirst%3DA.%2BJ.%26aulast%3DMoriarty%26aufirst%3DN.%2BW.%26aulast%3DOeffner%26aufirst%3DR.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26aulast%3DRichardson%26aufirst%3DD.%2BC.%26aulast%3DRichardson%26aufirst%3DJ.%2BS.%26aulast%3DTerwilliger%26aufirst%3DT.%2BC.%26aulast%3DZwart%26aufirst%3DP.%2BH.%26atitle%3DPHENIX%253A%2520a%2520comprehensive%2520python-based%2520system%2520for%2520macromolecular%2520structure%2520solution%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D213%26epage%3D221%26doi%3D10.1107%2Fs0907444909052925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, T. D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oldenburg, K. R.</span></span> <span> </span><span class="NLM_article-title">A simple statistical parameter for use in evaluation and validation of high throughput screening assays</span>. <i>J. Biomol. Screening</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">67</span>– <span class="NLM_lpage">73</span>, <span class="refDoi"> DOI: 10.1177/108705719900400206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1177%2F108705719900400206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10838414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A280%3ADC%252BC2sbit12juw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1999&pages=67-73&author=J.-H.+Zhangauthor=T.+D.+Y.+Chungauthor=K.+R.+Oldenburg&title=A+simple+statistical+parameter+for+use+in+evaluation+and+validation+of+high+throughput+screening+assays&doi=10.1177%2F108705719900400206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays</span></div><div class="casAuthors">Zhang; Chung; Oldenburg</div><div class="citationInfo"><span class="NLM_cas:title">Journal of biomolecular screening</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">67-73</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The ability to identify active compounds (3hits2) from large chemical libraries accurately and rapidly has been the ultimate goal in developing high-throughput screening (HTS) assays.  The ability to identify hits from a particular HTS assay depends largely on the suitability or quality of the assay used in the screening.  The criteria or parameters for evaluating the 3suitability2 of an HTS assay for hit identification are not well defined and hence it still remains difficult to compare the quality of assays directly.  In this report, a screening window coefficient, called 3Z-factor,2 is defined.  This coefficient is reflective of both the assay signal dynamic range and the data variation associated with the signal measurements, and therefore is suitable for assay quality assessment.  The Z-factor is a dimensionless, simple statistical characteristic for each HTS assay.  The Z-factor provides a useful tool for comparison and evaluation of the quality of assays, and can be utilized in assay optimization and validation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRkwW5JDdXnbsNIRw0GKUoEfW6udTcc2eYlwmQ2mNQWLbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sbit12juw%253D%253D&md5=0ec4ed2ccdd3b4a16521567a0975d31f</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1177%2F108705719900400206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F108705719900400206%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.-H.%26aulast%3DChung%26aufirst%3DT.%2BD.%2BY.%26aulast%3DOldenburg%26aufirst%3DK.%2BR.%26atitle%3DA%2520simple%2520statistical%2520parameter%2520for%2520use%2520in%2520evaluation%2520and%2520validation%2520of%2520high%2520throughput%2520screening%2520assays%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D1999%26volume%3D4%26spage%3D67%26epage%3D73%26doi%3D10.1177%2F108705719900400206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 5 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Adileh  Ayati</span>, <span class="hlFld-ContribAuthor ">Setareh  Moghimi</span>, <span class="hlFld-ContribAuthor ">Mahsa  Toolabi</span>, <span class="hlFld-ContribAuthor ">Alireza  Foroumadi</span>. </span><span class="cited-content_cbyCitation_article-title">Pyrimidine-based EGFR TK inhibitors in targeted cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>221 </em>, 113523. <a href="https://doi.org/10.1016/j.ejmech.2021.113523" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113523</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113523&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113523%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPyrimidine-based%252BEGFR%252BTK%252Binhibitors%252Bin%252Btargeted%252Bcancer%252Btherapy%26aulast%3DAyati%26aufirst%3DAdileh%26date%3D2021%26volume%3D221%26spage%3D113523" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Debasis  Das</span>, <span class="hlFld-ContribAuthor ">Jingbing  Wang</span>, <span class="hlFld-ContribAuthor ">Jian  Hong</span>. </span><span class="cited-content_cbyCitation_article-title">Next‐Generation Kinase Inhibitors Targeting Specific Biomarkers in Non‐Small Cell Lung Cancer (NSCLC): A Recent Overview. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2021,</strong> <em>71 </em><a href="https://doi.org/10.1002/cmdc.202100166" title="DOI URL">https://doi.org/10.1002/cmdc.202100166</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202100166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202100166%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DNext%2525E2%252580%252590Generation%252BKinase%252BInhibitors%252BTargeting%252BSpecific%252BBiomarkers%252Bin%252BNon%2525E2%252580%252590Small%252BCell%252BLung%252BCancer%252B%252528NSCLC%252529%25253A%252BA%252BRecent%252BOverview%26aulast%3DDas%26aufirst%3DDebasis%26date%3D2021%26date%3D2021%26volume%3D71" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Julio  Caballero</span>. </span><span class="cited-content_cbyCitation_article-title">The latest automated docking technologies for novel drug discovery. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Discovery</span><span> <strong>2021,</strong> <em>16 </em>
                                    (6)
                                     , 625-645. <a href="https://doi.org/10.1080/17460441.2021.1858793" title="DOI URL">https://doi.org/10.1080/17460441.2021.1858793</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17460441.2021.1858793&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17460441.2021.1858793%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Discovery%26atitle%3DThe%252Blatest%252Bautomated%252Bdocking%252Btechnologies%252Bfor%252Bnovel%252Bdrug%252Bdiscovery%26aulast%3DCaballero%26aufirst%3DJulio%26date%3D2021%26date%3D2020%26volume%3D16%26issue%3D6%26spage%3D625%26epage%3D645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yang-Ping  Deng</span>, <span class="hlFld-ContribAuthor ">Qin-Hua  Gan</span>, <span class="hlFld-ContribAuthor ">Xu  Gao</span>, <span class="hlFld-ContribAuthor ">Xiao-Qiang  Jiang</span>, <span class="hlFld-ContribAuthor ">Shi-Fan  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">A green and efficient method for one-step synthesis of novel oxazolo[3,2-c]pyrimidine derivatives in lactic acid. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2021,</strong> <em>14 </em>, 132276. <a href="https://doi.org/10.1016/j.tet.2021.132276" title="DOI URL">https://doi.org/10.1016/j.tet.2021.132276</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2021.132276&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2021.132276%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DA%252Bgreen%252Band%252Befficient%252Bmethod%252Bfor%252Bone-step%252Bsynthesis%252Bof%252Bnovel%252Boxazolo%25255B3%25252C2-c%25255Dpyrimidine%252Bderivatives%252Bin%252Blactic%252Bacid%26aulast%3DDeng%26aufirst%3DYang-Ping%26date%3D2021%26volume%3D14%26spage%3D132276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ting  Guo</span>, <span class="hlFld-ContribAuthor ">Shutao  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Advances in the Discovery of Multitargeted Tyrosine Kinase Inhibitors as Anticancer Agents. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2021,</strong> <em>16 </em>
                                    (4)
                                     , 600-620. <a href="https://doi.org/10.1002/cmdc.202000658" title="DOI URL">https://doi.org/10.1002/cmdc.202000658</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202000658&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202000658%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DRecent%252BAdvances%252Bin%252Bthe%252BDiscovery%252Bof%252BMultitargeted%252BTyrosine%252BKinase%252BInhibitors%252Bas%252BAnticancer%252BAgents%26aulast%3DGuo%26aufirst%3DTing%26date%3D2021%26date%3D2020%26volume%3D16%26issue%3D4%26spage%3D600%26epage%3D620" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/medium/jm9b00722_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/large/jm9b00722_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00722&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/medium/jm9b00722_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/large/jm9b00722_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. EGFR inhibitors design strategy from initial hit compound <b>1</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/large/jm9b00722_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00722&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/medium/jm9b00722_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/large/jm9b00722_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Binding site analysis for compound <b>2</b> (orange) docking with EGFR X-ray protein (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JQ7">4JQ7</a>). Compound <b>2</b> forms a covalent bond with Cys797 (as shown in the white color residue) and hydrogen bond with Met793 (as shown in the green color residue). The hydrophobic effect was contributed by Leu718, Val726, Ala743, Lys745, Leu788, and Leu844 (as shown in cyan color residues).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/large/jm9b00722_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00722&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/medium/jm9b00722_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/large/jm9b00722_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of the Building Blocks <b>7</b>, <b>10</b>, <b>13</b>, and <b>17</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/large/jm9b00722_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00722&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) AgNO<sub>3</sub>, H<sub>2</sub>O, acetone, reflux, 68%; (b) malononitrile, Et<sub>2</sub>NH, DMF, rt, 52%; (c) morpholine, S<sub>8</sub>, ethanol, 60 °C, 43%; (d) malononitrile, NH<sub>4</sub>OAc, acetic acid, benzene, reflux, 71%; (e) S<sub>8</sub>, Et<sub>2</sub>NH, ethanol, reflux, 83%; (f) NH<sub>2</sub>OH(aq), ethanol, rt; (g) NCS, DMF, rt; (h) NaOEt, malononitrile, rt to 45 °C, 51%.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/medium/jm9b00722_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/large/jm9b00722_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthetic Route of the EGFR Inhibitors for Simplification and Replacement of Furanopyrimidine through Scaffold Hopping<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/large/jm9b00722_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00722&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Ac<sub>2</sub>O, HCO<sub>2</sub>H, 100 °C; (b) HCONH<sub>2</sub>, 200 °C; (c) HCO<sub>2</sub>H, H<sub>2</sub>SO<sub>4</sub>, microwave; (d) (i) HC(OEt)<sub>3</sub>, toluene, 150 °C; (ii) NH<sub>3</sub> in methanol, ethanol, rt; (e) POCl<sub>3</sub>, heat; (f) <i>tert</i>-butyl nitrile, TMSCl, DMF, rt; (g) NBS, DMF, rt; (h) Et<sub>3</sub>N, ethanol, reflux; (i) Pd(PPh<sub>3</sub>)<sub>4</sub>, MeZnCl, THF, 80 °C; (j) NCS, DMF, rt; (k) SnCl<sub>2</sub>, ethanol, reflux; (l) H<sub>2</sub>, Pd/C; (m) iron powder, acid condition, ethanol, heat; (n) acrylic acid, EDCI; (o) acryloyl chloride, pyridine, rt; (p) TBAF, THF, rt.</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/medium/jm9b00722_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/large/jm9b00722_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of EGFR Inhibitors with Various Michael Acceptors<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/large/jm9b00722_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00722&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NBS, DMF; (b) <b>27</b> or (<i>R</i>)-(−)-2-phenylglycinol, Et<sub>3</sub>N, ethanol, heat; (c) Pd(dppf)<sub>2</sub>Cl<sub>2</sub>, 3-nitrophenylboronic acid, Na<sub>2</sub>CO<sub>3(aq)</sub>, heat; (d) SnCl<sub>2</sub>, ethanol, reflux; (e) H<sub>2</sub>, Pd/C; (f) iron powder, acetic acid, ethanol, 90 °C; (g) acryloyl chloride, pyridine, rt; (h) acrylic acid, EDCI; (i) 2-chloroethanesulfonyl chloride, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>; (j) (i) 4-bromocrotonoic acid, EDCI-HCl; (ii) various amine.</p></p></figure><figure data-id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/medium/jm9b00722_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/large/jm9b00722_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Characterization of inhibitor-binding modes: (A) the binding mode of compound <b>2</b> (pink) overlaid with <b>42</b> (green) in EGFR<sup>L858R/T790M</sup> protein (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CAS">5CAS</a>); (B) EGFR<sup>WT</sup> protein–inhibitor interactions for compound <b>74</b> (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JQ7">4JQ7</a>); (C) EGFR<sup>WT</sup> protein–inhibitor interactions for compound <b>77</b> (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JQ7">4JQ7</a>); (D) EGFR<sup>L858R/T790M</sup> protein–inhibitor interactions for compound <b>74</b> (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CAS">5CAS</a>); (E) EGFR<sup>L858R/T790M</sup> protein–inhibitor interactions for compound <b>77</b> (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CAS">5CAS</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/large/jm9b00722_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00722&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/medium/jm9b00722_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/large/jm9b00722_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Crystal structure of EGFR in the complex with <b>78</b> (yellow). For clarity, M766 (on αC helix) and P-loop were omitted in the figure (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6JZ0">6JZ0</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/large/jm9b00722_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00722&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/medium/jm9b00722_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/large/jm9b00722_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Compound <b>78</b> (yellow) forms a hydrogen bond network with the DFG (pink) and HRD motifs (magenta) in the activation loop through the hydroxyl group of the (<i>S</i>)-2-phenylglycinol fragment. The distances between <b>78</b> and EGFR kinase domain were labeled (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6JZ0">6JZ0</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/large/jm9b00722_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00722&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/medium/jm9b00722_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/large/jm9b00722_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Western blot analysis: (A) by using antiphospho-EGFR Y1068 and anti-EGFR immunoblots of HCC827 cell lysates treated with <b>78</b> and gefitinib; (B) by using antiphospho-EGFR Y1068 and anti-EGFR immunoblots of H1975 cell lysates treated with <b>78</b> and afatinib.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/large/jm9b00722_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00722&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/medium/jm9b00722_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/large/jm9b00722_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Kinase profiling of <b>78</b> using the KINOMEScan technology.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/large/jm9b00722_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00722&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/medium/jm9b00722_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/large/jm9b00722_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (A) In vivo antitumor efficacy of gefitinib, afatinib, and <b>78</b> in the HCC827 xenograft mouse model. (B) Body weight change (%) of the mice in the HCC827 xenograft mouse model.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/large/jm9b00722_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00722&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i63">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26474" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26474" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 61 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">World Health Organization (WHO)</span>. <span> </span><span class="NLM_article-title">Statistics Reports for Lung Cancer</span>. <a href="http://www.who.int/news-room/fact-sheets/detail/cancer" class="extLink">http://www.who.int/news-room/fact-sheets/detail/cancer</a> (accessed
Feb 1, <span class="NLM_year">2018</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=World+Health+Organization+%28WHO%29&title=Statistics+Reports+for+Lung+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DStatistics%2520Reports%2520for%2520Lung%2520Cancer%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jemal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bray, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Center, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferlay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forman, D.</span></span> <span> </span><span class="NLM_article-title">Global cancer statistics</span>. <i>Ca-Cancer J. Clin.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">69</span>– <span class="NLM_lpage">90</span>, <span class="refDoi"> DOI: 10.3322/caac.20107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.3322%2Fcaac.20107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=21296855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A280%3ADC%252BC3M3lt1Olsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2011&pages=69-90&author=A.+Jemalauthor=F.+Brayauthor=M.+M.+Centerauthor=J.+Ferlayauthor=E.+Wardauthor=D.+Forman&title=Global+cancer+statistics&doi=10.3322%2Fcaac.20107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Global cancer statistics</span></div><div class="casAuthors">Jemal Ahmedin; Bray Freddie; Center Melissa M; Ferlay Jacques; Ward Elizabeth; Forman David</div><div class="citationInfo"><span class="NLM_cas:title">CA: a cancer journal for clinicians</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">69-90</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The global burden of cancer continues to increase largely because of the aging and growth of the world population alongside an increasing adoption of cancer-causing behaviors, particularly smoking, in economically developing countries.  Based on the GLOBOCAN 2008 estimates, about 12.7 million cancer cases and 7.6 million cancer deaths are estimated to have occurred in 2008; of these, 56% of the cases and 64% of the deaths occurred in the economically developing world.  Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death among females, accounting for 23% of the total cancer cases and 14% of the cancer deaths.  Lung cancer is the leading cancer site in males, comprising 17% of the total new cancer cases and 23% of the total cancer deaths.  Breast cancer is now also the leading cause of cancer death among females in economically developing countries, a shift from the previous decade during which the most common cause of cancer death was cervical cancer.  Further, the mortality burden for lung cancer among females in developing countries is as high as the burden for cervical cancer, with each accounting for 11% of the total female cancer deaths.  Although overall cancer incidence rates in the developing world are half those seen in the developed world in both sexes, the overall cancer mortality rates are generally similar.  Cancer survival tends to be poorer in developing countries, most likely because of a combination of a late stage at diagnosis and limited access to timely and standard treatment.  A substantial proportion of the worldwide burden of cancer could be prevented through the application of existing cancer control knowledge and by implementing programs for tobacco control, vaccination (for liver and cervical cancers), and early detection and treatment, as well as public health campaigns promoting physical activity and a healthier dietary intake.  Clinicians, public health professionals, and policy makers can play an active role in accelerating the application of such interventions globally.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSpm5184kVGTVQKX3ooHxWjfW6udTcc2ebwv1GpM7tlD7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M3lt1Olsw%253D%253D&md5=4b8f63930a6c3e9749e0053a80132fd6</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.3322%2Fcaac.20107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3322%252Fcaac.20107%26sid%3Dliteratum%253Aachs%26aulast%3DJemal%26aufirst%3DA.%26aulast%3DBray%26aufirst%3DF.%26aulast%3DCenter%26aufirst%3DM.%2BM.%26aulast%3DFerlay%26aufirst%3DJ.%26aulast%3DWard%26aufirst%3DE.%26aulast%3DForman%26aufirst%3DD.%26atitle%3DGlobal%2520cancer%2520statistics%26jtitle%3DCa-Cancer%2520J.%2520Clin.%26date%3D2011%26volume%3D61%26spage%3D69%26epage%3D90%26doi%3D10.3322%2Fcaac.20107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Settleman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haber, D. A.</span></span> <span> </span><span class="NLM_article-title">Epidermal growth factor receptor mutations in lung cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">169</span>– <span class="NLM_lpage">181</span>, <span class="refDoi"> DOI: 10.1038/nrc2088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1038%2Fnrc2088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=17318210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=169-181&author=S.+V.+Sharmaauthor=D.+W.+Bellauthor=J.+Settlemanauthor=D.+A.+Haber&title=Epidermal+growth+factor+receptor+mutations+in+lung+cancer&doi=10.1038%2Fnrc2088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor mutations in lung cancer</span></div><div class="casAuthors">Sharma, Sreenath V.; Bell, Daphne W.; Settleman, Jeffrey; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">169-181</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The development and clin. application of inhibitors that target the epidermal growth factor receptor (EGFR) provide important insights for new lung cancer therapies, as well as for the broader field of targeted cancer therapies.  We review the results of genetic, biochem. and clin. studies focused on somatic mutations of EGFR that are assocd. with the phenomenon of oncogene addiction, describing 'oncogenic shock' as a mechanistic explanation for the apoptosis that follows the acute treatment of susceptible cells with kinase inhibitors.  Understanding the genetic heterogeneity of epithelial tumors and devising strategies to circumvent their rapid acquisition of resistance to targeted kinase inhibitors are essential to the successful use of targeted therapies in common epithelial cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMKw7Y4FUFM7Vg90H21EOLACvtfcHk0lgbBOLzxWB5iQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D&md5=46219ea3ae7b9f0977e4a4b7243fd875</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrc2088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2088%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520mutations%2520in%2520lung%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D169%26epage%3D181%26doi%3D10.1038%2Fnrc2088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prabhakar, C. N.</span></span> <span> </span><span class="NLM_article-title">Epidermal growth factor receptor in non-small cell lung cancer</span>. <i>Transl. Lung Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">110</span>– <span class="NLM_lpage">118</span>, <span class="refDoi"> DOI: 10.3978/j.issn.2218-6751.2015.01.01</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.3978%2Fj.issn.2218-6751.2015.01.01" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=25870793" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFCmt7fO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&pages=110-118&author=C.+N.+Prabhakar&title=Epidermal+growth+factor+receptor+in+non-small+cell+lung+cancer&doi=10.3978%2Fj.issn.2218-6751.2015.01.01"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor in non-small cell lung cancer</span></div><div class="casAuthors">Prabhakar, Charles N.</div><div class="citationInfo"><span class="NLM_cas:title">Translational Lung Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">110-118</span>CODEN:
                <span class="NLM_cas:coden">TLCRA9</span>;
        ISSN:<span class="NLM_cas:issn">2226-4477</span>.
    
            (<span class="NLM_cas:orgname">Pioneer Bioscience Publishing Co.</span>)
        </div><div class="casAbstract">Following the identification of a group of patients in the initial tyrosine kinase inhibitor (TKI) trials for lung cancer, there has been detailed focus on which patients may benefit from inhibitor therapy.  This article reviews the background, genetics and prevalence of epidermal growth factor mutations in non-small cell lung cancer (NSCLC).  Addnl., the prevalence in unselected patients is compared against various other reviews.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwFfYVYyyBkbVg90H21EOLACvtfcHk0lgbBOLzxWB5iQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFCmt7fO&md5=93c2024d68169f9b7f0167b7c25ce8e6</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.3978%2Fj.issn.2218-6751.2015.01.01&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3978%252Fj.issn.2218-6751.2015.01.01%26sid%3Dliteratum%253Aachs%26aulast%3DPrabhakar%26aufirst%3DC.%2BN.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520in%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DTransl.%2520Lung%2520Cancer%2520Res.%26date%3D2015%26volume%3D4%26spage%3D110%26epage%3D118%26doi%3D10.3978%2Fj.issn.2218-6751.2015.01.01" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Au, J. S.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thongprasert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivasan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khoa, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heeroma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itoh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornelio, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P.-C.</span></span> <span> </span><span class="NLM_article-title">A prospective, molecular epidemiology study of EGFR mutations in asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">154</span>– <span class="NLM_lpage">162</span>, <span class="refDoi"> DOI: 10.1097/jto.0000000000000033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1097%2Fjto.0000000000000033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=24419411" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpvVemsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=154-162&author=Y.+Shiauthor=J.+S.-K.+Auauthor=S.+Thongprasertauthor=S.+Srinivasanauthor=C.-M.+Tsaiauthor=M.+T.+Khoaauthor=K.+Heeromaauthor=Y.+Itohauthor=G.+Cornelioauthor=P.-C.+Yang&title=A+prospective%2C+molecular+epidemiology+study+of+EGFR+mutations+in+asian+patients+with+advanced+non-small-cell+lung+cancer+of+adenocarcinoma+histology+%28PIONEER%29&doi=10.1097%2Fjto.0000000000000033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)</span></div><div class="casAuthors">Shi, Yuankai; Au, Joseph Siu-Kie; Thongprasert, Sumitra; Srinivasan, Sankar; Tsai, Chun-Ming; Khoa, Mai Trong; Heeroma, Karin; Itoh, Yohji; Cornelio, Gerardo; Yang, Pan-Chyr</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thoracic Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">154-162</span>CODEN:
                <span class="NLM_cas:coden">JTOOB7</span>;
        ISSN:<span class="NLM_cas:issn">1556-0864</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Introduction: PIONEER (NCT01185314) was a prospective, multinational, epidemiol. study of epidermal growth factor receptor (EGFR) mutations in patients from Asia with newly diagnosed advanced lung adenocarcinoma.  Methods: Eligible patients (aged ≥20 years) had untreated stage IIIB/IV adenocarcinoma.  The EGFR mutation status (primary end point: pos., neg., or undetd.) of tumor samples (biopsy, surgical specimen, or cytol.) was detd. (Scorpion amplification refractory mutation system).  EGFR mutation frequency was calcd. and compared between demog. and clin. subgroups.  Results: Of 1482 patients from seven Asian regions, 43.4% of patients were female, median age was 60 years (range, 17-94), and 52.6% of patients were never-smokers.  EGFR mutation status was evaluable in tumors from 1450 patients (97.8%) (746 [51.4%] pos.; 704 [48.6%] neg.).  Country, sex, ethnicity, smoking status, pack-years (all p < 0.001), disease stage (p = 0.009), and histol. type (p = 0.016) correlated significantly with EGFR mutation frequency.  Mutation frequency was 61.1% in females, 44.0% in males; lower in patients from India (22.2%) compared with other areas (47.2%-64.2%); highest among never-smokers (60.7%); and decreased as pack-year no. increased (>0-10 pack-years, 57.9%; >50 pack-years, 31.4%) (similar trend by sex).  Ethnic group (p < 0.001) and pack-years (p < 0.001) had statistically significant assocns. with mutation frequency (multivariate anal.); sex was not significant when adjusted for smoking status.  Conclusion: PIONEER is the first prospective study to confirm high EGFR mutation frequency (51.4% overall) in tumors from Asian patients with adenocarcinoma.  The obsd. high mutation frequency in demog./clin. subgroups compared with white populations suggests that mutation testing should be considered for all patients with stage IIIB/IV adenocarcinoma, even males and regular smokers, among Asian populations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp__VKooo6Da7Vg90H21EOLACvtfcHk0lgbBOLzxWB5iQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpvVemsw%253D%253D&md5=3059251c81506dd1bd1ea4488a0f42e4</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1097%2Fjto.0000000000000033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252Fjto.0000000000000033%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DY.%26aulast%3DAu%26aufirst%3DJ.%2BS.-K.%26aulast%3DThongprasert%26aufirst%3DS.%26aulast%3DSrinivasan%26aufirst%3DS.%26aulast%3DTsai%26aufirst%3DC.-M.%26aulast%3DKhoa%26aufirst%3DM.%2BT.%26aulast%3DHeeroma%26aufirst%3DK.%26aulast%3DItoh%26aufirst%3DY.%26aulast%3DCornelio%26aufirst%3DG.%26aulast%3DYang%26aufirst%3DP.-C.%26atitle%3DA%2520prospective%252C%2520molecular%2520epidemiology%2520study%2520of%2520EGFR%2520mutations%2520in%2520asian%2520patients%2520with%2520advanced%2520non-small-cell%2520lung%2520cancer%2520of%2520adenocarcinoma%2520histology%2520%2528PIONEER%2529%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2014%26volume%3D9%26spage%3D154%26epage%3D162%26doi%3D10.1097%2Fjto.0000000000000033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan, D. L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segelov, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, R. S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbertson, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebbutt, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavlakis, N.</span></span> <span> </span><span class="NLM_article-title">Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer</span>. <i>Cochrane Database Syst. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">CD007047</span>, <span class="refDoi"> DOI: 10.1002/14651858.cd007047.pub2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1002%2F14651858.cd007047.pub2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=28654140" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2017&pages=CD007047&author=D.+L.+H.+Chanauthor=E.+Segelovauthor=R.+S.+H.+Wongauthor=A.+Smithauthor=R.+A.+Herbertsonauthor=B.+T.+Liauthor=N.+Tebbuttauthor=T.+Priceauthor=N.+Pavlakis&title=Epidermal+growth+factor+receptor+%28EGFR%29+inhibitors+for+metastatic+colorectal+cancer&doi=10.1002%2F14651858.cd007047.pub2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1002%2F14651858.cd007047.pub2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F14651858.cd007047.pub2%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DD.%2BL.%2BH.%26aulast%3DSegelov%26aufirst%3DE.%26aulast%3DWong%26aufirst%3DR.%2BS.%2BH.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DHerbertson%26aufirst%3DR.%2BA.%26aulast%3DLi%26aufirst%3DB.%2BT.%26aulast%3DTebbutt%26aufirst%3DN.%26aulast%3DPrice%26aufirst%3DT.%26aulast%3DPavlakis%26aufirst%3DN.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520inhibitors%2520for%2520metastatic%2520colorectal%2520cancer%26jtitle%3DCochrane%2520Database%2520Syst.%2520Rev.%26date%3D2017%26volume%3D6%26spage%3DCD007047%26doi%3D10.1002%2F14651858.cd007047.pub2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tan, C.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soo, R. A.</span></span> <span> </span><span class="NLM_article-title">Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer</span>. <i>Lung Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">68</span>, <span class="refDoi"> DOI: 10.1016/j.lungcan.2016.01.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1016%2Fj.lungcan.2016.01.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=26898616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A280%3ADC%252BC28jivVymtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2016&pages=59-68&author=C.-S.+Tanauthor=B.-C.+Choauthor=R.+A.+Soo&title=Next-generation+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitors+in+epidermal+growth+factor+receptor+-mutant+non-small+cell+lung+cancer&doi=10.1016%2Fj.lungcan.2016.01.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer</span></div><div class="casAuthors">Tan Chee-Seng; Cho Byoung-Chul; Soo Ross A</div><div class="citationInfo"><span class="NLM_cas:title">Lung cancer (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">59-68</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Since the discovery of sensitizing EGFR mutations as a predictive marker of sensitivity to EGFR tyrosine kinase inhibitors (TKIs), the field of targeted therapy in non-small cell lung cancer (NSCLC) has been revolutionized.  Patients harbouring these sensitizing mutations treated with EGFR TKI have derived significant clinical outcome when compared with standard platinum based chemotherapy doublets.  However disease progression invariably occurs at a median of about 9-13 months from initiation treatment, if acquired resistance commonly due to the development of EGFR T790M mutation.  A novel class of "third generation" EGFR TKIs have been developed that is sensitising and T790M mutant-specific whilst sparing WT EGFR, representing a significant breakthrough in the treatment in NSCLC patients with acquired resistance harboring these genotypes.  Early phase clinical data suggest the third generation EGFR TKIs such as osimertinib, rociletinib, and HM61713 are highly efficacious and well tolerated.  Another promising class of EGFR TKI such as AZD3759 has been designed to penetrate blood brain barrier to treat brain metastases and leptomeningeal disease and has showed promising responses in patients with brain metastases.  Acquired resistance to third generation EGFR TKIs has been reported including EGFR C797S.  Given its non-invasive nature, plasma ctDNA is being explored as a possible approach to detect T790M mutation and to also inform on novel molecular mechansims of tertiary resistance to third generation EGFR TKIs.  An understanding of the mechanisms of acquired resistance to the third-generation EGFR TKIs will greatly aid in the development of the next generation of EGFR TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ6MbARC-V4Af3jf77P2BG3fW6udTcc2ebAShdXoMGICrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28jivVymtA%253D%253D&md5=b1ab30df28665605ce44ce1b5de385ff</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2016.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2016.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DC.-S.%26aulast%3DCho%26aufirst%3DB.-C.%26aulast%3DSoo%26aufirst%3DR.%2BA.%26atitle%3DNext-generation%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitors%2520in%2520epidermal%2520growth%2520factor%2520receptor%2520-mutant%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DLung%2520Cancer%26date%3D2016%26volume%3D93%26spage%3D59%26epage%3D68%26doi%3D10.1016%2Fj.lungcan.2016.01.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muhsin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkpatrick, P.</span></span> <span> </span><span class="NLM_article-title">Gefitinib</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">515</span>– <span class="NLM_lpage">516</span>, <span class="refDoi"> DOI: 10.1038/nrd1136</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1038%2Fnrd1136" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=12841190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BD3sXks1Oqsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2003&pages=515-516&author=M.+Muhsinauthor=J.+Grahamauthor=P.+Kirkpatrick&title=Gefitinib&doi=10.1038%2Fnrd1136"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Fresh from the pipeline: Gefitinib</span></div><div class="casAuthors">Muhsin, Mohamed; Graham, Joanne; Kirkpatrick, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">515-516</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Gefitinib (Iressa; AstraZeneca) is the first in a new class of targeted anticancer drugs that inhibit the tyrosine kinase activity of the epidermal growth factor receptor.  Following Japanese approval in 2002, gefitinib was approved by the US FDA in May 2003 for the treatment of advanced non-small-cell lung cancer after other treatment options have failed.  Despite several setbacks during the development of gefitinib, might it now be back on the path to blockbuster status.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiu6Whpw8u7rVg90H21EOLACvtfcHk0lgO0mGn5BwoZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXks1Oqsr0%253D&md5=e9fb650f4d801eb2026a795db1b9f6bd</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnrd1136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1136%26sid%3Dliteratum%253Aachs%26aulast%3DMuhsin%26aufirst%3DM.%26aulast%3DGraham%26aufirst%3DJ.%26aulast%3DKirkpatrick%26aufirst%3DP.%26atitle%3DGefitinib%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2003%26volume%3D2%26spage%3D515%26epage%3D516%26doi%3D10.1038%2Fnrd1136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridhara, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">FDA drug approval summary: erlotinib (Tarceva) tablets</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">461</span>– <span class="NLM_lpage">466</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.10-7-461</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1634%2Ftheoncologist.10-7-461" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=461-466&author=M.+H.+Cohenauthor=J.+R.+Johnsonauthor=Y.+F.+Chenauthor=R.+Sridharaauthor=R.+Pazdur&title=FDA+drug+approval+summary%3A+erlotinib+%28Tarceva%29+tablets&doi=10.1634%2Ftheoncologist.10-7-461"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.10-7-461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.10-7-461%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DM.%2BH.%26aulast%3DJohnson%26aufirst%3DJ.%2BR.%26aulast%3DChen%26aufirst%3DY.%2BF.%26aulast%3DSridhara%26aufirst%3DR.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DFDA%2520drug%2520approval%2520summary%253A%2520erlotinib%2520%2528Tarceva%2529%2520tablets%26jtitle%3DOncologist%26date%3D2015%26volume%3D10%26spage%3D461%26epage%3D466%26doi%3D10.1634%2Ftheoncologist.10-7-461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peters, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adjei, A. A.</span></span> <span> </span><span class="NLM_article-title">Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug–drug interactions</span>. <i>Cancer Treat. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">917</span>– <span class="NLM_lpage">926</span>, <span class="refDoi"> DOI: 10.1016/j.ctrv.2014.06.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1016%2Fj.ctrv.2014.06.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=25027951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFGmtbrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2014&pages=917-926&author=S.+Petersauthor=S.+Zimmermannauthor=A.+A.+Adjei&title=Oral+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitors+for+the+treatment+of+non-small+cell+lung+cancer%3A+comparative+pharmacokinetics+and+drug%E2%80%93drug+interactions&doi=10.1016%2Fj.ctrv.2014.06.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: Comparative pharmacokinetics and drug-drug interactions</span></div><div class="casAuthors">Peters, Solange; Zimmermann, Stefan; Adjei, Alex A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">917-926</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The development of orally active small mol. inhibitors of the epidermal growth factor receptor (EGFR) has led to new treatment options for non-small cell lung cancer (NSCLC).  Patients with activating mutations of the EGFR gene show sensitivity to, and clin. benefit from, treatment with EGFR tyrosine kinase inhibitors (EGFR-TKls).  First generation reversible ATP-competitive EGFR-TKls, gefitinib and erlotinib, are effective as first, second-line or maintenance therapy.  Despite initial benefit, most patients develop resistance within a year, 50-60% of cases being related to the appearance of a T790M gatekeeper mutation.  Newer, irreversible EGFR-TKls - afatinib and dacomitinib - covalently bind to and inhibit multiple receptors in the ErbB family (EGFR, HER2 and HER4).  These agents have been mainly evaluated for first-line treatment but also in the setting of acquired resistance to first-generation EGFR-TKls.  Afatinib is the first ErbB family blocker approved for patients with NSCLC with activating EGFR mutations; dacomitinib is in late stage clin. development.  Mutant-selective EGFR inhibitors (AZD9291, CO-1686, HM61713) that specifically target the T790M resistance mutation are in early development.  The EGFR-TKIs differ in their spectrum of target kinases, reversibility of binding to EGFR receptor, pharmacokinetics and potential for drug-drug interactions, as discussed in this review.  For the clinician, these differences are relevant in the setting of polymedicated patients with NSCLC, as well as from the perspective of innovative anticancer drug combination strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLFElQmV4ha7Vg90H21EOLACvtfcHk0lhiCGFtABLw6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFGmtbrP&md5=31253f81e203aa012a5d87ad29ff6fc3</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2014.06.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2014.06.010%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DS.%26aulast%3DZimmermann%26aufirst%3DS.%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26atitle%3DOral%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520non-small%2520cell%2520lung%2520cancer%253A%2520comparative%2520pharmacokinetics%2520and%2520drug%25E2%2580%2593drug%2520interactions%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2014%26volume%3D40%26spage%3D917%26epage%3D926%26doi%3D10.1016%2Fj.ctrv.2014.06.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Molina, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassivi, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schild, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adjei, A. A.</span></span> <span> </span><span class="NLM_article-title">Non–small cell lung cancer: epidemiology, risk factors, treatment, and survivorship</span>. <i>Mayo Clin. Proc.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">584</span>– <span class="NLM_lpage">594</span>, <span class="refDoi"> DOI: 10.4065/83.5.584</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.4065%2F83.5.584" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=18452692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A280%3ADC%252BD1c3ovFyhtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2008&pages=584-594&author=J.+R.+Molinaauthor=P.+Yangauthor=S.+D.+Cassiviauthor=S.+E.+Schildauthor=A.+A.+Adjei&title=Non%E2%80%93small+cell+lung+cancer%3A+epidemiology%2C+risk+factors%2C+treatment%2C+and+survivorship&doi=10.4065%2F83.5.584"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship</span></div><div class="casAuthors">Molina Julian R; Yang Ping; Cassivi Stephen D; Schild Steven E; Adjei Alex A</div><div class="citationInfo"><span class="NLM_cas:title">Mayo Clinic proceedings</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">584-94</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Lung cancer is the leading cause of cancer-related mortality not only in the United States but also around the world.  In North America, lung cancer has become more predominant among former than current smokers.  Yet in some countries, such as China, which has experienced a dramatic increase in the cigarette smoking rate during the past 2 decades, a peak in lung cancer incidence is still expected.  Approximately two-thirds of adult Chinese men are smokers, representing one-third of all smokers worldwide.  Non-small cell lung cancer accounts for 85% of all lung cancer cases in the United States.  After the initial diagnosis, accurate staging of non-small cell lung cancer using computed tomography or positron emission tomography is crucial for determining appropriate therapy.  When feasible, surgical resection remains the single most consistent and successful option for cure.  However, close to 70% of patients with lung cancer present with locally advanced or metastatic disease at the time of diagnosis.  Chemotherapy is beneficial for patients with metastatic disease, and the administration of concurrent chemotherapy and radiation is indicated for stage III lung cancer.  The introduction of angiogenesis, epidermal growth factor receptor inhibitors, and other new anti-cancer agents is changing the present and future of this disease and will certainly increase the number of lung cancer survivors.  We identified studies for this review by searching the MEDLINE and PubMed databases for English-language articles published from January 1, 1980, through January 31, 2008.  Key terms used for this search included non-small cell lung cancer, adenocarcinoma, squamous cell carcinoma, bronchioalveolar cell carcinoma, large cell carcinoma, lung cancer epidemiology, genetics, survivorship, surgery, radiation therapy, chemotherapy, targeted therapy, bevacizumab, erlotinib, and epidermal growth factor receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSmyOu2OSFHeW52AMpI4GK2fW6udTcc2eY90Vbtr1GnSbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c3ovFyhtQ%253D%253D&md5=7d7f1147c10a3c6b0fd344757694b4aa</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.4065%2F83.5.584&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4065%252F83.5.584%26sid%3Dliteratum%253Aachs%26aulast%3DMolina%26aufirst%3DJ.%2BR.%26aulast%3DYang%26aufirst%3DP.%26aulast%3DCassivi%26aufirst%3DS.%2BD.%26aulast%3DSchild%26aufirst%3DS.%2BE.%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26atitle%3DNon%25E2%2580%2593small%2520cell%2520lung%2520cancer%253A%2520epidemiology%252C%2520risk%2520factors%252C%2520treatment%252C%2520and%2520survivorship%26jtitle%3DMayo%2520Clin.%2520Proc.%26date%3D2008%26volume%3D83%26spage%3D584%26epage%3D594%26doi%3D10.4065%2F83.5.584" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Politi, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somwar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zakowski, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kris, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varmus, H.</span></span> <span> </span><span class="NLM_article-title">Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain</span>. <i>PLoS Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>2</i></span>, <span class="NLM_elocation-id">e73</span> <span class="refDoi"> DOI: 10.1371/journal.pmed.0020073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1371%2Fjournal.pmed.0020073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=15737014" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A280%3ADC%252BD2MzjtVehsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&author=W.+Paoauthor=V.+A.+Millerauthor=K.+A.+Politiauthor=G.+J.+Rielyauthor=R.+Somwarauthor=M.+F.+Zakowskiauthor=M.+G.+Krisauthor=H.+Varmus&title=Acquired+resistance+of+lung+adenocarcinomas+to+gefitinib+or+erlotinib+is+associated+with+a+second+mutation+in+the+EGFR+kinase+domain&doi=10.1371%2Fjournal.pmed.0020073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain</span></div><div class="casAuthors">Pao William; Miller Vincent A; Politi Katerina A; Riely Gregory J; Somwar Romel; Zakowski Maureen F; Kris Mark G; Varmus Harold</div><div class="citationInfo"><span class="NLM_cas:title">PLoS medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e73</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Lung adenocarcinomas from patients who respond to the tyrosine kinase inhibitors gefitinib (Iressa) or erlotinib (Tarceva) usually harbor somatic gain-of-function mutations in exons encoding the kinase domain of the epidermal growth factor receptor (EGFR).  Despite initial responses, patients eventually progress by unknown mechanisms of "acquired" resistance.  METHODS AND FINDINGS:  We show that in two of five patients with acquired resistance to gefitinib or erlotinib, progressing tumors contain, in addition to a primary drug-sensitive mutation in EGFR, a secondary mutation in exon 20, which leads to substitution of methionine for threonine at position 790 (T790M) in the kinase domain.  Tumor cells from a sixth patient with a drug-sensitive EGFR mutation whose tumor progressed on adjuvant gefitinib after complete resection also contained the T790M mutation.  This mutation was not detected in untreated tumor samples.  Moreover, no tumors with acquired resistance had KRAS mutations, which have been associated with primary resistance to these drugs.  Biochemical analyses of transfected cells and growth inhibition studies with lung cancer cell lines demonstrate that the T790M mutation confers resistance to EGFR mutants usually sensitive to either gefitinib or erlotinib.  Interestingly, a mutation analogous to T790M has been observed in other kinases with acquired resistance to another kinase inhibitor, imatinib (Gleevec).  CONCLUSION:  In patients with tumors bearing gefitinib- or erlotinib-sensitive EGFR mutations, resistant subclones containing an additional EGFR mutation emerge in the presence of drug.  This observation should help guide the search for more effective therapy against a specific subset of lung cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcREkXMV3u1nwwMthz5_Rx5rfW6udTcc2eYBhHL_fvXJgbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MzjtVehsw%253D%253D&md5=3e626105e0dea2a38997156ae513f56b</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pmed.0020073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pmed.0020073%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPoliti%26aufirst%3DK.%2BA.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DSomwar%26aufirst%3DR.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DVarmus%26aufirst%3DH.%26atitle%3DAcquired%2520resistance%2520of%2520lung%2520adenocarcinomas%2520to%2520gefitinib%2520or%2520erlotinib%2520is%2520associated%2520with%2520a%2520second%2520mutation%2520in%2520the%2520EGFR%2520kinase%2520domain%26jtitle%3DPLoS%2520Med.%26date%3D2005%26volume%3D2%26doi%3D10.1371%2Fjournal.pmed.0020073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of resistance to EGFR tyrosine kinase inhibitors</span>. <i>Acta Pharm. Sin. B</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">390</span>– <span class="NLM_lpage">401</span>, <span class="refDoi"> DOI: 10.1016/j.apsb.2015.07.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1016%2Fj.apsb.2015.07.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=26579470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A280%3ADC%252BC28rgtlOqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=390-401&author=L.+Huangauthor=L.+Fu&title=Mechanisms+of+resistance+to+EGFR+tyrosine+kinase+inhibitors&doi=10.1016%2Fj.apsb.2015.07.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of resistance to EGFR tyrosine kinase inhibitors</span></div><div class="casAuthors">Huang Lihua; Fu Liwu</div><div class="citationInfo"><span class="NLM_cas:title">Acta pharmaceutica Sinica. B</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">390-401</span>
        ISSN:<span class="NLM_cas:issn">2211-3835</span>.
    </div><div class="casAbstract">Since the discovery that non-small cell lung cancer (NSCLC) is driven by epidermal growth factor receptor (EGFR) mutations, the EGFR tyrosine kinase inhibitors (EGFR-TKIs, e.g., gefitinib and elrotinib) have been effectively used for clinical treatment.  However, patients eventually develop drug resistance.  Resistance to EGFR-TKIs is inevitable due to various mechanisms, such as the secondary mutation (T790M), activation of alternative pathways (c-Met, HGF, AXL), aberrance of the downstream pathways (K-RAS mutations, loss of PTEN), impairment of the EGFR-TKIs-mediated apoptosis pathway (BCL2-like 11/BIM deletion polymorphism), histologic transformation, ATP binding cassette (ABC) transporter effusion, etc.  Here we review and summarize the known resistant mechanisms to EGFR-TKIs and provide potential targets for development of new therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ-qtzzXrDFl75XHngOXiV_fW6udTcc2eYBhHL_fvXJgbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rgtlOqsw%253D%253D&md5=8429fc78384f6e540b1fa8f6c57c363b</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.apsb.2015.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.apsb.2015.07.001%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DFu%26aufirst%3DL.%26atitle%3DMechanisms%2520of%2520resistance%2520to%2520EGFR%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DActa%2520Pharm.%2520Sin.%2520B%26date%3D2015%26volume%3D5%26spage%3D390%26epage%3D401%26doi%3D10.1016%2Fj.apsb.2015.07.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziehr, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agulnik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M.</span></span> <span> </span><span class="NLM_article-title">Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC</span>. <i>OncoTargets Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>2013</i></span>,  <span class="NLM_fpage">135</span>– <span class="NLM_lpage">143</span>, <span class="refDoi"> DOI: 10.2147/OTT.S23165</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.2147%2FOTT.S23165" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2013&publication_year=2013&pages=135-143&author=V.+Nelsonauthor=J.+Ziehrauthor=M.+Agulnikauthor=M.+Johnson&title=Afatinib%3A+emerging+next-generation+tyrosine+kinase+inhibitor+for+NSCLC&doi=10.2147%2FOTT.S23165"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.2147%2FOTT.S23165&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FOTT.S23165%26sid%3Dliteratum%253Aachs%26aulast%3DNelson%26aufirst%3DV.%26aulast%3DZiehr%26aufirst%3DJ.%26aulast%3DAgulnik%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DM.%26atitle%3DAfatinib%253A%2520emerging%2520next-generation%2520tyrosine%2520kinase%2520inhibitor%2520for%2520NSCLC%26jtitle%3DOncoTargets%2520Ther.%26date%3D2013%26volume%3D2013%26spage%3D135%26epage%3D143%26doi%3D10.2147%2FOTT.S23165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dungo, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keating, G. M.</span></span> <span> </span><span class="NLM_article-title">Afatinib: first global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">1503</span>– <span class="NLM_lpage">1515</span>, <span class="refDoi"> DOI: 10.1007/s40265-013-0111-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1007%2Fs40265-013-0111-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=23982599" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVWmurnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=1503-1515&author=R.+T.+Dungoauthor=G.+M.+Keating&title=Afatinib%3A+first+global+approval&doi=10.1007%2Fs40265-013-0111-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Afatinib: First Global Approval</span></div><div class="casAuthors">Dungo, Rosselle T.; Keating, Gillian M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1503-1515</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Afatinib, an irreversible inhibitor of the ErbB family of tyrosine kinases, is under development with Boehringer Ingelheim for the once-daily, oral treatment of cancer.  Afatinib downregulates ErbB signalling by covalently binding to epidermal growth factor receptor (EGFR), human epidermal growth factor receptor (HER) 2 and HER4, irreversibly inhibiting tyrosine kinase autophosphorylation.  It also inhibits transphosphorylation of HER3.  Oral afatinib (Gilotrif®) has been approved in the US for the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) who have tumors with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by a US FDA-approved test.  Afatinib has also been approved in Taiwan for the first-line treatment of patients with EGFR mutation-pos. NSCLC.  In addn., the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of afatinib (Giotrif) for the treatment of patients with locally advanced or metastatic NSCLC with activating EGFR mutations who are EGFR tyrosine kinase inhibitor naive.  Afatinib is also under regulatory review in Canada, Japan and other Asian countries.  This article summarizes the milestones in the development of afatinib, leading to this first approval in patients with metastatic NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdPcU5aIqrY7Vg90H21EOLACvtfcHk0lj4l8qr_mnzvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVWmurnM&md5=21851cbfac56e2fffcba6c731f123cff</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1007%2Fs40265-013-0111-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-013-0111-6%26sid%3Dliteratum%253Aachs%26aulast%3DDungo%26aufirst%3DR.%2BT.%26aulast%3DKeating%26aufirst%3DG.%2BM.%26atitle%3DAfatinib%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2013%26volume%3D73%26spage%3D1503%26epage%3D1515%26doi%3D10.1007%2Fs40265-013-0111-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">U.S. Food and
Drug Administration</span>. <span> </span><span class="NLM_article-title">FDA Broadens
Afatinib Indication
to Previously Untreated, Metastatic NSCLC with Other Non-Resistant
EGFR Mutations</span>. <a href="https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm592558.htm" class="extLink">https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm592558.htm</a> (accessed Jan 16, <span class="NLM_year">2018</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=U.S.+Food+and%0ADrug+Administration&title=FDA+Broadens%0AAfatinib+Indication%0Ato+Previously+Untreated%2C+Metastatic+NSCLC+with+Other+Non-Resistant%0AEGFR+Mutations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DFDA%2520Broadens%250AAfatinib%2520Indication%250Ato%2520Previously%2520Untreated%252C%2520Metastatic%2520NSCLC%2520with%2520Other%2520Non-Resistant%250AEGFR%2520Mutations%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planchard, D.</span></span> <span> </span><span class="NLM_article-title">Next-generation EGFR tyrosine kinase inhibitors for treating EGFR-mutant lung cancer beyond first line</span>. <i>Front. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">76</span>, <span class="refDoi"> DOI: 10.3389/fmed.2016.00076</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.3389%2Ffmed.2016.00076" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2017&pages=76&author=I.+Sullivanauthor=D.+Planchard&title=Next-generation+EGFR+tyrosine+kinase+inhibitors+for+treating+EGFR-mutant+lung+cancer+beyond+first+line&doi=10.3389%2Ffmed.2016.00076"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.3389%2Ffmed.2016.00076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffmed.2016.00076%26sid%3Dliteratum%253Aachs%26aulast%3DSullivan%26aufirst%3DI.%26aulast%3DPlanchard%26aufirst%3DD.%26atitle%3DNext-generation%2520EGFR%2520tyrosine%2520kinase%2520inhibitors%2520for%2520treating%2520EGFR-mutant%2520lung%2520cancer%2520beyond%2520first%2520line%26jtitle%3DFront.%2520Med.%26date%3D2017%26volume%3D3%26spage%3D76%26doi%3D10.3389%2Ffmed.2016.00076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Y.</span></span> <span> </span><span class="NLM_article-title">Recent development of the second and third generation irreversible epidermal growth factor receptor inhibitors</span>. <i>Chem. Biodiversity</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>14</i></span>, <span class="NLM_elocation-id">e1600372</span> <span class="refDoi"> DOI: 10.1002/cbdv.201600372</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1002%2Fcbdv.201600372" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2017&author=W.+Hanauthor=Y.+Du&title=Recent+development+of+the+second+and+third+generation+irreversible+epidermal+growth+factor+receptor+inhibitors&doi=10.1002%2Fcbdv.201600372"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1002%2Fcbdv.201600372&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbdv.201600372%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DW.%26aulast%3DDu%26aufirst%3DY.%26atitle%3DRecent%2520development%2520of%2520the%2520second%2520and%2520third%2520generation%2520irreversible%2520epidermal%2520growth%2520factor%2520receptor%2520inhibitors%26jtitle%3DChem.%2520Biodiversity%26date%3D2017%26volume%3D14%26doi%3D10.1002%2Fcbdv.201600372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">U.S. Food and Drug Administration</span>. <span> </span><span class="NLM_article-title">Osimertinib (TAGRISSO)</span>. <a href="https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm549683.htm" class="extLink">https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm549683.htm</a> (accessed Jul 28, <span class="NLM_year">2017</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=U.S.+Food+and+Drug+Administration&title=Osimertinib+%28TAGRISSO%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DOsimertinib%2520%2528TAGRISSO%2529%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Finlay, M. R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bethel, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Box, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradbury, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butterworth, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chorley, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colclough, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D. A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grist, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassall, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemmitt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinowska, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McFarland, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orme, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkins, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkins, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waring, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrigley, G. L.</span></span> <span> </span><span class="NLM_article-title">Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">8249</span>– <span class="NLM_lpage">8267</span>, <span class="refDoi"> DOI: 10.1021/jm500973a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500973a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1KhurrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=8249-8267&author=M.+R.+V.+Finlayauthor=M.+Andertonauthor=S.+Ashtonauthor=P.+Ballardauthor=P.+A.+Bethelauthor=M.+R.+Boxauthor=R.+H.+Bradburyauthor=S.+J.+Brownauthor=S.+Butterworthauthor=A.+Campbellauthor=C.+Chorleyauthor=N.+Colcloughauthor=D.+A.+E.+Crossauthor=G.+S.+Currieauthor=M.+Gristauthor=L.+Hassallauthor=G.+B.+Hillauthor=D.+Jamesauthor=M.+Jamesauthor=P.+Kemmittauthor=T.+Klinowskaauthor=G.+Lamontauthor=S.+G.+Lamontauthor=N.+Martinauthor=H.+L.+McFarlandauthor=M.+J.+Mellorauthor=J.+P.+Ormeauthor=D.+Perkinsauthor=P.+Perkinsauthor=G.+Richmondauthor=P.+Smithauthor=R.+A.+Wardauthor=M.+J.+Waringauthor=D.+Whittakerauthor=S.+Wellsauthor=G.+L.+Wrigley&title=Discovery+of+a+potent+and+selective+EGFR+inhibitor+%28AZD9291%29+of+both+sensitizing+and+T790M+resistance+mutations+that+spares+the+wild+type+form+of+the+receptor&doi=10.1021%2Fjm500973a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor</span></div><div class="casAuthors">Finlay, M. Raymond V.; Anderton, Mark; Ashton, Susan; Ballard, Peter; Bethel, Paul A.; Box, Matthew R.; Bradbury, Robert H.; Brown, Simon J.; Butterworth, Sam; Campbell, Andrew; Chorley, Christopher; Colclough, Nicola; Cross, Darren A. E.; Currie, Gordon S.; Grist, Matthew; Hassall, Lorraine; Hill, George B.; James, Daniel; James, Michael; Kemmitt, Paul; Klinowska, Teresa; Lamont, Gillian; Lamont, Scott G.; Martin, Nathaniel; McFarland, Heather L.; Mellor, Martine J.; Orme, Jonathon P.; Perkins, David; Perkins, Paula; Richmond, Graham; Smith, Peter; Ward, Richard A.; Waring, Michael J.; Whittaker, David; Wells, Stuart; Wrigley, Gail L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8249-8267</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) inhibitors have been used clin. in the treatment of nonsmall-cell lung cancer (NSCLC) patients harboring sensitizing (or activating) mutations for a no. of years.  Despite encouraging clin. efficacy with these agents, in many patients resistance develops leading to disease progression.  In most cases, this resistance is in the form of the T790M mutation.  In addn., EGFR wild type receptor inhibition inherent with these agents can lead to dose limiting toxicities of rash and diarrhea.  The authors describe herein the evolution of an early, mutant selective lead to the clin. candidate AZD9291 I, an irreversible inhibitor of both EGFR sensitizing (EGFRm+) and T790M resistance mutations with selectivity over the wild type form of the receptor.  Following observations of significant tumor inhibition in preclin. models, the clin. candidate was administered clin. to patients with T790M pos. EGFR-TKI resistant NSCLC and early efficacy has been obsd., accompanied by an encouraging safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouPAWG9N0Ro7Vg90H21EOLACvtfcHk0lj4l8qr_mnzvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1KhurrI&md5=db9db624bb4324c2e22b1ab12035263b</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm500973a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500973a%26sid%3Dliteratum%253Aachs%26aulast%3DFinlay%26aufirst%3DM.%2BR.%2BV.%26aulast%3DAnderton%26aufirst%3DM.%26aulast%3DAshton%26aufirst%3DS.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DBethel%26aufirst%3DP.%2BA.%26aulast%3DBox%26aufirst%3DM.%2BR.%26aulast%3DBradbury%26aufirst%3DR.%2BH.%26aulast%3DBrown%26aufirst%3DS.%2BJ.%26aulast%3DButterworth%26aufirst%3DS.%26aulast%3DCampbell%26aufirst%3DA.%26aulast%3DChorley%26aufirst%3DC.%26aulast%3DColclough%26aufirst%3DN.%26aulast%3DCross%26aufirst%3DD.%2BA.%2BE.%26aulast%3DCurrie%26aufirst%3DG.%2BS.%26aulast%3DGrist%26aufirst%3DM.%26aulast%3DHassall%26aufirst%3DL.%26aulast%3DHill%26aufirst%3DG.%2BB.%26aulast%3DJames%26aufirst%3DD.%26aulast%3DJames%26aufirst%3DM.%26aulast%3DKemmitt%26aufirst%3DP.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DLamont%26aufirst%3DG.%26aulast%3DLamont%26aufirst%3DS.%2BG.%26aulast%3DMartin%26aufirst%3DN.%26aulast%3DMcFarland%26aufirst%3DH.%2BL.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DPerkins%26aufirst%3DD.%26aulast%3DPerkins%26aufirst%3DP.%26aulast%3DRichmond%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26aulast%3DWhittaker%26aufirst%3DD.%26aulast%3DWells%26aufirst%3DS.%26aulast%3DWrigley%26aufirst%3DG.%2BL.%26atitle%3DDiscovery%2520of%2520a%2520potent%2520and%2520selective%2520EGFR%2520inhibitor%2520%2528AZD9291%2529%2520of%2520both%2520sensitizing%2520and%2520T790M%2520resistance%2520mutations%2520that%2520spares%2520the%2520wild%2520type%2520form%2520of%2520the%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D8249%26epage%3D8267%26doi%3D10.1021%2Fjm500973a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">U.S. Food and Drug Administration</span>. <span> </span><span class="NLM_article-title">FDA Approves Osimertinib for First-Line
Treatment of Metastatic NSCLC with Most Common EGFR Mutations</span>. <a href="https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm605113.htm" class="extLink">https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm605113.htm</a> (accessed Apr 19, <span class="NLM_year">2018</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=U.S.+Food+and+Drug+Administration&title=FDA+Approves+Osimertinib+for+First-Line%0ATreatment+of+Metastatic+NSCLC+with+Most+Common+EGFR+Mutations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DFDA%2520Approves%2520Osimertinib%2520for%2520First-Line%250ATreatment%2520of%2520Metastatic%2520NSCLC%2520with%2520Most%2520Common%2520EGFR%2520Mutations%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, D. B.</span></span> <span> </span><span class="NLM_article-title">The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer</span>. <i>Expert Rev. Anticancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">383</span>– <span class="NLM_lpage">390</span>, <span class="refDoi"> DOI: 10.1586/14737140.2016.1162103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1586%2F14737140.2016.1162103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=26943236" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BC28Xks1yhtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=383-390&author=X.+Gaoauthor=X.+Leauthor=D.+B.+Costa&title=The+safety+and+efficacy+of+osimertinib+for+the+treatment+of+EGFR+T790M+mutation+positive+non-small-cell+lung+cancer&doi=10.1586%2F14737140.2016.1162103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer</span></div><div class="casAuthors">Gao, Xin; Le, Xiuning; Costa, Daniel B.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anticancer Therapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">383-390</span>CODEN:
                <span class="NLM_cas:coden">ERATBJ</span>;
        ISSN:<span class="NLM_cas:issn">1473-7140</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">First- and second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the evidence-based first-line treatment for metastatic non-small-cell lung cancers (NSCLCs) that harbor sensitizing EGFR mutations (i.e. exon 19 deletions or L858R).  However, acquired resistance to EGFR TKI monotherapy occurs invariably within a median time frame of one year.  The most common form of biol. resistance is through the selection of tumor clones harboring the EGFR T790M mutation, present in >50% of repeat biopsies.  The presence of the EGFR T790M mutation negates the inhibitory activity of gefitinib, erlotinib, and afatinib.  A novel class of third-generation EGFR TKIs has been identified by probing a series of covalent pyrimidine EGFR inhibitors that bind to amino-acid residue C797 of EGFR and preferentially inhibit mutant forms of EGFR vs. the wild-type receptor.  We review the rapid clin. development and approval of the third-generation EGFR TKI osimertinib for treatment of NSCLCs with EGFR-T790M.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnBfOip3HqtrVg90H21EOLACvtfcHk0lh4Ygc9AqFUCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xks1yhtb0%253D&md5=6fd22c935476d396b1560f9a784cb9df</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1586%2F14737140.2016.1162103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14737140.2016.1162103%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DX.%26aulast%3DLe%26aufirst%3DX.%26aulast%3DCosta%26aufirst%3DD.%2BB.%26atitle%3DThe%2520safety%2520and%2520efficacy%2520of%2520osimertinib%2520for%2520the%2520treatment%2520of%2520EGFR%2520T790M%2520mutation%2520positive%2520non-small-cell%2520lung%2520cancer%26jtitle%3DExpert%2520Rev.%2520Anticancer%2520Ther.%26date%3D2016%26volume%3D16%26spage%3D383%26epage%3D390%26doi%3D10.1586%2F14737140.2016.1162103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Z.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.-J.</span></span> <span> </span><span class="NLM_article-title">Osimertinib resistance in non-small cell lung cancer: mechanisms and therapeutic strategies</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>420</i></span>,  <span class="NLM_fpage">242</span>– <span class="NLM_lpage">246</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2018.02.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1016%2Fj.canlet.2018.02.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=29425688" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjtFalt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=420&publication_year=2018&pages=242-246&author=Z.-H.+Tangauthor=J.-J.+Lu&title=Osimertinib+resistance+in+non-small+cell+lung+cancer%3A+mechanisms+and+therapeutic+strategies&doi=10.1016%2Fj.canlet.2018.02.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies</span></div><div class="casAuthors">Tang, Zheng-Hai; Lu, Jin-Jian</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">420</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">242-246</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Given the successful identification of epidermal growth factor receptor EGFR T790M, the third-generation EGFR tyrosine kinase inhibitor (TKI), osimertinib (OSI, AZD9291), was developed to target EGFR T790M mutation.  OSI was approved for the treatment of patients with non-small cell lung cancer (NSCLC) harboring EGFR T790M mutation.  However, the disease would progress after the patient received OSI treatment for approx. 10 mo.  Resistance mechanisms to OSI, such as addnl. mutation of EGFR and alternative kinase activation, were recently identified, and some novel therapeutic strategies were proposed to overcome OSI resistance.  In this review, the resistance mechanisms and therapeutic strategies for OSI-resistant NSCLC were summarized to direct further use of OSI and aid in the development of novel drugs or strategies for OSI-resistant NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7MEZOSD4CQrVg90H21EOLACvtfcHk0lh4Ygc9AqFUCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjtFalt74%253D&md5=a2f1d0d576a24d137bd23584f40df973</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2018.02.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2018.02.004%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DZ.-H.%26aulast%3DLu%26aufirst%3DJ.-J.%26atitle%3DOsimertinib%2520resistance%2520in%2520non-small%2520cell%2520lung%2520cancer%253A%2520mechanisms%2520and%2520therapeutic%2520strategies%26jtitle%3DCancer%2520Lett.%26date%3D2018%26volume%3D420%26spage%3D242%26epage%3D246%26doi%3D10.1016%2Fj.canlet.2018.02.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Russo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franchina, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricciardi, G. R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smiroldo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picciotto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanghì, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolfo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adamo, V.</span></span> <span> </span><span class="NLM_article-title">Third generation EGFR TKIs in EGFR-mutated NSCLC: where are we now and where are we going</span>. <i>Crit. Rev. Oncol. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">38</span>– <span class="NLM_lpage">47</span>, <span class="refDoi"> DOI: 10.1016/j.critrevonc.2017.07.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1016%2Fj.critrevonc.2017.07.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=28807234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A280%3ADC%252BC1cfnsVyktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2017&pages=38-47&author=A.+Russoauthor=T.+Franchinaauthor=G.+R.+R.+Ricciardiauthor=V.+Smiroldoauthor=M.+Picciottoauthor=M.+Zangh%C3%ACauthor=C.+Rolfoauthor=V.+Adamo&title=Third+generation+EGFR+TKIs+in+EGFR-mutated+NSCLC%3A+where+are+we+now+and+where+are+we+going&doi=10.1016%2Fj.critrevonc.2017.07.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going</span></div><div class="casAuthors">Russo A; Franchina T; Ricciardi G R R; Smiroldo V; Picciotto M; Zanghi M; Rolfo C; Adamo V</div><div class="citationInfo"><span class="NLM_cas:title">Critical reviews in oncology/hematology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">38-47</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The therapeutic landscape of Non Small Lung Cancer (NSCLC) has been profoundly changed over the last decade with the clinical introduction of Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors (TKIs) and the discovery of EGFR activating mutations as the major predictive factor to these agents.  Despite impressive clinical activity against EGFR-mutated NSCLCs, the benefit seen with 1st and 2nd generation EGFR TKIs is usually transient and virtually all patients become resistant.  Several different mechanisms of acquired resistance have been reported to date, but the vast majority of patients develop a secondary exon 20 mutation in the ATP-binding site of EGFR, namely T790M.  The discovery of mutant-selective EGFR TKIs that selectively inhibit EGFR-mutants, including T790M-harboring NSCLCs, while sparing EGFR wild type, provide the opportunity for overcoming the major mechanism of acquired resistance to 1st and 2nd generation EGFR TKIs, with a relatively favorable toxicity profile.  The development of this novel class of EGFR inhibitors poses novel challenges in the rapidly evolving therapeutic paradigm of EGFR-mutated NSCLCs and the next few years will witness the beginning of a new era for EGFR inhibition in lung cancer.  The aim of this paper is to provide a comprehensive overview of the increasing body of data emerging from the ongoing clinical trials with this promising novel therapeutic class of EGFR inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRY-2a_VQlONY2y4bB4mnvYfW6udTcc2eZZuuU30kIqkLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cfnsVyktA%253D%253D&md5=216afe73f667516142ebd4eb04425a57</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.critrevonc.2017.07.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.critrevonc.2017.07.003%26sid%3Dliteratum%253Aachs%26aulast%3DRusso%26aufirst%3DA.%26aulast%3DFranchina%26aufirst%3DT.%26aulast%3DRicciardi%26aufirst%3DG.%2BR.%2BR.%26aulast%3DSmiroldo%26aufirst%3DV.%26aulast%3DPicciotto%26aufirst%3DM.%26aulast%3DZangh%25C3%25AC%26aufirst%3DM.%26aulast%3DRolfo%26aufirst%3DC.%26aulast%3DAdamo%26aufirst%3DV.%26atitle%3DThird%2520generation%2520EGFR%2520TKIs%2520in%2520EGFR-mutated%2520NSCLC%253A%2520where%2520are%2520we%2520now%2520and%2520where%2520are%2520we%2520going%26jtitle%3DCrit.%2520Rev.%2520Oncol.%2520Hematol.%26date%3D2017%26volume%3D117%26spage%3D38%26epage%3D47%26doi%3D10.1016%2Fj.critrevonc.2017.07.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smaill, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">Targeting EGFRL858R/T790M and EGFRL858R/T790M/C797S resistance mutations in NSCLC: current developments in medicinal chemistry</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">1550</span>– <span class="NLM_lpage">1581</span>, <span class="refDoi"> DOI: 10.1002/med.21488</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1002%2Fmed.21488" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=29377179" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVyqu73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2018&pages=1550-1581&author=X.+Luauthor=L.+Yuauthor=Z.+Zhangauthor=X.+Renauthor=J.+B.+Smaillauthor=K.+Ding&title=Targeting+EGFRL858R%2FT790M+and+EGFRL858R%2FT790M%2FC797S+resistance+mutations+in+NSCLC%3A+current+developments+in+medicinal+chemistry&doi=10.1002%2Fmed.21488"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting EGFRL858R/T790M and EGFRL858R/T790M/C797S resistance mutations in NSCLC: Current developments in medicinal chemistry</span></div><div class="casAuthors">Lu, Xiaoyun; Yu, Lei; Zhang, Zhang; Ren, Xiaomei; Smaill, Jeff B.; Ding, Ke</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1550-1581</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Both the first-generation reversible epidermal growth factor receptor (EGFR) inhibitors gefitinib and erlotinib and the second-generation covalent epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) afatinib have significantly improved the survival of non-small-cell lung cancer (NSCLC) patients with activating EGFR mutations.  However, a secondary EGFRT790M mutation leads to the clin. acquired resistance to the first- and second-generation EGFR-TKIs drugs.  A no. of the third-generation wild-type sparing EGFR inhibitors, for example, WZ4002, CO1686, AZD9291, HM61713, EGF816, ASP8173, and PF0674775, have been developed, among which AZD9291 has been approved by US FDA for the treatment of NSCLC patients with EGFRT790M.  More recently, a tertiary EGFRC797S mutation was reported as the dominant resistance mechanism to the third-generation irreversible inhibitors.  It is highly desirable to develop the fourth-generation EGFR inhibitors.  This review summarizes the mechanisms of acquired resistance and the latest medicinal chem. advances on the third- and fourth-generation EGFR inhibitors, with special attention being paid to the allosteric and reversible inhibitors combating the tertiary EGFRC797S mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNK_1c8SI0qbVg90H21EOLACvtfcHk0lgJKb8W-dZKBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVyqu73P&md5=71288118ca1d9eaab6d07b056bb5ab56</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1002%2Fmed.21488&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21488%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DTargeting%2520EGFRL858R%252FT790M%2520and%2520EGFRL858R%252FT790M%252FC797S%2520resistance%2520mutations%2520in%2520NSCLC%253A%2520current%2520developments%2520in%2520medicinal%2520chemistry%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2018%26volume%3D38%26spage%3D1550%26epage%3D1581%26doi%3D10.1002%2Fmed.21488" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">U.S. Food and Drug Administration</span>. <span> </span><span class="NLM_article-title">FDA Approves Dacomitinib for Metastatic
Non-Small Cell Lung Cancer</span>. <a href="https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm621967.htm" class="extLink">https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm621967.htm</a> (accessed Sep 28, <span class="NLM_year">2018</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=U.S.+Food+and+Drug+Administration&title=FDA+Approves+Dacomitinib+for+Metastatic%0ANon-Small+Cell+Lung+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DFDA%2520Approves%2520Dacomitinib%2520for%2520Metastatic%250ANon-Small%2520Cell%2520Lung%2520Cancer%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niho, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuji, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linke, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corral, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Migliorino, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pluzanski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sbar, E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadanaciva, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mok, T. S.</span></span> <span> </span><span class="NLM_article-title">Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1454</span>– <span class="NLM_lpage">1466</span>, <span class="refDoi"> DOI: 10.1016/s1470-2045(17)30608-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1016%2Fs1470-2045%2817%2930608-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=28958502" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFGntLfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=1454-1466&author=Y.-L.+Wuauthor=Y.+Chengauthor=X.+Zhouauthor=K.+H.+Leeauthor=K.+Nakagawaauthor=S.+Nihoauthor=F.+Tsujiauthor=R.+Linkeauthor=R.+Rosellauthor=J.+Corralauthor=M.+R.+Migliorinoauthor=A.+Pluzanskiauthor=E.+I.+Sbarauthor=T.+Wangauthor=J.+L.+Whiteauthor=S.+Nadanacivaauthor=R.+Sandinauthor=T.+S.+Mok&title=Dacomitinib+versus+gefitinib+as+first-line+treatment+for+patients+with+EGFR-mutation-positive+non-small-cell+lung+cancer+%28ARCHER+1050%29%3A+a+randomised%2C+open-label%2C+phase+3+trial&doi=10.1016%2Fs1470-2045%2817%2930608-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial</span></div><div class="casAuthors">Wu, Yi-Long; Cheng, Ying; Zhou, Xiangdong; Lee, Ki Hyeong; Nakagawa, Kazuhiko; Niho, Seiji; Tsuji, Fumito; Linke, Rolf; Rosell, Rafael; Corral, Jesus; Migliorino, Maria Rita; Pluzanski, Adam; Sbar, Eric I.; Wang, Tao; White, Jane Liang; Nadanaciva, Sashi; Sandin, Rickard; Mok, Tony S.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1454-1466</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Dacomitinib is a second-generation, irreversible EGFR tyrosine kinase inhibitor.  We compared its efficacy and safety with that of the reversible EGFR tyrosine kinase inhibitor gefitinib in the first-line treatment of patients with advanced EGFR-mutation-pos. non-small-cell lung cancer (NSCLC).  In this international, multicenter, randomized, open-label, phase 3 study (ARCHER 1050), we enrolled adults (aged ≥18 years or ≥20 years in Japan and South Korea) with newly diagnosed advanced NSCLC and one EGFR mutation (exon 19 deletion or Leu858Arg) at 71 academic medical centers and university hospitals in seven countries or special administrative regions.  We randomly assigned participants (1:1) to receive oral dacomitinib 45 mg/day (in 28-day cycles) or oral gefitinib 250 mg/day (in 28-day cycles) until disease progression or another discontinuation criterion was met.  Randomisation, stratified by race and EGFR mutation type, was done with a computer-generated random code assigned by a central interactive web response system.  The primary endpoint was progression-free survival assessed by masked independent review in the intention-to-treat population.  Safety was assessed in all patients who received at least one dose of study treatment.  This study is registered with ClinicalTrials.gov, no. NCT01774721, and is ongoing but no longer recruiting patients.  Between May 9, 2013, and March 20, 2015, 452 eligible patients were randomly assigned to receive dacomitinib (n=227) or gefitinib (n=225).  Median duration of follow-up for progression-free survival was 22·1 mo (95% CI 20·3-23·9).  Median progression-free survival according to masked independent review was 14·7 mo (95% CI 11·1-16·6) in the dacomitinib group and 9·2 mo (9·1-11·0) in the gefitinib group (hazard ratio 0·59, 95% CI 0·47-0·74; p<0·0001).  The most common grade 3-4 adverse events were dermatitis acneiform (31 [14%] of 227 patients given dacomitinib vs none of 224 patients given gefitinib), diarrhea (19 [8%] vs two [1%]), and raised alanine aminotransferase levels (two [1%] vs 19 [8%]).  Treatment-related serious adverse events were reported in 21 (9%) patients given dacomitinib and in ten (4%) patients given gefitinib.  Two treatment-related deaths occurred in the dacomitinib group (one related to untreated diarrhea and one to untreated cholelithases/liver disease) and one in the gefitinib group (related to sigmoid colon diverticulitis/rupture complicated by pneumonia).  Dacomitinib significantly improved progression-free survival over gefitinib in first-line treatment of patients with EGFR-mutation-pos. NSCLC and should be considered as a new treatment option for this population.  SFJ Pharmaceuticals Group and Pfizer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqZ8AKr7cDZLVg90H21EOLACvtfcHk0lgJKb8W-dZKBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFGntLfI&md5=89eb8749060bfa3dfe79a84537b2b27b</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fs1470-2045%2817%2930608-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs1470-2045%252817%252930608-3%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DY.-L.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3DNakagawa%26aufirst%3DK.%26aulast%3DNiho%26aufirst%3DS.%26aulast%3DTsuji%26aufirst%3DF.%26aulast%3DLinke%26aufirst%3DR.%26aulast%3DRosell%26aufirst%3DR.%26aulast%3DCorral%26aufirst%3DJ.%26aulast%3DMigliorino%26aufirst%3DM.%2BR.%26aulast%3DPluzanski%26aufirst%3DA.%26aulast%3DSbar%26aufirst%3DE.%2BI.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DWhite%26aufirst%3DJ.%2BL.%26aulast%3DNadanaciva%26aufirst%3DS.%26aulast%3DSandin%26aufirst%3DR.%26aulast%3DMok%26aufirst%3DT.%2BS.%26atitle%3DDacomitinib%2520versus%2520gefitinib%2520as%2520first-line%2520treatment%2520for%2520patients%2520with%2520EGFR-mutation-positive%2520non-small-cell%2520lung%2520cancer%2520%2528ARCHER%25201050%2529%253A%2520a%2520randomised%252C%2520open-label%252C%2520phase%25203%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2017%26volume%3D18%26spage%3D1454%26epage%3D1466%26doi%3D10.1016%2Fs1470-2045%2817%2930608-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coumar, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiao, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leou, J.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lien, T.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, M.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chittimalla, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J. T.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, H.-P.</span></span> <span> </span><span class="NLM_article-title">Fast-forwarding hit to lead: aurora and epidermal growth factor receptor kinase inhibitor lead identification</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">4980</span>– <span class="NLM_lpage">4988</span>, <span class="refDoi"> DOI: 10.1021/jm1000198</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1000198" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnsFyhs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=4980-4988&author=M.+S.+Coumarauthor=C.-Y.+Chuauthor=C.-W.+Linauthor=H.-Y.+Shiaoauthor=Y.-L.+Hoauthor=R.+Reddyauthor=W.-H.+Linauthor=C.-H.+Chenauthor=Y.-H.+Pengauthor=J.-S.+Leouauthor=T.-W.+Lienauthor=C.-T.+Huangauthor=M.-Y.+Fangauthor=S.-H.+Wuauthor=J.-S.+Wuauthor=S.+K.+Chittimallaauthor=J.-S.+Songauthor=J.+T.-A.+Hsuauthor=S.-Y.+Wuauthor=C.-C.+Liaoauthor=Y.-S.+Chaoauthor=H.-P.+Hsieh&title=Fast-forwarding+hit+to+lead%3A+aurora+and+epidermal+growth+factor+receptor+kinase+inhibitor+lead+identification&doi=10.1021%2Fjm1000198"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Fast-Forwarding Hit to Lead: Aurora and Epidermal Growth Factor Receptor Kinase Inhibitor Lead Identification</span></div><div class="casAuthors">Coumar, Mohane Selvaraj; Chu, Chang-Ying; Lin, Cheng-Wei; Shiao, Hui-Yi; Ho, Yun-Lung; Reddy, Randheer; Lin, Wen-Hsing; Chen, Chun-Hwa; Peng, Yi-Hui; Leou, Jiun-Shyang; Lien, Tzu-Wen; Huang, Chin-Ting; Fang, Ming-Yu; Wu, Szu-Huei; Wu, Jian-Sung; Chittimalla, Santhosh Kumar; Song, Jen-Shin; Hsu, John T.-A.; Wu, Su-Ying; Liao, Chun-Chen; Chao, Yu-Sheng; Hsieh, Hsing-Pang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4980-4988</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Furanopyrimidines such as I [R = (S)-HOCH2CHPh; R1 = 3-(H2C:CCONH)C6H4] are prepd. as Aurora A kinase and epidermal growth factor receptor (EGFR) inhibitors by prepn. of a combinatorial library of approx. 350 furanopyridines and optimization of the inhibitors found from the library.  The initial hit compd. I (R = HOCH2CH2; R1 = Ph) was modified to better fit the back pocket to produce the potent Aurora A kinase inhibitor I (R = 4-PhNHCONHC6H4; R1 = Ph) with submicromolar antiproliferative activity in the HCT-116 human colon cancer cell line.  On the basis of docking studies with EGFR hit I [R = (S)-HOCH2CHPh; R1 = Ph], introduction of an acrylamide Michael acceptor group led to I [R = (S)-HOCH2CHPh; R1 = 3-(H2C:CCONH)C6H4], which inhibited both the wild and mutant EGFR kinases and also showed antiproliferative activity in the gefitinib-resistant HCC827 human lung cancer cells.  The X-ray cocrystal structures of I (R = HOCH2CH2, 4-PhNHCONHC6H4; R1 = Ph) bound to Aurora A kinase and the crystal structure of I [R = (S)-HOCH2CHPh; R1 = 3-(H2C:CCONH)C6H4] bound to EGFR confirmed their hypothesized binding modes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCOPMtJ1xilrVg90H21EOLACvtfcHk0lgOQwS-WJW51A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnsFyhs7s%253D&md5=8064e99d8d31603c7186b5fa33e019a6</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm1000198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1000198%26sid%3Dliteratum%253Aachs%26aulast%3DCoumar%26aufirst%3DM.%2BS.%26aulast%3DChu%26aufirst%3DC.-Y.%26aulast%3DLin%26aufirst%3DC.-W.%26aulast%3DShiao%26aufirst%3DH.-Y.%26aulast%3DHo%26aufirst%3DY.-L.%26aulast%3DReddy%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DW.-H.%26aulast%3DChen%26aufirst%3DC.-H.%26aulast%3DPeng%26aufirst%3DY.-H.%26aulast%3DLeou%26aufirst%3DJ.-S.%26aulast%3DLien%26aufirst%3DT.-W.%26aulast%3DHuang%26aufirst%3DC.-T.%26aulast%3DFang%26aufirst%3DM.-Y.%26aulast%3DWu%26aufirst%3DS.-H.%26aulast%3DWu%26aufirst%3DJ.-S.%26aulast%3DChittimalla%26aufirst%3DS.%2BK.%26aulast%3DSong%26aufirst%3DJ.-S.%26aulast%3DHsu%26aufirst%3DJ.%2BT.-A.%26aulast%3DWu%26aufirst%3DS.-Y.%26aulast%3DLiao%26aufirst%3DC.-C.%26aulast%3DChao%26aufirst%3DY.-S.%26aulast%3DHsieh%26aufirst%3DH.-P.%26atitle%3DFast-forwarding%2520hit%2520to%2520lead%253A%2520aurora%2520and%2520epidermal%2520growth%2520factor%2520receptor%2520kinase%2520inhibitor%2520lead%2520identification%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D4980%26epage%3D4988%26doi%3D10.1021%2Fjm1000198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagar, B.</span></span> <span> </span><span class="NLM_article-title">c-Abl tyrosine kinase and inhibition by the cancer drug imatinib (Gleevec/STI-571)</span>. <i>J. Nutr.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">1518S</span>– <span class="NLM_lpage">1523S</span>, <span class="refDoi"> DOI: 10.1093/jn/137.6.1518s</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1093%2Fjn%2F137.6.1518s" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=17513418" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmt1elur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2007&pages=1518S-1523S&author=B.+Nagar&title=c-Abl+tyrosine+kinase+and+inhibition+by+the+cancer+drug+imatinib+%28Gleevec%2FSTI-571%29&doi=10.1093%2Fjn%2F137.6.1518s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">c-Abl tyrosine kinase and inhibition by the cancer drug imatinib (Gleevec/STI-571)</span></div><div class="casAuthors">Nagar, Bhushan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nutrition</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">6S-1</span>),
    <span class="NLM_cas:pages">1518S-1523S</span>CODEN:
                <span class="NLM_cas:coden">JONUAI</span>;
        ISSN:<span class="NLM_cas:issn">0022-3166</span>.
    
            (<span class="NLM_cas:orgname">American Society for Nutrition</span>)
        </div><div class="casAbstract">The search for specific protein kinase inhibitors is an intense area of research because of the potential for drug development.  The small-mol. inhibitor imatinib (Gleevec/STI-571) can specifically inactivate the tyrosine kinase c-Abl, whose normal mechanism of autoinhibition is disrupted in chronic myelogenous leukemia.  Crystallog. anal. of c-Abl reveals that imatinib recognizes a distinct inactive conformation of the Abl kinase domain that relies on the mechanism of autoinhibition achieved in the context of a larger fragment of the protein.  This mechanism is distinct from that seen in the related Src family kinases, where autoinhibition is achieved through the internal engagement of a C-terminal phosphotyrosine residue by the Src homol. 2 domain (SH2) domain.  Notably, this phosphotyrosine residue is lacking in c-Abl, where instead autoinhibition is mediated by an interaction between the kinase domain and the N-terminal myristoyl modification.  Within the framework of these 2 distinct modes of autoinhibition, the SH3-SH2 unit is structurally conserved between Abl and Src, leading to large conformational differences in their kinase domains.  These differences help explain the ability of imatinib to preferentially inhibit Abl over Src.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbSjfYUuL1FLVg90H21EOLACvtfcHk0lgOQwS-WJW51A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmt1elur4%253D&md5=8c11f5f4abed3ab4b86ad99158ef0d8d</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1093%2Fjn%2F137.6.1518s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjn%252F137.6.1518s%26sid%3Dliteratum%253Aachs%26aulast%3DNagar%26aufirst%3DB.%26atitle%3Dc-Abl%2520tyrosine%2520kinase%2520and%2520inhibition%2520by%2520the%2520cancer%2520drug%2520imatinib%2520%2528Gleevec%252FSTI-571%2529%26jtitle%3DJ.%2520Nutr.%26date%3D2007%26volume%3D137%26spage%3D1518S%26epage%3D1523S%26doi%3D10.1093%2Fjn%2F137.6.1518s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, S. R.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">5572</span>– <span class="NLM_lpage">5581</span>, <span class="refDoi"> DOI: 10.1093/emboj/16.18.5572</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1093%2Femboj%2F16.18.5572" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=9312016" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADyaK2sXmsFWmt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1997&pages=5572-5581&author=S.+R.+Hubbard&title=Crystal+structure+of+the+activated+insulin+receptor+tyrosine+kinase+in+complex+with+peptide+substrate+and+ATP+analog&doi=10.1093%2Femboj%2F16.18.5572"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog</span></div><div class="casAuthors">Hubbard, Stevan R.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5572-5581</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The crystal structure of the phosphorylated, activated form of insulin receptor tyrosine kinase (I) in complex with an 18-residue peptide substrate (KKKLPATGDYMNMSPVGD), and the nonhydrolyzable ATP analog, AMP-PNP, was detd. at 1.9 Å resoln.  The activation loop (A-loop) of I undergoes a major conformational change upon autophosphorylation of Tyr-1158, Tyr-1162, and Tyr-1163 within the loop, resulting in unrestricted access of ATP and protein substrates to the I active site.  Phosphorylated Tyr-1163 (pTyr-1163) was the key phospho-Tyr group in stabilizing the conformation of the tris-phosphorylated A-loop, whereas pTyr-1158 was completely solvent-exposed, suggesting an availability for interaction with downstream signaling proteins.  The YMXM-contg. peptide substrate bound as a short anti-parallel β-strand to the C-terminal end of the A-loop, with the Met side-chains occupying 2 hydrophobic pockets on the C-terminal lobe of I.  The structure thus reveals the mol. basis for insulin receptor activation via autophosphorylation, and provides insights into I substrate specificity and the mechanism of phosphotransfer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlJGdy9gorfbVg90H21EOLACvtfcHk0lgOQwS-WJW51A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmsFWmt74%253D&md5=99c1865418541c085220185310b7b533</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1093%2Femboj%2F16.18.5572&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Femboj%252F16.18.5572%26sid%3Dliteratum%253Aachs%26aulast%3DHubbard%26aufirst%3DS.%2BR.%26atitle%3DCrystal%2520structure%2520of%2520the%2520activated%2520insulin%2520receptor%2520tyrosine%2520kinase%2520in%2520complex%2520with%2520peptide%2520substrate%2520and%2520ATP%2520analog%26jtitle%3DEMBO%2520J.%26date%3D1997%26volume%3D16%26spage%3D5572%26epage%3D5581%26doi%3D10.1093%2Femboj%2F16.18.5572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, N. P.</span></span> <span> </span><span class="NLM_article-title">Ins and outs of kinase DFG motifs</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">745</span>– <span class="NLM_lpage">746</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2013.06.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1016%2Fj.chembiol.2013.06.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=23790484" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVWgtLrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=745-746&author=D.+K.+Treiberauthor=N.+P.+Shah&title=Ins+and+outs+of+kinase+DFG+motifs&doi=10.1016%2Fj.chembiol.2013.06.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Ins and Outs of Kinase DFG Motifs</span></div><div class="casAuthors">Treiber, Daniel K.; Shah, Neil P.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">745-746</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  In this issue of Chem. & Biol., Hari and colleagues show that two positions in kinase active sites, including the well-known "gatekeeper" residue, regulate "in" vs. "out" conformations of the conserved "DFG" motif.  These findings suggest yet another role for the gatekeeper residue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXsx2RYZgddLVg90H21EOLACvtfcHk0lgjTpcZADnq6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVWgtLrI&md5=f2c8ebbdadd4a9c485a95dc7b9b56449</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2013.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2013.06.001%26sid%3Dliteratum%253Aachs%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DShah%26aufirst%3DN.%2BP.%26atitle%3DIns%2520and%2520outs%2520of%2520kinase%2520DFG%2520motifs%26jtitle%3DChem.%2520Biol.%26date%3D2013%26volume%3D20%26spage%3D745%26epage%3D746%26doi%3D10.1016%2Fj.chembiol.2013.06.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiao, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J. T.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amancha, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coumar, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyu, P.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, H.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.-Y.</span></span> <span> </span><span class="NLM_article-title">Protein kinase inhibitor design by targeting the Asp-Phe-Gly (DFG) motif: the role of the DFG motif in the design of epidermal growth factor receptor inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">3889</span>– <span class="NLM_lpage">3903</span>, <span class="refDoi"> DOI: 10.1021/jm400072p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400072p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmtlWgs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=3889-3903&author=Y.-H.+Pengauthor=H.-Y.+Shiaoauthor=C.-H.+Tuauthor=P.-M.+Liuauthor=J.+T.-A.+Hsuauthor=P.+K.+Amanchaauthor=J.-S.+Wuauthor=M.+S.+Coumarauthor=C.-H.+Chenauthor=S.-Y.+Wangauthor=W.-H.+Linauthor=H.-Y.+Sunauthor=Y.-S.+Chaoauthor=P.-C.+Lyuauthor=H.-P.+Hsiehauthor=S.-Y.+Wu&title=Protein+kinase+inhibitor+design+by+targeting+the+Asp-Phe-Gly+%28DFG%29+motif%3A+the+role+of+the+DFG+motif+in+the+design+of+epidermal+growth+factor+receptor+inhibitors&doi=10.1021%2Fjm400072p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Protein Kinase Inhibitor Design by Targeting the Asp-Phe-Gly (DFG) Motif: The Role of the DFG Motif in the Design of Epidermal Growth Factor Receptor Inhibitors</span></div><div class="casAuthors">Peng, Yi-Hui; Shiao, Hui-Yi; Tu, Chih-Hsiang; Liu, Pang-Min; Hsu, John Tsu-An; Amancha, Prashanth Kumar; Wu, Jian-Sung; Coumar, Mohane Selvaraj; Chen, Chun-Hwa; Wang, Sing-Yi; Lin, Wen-Hsing; Sun, Hsu-Yi; Chao, Yu-Sheng; Lyu, Ping-Chiang; Hsieh, Hsing-Pang; Wu, Su-Ying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3889-3903</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The Asp-Phe-Gly (DFG) motif plays an important role in the regulation of kinase activity.  Structure-based drug design was performed to design compds. able to interact with the DFG motif; epidermal growth factor receptor (EGFR) was selected as an example.  Structural insights obtained from the EGFR/2a complex suggested that an extension from the meta-position on the Ph group (ring-5) would improve interactions with the DFG motif.  Indeed, introduction of an N,N-dimethylamino tail resulted in N-[3-(4-{[(1S)-2-Hydroxy-1-phenylethyl]amino}-6phenylfuro[2,3-d]pyrimidin-5-yl)phenyl]-N3,N3-dimethyl-y-alaninamide, which showed almost 50-fold improvement in inhibition compared to (2S)-2-[(5,6-Diphenylfuro[2,3-d]pyrimidin-4-yl)amino]-2phenylethanol.  Structural studies confirmed this N,N-dimethylamino tail moved toward the DFG motif to form a salt bridge with the side chain of Asp831.  That the interactions with the DFG motif greatly contribute to the potency of N-[3-(4-{[(1S)-2-Hydroxy-1-phenylethyl]amino}-6phenylfuro[2,3-d]pyrimidin-5-yl)phenyl]-N3,N3-dimethyl-y-alaninamide is strongly evidenced by synthesizing and testing compds. (2S)-2-[(5,6-Diphenylfuro[2,3-d]pyrimidin-4-yl)amino]-2phenylethanol, N-[3-(4-{[(1S)-2-Hydroxy-1-phenylethyl]amino}-6phenylfuro[2,3-d]pyrimidin-5-yl)phenyl]acetamide, and N-[3-(4-{[(1S)-2-Hydroxy-1-phenylethyl]amino}-6phenylfuro[2,3-d]pyrimidin-5-yl)phenyl]-5-methylhexanamide: when the charge interactions are absent, the inhibitory activity decreased significantly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpww4-N_WLlNrVg90H21EOLACvtfcHk0lgjTpcZADnq6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmtlWgs7Y%253D&md5=76994a666b2223510c09bb7e4524eae9</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm400072p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400072p%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DY.-H.%26aulast%3DShiao%26aufirst%3DH.-Y.%26aulast%3DTu%26aufirst%3DC.-H.%26aulast%3DLiu%26aufirst%3DP.-M.%26aulast%3DHsu%26aufirst%3DJ.%2BT.-A.%26aulast%3DAmancha%26aufirst%3DP.%2BK.%26aulast%3DWu%26aufirst%3DJ.-S.%26aulast%3DCoumar%26aufirst%3DM.%2BS.%26aulast%3DChen%26aufirst%3DC.-H.%26aulast%3DWang%26aufirst%3DS.-Y.%26aulast%3DLin%26aufirst%3DW.-H.%26aulast%3DSun%26aufirst%3DH.-Y.%26aulast%3DChao%26aufirst%3DY.-S.%26aulast%3DLyu%26aufirst%3DP.-C.%26aulast%3DHsieh%26aufirst%3DH.-P.%26aulast%3DWu%26aufirst%3DS.-Y.%26atitle%3DProtein%2520kinase%2520inhibitor%2520design%2520by%2520targeting%2520the%2520Asp-Phe-Gly%2520%2528DFG%2529%2520motif%253A%2520the%2520role%2520of%2520the%2520DFG%2520motif%2520in%2520the%2520design%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D3889%26epage%3D3903%26doi%3D10.1021%2Fjm400072p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Center of Drug Evaluation</span>. <span> </span><span class="NLM_article-title">Taiwan, Phase I Clinical Trial for
DBPR112</span>. <a href="http://www1.cde.org.tw/ct_taiwan/search_case2_tornado.php?caseno=2107" class="extLink">http://www1.cde.org.tw/ct_taiwan/search_case2_tornado.php?caseno=2107</a> (accessed Jul 28, <span class="NLM_year">2018</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=Center+of+Drug+Evaluation&title=Taiwan%2C+Phase+I+Clinical+Trial+for%0ADBPR112"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DTaiwan%252C%2520Phase%2520I%2520Clinical%2520Trial%2520for%250ADBPR112%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karikios, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyer, M. J.</span></span> <span> </span><span class="NLM_article-title">Irreversible EGFR inhibitors in advanced non-small-cell lung carcinoma: rationale and clinical evidence</span>. <i>Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">317</span>– <span class="NLM_lpage">325</span>, <span class="refDoi"> DOI: 10.4155/cli.12.7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.4155%2Fcli.12.7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BC38XktVGgur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=317-325&author=D.+J.+Karikiosauthor=M.+J.+Boyer&title=Irreversible+EGFR+inhibitors+in+advanced+non-small-cell+lung+carcinoma%3A+rationale+and+clinical+evidence&doi=10.4155%2Fcli.12.7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Irreversible EGFR inhibitors in advanced non-small-cell lung carcinoma: rationale and clinical evidence</span></div><div class="casAuthors">Karikios, Deme John; Boyer, Michael Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Investigation (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">317-325</span>CODEN:
                <span class="NLM_cas:coden">CILUAP</span>;
        ISSN:<span class="NLM_cas:issn">2041-6792</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  The EGFR has become an important target in lung cancer treatment.  Reversible inhibitors of this receptor have been shown to improve outcomes for patients whose tumors harbor EGFR mutations, as well as for those with wild-type EGFR.  The development of resistance (either primary or acquired) to EGFR tyrosine kinase inhibitors is a common occurrence and irreversible EGFR inhibitors have been developed to overcome this problem.  There are now emerging clin. data for the two major irreversible inhibitors; afatinib and dacomitinib.  The question of how and when we use these irreversible inhibitors still needs to be answered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjR73MvS5xZrVg90H21EOLACvtfcHk0lgjTpcZADnq6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktVGgur8%253D&md5=b487cb2d247f308000f7bec7be1d60c0</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.4155%2Fcli.12.7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Fcli.12.7%26sid%3Dliteratum%253Aachs%26aulast%3DKarikios%26aufirst%3DD.%2BJ.%26aulast%3DBoyer%26aufirst%3DM.%2BJ.%26atitle%3DIrreversible%2520EGFR%2520inhibitors%2520in%2520advanced%2520non-small-cell%2520lung%2520carcinoma%253A%2520rationale%2520and%2520clinical%2520evidence%26jtitle%3DClin.%2520Invest.%26date%3D2012%26volume%3D2%26spage%3D317%26epage%3D325%26doi%3D10.4155%2Fcli.12.7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ho, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luh, T. Y.</span></span> <span> </span><span class="NLM_article-title">Transition metal promoted reactions. Part 27. Nickel(II)-lithium aluminum hydride mediated reduction of carbon-sulfur bonds</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">4474</span>– <span class="NLM_lpage">4476</span>, <span class="refDoi"> DOI: 10.1021/jo00279a046</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo00279a046" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADyaL1MXltlegsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=1989&pages=4474-4476&author=K.+M.+Hoauthor=C.+H.+Lamauthor=T.+Y.+Luh&title=Transition+metal+promoted+reactions.+Part+27.+Nickel%28II%29-lithium+aluminum+hydride+mediated+reduction+of+carbon-sulfur+bonds&doi=10.1021%2Fjo00279a046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Transition metal promoted reactions.  Part 27.  Nickel(II)-lithium aluminum hydride mediated reduction of carbon-sulfur bonds</span></div><div class="casAuthors">Ho, Kim Man; Lam, Chun Hon; Luh, Tien Yau</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4474-6</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    </div><div class="casAbstract">Bis(triphenylphospine)nickel dibromide-lithium aluminum hydride was shown to be an effective desulfurization reagent.  Carbon-sulfur bonds in thiols, thioethers, sulfoxides and sulfones can be readily reduced in satisfactory to excellent yields.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpl98KzWd3ve7Vg90H21EOLACvtfcHk0liGpBZZyK2zWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXltlegsbw%253D&md5=8f8cc57906646d4be10528883b39d635</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjo00279a046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00279a046%26sid%3Dliteratum%253Aachs%26aulast%3DHo%26aufirst%3DK.%2BM.%26aulast%3DLam%26aufirst%3DC.%2BH.%26aulast%3DLuh%26aufirst%3DT.%2BY.%26atitle%3DTransition%2520metal%2520promoted%2520reactions.%2520Part%252027.%2520Nickel%2528II%2529-lithium%2520aluminum%2520hydride%2520mediated%2520reduction%2520of%2520carbon-sulfur%2520bonds%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1989%26volume%3D54%26spage%3D4474%26epage%3D4476%26doi%3D10.1021%2Fjo00279a046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coumar, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, M.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uang, B.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, T.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leou, J.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, M.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J. T.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, H.-P.</span></span> <span> </span><span class="NLM_article-title">Identification, SAR studies, and x-ray co-crystallographic analysis of a novel furanopyrimidine aurora kinase an inhibitor</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">255</span>– <span class="NLM_lpage">267</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200900339</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1002%2Fcmdc.200900339" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=20039358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtl2nsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=255-267&author=M.+S.+Coumarauthor=M.-T.+Tsaiauthor=C.-Y.+Chuauthor=B.-J.+Uangauthor=W.-H.+Linauthor=C.-Y.+Changauthor=T.-Y.+Changauthor=J.-S.+Leouauthor=C.-H.+Tengauthor=J.-S.+Wuauthor=M.-Y.+Fangauthor=C.-H.+Chenauthor=J.+T.-A.+Hsuauthor=S.-Y.+Wuauthor=Y.-S.+Chaoauthor=H.-P.+Hsieh&title=Identification%2C+SAR+studies%2C+and+x-ray+co-crystallographic+analysis+of+a+novel+furanopyrimidine+aurora+kinase+an+inhibitor&doi=10.1002%2Fcmdc.200900339"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Identification, SAR Studies, and X-ray Co-crystallographic Analysis of a Novel Furanopyrimidine Aurora Kinase A Inhibitor</span></div><div class="casAuthors">Coumar, Mohane Selvaraj; Tsai, Ming-Tsung; Chu, Chang-Ying; Uang, Biing-Jiun; Lin, Wen-Hsing; Chang, Chun-Yu; Chang, Teng-Yuan; Leou, Jiun-Shyang; Teng, Chi-Huang; Wu, Jian-Sung; Fang, Ming-Yu; Chen, Chun-Hwa; Hsu, John T.-A.; Wu, Su-Ying; Chao, Yu-Sheng; Hsieh, Hsing-Pang</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">255-267</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Herein we reveal a simple method for the identification of novel Aurora kinase A inhibitors through substructure searching of an inhouse compd. library to select compds. for testing.  A hydrazone fragment conferring Aurora kinase activity and heterocyclic rings most frequently reported in kinase inhibitors were used as substructure queries to filter the inhouse compd. library collection prior to testing.  Five new series of Aurora kinase inhibitors were identified through this strategy, with IC50 values ranging from ∼300 nM to ∼15 μM, by testing only 133 compds. from a database of ∼125 000 compds.  Structure-activity relationship studies and X-ray co-crystallog. anal. of the most potent compd., 8 (I), a furanopyrimidine deriv. with an IC50 value of 309 nM toward Aurora kinase A, were carried out.  The knowledge gained through these studies could help in the future design of potent Aurora kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEUSBLKwZNYrVg90H21EOLACvtfcHk0liGpBZZyK2zWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtl2nsLk%253D&md5=c43554591b114d09047bdd74a01b0f64</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200900339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200900339%26sid%3Dliteratum%253Aachs%26aulast%3DCoumar%26aufirst%3DM.%2BS.%26aulast%3DTsai%26aufirst%3DM.-T.%26aulast%3DChu%26aufirst%3DC.-Y.%26aulast%3DUang%26aufirst%3DB.-J.%26aulast%3DLin%26aufirst%3DW.-H.%26aulast%3DChang%26aufirst%3DC.-Y.%26aulast%3DChang%26aufirst%3DT.-Y.%26aulast%3DLeou%26aufirst%3DJ.-S.%26aulast%3DTeng%26aufirst%3DC.-H.%26aulast%3DWu%26aufirst%3DJ.-S.%26aulast%3DFang%26aufirst%3DM.-Y.%26aulast%3DChen%26aufirst%3DC.-H.%26aulast%3DHsu%26aufirst%3DJ.%2BT.-A.%26aulast%3DWu%26aufirst%3DS.-Y.%26aulast%3DChao%26aufirst%3DY.-S.%26aulast%3DHsieh%26aufirst%3DH.-P.%26atitle%3DIdentification%252C%2520SAR%2520studies%252C%2520and%2520x-ray%2520co-crystallographic%2520analysis%2520of%2520a%2520novel%2520furanopyrimidine%2520aurora%2520kinase%2520an%2520inhibitor%26jtitle%3DChemMedChem%26date%3D2010%26volume%3D5%26spage%3D255%26epage%3D267%26doi%3D10.1002%2Fcmdc.200900339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iyengar, R. R.</span>; <span class="NLM_string-name">Judd, A. S.</span>; <span class="NLM_string-name">Zhao, G.</span>; <span class="NLM_string-name">Kym, P. R.</span>; <span class="NLM_string-name">Sham, H. L.</span>; <span class="NLM_string-name">Gu, Y.</span>; <span class="NLM_string-name">Liu, G.</span>; <span class="NLM_string-name">Liu, M.</span>; <span class="NLM_string-name">Zhao, H.</span>; <span class="NLM_string-name">Clark, R. F.</span>; <span class="NLM_string-name">Frevert, E. U.</span>; <span class="NLM_string-name">Cool, B. L.</span>; <span class="NLM_string-name">Zhang, T.</span>; <span class="NLM_string-name">Keyes, R. F.</span>; <span class="NLM_string-name">Hansen, T. M.</span>; <span class="NLM_string-name">Xin, Z.</span></span> <span> </span><span class="NLM_article-title">Thienopyridones as AMPK Activators for the Treatment of Diabetes and Obesity</span>. U.S. Patent <span class="NLM_patent">0,038,068 A1</span>, Feb 17, <span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=R.+R.+Iyengar&author=A.+S.+Judd&author=G.+Zhao&author=P.+R.+Kym&author=H.+L.+Sham&author=Y.+Gu&author=G.+Liu&author=M.+Liu&author=H.+Zhao&author=R.+F.+Clark&author=E.+U.+Frevert&author=B.+L.+Cool&author=T.+Zhang&author=R.+F.+Keyes&author=T.+M.+Hansen&author=Z.+Xin&title=Thienopyridones+as+AMPK+Activators+for+the+Treatment+of+Diabetes+and+Obesity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DIyengar%26aufirst%3DR.%2BR.%26atitle%3DThienopyridones%2520as%2520AMPK%2520Activators%2520for%2520the%2520Treatment%2520of%2520Diabetes%2520and%2520Obesity%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frey, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtin, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albert, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arries, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlozzari, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauch, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouska, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bousquet, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunha, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glaser, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcotte, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moskey, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pease, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoll, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tapang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wishart, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidsen, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michaelides, M. R.</span></span> <span> </span><span class="NLM_article-title">Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">6066</span>– <span class="NLM_lpage">6083</span>, <span class="refDoi"> DOI: 10.1021/jm050458h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm050458h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpt1Wht7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6066-6083&author=Y.+Daiauthor=Y.+Guoauthor=R.+R.+Freyauthor=Z.+Jiauthor=M.+L.+Curtinauthor=A.+A.+Ahmedauthor=D.+H.+Albertauthor=L.+Arnoldauthor=S.+S.+Arriesauthor=T.+Barlozzariauthor=J.+L.+Bauchauthor=J.+J.+Bouskaauthor=P.+F.+Bousquetauthor=G.+A.+Cunhaauthor=K.+B.+Glaserauthor=J.+Guoauthor=J.+Liauthor=P.+A.+Marcotteauthor=K.+C.+Marshauthor=M.+D.+Moskeyauthor=L.+J.+Peaseauthor=K.+D.+Stewartauthor=V.+S.+Stollauthor=P.+Tapangauthor=N.+Wishartauthor=S.+K.+Davidsenauthor=M.+R.+Michaelides&title=Thienopyrimidine+ureas+as+novel+and+potent+multitargeted+receptor+tyrosine+kinase+inhibitors&doi=10.1021%2Fjm050458h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Thienopyrimidine Ureas as Novel and Potent Multitargeted Receptor Tyrosine Kinase Inhibitors</span></div><div class="casAuthors">Dai, Yujia; Guo, Yan; Frey, Robin R.; Ji, Zhiqin; Curtin, Michael L.; Ahmed, Asma A.; Albert, Daniel H.; Arnold, Lee; Arries, Shannon S.; Barlozzari, Teresa; Bauch, Joy L.; Bouska, Jennifer J.; Bousquet, Peter F.; Cunha, George A.; Glaser, Keith B.; Guo, Jun; Li, Junling; Marcotte, Patrick A.; Marsh, Kennan C.; Moskey, Maria D.; Pease, Lori J.; Stewart, Kent D.; Stoll, Vincent S.; Tapang, Paul; Wishart, Neil; Davidsen, Steven K.; Michaelides, Michael R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6066-6083</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of novel thienopyrimidine-based receptor tyrosine kinase inhibitors has been discovered.  Investigation of structure-activity relationships at the 5- and 6-positions of the thienopyrimidine nucleus led to a series of N,N'-diaryl ureas that potently inhibit all of the vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptor tyrosine kinases.  A kinase insert domain-contg. receptor (KDR) homol. model suggests that these compds. bind to the "inactive conformation" of the enzyme with the urea portion extending into the back hydrophobic pocket adjacent to the ATP (ATP) binding site.  A no. of compds. have been identified as displaying excellent in vivo potency.  In particular, compds. 28 and 76 possess favorable pharmacokinetic (PK) profiles and demonstrate potent antitumor efficacy against the HT1080 human fibrosarcoma xenograft tumor growth model (tumor growth inhibition (TGI) = 75% at 25 mg/kg·day, per os (po)).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYifOiC_HYHrVg90H21EOLACvtfcHk0liGpBZZyK2zWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpt1Wht7Y%253D&md5=ef245a26e40d18cfaf7f98260827f274</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm050458h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050458h%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DY.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DFrey%26aufirst%3DR.%2BR.%26aulast%3DJi%26aufirst%3DZ.%26aulast%3DCurtin%26aufirst%3DM.%2BL.%26aulast%3DAhmed%26aufirst%3DA.%2BA.%26aulast%3DAlbert%26aufirst%3DD.%2BH.%26aulast%3DArnold%26aufirst%3DL.%26aulast%3DArries%26aufirst%3DS.%2BS.%26aulast%3DBarlozzari%26aufirst%3DT.%26aulast%3DBauch%26aufirst%3DJ.%2BL.%26aulast%3DBouska%26aufirst%3DJ.%2BJ.%26aulast%3DBousquet%26aufirst%3DP.%2BF.%26aulast%3DCunha%26aufirst%3DG.%2BA.%26aulast%3DGlaser%26aufirst%3DK.%2BB.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DMarcotte%26aufirst%3DP.%2BA.%26aulast%3DMarsh%26aufirst%3DK.%2BC.%26aulast%3DMoskey%26aufirst%3DM.%2BD.%26aulast%3DPease%26aufirst%3DL.%2BJ.%26aulast%3DStewart%26aufirst%3DK.%2BD.%26aulast%3DStoll%26aufirst%3DV.%2BS.%26aulast%3DTapang%26aufirst%3DP.%26aulast%3DWishart%26aufirst%3DN.%26aulast%3DDavidsen%26aufirst%3DS.%2BK.%26aulast%3DMichaelides%26aufirst%3DM.%2BR.%26atitle%3DThienopyrimidine%2520ureas%2520as%2520novel%2520and%2520potent%2520multitargeted%2520receptor%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6066%26epage%3D6083%26doi%3D10.1021%2Fjm050458h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beccalli, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manfredi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchesini, A.</span></span> <span> </span><span class="NLM_article-title">Alkynes from 5-aminoisoxazoles</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">2372</span>– <span class="NLM_lpage">2375</span>, <span class="refDoi"> DOI: 10.1021/jo00213a034</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo00213a034" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADyaL2MXkt1Wru78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1985&pages=2372-2375&author=E.+M.+Beccalliauthor=A.+Manfrediauthor=A.+Marchesini&title=Alkynes+from+5-aminoisoxazoles&doi=10.1021%2Fjo00213a034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Alkynes from 5-aminoisoxazoles</span></div><div class="casAuthors">Beccalli, Egle M.; Manfredi, Amadea; Marchesini, Alessandro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2372-5</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    </div><div class="casAbstract">Diazotization of 5-aminoisoxazoles I [R = Ph, H, CO2Et, Me; R1 = CONH2, CO2Et, p-O2NC6H4, 4-pyridyl, etc. (≥1 of R and R1 is an electron-withdrawing group)] by reaction with NaNO2 in AcOH-H2O afforded the corresponding RC≡CR1.  A reaction path involving an intermediate isoxazol-5-yl radical is proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHMoVHKHwRFbVg90H21EOLACvtfcHk0lgiRXDrRbUo9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXkt1Wru78%253D&md5=f97bd280fc4db2675a1abb732acac8c0</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjo00213a034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00213a034%26sid%3Dliteratum%253Aachs%26aulast%3DBeccalli%26aufirst%3DE.%2BM.%26aulast%3DManfredi%26aufirst%3DA.%26aulast%3DMarchesini%26aufirst%3DA.%26atitle%3DAlkynes%2520from%25205-aminoisoxazoles%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1985%26volume%3D50%26spage%3D2372%26epage%3D2375%26doi%3D10.1021%2Fjo00213a034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tormyshev, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flinn, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trukhin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogozhnikova, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikhalina, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troitskaya, T.</span></span> <span> </span><span class="NLM_article-title">Aryl alkyl ketones in a one-pot Gewald synthesis of 2-aminothiophenes</span>. <i>Synlett</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_fpage">2559</span>– <span class="NLM_lpage">2564</span>, <span class="refDoi"> DOI: 10.1055/s-2006-951484</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1055%2Fs-2006-951484" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1WkurbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&pages=2559-2564&author=V.+Tormyshevauthor=A.+Flinnauthor=D.+Trukhinauthor=O.+Rogozhnikovaauthor=T.+Mikhalinaauthor=T.+Troitskaya&title=Aryl+alkyl+ketones+in+a+one-pot+Gewald+synthesis+of+2-aminothiophenes&doi=10.1055%2Fs-2006-951484"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Aryl alkyl ketones in a one-pot Gewald synthesis of 2-aminothiophenes</span></div><div class="casAuthors">Tormyshev, Victor M.; Trukhin, Dmitry V.; Rogozhnikova, Olga Yu.; Mikhalina, Tatiana V.; Troitskaya, Tatiana I.; Flinn, Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Synlett</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2559-2564</span>CODEN:
                <span class="NLM_cas:coden">SYNLES</span>;
        ISSN:<span class="NLM_cas:issn">0936-5214</span>.
    
            (<span class="NLM_cas:orgname">Georg Thieme Verlag</span>)
        </div><div class="casAbstract">2-Aminothiophene-3-carboxylates, e.g., I, bearing various aryl groups at the 4-position are readily obtained in good to moderate yields by the one-pot Gewald reaction of aryl alkyl ketones with Et cyanoacetate and elemental sulfur in the presence of morpholinium acetate and excess morpholine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUx_V-SKs367Vg90H21EOLACvtfcHk0lgiRXDrRbUo9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1WkurbM&md5=625f8985df859b6405bc3764c9e12276</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1055%2Fs-2006-951484&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2006-951484%26sid%3Dliteratum%253Aachs%26aulast%3DTormyshev%26aufirst%3DV.%26aulast%3DFlinn%26aufirst%3DA.%26aulast%3DTrukhin%26aufirst%3DD.%26aulast%3DRogozhnikova%26aufirst%3DO.%26aulast%3DMikhalina%26aufirst%3DT.%26aulast%3DTroitskaya%26aufirst%3DT.%26atitle%3DAryl%2520alkyl%2520ketones%2520in%2520a%2520one-pot%2520Gewald%2520synthesis%2520of%25202-aminothiophenes%26jtitle%3DSynlett%26date%3D2006%26spage%3D2559%26epage%3D2564%26doi%3D10.1055%2Fs-2006-951484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Therkelsen, F. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rottländer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorup, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedersen, E. B.</span></span> <span> </span><span class="NLM_article-title">4-Metalated condensed pyrimidines: their preparation and reaction with aldehydes under Barbier-type conditions</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1991</span>– <span class="NLM_lpage">1994</span>, <span class="refDoi"> DOI: 10.1021/ol049432v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol049432v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjslOhsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2004&pages=1991-1994&author=F.+D.+Therkelsenauthor=M.+Rottl%C3%A4nderauthor=N.+Thorupauthor=E.+B.+Pedersen&title=4-Metalated+condensed+pyrimidines%3A+their+preparation+and+reaction+with+aldehydes+under+Barbier-type+conditions&doi=10.1021%2Fol049432v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">4-Metalated Condensed Pyrimidines: Their Preparation and Reaction with Aldehydes under Barbier-Type Conditions</span></div><div class="casAuthors">Therkelsen, Frans D.; Rottlaender, Mario; Thorup, Niels; Pedersen, Erik Bjerregaard</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1991-1994</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The organometallic intermediate obtained from halogen-metal exchanges of 4-iodo-6-phenylthieno[2,3-d]pyrimidine under Barbier-type conditions was reacted with aldehydes to form the corresponding alcs. in moderate yields.  The reaction involving an organolithium intermediate proceeded only at low temp., whereas the reaction involving a magnesium ate intermediate also proceeded at room temp.  A crystal structure confirms that the expected constitutional alc. isomer is formed, where no migration has taken place.  The conditions were also suitable for 9-benzyl-6-iodopurine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdJIUdumgrdrVg90H21EOLACvtfcHk0lgiRXDrRbUo9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjslOhsbk%253D&md5=e797a069a3e7095dfbae72d99897e503</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fol049432v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol049432v%26sid%3Dliteratum%253Aachs%26aulast%3DTherkelsen%26aufirst%3DF.%2BD.%26aulast%3DRottl%25C3%25A4nder%26aufirst%3DM.%26aulast%3DThorup%26aufirst%3DN.%26aulast%3DPedersen%26aufirst%3DE.%2BB.%26atitle%3D4-Metalated%2520condensed%2520pyrimidines%253A%2520their%2520preparation%2520and%2520reaction%2520with%2520aldehydes%2520under%2520Barbier-type%2520conditions%26jtitle%3DOrg.%2520Lett.%26date%3D2004%26volume%3D6%26spage%3D1991%26epage%3D1994%26doi%3D10.1021%2Fol049432v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Capoferri, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lodola, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mor, M.</span></span> <span> </span><span class="NLM_article-title">Quantum mechanics/molecular mechanics modeling of covalent addition between EGFR-cysteine 797 and N-(4-anilinoquinazolin-6-yl) acrylamide</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">589</span>– <span class="NLM_lpage">599</span>, <span class="refDoi"> DOI: 10.1021/ci500720e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci500720e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BC2MXit12rtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2015&pages=589-599&author=L.+Capoferriauthor=A.+Lodolaauthor=S.+Rivaraauthor=M.+Mor&title=Quantum+mechanics%2Fmolecular+mechanics+modeling+of+covalent+addition+between+EGFR-cysteine+797+and+N-%284-anilinoquinazolin-6-yl%29+acrylamide&doi=10.1021%2Fci500720e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Quantum Mechanics/Molecular Mechanics Modeling of Covalent Addition between EGFR-Cysteine 797 and N-(4-Anilinoquinazolin-6-yl) Acrylamide</span></div><div class="casAuthors">Capoferri, Luigi; Lodola, Alessio; Rivara, Silvia; Mor, Marco</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">589-599</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Irreversible epidermal growth factor receptor (EGFR) inhibitors can circumvent resistance to first-generation ATP-competitive inhibitors in the treatment of nonsmall-cell lung cancer.  They covalently bind a noncatalytic cysteine (Cys797) at the surface of EGFR active site by an acrylamide warhead.  Herein, we used a hybrid quantum mechanics/mol. mechanics (QM/MM) potential in combination with umbrella sampling in the path-collective variable space to investigate the mechanism of alkylation of Cys797 by the prototypical covalent inhibitor N-(4-anilinoquinazolin-6-yl) acrylamide.  Calcns. show that Cys797 reacts with the acrylamide group of the inhibitor through a direct addn. mechanism, with Asp800 acting as a general base/general acid in distinct steps of the reaction.  The obtained reaction free energy is neg. (ΔA = -12 kcal/mol) consistent with the spontaneous and irreversible alkylation of Cys797 by N-(4-anilinoquinazolin-6-yl) acrylamide.  Our calcns. identify desolvation of Cys797 thiolate anion as a key step of the alkylation process, indicating that changes in the intrinsic reactivity of the acrylamide would have only a minor impact on the inhibitor potency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowDcsiGT9gD7Vg90H21EOLACvtfcHk0lhbf2jjNDAIyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXit12rtrY%253D&md5=8f1c5df9cd62228ff22711e41a7d7a5c</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fci500720e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci500720e%26sid%3Dliteratum%253Aachs%26aulast%3DCapoferri%26aufirst%3DL.%26aulast%3DLodola%26aufirst%3DA.%26aulast%3DRivara%26aufirst%3DS.%26aulast%3DMor%26aufirst%3DM.%26atitle%3DQuantum%2520mechanics%252Fmolecular%2520mechanics%2520modeling%2520of%2520covalent%2520addition%2520between%2520EGFR-cysteine%2520797%2520and%2520N-%25284-anilinoquinazolin-6-yl%2529%2520acrylamide%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2015%26volume%3D55%26spage%3D589%26epage%3D599%26doi%3D10.1021%2Fci500720e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carmi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lodola, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacondio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavazzoni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfieri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ardizzoni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petronini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mor, M.</span></span> <span> </span><span class="NLM_article-title">Epidermal growth factor receptor irreversible inhibitors: chemical exploration of the cysteine-trap portion</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1019</span>– <span class="NLM_lpage">1030</span>, <span class="refDoi"> DOI: 10.2174/138955711797247725</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.2174%2F138955711797247725" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=21861809" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1OnsL3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=1019-1030&author=C.+Carmiauthor=A.+Lodolaauthor=S.+Rivaraauthor=F.+Vacondioauthor=A.+Cavazzoniauthor=R.+Alfieriauthor=A.+Ardizzoniauthor=P.+Petroniniauthor=M.+Mor&title=Epidermal+growth+factor+receptor+irreversible+inhibitors%3A+chemical+exploration+of+the+cysteine-trap+portion&doi=10.2174%2F138955711797247725"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor irreversible inhibitors: chemical exploration of the cysteine-trap portion</span></div><div class="casAuthors">Carmi, C.; Lodola, A.; Rivara, S.; Vacondio, F.; Cavazzoni, A.; Alfieri, R. R.; Ardizzoni, A.; Petronini, P. G.; Mor, M.</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1019-1030</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Covalent EGFR irreversible inhibitors showed promising potential for the treatment of gefitinib-resistant tumors and for imaging purposes.  They contain a cysteine-reactive portion forming a covalent bond with the protein.  Irreversible kinase inhibitors have been advanced to clin. studies, mostly characterized by an acrylamide or butynamide warhead.  However, the clin. usefulness of these compds. has been hampered by resistances, toxicity and pharmacokinetic problems.  Investigation on the structure-activity and structure-reactivity relationships may provide useful information for compds. with improved selectivity and pharmacokinetic properties.  This review focuses on the exploration of the cysteine-trap portions able to irreversibly inhibit EGFR and other erbB receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoupbZjLNpfFrVg90H21EOLACvtfcHk0lhbf2jjNDAIyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1OnsL3O&md5=d531960c09e4676366b3611c3187533d</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.2174%2F138955711797247725&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955711797247725%26sid%3Dliteratum%253Aachs%26aulast%3DCarmi%26aufirst%3DC.%26aulast%3DLodola%26aufirst%3DA.%26aulast%3DRivara%26aufirst%3DS.%26aulast%3DVacondio%26aufirst%3DF.%26aulast%3DCavazzoni%26aufirst%3DA.%26aulast%3DAlfieri%26aufirst%3DR.%26aulast%3DArdizzoni%26aufirst%3DA.%26aulast%3DPetronini%26aufirst%3DP.%26aulast%3DMor%26aufirst%3DM.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520irreversible%2520inhibitors%253A%2520chemical%2520exploration%2520of%2520the%2520cysteine-trap%2520portion%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2011%26volume%3D11%26spage%3D1019%26epage%3D1030%26doi%3D10.2174%2F138955711797247725" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Kane, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradbury, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feld, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leighl, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pisters, K.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamel-Reid, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsao, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepherd, F. A.</span></span> <span> </span><span class="NLM_article-title">Uncommon EGFR mutations in advanced non-small cell lung cancer</span>. <i>Lung Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">137</span>– <span class="NLM_lpage">144</span>, <span class="refDoi"> DOI: 10.1016/j.lungcan.2017.04.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1016%2Fj.lungcan.2017.04.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=28577943" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A280%3ADC%252BC1cnks1Wrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2017&pages=137-144&author=G.+M.+O%E2%80%99Kaneauthor=P.+A.+Bradburyauthor=R.+Feldauthor=N.+B.+Leighlauthor=G.+Liuauthor=K.-M.+Pistersauthor=S.+Kamel-Reidauthor=M.+S.+Tsaoauthor=F.+A.+Shepherd&title=Uncommon+EGFR+mutations+in+advanced+non-small+cell+lung+cancer&doi=10.1016%2Fj.lungcan.2017.04.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Uncommon EGFR mutations in advanced non-small cell lung cancer</span></div><div class="casAuthors">O'Kane Grainne M; Bradbury Penelope A; Feld Ronald; Leighl Natasha B; Liu Geoffrey; Pisters Katherine-M; Kamel-Reid Suzanne; Tsao Ming S; Shepherd Frances A</div><div class="citationInfo"><span class="NLM_cas:title">Lung cancer (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">137-144</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Molecular profiling in advanced non-small cell lung cancer (NSCLC) has allowed for the detection of actionable mutations, which has revolutionized the treatment paradigm in this highly fatal disease.  Mutations involving the epidermal growth factor receptor (EGFR) gene are most common and the 'classical mutations', exon 19 deletions and the point mutation L858R at exon 21, predict response to EGFR tyrosine kinase inhibitors (TKIs).  The 'uncommon' EGFR mutations account for 10-18% of all EGFR mutations and primarily consist of exon 20 insertions, exon 18 point mutations and complex mutations.  Improved detection techniques have broadened the spectrum of reported aberrations within the 'uncommon group' but response to TKIs is variable and not fully elucidated.  This review provides an overview of the biology and incidence of uncommon EGFR mutations and summarizes reported outcomes when treated with EGFR-TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRiqu-LITqhZMAKB7Fa-xrUfW6udTcc2eaJITeu2TOxJ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cnks1Wrtg%253D%253D&md5=fd51b60c9b8a5a65fb52e21c8223b66d</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2017.04.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2017.04.016%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Kane%26aufirst%3DG.%2BM.%26aulast%3DBradbury%26aufirst%3DP.%2BA.%26aulast%3DFeld%26aufirst%3DR.%26aulast%3DLeighl%26aufirst%3DN.%2BB.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DPisters%26aufirst%3DK.-M.%26aulast%3DKamel-Reid%26aufirst%3DS.%26aulast%3DTsao%26aufirst%3DM.%2BS.%26aulast%3DShepherd%26aufirst%3DF.%2BA.%26atitle%3DUncommon%2520EGFR%2520mutations%2520in%2520advanced%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DLung%2520Cancer%26date%3D2017%26volume%3D109%26spage%3D137%26epage%3D144%26doi%3D10.1016%2Fj.lungcan.2017.04.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arcila, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nafa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaft, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rekhtman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reva, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zakowski, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kris, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladanyi, M.</span></span> <span> </span><span class="NLM_article-title">EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">220</span>– <span class="NLM_lpage">229</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.mct-12-0620</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1158%2F1535-7163.mct-12-0620" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=23371856" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BC3sXitlWisrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=220-229&author=M.+E.+Arcilaauthor=K.+Nafaauthor=J.+E.+Chaftauthor=N.+Rekhtmanauthor=C.+Lauauthor=B.+A.+Revaauthor=M.+F.+Zakowskiauthor=M.+G.+Krisauthor=M.+Ladanyi&title=EGFR+exon+20+insertion+mutations+in+lung+adenocarcinomas%3A+prevalence%2C+molecular+heterogeneity%2C+and+clinicopathologic+characteristics&doi=10.1158%2F1535-7163.mct-12-0620"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics</span></div><div class="casAuthors">Arcila, Maria E.; Nafa, Khedoudja; Chaft, Jamie E.; Rekhtman, Natasha; Lau, Christopher; Reva, Boris A.; Zakowski, Maureen F.; Kris, Mark G.; Ladanyi, Marc</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">220-229</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">In contrast to other primary epidermal growth factor receptor (EGFR) mutations in lung adenocarcinomas, insertions in exon 20 of EGFR have been generally assocd. with resistance to EGFR-tyrosine kinase inhibitors.  Their mol. spectrum, clinicopathol. characteristics, and prevalence are not well established.  Tumors harboring EGFR exon 20 insertions were identified through an algorithmic screen of 1,500 lung adenocarcinomas.  Cases were first tested for common mutations in EGFR (exons 19 and 21) and KRAS (exon 2) and, if neg., further analyzed for EGFR exon 20 insertions.  All samples underwent extended genotyping for other driver mutations in EGFR, KRAS, BRAF, ERBB2/HER2, NRAS, PIK3CA, MEK1, and AKT by mass spectrometry; a subset was evaluated for ALK rearrangements.  We identified 33 EGFR exon 20 insertion cases [2.2%, 95% confidence interval (CI), 1.6-3.1], all mutually exclusive with mutations in the other genes tested (except PIK3CA).  They were more common among never-smokers (P < 0.0001).  There was no assocn. with age, sex, race, or stage.  Morphol., tumors were similar to those with common EGFR mutations but with frequent solid histol.  Insertions were highly variable in position and size, ranging from 3 to 12 bp, resulting in 13 different insertions, which, by mol. modeling, are predicted to have potentially different effects on erlotinib binding.  EGFR exon 20 insertion testing identifies a distinct subset of lung adenocarcinomas, accounting for at least 9% of all EGFR-mutated cases, representing the third most common type of EGFR mutation after exon 19 deletions and L858R.  Insertions are structurally heterogeneous with potential implications for response to EGFR inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv1GpDUzx3KLVg90H21EOLACvtfcHk0lgzCXsD62Ih8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXitlWisrc%253D&md5=5f9c4df38f65a6948af8572c5dbfd222</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.mct-12-0620&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.mct-12-0620%26sid%3Dliteratum%253Aachs%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DNafa%26aufirst%3DK.%26aulast%3DChaft%26aufirst%3DJ.%2BE.%26aulast%3DRekhtman%26aufirst%3DN.%26aulast%3DLau%26aufirst%3DC.%26aulast%3DReva%26aufirst%3DB.%2BA.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DLadanyi%26aufirst%3DM.%26atitle%3DEGFR%2520exon%252020%2520insertion%2520mutations%2520in%2520lung%2520adenocarcinomas%253A%2520prevalence%252C%2520molecular%2520heterogeneity%252C%2520and%2520clinicopathologic%2520characteristics%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2013%26volume%3D12%26spage%3D220%26epage%3D229%26doi%3D10.1158%2F1535-7163.mct-12-0620" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oxnard, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlberg, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindeman, N. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butaney, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackman, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span> <span> </span><span class="NLM_article-title">Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">179</span>– <span class="NLM_lpage">184</span>, <span class="refDoi"> DOI: 10.1097/jto.0b013e3182779d18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1097%2Fjto.0b013e3182779d18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=23328547" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1Kms7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=179-184&author=G.+R.+Oxnardauthor=P.+C.+Loauthor=M.+Nishinoauthor=S.+E.+Dahlbergauthor=N.+I.+Lindemanauthor=M.+Butaneyauthor=D.+M.+Jackmanauthor=B.+E.+Johnsonauthor=P.+A.+J%C3%A4nne&title=Natural+history+and+molecular+characteristics+of+lung+cancers+harboring+EGFR+exon+20+insertions&doi=10.1097%2Fjto.0b013e3182779d18"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions</span></div><div class="casAuthors">Oxnard, Geoffrey R.; Lo, Peter C.; Nishino, Mizuki; Dahlberg, Suzanne E.; Lindeman, Neal I.; Butaney, Mohit; Jackman, David M.; Johnson, Bruce E.; Jaenne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thoracic Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">179-184</span>CODEN:
                <span class="NLM_cas:coden">JTOOB7</span>;
        ISSN:<span class="NLM_cas:issn">1556-0864</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Introduction: Exon 20 insertions are the third most common family of epidermal growth factor receptor (EGFR) mutations found in non-small-cell lung cancer (NSCLC).  Little is known about cancers harboring these mutations aside from their lack of response to EGFR tyrosine kinase inhibitors, impairing the development of effective targeted therapies.  Methods: NSCLC patients with EGFR genotyping were studied using a mechanism approved by the Institutional Review Board.  Cancers with exon 20 insertions were indentified, sequences were characterized, and effectiveness of different treatment regimens was reviewed retrospectively.  Clin. characteristics and survival were compared with cancers harboring common EGFR mutations and cancers with wild-type EGFR.  Results: One thousand eighty-six patients underwent EGFR genotyping from 2004 to 2012.  Twenty seven (2.5%) harbored exon 20 insertions, making up 9.2% of all cancers with documented EGFR mutations.  Compared with wild-type cancers, those with exon 20 insertions were more commonly found in never-smokers and Asian patients.  Insertion sequences were highly variable, with the most common variant (V769D770insASV) making up only 22% of cases.  Median survival of patients with exon 20 insertions was 16 mo, similar to the survival of wild-type cancers and shorter than the survival of cancers with common EGFR mutations.  Conclusions: Patients with EGFR exon 20 insertions have similar clin. characteristics to those with common EGFR mutations but a poorer prognosis.  The prevalence of this subset of NSCLC is similar to that of other genotype-defined subsets of lung adenocarcinoma (e.g. those with BRAF mutations, HER2 insertions, ROS1 rearrangements) and is a population of interest for trials of new targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvsALCA978j7Vg90H21EOLACvtfcHk0lgzCXsD62Ih8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1Kms7k%253D&md5=1448f6533853c20970ca59fe23649df3</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1097%2Fjto.0b013e3182779d18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252Fjto.0b013e3182779d18%26sid%3Dliteratum%253Aachs%26aulast%3DOxnard%26aufirst%3DG.%2BR.%26aulast%3DLo%26aufirst%3DP.%2BC.%26aulast%3DNishino%26aufirst%3DM.%26aulast%3DDahlberg%26aufirst%3DS.%2BE.%26aulast%3DLindeman%26aufirst%3DN.%2BI.%26aulast%3DButaney%26aufirst%3DM.%26aulast%3DJackman%26aufirst%3DD.%2BM.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DNatural%2520history%2520and%2520molecular%2520characteristics%2520of%2520lung%2520cancers%2520harboring%2520EGFR%2520exon%252020%2520insertions%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2013%26volume%3D8%26spage%3D179%26epage%3D184%26doi%3D10.1097%2Fjto.0b013e3182779d18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ning, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wery, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.-X.</span></span> <span> </span><span class="NLM_article-title">NSCLC harboring EGFR exon-20 insertions after the regulatory C-helix of kinase domain responds poorly to known EGFR inhibitors</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>139</i></span>,  <span class="NLM_fpage">171</span>– <span class="NLM_lpage">176</span>, <span class="refDoi"> DOI: 10.1002/ijc.30047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1002%2Fijc.30047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=26891175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BC28XkvVyht7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2016&pages=171-176&author=M.+Yangauthor=X.+Xuauthor=J.+Caiauthor=J.+Ningauthor=J.+P.+Weryauthor=Q.-X.+Li&title=NSCLC+harboring+EGFR+exon-20+insertions+after+the+regulatory+C-helix+of+kinase+domain+responds+poorly+to+known+EGFR+inhibitors&doi=10.1002%2Fijc.30047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">NSCLC harboring EGFR exon-20 insertions after the regulatory C-helix of kinase domain responds poorly to known EGFR inhibitors</span></div><div class="casAuthors">Yang, Mengmeng; Xu, Xiaoxi; Cai, Jie; Ning, Jinying; Wery, Jean Pierre; Li, Qi-Xiang</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">139</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">171-176</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Anecdote clin. observations hint that non-small cell lung cancer (NSCLC) with exon-20 insertions might respond poorly to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), contrasting to those with classic mutations.  Lack of patient-derived exptl. models has been a major hurdle for the discovery of new treatment for the diseases.  We established two NSCLC-PDXs harboring two different exon-20 insertions, LU0387-adenocarcinoma (ADC) with a nine-base insertion at 2319 (H773-V774insNPH) and LU3075-squamous cell carcinoma (SCC) with a nine-base insertion at 2316 (P772-H773insDNP).  Both insertions immediately follow the regulatory C-helix of the kinase domain.  Contrary to the generally good responses to EGFR inhibitors obsd. in PDXs with classic mutations, both exon-20 insertions are largely resistant to cetuximab and TKIs in vivo, suggesting fundamental difference from the classic EGFR mutations, consistent with the poor response rate to TKI seen in anecdotal clinic reports.  It is worth noting that although responses are generally poor, they differ between the two exon-20 mutants depending on the type of TKI.  In vitro drug sensitivity assays using established primary cell lines from our two PDXs largely confirmed the in vivo data.  Our data from patient-derived exptl. models confirmed that exon-20 insertions in domain immediately following the C-helix confer poor response to all known EGFR inhibitors, and suggested that these models can be utilized to facilitate the discovery of new therapies targeting NSCLC harboring exon-20 insertions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroWeElBAFqVLVg90H21EOLACvtfcHk0lgzCXsD62Ih8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XkvVyht7o%253D&md5=19df87ac0356538b8fee4cc0bc7b92f3</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1002%2Fijc.30047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.30047%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DCai%26aufirst%3DJ.%26aulast%3DNing%26aufirst%3DJ.%26aulast%3DWery%26aufirst%3DJ.%2BP.%26aulast%3DLi%26aufirst%3DQ.-X.%26atitle%3DNSCLC%2520harboring%2520EGFR%2520exon-20%2520insertions%2520after%2520the%2520regulatory%2520C-helix%2520of%2520kinase%2520domain%2520responds%2520poorly%2520to%2520known%2520EGFR%2520inhibitors%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2016%26volume%3D139%26spage%3D171%26epage%3D176%26doi%3D10.1002%2Fijc.30047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aisner, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaft, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kako, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kris, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varella-Garcia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arcila, M. E.</span></span> <span> </span><span class="NLM_article-title">HER2 amplification and HER2 mutation are distinct molecular targets in lung cancers</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">414</span>– <span class="NLM_lpage">419</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2015.10.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1016%2Fj.jtho.2015.10.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=26723242" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A280%3ADC%252BC28rmsFSlug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=414-419&author=B.+T.+Liauthor=D.+S.+Rossauthor=D.+L.+Aisnerauthor=J.+E.+Chaftauthor=M.+Hsuauthor=S.+L.+Kakoauthor=M.+G.+Krisauthor=M.+Varella-Garciaauthor=M.+E.+Arcila&title=HER2+amplification+and+HER2+mutation+are+distinct+molecular+targets+in+lung+cancers&doi=10.1016%2Fj.jtho.2015.10.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers</span></div><div class="casAuthors">Li Bob T; Ross Dara S; Aisner Dara L; Kako Severine L; Varella-Garcia Marileila; Chaft Jamie E; Kris Mark G; Hsu Meier; Arcila Maria E</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">414-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  Human epidermal growth factor receptor 2 gene (HER2 [also known as ERBB2]) alterations have been identified as oncogenic drivers and potential therapeutic targets in lung cancers.  The molecular associations of HER2 gene amplification, mutation, and HER2 protein overexpression in lung cancers have not been distinctly defined.  To explore these associations, Memorial Sloan Kettering Cancer Center and the University of Colorado combined their data on HER2 alterations in lung cancers.  METHODS:  Tumor specimens from 175 patients with lung adenocarcinomas and no prior targeted therapy were evaluated for the presence of HER2 amplification and mutation and HER2 protein overexpression.  Amplification was assessed by fluorescence in situ hybridization (FISH) and defined as an HER2-to-chromosome enumeration probe 17 ratio of at least 2.0.  Mutation was assessed by fragment analysis, mass spectrometry genotyping, and Sanger sequencing.  Overexpression was assessed by immunohistochemical (IHC) staining.  The frequencies of HER2 amplification and mutation and HER2 overexpression were calculated and their overlap examined.  RESULTS:  HER2 amplification was detected by FISH in 5 of 175 cases (3%).  HER2 mutation was detected in 4 of 148 specimens (3%), including three identical 12-base pair insertions (p.A775_G776insYVMA) and a 9-base pair insertion, all in exon 20.  None of the HER2-mutant cases was amplified.  HER2 overexpression (2+ or 3+) on IHC staining was not detected in the 25 specimens available for testing, and negative IHC staining correlated with the negative results according to FISH.  CONCLUSIONS:  HER2 mutations are not associated with HER2 amplification, thus suggesting a distinct entity and therapeutic target.  HER2-positive lung cancer may not be an adequate term, and patient cohorts for the study of HER2-targeted agents should be defined by the specific HER2 alteration present.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS9sBZvWYUoddFxYDaSSP8XfW6udTcc2ebfjUAe7xSMVrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rmsFSlug%253D%253D&md5=c127ca81946d6a6d9b0f5b93cc47c0b9</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2015.10.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2015.10.025%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DB.%2BT.%26aulast%3DRoss%26aufirst%3DD.%2BS.%26aulast%3DAisner%26aufirst%3DD.%2BL.%26aulast%3DChaft%26aufirst%3DJ.%2BE.%26aulast%3DHsu%26aufirst%3DM.%26aulast%3DKako%26aufirst%3DS.%2BL.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DVarella-Garcia%26aufirst%3DM.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26atitle%3DHER2%2520amplification%2520and%2520HER2%2520mutation%2520are%2520distinct%2520molecular%2520targets%2520in%2520lung%2520cancers%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2016%26volume%3D11%26spage%3D414%26epage%3D419%26doi%3D10.1016%2Fj.jtho.2015.10.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">U.S.
National Library of Medicine</span>. <span> </span><span class="NLM_article-title">ClinicalTrials.gov</span>. <a href="https://clinicaltrials.gov/ct2/show/NCT03066206" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03066206</a> (accessed Mar 15, <span class="NLM_year">2019</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=U.S.%0ANational+Library+of+Medicine&title=ClinicalTrials.gov"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DClinicalTrials.gov%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">U.S. National Library of Medicine</span>. <span> </span><span class="NLM_article-title">ClinicalTrials.gov</span>. <a href="https://clinicaltrials.gov/ct2/show/NCT02716116" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02716116</a> (accessed Mar 15, <span class="NLM_year">2019</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=U.S.+National+Library+of+Medicine&title=ClinicalTrials.gov"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DClinicalTrials.gov%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robichaux, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elamin, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poteete, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrada-Bernal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roarty, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brahmer, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadimitrakopoulou, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Politi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doebele, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heymach, J. V.</span></span> <span> </span><span class="NLM_article-title">Mechanisms and clinical activity of an EGFR and HER2 exon 20 selective kinase inhibitor in non–small cell Lung cancer</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">638</span>– <span class="NLM_lpage">646</span>, <span class="refDoi"> DOI: 10.1038/s41591-018-0007-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1038%2Fs41591-018-0007-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=29686424" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BC1cXosVCnsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=638-646&author=J.+P.+Robichauxauthor=Y.+Y.+Elaminauthor=Z.+Tanauthor=B.+W.+Carterauthor=S.+Zhangauthor=S.+Liuauthor=S.+Liauthor=T.+Chenauthor=A.+Poteeteauthor=A.+Estrada-Bernalauthor=A.+T.+Leauthor=A.+Truiniauthor=M.+B.+Nilssonauthor=H.+Sunauthor=E.+Roartyauthor=S.+B.+Goldbergauthor=J.+R.+Brahmerauthor=M.+Altanauthor=C.+Luauthor=V.+Papadimitrakopoulouauthor=K.+Politiauthor=R.+C.+Doebeleauthor=K.-K.+Wongauthor=J.+V.+Heymach&title=Mechanisms+and+clinical+activity+of+an+EGFR+and+HER2+exon+20+selective+kinase+inhibitor+in+non%E2%80%93small+cell+Lung+cancer&doi=10.1038%2Fs41591-018-0007-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer</span></div><div class="casAuthors">Robichaux, Jacqulyne P.; Elamin, Yasir Y.; Tan, Zhi; Carter, Brett W.; Zhang, Shuxing; Liu, Shengwu; Li, Shuai; Chen, Ting; Poteete, Alissa; Estrada-Bernal, Adriana; Le, Anh T.; Truini, Anna; Nilsson, Monique B.; Sun, Huiying; Roarty, Emily; Goldberg, Sarah B.; Brahmer, Julie R.; Altan, Mehmet; Lu, Charles; Papadimitrakopoulou, Vassiliki; Politi, Katerina; Doebele, Robert C.; Wong, Kwok-Kin; Heymach, John V.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">638-646</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Although most activating mutations of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancers (NSCLCs) are sensitive to available EGFR tyrosine kinase inhibitors (TKIs), a subset with alterations in exon 20 of EGFR and HER2 are intrinsically resistant and lack an effective therapy.  We used in silico, in vitro, and in vivo testing to model structural alterations induced by exon 20 mutations and to identify effective inhibitors. 3D modeling indicated alterations restricted the size of the drug-binding pocket, limiting the binding of large, rigid inhibitors.  We found that poziotinib, owing to its small size and flexibility, can circumvent these steric changes and is a potent inhibitor of the most common EGFR and HER2 exon 20 mutants.  Poziotinib demonstrated greater activity than approved EGFR TKIs in vitro and in patient-derived xenograft models of EGFR or HER2 exon 20 mutant NSCLC and in genetically engineered mouse models of NSCLC.  In a phase 2 trial, the first 11 patients with NSCLC with EGFR exon 20 mutations receiving poziotinib had a confirmed objective response rate of 64%.  These data identify poziotinib as a potent, clin. active inhibitor of EGFR and HER2 exon 20 mutations and illuminate the mol. features of TKIs that may circumvent steric changes induced by these mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrk6UyVpv0h47Vg90H21EOLACvtfcHk0likHXnjVf4L4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXosVCnsLs%253D&md5=316a0a0765ebc9eec9b6460d27b28bb5</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1038%2Fs41591-018-0007-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41591-018-0007-9%26sid%3Dliteratum%253Aachs%26aulast%3DRobichaux%26aufirst%3DJ.%2BP.%26aulast%3DElamin%26aufirst%3DY.%2BY.%26aulast%3DTan%26aufirst%3DZ.%26aulast%3DCarter%26aufirst%3DB.%2BW.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DPoteete%26aufirst%3DA.%26aulast%3DEstrada-Bernal%26aufirst%3DA.%26aulast%3DLe%26aufirst%3DA.%2BT.%26aulast%3DTruini%26aufirst%3DA.%26aulast%3DNilsson%26aufirst%3DM.%2BB.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DRoarty%26aufirst%3DE.%26aulast%3DGoldberg%26aufirst%3DS.%2BB.%26aulast%3DBrahmer%26aufirst%3DJ.%2BR.%26aulast%3DAltan%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DPapadimitrakopoulou%26aufirst%3DV.%26aulast%3DPoliti%26aufirst%3DK.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DHeymach%26aufirst%3DJ.%2BV.%26atitle%3DMechanisms%2520and%2520clinical%2520activity%2520of%2520an%2520EGFR%2520and%2520HER2%2520exon%252020%2520selective%2520kinase%2520inhibitor%2520in%2520non%25E2%2580%2593small%2520cell%2520Lung%2520cancer%26jtitle%3DNat.%2520Med.%26date%3D2018%26volume%3D24%26spage%3D638%26epage%3D646%26doi%3D10.1038%2Fs41591-018-0007-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heymach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negrao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robichaux, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbons, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fossella, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumenschein, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsao, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mott, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mack, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roeck, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadimitrakopoulou, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elamin, Y.</span></span> <span> </span><span class="NLM_article-title">A phase II trial of poziotinib in EGFR and HER2 exon 20 mutant non-small cell lung cancer (NSCLC)</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">S323</span>– <span class="NLM_lpage">S324</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2018.08.243</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1016%2Fj.jtho.2018.08.243" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=29396253" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=S323-S324&author=J.+Heymachauthor=M.+Negraoauthor=J.+Robichauxauthor=B.+Carterauthor=A.+Patelauthor=M.+Altanauthor=D.+Gibbonsauthor=F.+Fossellaauthor=G.+Simonauthor=V.+Lamauthor=G.+Blumenscheinauthor=A.+Tsaoauthor=J.+Kurieauthor=F.+Mottauthor=D.+Jenkinsauthor=D.+Mackauthor=L.+Fengauthor=B.+Roeckauthor=Z.+Yangauthor=V.+Papadimitrakopoulouauthor=Y.+Elamin&title=A+phase+II+trial+of+poziotinib+in+EGFR+and+HER2+exon+20+mutant+non-small+cell+lung+cancer+%28NSCLC%29&doi=10.1016%2Fj.jtho.2018.08.243"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2018.08.243&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2018.08.243%26sid%3Dliteratum%253Aachs%26aulast%3DHeymach%26aufirst%3DJ.%26aulast%3DNegrao%26aufirst%3DM.%26aulast%3DRobichaux%26aufirst%3DJ.%26aulast%3DCarter%26aufirst%3DB.%26aulast%3DPatel%26aufirst%3DA.%26aulast%3DAltan%26aufirst%3DM.%26aulast%3DGibbons%26aufirst%3DD.%26aulast%3DFossella%26aufirst%3DF.%26aulast%3DSimon%26aufirst%3DG.%26aulast%3DLam%26aufirst%3DV.%26aulast%3DBlumenschein%26aufirst%3DG.%26aulast%3DTsao%26aufirst%3DA.%26aulast%3DKurie%26aufirst%3DJ.%26aulast%3DMott%26aufirst%3DF.%26aulast%3DJenkins%26aufirst%3DD.%26aulast%3DMack%26aufirst%3DD.%26aulast%3DFeng%26aufirst%3DL.%26aulast%3DRoeck%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DPapadimitrakopoulou%26aufirst%3DV.%26aulast%3DElamin%26aufirst%3DY.%26atitle%3DA%2520phase%2520II%2520trial%2520of%2520poziotinib%2520in%2520EGFR%2520and%2520HER2%2520exon%252020%2520mutant%2520non-small%2520cell%2520lung%2520cancer%2520%2528NSCLC%2529%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2018%26volume%3D13%26spage%3DS323%26epage%3DS324%26doi%3D10.1016%2Fj.jtho.2018.08.243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span> </span><span class="NLM_article-title">Reaction Biology Corporation Home Page</span>. <a href="http://www.reactionbiology.com/webapps/site/KinaseAssay.aspx" class="extLink">http://www.reactionbiology.com/webapps/site/KinaseAssay.aspx</a> (accessed Jan 6, <span class="NLM_year">2019</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Reaction+Biology+Corporation+Home+Page.+http%3A%2F%2Fwww.reactionbiology.com%2Fwebapps%2Fsite%2FKinaseAssay.aspx+%28accessed+Jan+6%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DReaction%2520Biology%2520Corporation%2520Home%2520Page%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan-Jacob, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moebitz, H.</span></span> <span> </span><span class="NLM_article-title">Ten things you should know about protein kinases: IUPHAR review 14</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">2675</span>– <span class="NLM_lpage">2700</span>, <span class="refDoi"> DOI: 10.1111/bph.13096</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1111%2Fbph.13096" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=25630872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVent7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2015&pages=2675-2700&author=D.+Fabbroauthor=S.+W.+Cowan-Jacobauthor=H.+Moebitz&title=Ten+things+you+should+know+about+protein+kinases%3A+IUPHAR+review+14&doi=10.1111%2Fbph.13096"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Ten things you should know about protein kinases: IUPHAR Review 14</span></div><div class="casAuthors">Fabbro, Doriano; Cowan-Jacob, Sandra W.; Moebitz, Henrik</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2675-2700</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Many human malignancies are assocd. with aberrant regulation of protein or lipid kinases due to mutations, chromosomal rearrangements and/or gene amplification.  Protein and lipid kinases represent an important target class for treating human disorders.  This review focus on 'the 10 things you should know about protein kinases and their inhibitors', including a short introduction on the history of protein kinases and their inhibitors and ending with a perspective on kinase drug discovery.  Although the '10 things' have been, to a certain extent, chosen arbitrarily, they cover in a comprehensive way the past and present efforts in kinase drug discovery and summarize the status quo of the current kinase inhibitors as well as knowledge about kinase structure and binding modes.  Besides describing the potentials of protein kinase inhibitors as drugs, this review also focus on their limitations, particularly on how to circumvent emerging resistance against kinase inhibitors in oncol. indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryyzn-icN30rVg90H21EOLACvtfcHk0liHaFkn6w5rEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVent7zP&md5=160b754efc7f29460712fa03bb2274b1</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1111%2Fbph.13096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.13096%26sid%3Dliteratum%253Aachs%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DMoebitz%26aufirst%3DH.%26atitle%3DTen%2520things%2520you%2520should%2520know%2520about%2520protein%2520kinases%253A%2520IUPHAR%2520review%252014%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2015%26volume%3D172%26spage%3D2675%26epage%3D2700%26doi%3D10.1111%2Fbph.13096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hasenahuer, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barletta, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Alberti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parisi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fornasari, M. S.</span></span> <span> </span><span class="NLM_article-title">Pockets as structural descriptors of EGFR kinase conformations</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>, <span class="NLM_elocation-id">e0189147</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0189147</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1371%2Fjournal.pone.0189147" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=29228029" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsV2rurvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&author=M.+A.+Hasenahuerauthor=G.+P.+Barlettaauthor=S.+Fernandez-Albertiauthor=G.+Parisiauthor=M.+S.+Fornasari&title=Pockets+as+structural+descriptors+of+EGFR+kinase+conformations&doi=10.1371%2Fjournal.pone.0189147"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Pockets as structural descriptors of EGFR kinase conformations</span></div><div class="casAuthors">Hasenahuer, Marcia Anahi; Barletta, German Patricio; Fernandez-Alberti, Sebastian; Parisi, Gustavo; Fornasari, Maria Silvina</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">e0189147/1-e0189147/17</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Epidermal Growth Factor Receptor (EGFR), a tyrosine kinase receptor, is one of the main tumor markers in different types of cancers.  The kinase native state is mainly composed of two populations of conformers: active and inactive.  Several sequence variations in EGFR kinase region promote the differential enrichment of conformers with higher activity.  Some structural characteristics have been proposed to differentiate kinase conformations, but these considerations could lead to ambiguous classifications.  We present a structural characterization of EGFR kinase conformers, focused on active site pocket comparisons, and the mapping of known pathol. sequence variations.  A structural based clustering of this pocket accurately discriminates active from inactive, well-characterised conformations.  Furthermore, this main pocket contains, or is in close contact with, ≈65% of cancer-related variation positions.  Although the relevance of protein dynamics to explain biol. function has been extensively recognized, the usage of the ensemble of conformations in dynamic equil. to represent the functional state of proteins and the importance of pockets, cavities and/or tunnels was often neglected in previous studies.  These functional structures and the equil. between them could be structurally analyzed in wild type as well as in sequence variants.  Our results indicate that biol. important pockets, as well as their shape and dynamics, are central to understanding protein function in wild-type, polymorphic or disease-related variations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpul4xajmXXhbVg90H21EOLACvtfcHk0liHaFkn6w5rEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsV2rurvL&md5=eeb15ac0d039f004bdcef80d87556d01</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0189147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0189147%26sid%3Dliteratum%253Aachs%26aulast%3DHasenahuer%26aufirst%3DM.%2BA.%26aulast%3DBarletta%26aufirst%3DG.%2BP.%26aulast%3DFernandez-Alberti%26aufirst%3DS.%26aulast%3DParisi%26aufirst%3DG.%26aulast%3DFornasari%26aufirst%3DM.%2BS.%26atitle%3DPockets%2520as%2520structural%2520descriptors%2520of%2520EGFR%2520kinase%2520conformations%26jtitle%3DPLoS%2520One%26date%3D2017%26volume%3D12%26doi%3D10.1371%2Fjournal.pone.0189147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Songtawee, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gleeson, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choowongkomon, K.</span></span> <span> </span><span class="NLM_article-title">Computational study of EGFR inhibition: molecular dynamics studies on the active and inactive protein conformations</span>. <i>J. Mol. Model.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">497</span>– <span class="NLM_lpage">509</span>, <span class="refDoi"> DOI: 10.1007/s00894-012-1559-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1007%2Fs00894-012-1559-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=22955422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1ehtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=497-509&author=N.+Songtaweeauthor=M.+P.+Gleesonauthor=K.+Choowongkomon&title=Computational+study+of+EGFR+inhibition%3A+molecular+dynamics+studies+on+the+active+and+inactive+protein+conformations&doi=10.1007%2Fs00894-012-1559-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Computational study of EGFR inhibition: molecular dynamics studies on the active and inactive protein conformations</span></div><div class="casAuthors">Songtawee, Napat; Gleeson, M. Paul; Choowongkomon, Kiattawee</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Modeling</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">497-509</span>CODEN:
                <span class="NLM_cas:coden">JMMOFK</span>;
        ISSN:<span class="NLM_cas:issn">0948-5023</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The structural diversity obsd. across protein kinases, resulting in subtly different active site cavities, is highly desirable in the pursuit of selective inhibitors, yet it can also be a hindrance from a structure-based design perspective.  An important challenge in structure-based design is to better understand the dynamic nature of protein kinases and the underlying reasons for specific conformational preferences in the presence of different inhibitors.  To investigate this issue, we performed mol. dynamics simulation on both the active and inactive wild type epidermal growth factor receptor (EGFR) protein with both type-I and type-II inhibitors.  Our goal is to better understand the origin of the two distinct EGFR protein conformations, their dynamic differences, and their relative preference for Type-I inhibitors such as gefitinib and Type-II inhibitors such as lapatinib.  We discuss the implications of protein dynamics from a structure-based design perspective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPx-eH9xSM3rVg90H21EOLACvtfcHk0liHaFkn6w5rEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1ehtLw%253D&md5=18f66b72eb206a39f580f749d2e8cd01</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1007%2Fs00894-012-1559-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00894-012-1559-0%26sid%3Dliteratum%253Aachs%26aulast%3DSongtawee%26aufirst%3DN.%26aulast%3DGleeson%26aufirst%3DM.%2BP.%26aulast%3DChoowongkomon%26aufirst%3DK.%26atitle%3DComputational%2520study%2520of%2520EGFR%2520inhibition%253A%2520molecular%2520dynamics%2520studies%2520on%2520the%2520active%2520and%2520inactive%2520protein%2520conformations%26jtitle%3DJ.%2520Mol.%2520Model.%26date%3D2013%26volume%3D19%26spage%3D497%26epage%3D509%26doi%3D10.1007%2Fs00894-012-1559-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, C. T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwoh, C. K.</span></span> <span> </span><span class="NLM_article-title">CovalentDock: automated covalent docking with parameterized covalent linkage energy estimation and molecular geometry constraints</span>. <i>J. Comput. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">326</span>– <span class="NLM_lpage">336</span>, <span class="refDoi"> DOI: 10.1002/jcc.23136</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1002%2Fjcc.23136" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=23034731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVKksLbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2013&pages=326-336&author=X.+Ouyangauthor=S.+Zhouauthor=C.+T.+T.+Suauthor=Z.+Geauthor=R.+Liauthor=C.+K.+Kwoh&title=CovalentDock%3A+automated+covalent+docking+with+parameterized+covalent+linkage+energy+estimation+and+molecular+geometry+constraints&doi=10.1002%2Fjcc.23136"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">CovalentDock: Automated covalent docking with parameterized covalent linkage energy estimation and molecular geometry constrains</span></div><div class="casAuthors">Ouyang, Xuchang; Zhou, Shuo; Su, Chinh Tran To; Ge, Zemei; Li, Runtao; Kwoh, Chee Keong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">326-336</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Covalent linkage formation is a very important mechanism for many covalent drugs to work.  However, partly due to the limitations of proper computational tools for covalent docking, most covalent drugs are not discovered systematically.  In this article, we present a new covalent docking package, the CovalentDock, built on the top of the source code of Autodock.  We developed an empirical model of free energy change estn. for covalent linkage formation, which is compatible with existing scoring functions used in docking, while handling the mol. geometry constrains of the covalent linkage with special atom types and directional grid maps.  Integrated prepn. scripts are also written for the automation of the whole covalent docking workflow.  The result tested on existing crystal structures with covalent linkage shows that CovalentDock can reproduce the native covalent complexes with significant improved accuracy when compared with the default covalent docking method in Autodock.  Expts. also suggest that CovalentDock is capable of covalent virtual screening with satisfactory enrichment performance.  In addn., the investigation on the results also shows that the chirality and target selectivity along with the mol. geometry constrains are well preserved by CovalentDock, showing great capability of this method in the application for covalent drug discovery. © 2012 Wiley Periodicals, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1kpnxsCasoLVg90H21EOLACvtfcHk0lg8gy7IU6r5qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVKksLbJ&md5=5f548c115755f2e1470848ba6f6d701b</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1002%2Fjcc.23136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.23136%26sid%3Dliteratum%253Aachs%26aulast%3DOuyang%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DS.%26aulast%3DSu%26aufirst%3DC.%2BT.%2BT.%26aulast%3DGe%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DR.%26aulast%3DKwoh%26aufirst%3DC.%2BK.%26atitle%3DCovalentDock%253A%2520automated%2520covalent%2520docking%2520with%2520parameterized%2520covalent%2520linkage%2520energy%2520estimation%2520and%2520molecular%2520geometry%2520constraints%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D2013%26volume%3D34%26spage%3D326%26epage%3D336%26doi%3D10.1002%2Fjcc.23136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, C. L.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackerell, A. D.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrella, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roux, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Won, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Archontis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartels, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boresch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caflisch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caves, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinner, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feig, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodoscek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuczera, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazaridis, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ovchinnikov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paci, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastor, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Post, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaefer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tidor, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venable, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodcock, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">York, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karplus, M.</span></span> <span> </span><span class="NLM_article-title">CHARMM: the biomolecular simulation program</span>. <i>J. Comput. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">1545</span>– <span class="NLM_lpage">1614</span>, <span class="refDoi"> DOI: 10.1002/jcc.21287</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1002%2Fjcc.21287" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=19444816" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BD1MXms1Ciu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2009&pages=1545-1614&author=B.+R.+Brooksauthor=C.+L.+Brooksauthor=A.+D.+Mackerellauthor=L.+Nilssonauthor=R.+J.+Petrellaauthor=B.+Rouxauthor=Y.+Wonauthor=G.+Archontisauthor=C.+Bartelsauthor=S.+Boreschauthor=A.+Caflischauthor=L.+Cavesauthor=Q.+Cuiauthor=A.+R.+Dinnerauthor=M.+Feigauthor=S.+Fischerauthor=J.+Gaoauthor=M.+Hodoscekauthor=W.+Imauthor=K.+Kuczeraauthor=T.+Lazaridisauthor=J.+Maauthor=V.+Ovchinnikovauthor=E.+Paciauthor=R.+W.+Pastorauthor=C.+B.+Postauthor=J.+Z.+Puauthor=M.+Schaeferauthor=B.+Tidorauthor=R.+M.+Venableauthor=H.+L.+Woodcockauthor=X.+Wuauthor=W.+Yangauthor=D.+M.+Yorkauthor=M.+Karplus&title=CHARMM%3A+the+biomolecular+simulation+program&doi=10.1002%2Fjcc.21287"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">CHARMM: The biomolecular simulation program</span></div><div class="casAuthors">Brooks, B. R.; Brooks, C. L., III; Mackerell, A. D., Jr.; Nilsson, L.; Petrella, R. J.; Roux, B.; Won, Y.; Archontis, G.; Bartels, C.; Boresch, S.; Caflisch, A.; Caves, L.; Cui, Q.; Dinner, A. R.; Feig, M.; Fischer, S.; Gao, J.; Hodoscek, M.; Im, W.; Kuczera, K.; Lazaridis, T.; Ma, J.; Ovchinnikov, V.; Paci, E.; Pastor, R. W.; Post, C. B.; Pu, J. Z.; Schaefer, M.; Tidor, B.; Venable, R. M.; Woodcock, H. L.; Wu, X.; Yang, W.; York, D. M.; Karplus, M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1545-1614</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  CHARMM (Chem. at HARvard Mol. Mechanics) is a highly versatile and widely used mol. simulation program.  It has been developed over the last three decades with a primary focus on mols. of biol. interest, including proteins, peptides, lipids, nucleic acids, carbohydrates, and small mol. ligands, as they occur in soln., crystals, and membrane environments.  For the study of such systems, the program provides a large suite of computational tools that include numerous conformational and path sampling methods, free energy estimators, mol. minimization, dynamics, and anal. techniques, and model-building capabilities.  The CHARMM program is applicable to problems involving a much broader class of many-particle systems.  Calcns. with CHARMM can be performed using a no. of different energy functions and models, from mixed quantum mech.-mol. mech. force fields, to all-atom classical potential energy functions with explicit solvent and various boundary conditions, to implicit solvent and membrane models.  The program has been ported to numerous platforms in both serial and parallel architectures.  This article provides an overview of the program as it exists today with an emphasis on developments since the publication of the original CHARMM article in 1983.  © 2009 Wiley Periodicals, Inc. J Comput Chem, 2009.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOXZCtNIqoCbVg90H21EOLACvtfcHk0lg8gy7IU6r5qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXms1Ciu70%253D&md5=2c6a2be869362d7131f5aea8411c1552</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1002%2Fjcc.21287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.21287%26sid%3Dliteratum%253Aachs%26aulast%3DBrooks%26aufirst%3DB.%2BR.%26aulast%3DBrooks%26aufirst%3DC.%2BL.%26aulast%3DMackerell%26aufirst%3DA.%2BD.%26aulast%3DNilsson%26aufirst%3DL.%26aulast%3DPetrella%26aufirst%3DR.%2BJ.%26aulast%3DRoux%26aufirst%3DB.%26aulast%3DWon%26aufirst%3DY.%26aulast%3DArchontis%26aufirst%3DG.%26aulast%3DBartels%26aufirst%3DC.%26aulast%3DBoresch%26aufirst%3DS.%26aulast%3DCaflisch%26aufirst%3DA.%26aulast%3DCaves%26aufirst%3DL.%26aulast%3DCui%26aufirst%3DQ.%26aulast%3DDinner%26aufirst%3DA.%2BR.%26aulast%3DFeig%26aufirst%3DM.%26aulast%3DFischer%26aufirst%3DS.%26aulast%3DGao%26aufirst%3DJ.%26aulast%3DHodoscek%26aufirst%3DM.%26aulast%3DIm%26aufirst%3DW.%26aulast%3DKuczera%26aufirst%3DK.%26aulast%3DLazaridis%26aufirst%3DT.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DOvchinnikov%26aufirst%3DV.%26aulast%3DPaci%26aufirst%3DE.%26aulast%3DPastor%26aufirst%3DR.%2BW.%26aulast%3DPost%26aufirst%3DC.%2BB.%26aulast%3DPu%26aufirst%3DJ.%2BZ.%26aulast%3DSchaefer%26aufirst%3DM.%26aulast%3DTidor%26aufirst%3DB.%26aulast%3DVenable%26aufirst%3DR.%2BM.%26aulast%3DWoodcock%26aufirst%3DH.%2BL.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DYork%26aufirst%3DD.%2BM.%26aulast%3DKarplus%26aufirst%3DM.%26atitle%3DCHARMM%253A%2520the%2520biomolecular%2520simulation%2520program%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D2009%26volume%3D30%26spage%3D1545%26epage%3D1614%26doi%3D10.1002%2Fjcc.21287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Otwinowski, Z.</span>; <span class="NLM_string-name">Minor, W.</span></span> <span> </span><span class="NLM_article-title">Processing of X-ray Diffraction Data Collected in Oscillation Mode</span>. In  <i>Methods in Enzymology</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, C. W.,  Jr.</span></span>, Ed.; <span class="NLM_publisher-name">Academic</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">1997</span>; Vol.  <span class="NLM_volume">276</span>, pp <span class="NLM_fpage">307</span>– <span class="NLM_lpage">326</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1016%2FS0076-6879%2897%2976066-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1997&pages=307-326&author=Z.+Otwinowski&author=W.+Minorauthor=C.+W.+Carter&title=Methods+in+Enzymology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2FS0076-6879%2897%2976066-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FS0076-6879%252897%252976066-X%26sid%3Dliteratum%253Aachs%26aulast%3DOtwinowski%26aufirst%3DZ.%26atitle%3DProcessing%2520of%2520X-ray%2520Diffraction%2520Data%2520Collected%2520in%2520Oscillation%2520Mode%26btitle%3DMethods%2520in%2520Enzymology%26aulast%3DCarter%26aufirst%3DC.%2BW.%26pub%3DAcademic%26date%3D1997%26volume%3D276%26spage%3D307%26epage%3D326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adams, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afonine, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunkóczi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Echols, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Headd, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, L.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapral, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosse-Kunstleve, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriarty, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oeffner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terwilliger, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zwart, P. H.</span></span> <span> </span><span class="NLM_article-title">PHENIX: a comprehensive python-based system for macromolecular structure solution</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.1107/s0907444909052925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1107%2FS0907444909052925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=20124702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1Sisbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=213-221&author=P.+D.+Adamsauthor=P.+V.+Afonineauthor=G.+Bunk%C3%B3cziauthor=V.+B.+Chenauthor=I.+W.+Davisauthor=N.+Echolsauthor=J.+J.+Headdauthor=L.-W.+Hungauthor=G.+J.+Kapralauthor=R.+W.+Grosse-Kunstleveauthor=A.+J.+McCoyauthor=N.+W.+Moriartyauthor=R.+Oeffnerauthor=R.+J.+Readauthor=D.+C.+Richardsonauthor=J.+S.+Richardsonauthor=T.+C.+Terwilligerauthor=P.+H.+Zwart&title=PHENIX%3A+a+comprehensive+python-based+system+for+macromolecular+structure+solution&doi=10.1107%2Fs0907444909052925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">PHENIX: a comprehensive Python-based system for macromolecular structure solution</span></div><div class="casAuthors">Adams, Paul D.; Afonine, Pavel V.; Bunkoczi, Gabor; Chen, Vincent B.; Davis, Ian W.; Echols, Nathaniel; Headd, Jeffrey J.; Hung, Li Wei; Kapral, Gary J.; Grosse-Kunstleve, Ralf W.; McCoy, Airlie J.; Moriarty, Nigel W.; Oeffner, Robert; Read, Randy J.; Richardson, David C.; Richardson, Jane S.; Terwilliger, Thomas C.; Zwart, Peter H.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">213-221</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">A review.  Macromol. X-ray crystallog. is routinely applied to understand biol. processes at a mol. level.  However, significant time and effort are still required to solve and complete many of these structures because of the need for manual interpretation of complex numerical data using many software packages and the repeated use of interactive three-dimensional graphics.  PHENIX has been developed to provide a comprehensive system for macromol. crystallog. structure soln. with an emphasis on the automation of all procedures.  This has relied on the development of algorithms that minimize or eliminate subjective input, the development of algorithms that automate procedures that are traditionally performed by hand and, finally, the development of a framework that allows a tight integration between the algorithms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm_HgKRpa-ObVg90H21EOLACvtfcHk0lg8gy7IU6r5qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1Sisbc%253D&md5=67b439ff4bd61c659cae37ca4209b7bc</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1107%2FS0907444909052925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909052925%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DP.%2BD.%26aulast%3DAfonine%26aufirst%3DP.%2BV.%26aulast%3DBunk%25C3%25B3czi%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DV.%2BB.%26aulast%3DDavis%26aufirst%3DI.%2BW.%26aulast%3DEchols%26aufirst%3DN.%26aulast%3DHeadd%26aufirst%3DJ.%2BJ.%26aulast%3DHung%26aufirst%3DL.-W.%26aulast%3DKapral%26aufirst%3DG.%2BJ.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DMcCoy%26aufirst%3DA.%2BJ.%26aulast%3DMoriarty%26aufirst%3DN.%2BW.%26aulast%3DOeffner%26aufirst%3DR.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26aulast%3DRichardson%26aufirst%3DD.%2BC.%26aulast%3DRichardson%26aufirst%3DJ.%2BS.%26aulast%3DTerwilliger%26aufirst%3DT.%2BC.%26aulast%3DZwart%26aufirst%3DP.%2BH.%26atitle%3DPHENIX%253A%2520a%2520comprehensive%2520python-based%2520system%2520for%2520macromolecular%2520structure%2520solution%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D213%26epage%3D221%26doi%3D10.1107%2Fs0907444909052925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, T. D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oldenburg, K. R.</span></span> <span> </span><span class="NLM_article-title">A simple statistical parameter for use in evaluation and validation of high throughput screening assays</span>. <i>J. Biomol. Screening</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">67</span>– <span class="NLM_lpage">73</span>, <span class="refDoi"> DOI: 10.1177/108705719900400206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10.1177%2F108705719900400206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=10838414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;key=1%3ACAS%3A280%3ADC%252BC2sbit12juw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1999&pages=67-73&author=J.-H.+Zhangauthor=T.+D.+Y.+Chungauthor=K.+R.+Oldenburg&title=A+simple+statistical+parameter+for+use+in+evaluation+and+validation+of+high+throughput+screening+assays&doi=10.1177%2F108705719900400206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays</span></div><div class="casAuthors">Zhang; Chung; Oldenburg</div><div class="citationInfo"><span class="NLM_cas:title">Journal of biomolecular screening</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">67-73</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The ability to identify active compounds (3hits2) from large chemical libraries accurately and rapidly has been the ultimate goal in developing high-throughput screening (HTS) assays.  The ability to identify hits from a particular HTS assay depends largely on the suitability or quality of the assay used in the screening.  The criteria or parameters for evaluating the 3suitability2 of an HTS assay for hit identification are not well defined and hence it still remains difficult to compare the quality of assays directly.  In this report, a screening window coefficient, called 3Z-factor,2 is defined.  This coefficient is reflective of both the assay signal dynamic range and the data variation associated with the signal measurements, and therefore is suitable for assay quality assessment.  The Z-factor is a dimensionless, simple statistical characteristic for each HTS assay.  The Z-factor provides a useful tool for comparison and evaluation of the quality of assays, and can be utilized in assay optimization and validation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRkwW5JDdXnbsNIRw0GKUoEfW6udTcc2eZU_CHILkXAvrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sbit12juw%253D%253D&md5=0ec4ed2ccdd3b4a16521567a0975d31f</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1177%2F108705719900400206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F108705719900400206%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.-H.%26aulast%3DChung%26aufirst%3DT.%2BD.%2BY.%26aulast%3DOldenburg%26aufirst%3DK.%2BR.%26atitle%3DA%2520simple%2520statistical%2520parameter%2520for%2520use%2520in%2520evaluation%2520and%2520validation%2520of%2520high%2520throughput%2520screening%2520assays%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D1999%26volume%3D4%26spage%3D67%26epage%3D73%26doi%3D10.1177%2F108705719900400206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JQ7" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JQ7','PDB','4JQ7'); return false;">PDB: 4JQ7</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CAS" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CAS','PDB','5CAS'); return false;">PDB: 5CAS</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6JZ0" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6JZ0','PDB','6JZ0'); return false;">PDB: 6JZ0</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i59"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00722">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_38763"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.9b00722">10.1021/acs.jmedchem.9b00722</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Supplementary methods and general procedures for the  preparation of the compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00722/suppl_file/jm9b00722_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings of the final compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00722/suppl_file/jm9b00722_si_001.pdf">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00722/suppl_file/jm9b00722_si_001.pdf">jm9b00722_si_001.pdf (794.11 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00722/suppl_file/jm9b00722_si_002.csv">jm9b00722_si_002.csv (1.85 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB ID for EGFR WT with compound <b>78</b> is <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6JZ0">6JZ0</a>. The authors will release the atomic coordinates and experimental data upon article publication.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b00722&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b00722%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-22" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b00722" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6798fe9aebf13d9a","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
